HUMAN CALCIUM CHANNEL COMPOSITIONS AND METHODS USING THEM

Abstract: Isolated DNA encoding each of human calcium chanel alpha 1-, alpha 2-, beta - and gamma -subunits, including subunits that arise as splice variants of primary transcripts, is provided. In particular DNA clones encoding each of the alpha 1A-1, alpha 1A-2, alpha 1E-1, alpha 1C-2, alpha 1E-3, beta 3-1, beta 2C, beta 2D, beta 2E and beta 4 subunits of human calcium channels are provided. Cells and vectors containing the DNA, subunit specific antibodies and nucleic acid probes and methods for identifying compounds that modulate the activity of human calcium channels are also provided.

Description: HUMAN CALCIUM CHANNEL COMPOSITIONS AND METHODS USING THEM TECHNICAL FIELD The present invention relates to molecular biology and pharmacology. More particularly, the invention relates to calcium channel compositions and methods of making and using the same. BACKGROUND OF THE INVENTION Calcium channels are membrane-spanning, multi-subunit proteins that allow controlled entry of Ca 2+ ions into cells from the extracellular fluid. Cells throughout the animal kingdom, and at least some bacterial, fungal and plant cells, possess one or more types of calcium channel. The most common type of calcium channel is voltage dependent. "Opening" of a voltage-dependent channel to allow an influx of Ca 2+ ions into the cells requires a depolarization to a certain level of the potential difference between the inside of the cell bearing the channel and the extracellular medium bathing the cell. The rate of influx of Ca 2+ into the cell depends on this potential difference. All "excitable" cells in animals, such as neurons of the central nervous system (CNS) , peripheral nerve cells and muscle cells, including those of skeletal muscles, cardiac muscles, and venous and arterial smooth muscles, have voltage-dependent calcium channels. Multiple types of calcium channels have been identified in mammalian cells from various tissues, including skeletal muscle, cardiac muscle, lung, smooth muscle and brain, [see, e. g. , Bean, B.P. (1989) Ann. Rev. Phyεiol . 52:367-384 and Hess, P. (1990) Arm. Rev. Neurosci . 56: 331] . The different types of calcium channels have been broadly categorized into four classes, L-, T-, N-, and P-type, distinguished by current kinetics, holding potential sensitivity and sensitivity to calcium channel agonists and antagonists. Calcium channels are multisubunit proteins that contain two large subunits, designated α. and α. 2 , which have molecular weights between about 130 and about 200 kilodaltons ("kD"), and one to three different smaller subunits of less than about 60 kD in molecular weight. At least one of the larger subunits and possibly some of the smaller subunits are glycosylated. Some of the subunits are capable of being phosphorylated. The α. subunit has a molecular weight of about 150 to about 170 kD when analyzed by sodium dodecylsulfate (SDS) -polyacrylamide gel electrophoresis (PAGE) after isolation from mammalian muscle tissue and has specific binding sites for various 1,4-dihydropyridines (DHPs) and phenylalkylamines. Under non-reducing conditions (in the presence of N-ethylmaleimide) , the 2 subunit migrates in SDS-PAGE as a band corresponding to a molecular weight of about 160-190 kD. Upon reduction, a large fragment and smaller fragments are released. The β subunit of the rabbit skeletal muscle calcium channel is a phosphorylated protein that has a molecular weight of 52-65 kD as determined by SDS- PAGE analysis. This subunit is insensitive to reducing conditions. The γ subunit of the calcium channel, which is not observed in all purified preparations, appears to be a glycoprotein with an apparent molecular weight of 30-33 kD, as determined by SDS-PAGE analysis. In order to study calcium channel structure and function, large amounts of pure channel protein are needed. Because of the complex nature of these multisubunit proteins, the varying concentrations of calcium channels in tissue sources of the protein, the presence of mixed populations of calcium channels in tissues, difficulties in obtaining tissues of interest, and the modifications of the native protein that can occur during the isolation procedure, it is extremely difficult to obtain large amounts of highly purified, completely intact calcium channel protein. Characterization of a particular type of calcium channel by analysis of whole cells is severely restricted by the presence of mixed populations of different types of calcium channels in the majority of cells. Single-channel recording methods that are used to examine individual calcium channels do not reveal any information regarding the molecular structure or biochemical composition of the channel. Furthermore, in performing this type of analysis, the channel is isolated from other cellular constituents that might be important for natural functions and pharmacological interactions. Characterization of the gene or genes encoding calcium channels provides another means of characterization of different types of calcium channels. The amino acid sequence determined from a complete nucleotide sequence of the coding region of a gene encoding a calcium channel protein represents the primary structure of the protein. Furthermore, secondary structure of the calcium channel protein and the relationship of the protein to the membrane may be predicted based on analysis of the primary structure. For instance, hydropathy plots of the α.. subunit protein of the rabbit skeletal muscle calcium channel indicate that it contains four internal repeats, each containing six putative transmembrane regions [Tanabe, T. et al . (1987) Nature 328:313] . Because calcium channels are present in various tissues and have a central role in regulating intracellular calcium ion concentrations, they are implicated in a number of vital processes in animals, including neurotransmitter release, muscle contraction, pacemaker activity, and secretion of hormones and other substances. These processes appear to be involved in numerous human disorders, such as CΝS and cardiovascular diseases. Calcium channels, thus, are also implicated in numerous disorders. A number of compounds useful for treating various cardiovascular diseases in animals, including humans, are thought to exert their beneficial effects by modulating functions of voltage- dependent calcium channels present in cardiac and/or vascular smooth muscle. Many of these compounds bind to calcium channels and block, or reduce the rate of, influx of Ca + into the cells in response to depolarization of the cell membrane. The results of studies of recombinant expression of rabbit calcium channel α. subunit-encoding cDNA clones and transcripts of the cDNA clones indicate that the α. subunit forms the pore through which calcium enters cells. The relevance of the barium currents generated in these recombinant cells to the actual current generated by calcium channels containing as one component the respective α. subunits in vivo is unclear. In order to completely and accurately characterize and evaluate different calcium channel types, however, it is essential to examine the functional properties of recombinant channels containing all of the subunits as found in vivo. In order to conduct this examination and to fully understand calcium channel structure and function, it is critical to identify and characterize as many calcium channel subunits as possible. Also in order to prepare recombinant cells for use in identifying compounds that interact with calcium channels, it is necessary to be able to produce cells that express uniform populations of calcium channels containing defined subunits. An understanding of the pharmacology of compounds that interact with calcium channels in other organ systems, such as the CNS, may aid in the rational design of compounds that specifically interact with subtypes of human calcium channels to have desired therapeutic effects, such as in the treatment of neurodegenerative and cardiovascular disorders. Such understanding and the ability to rationally design therapeutically effective compounds, however, have been hampered by an inability to independently determine the types of human calcium channels and the molecular nature of individual subtypes, particularly in the CNS, and by the unavailability of pure preparations of specific channel subtypes to use for evaluation of the specificity of calcium channel-effecting compounds. Thus, identification of DNA encoding human calcium channel subunits and the use of such DNA for expression of calcium channel subunits and functional calcium channels would aid in screening and designing therapeutically effective compounds. Therefore, it is an object herein, to provide DNA encoding specific calcium channel subunits and to provide eukaryotic cells bearing recombinant tissue-specific or subtype- specific calcium channels. It is also an object to provide assays for identification of potentially therapeutic compounds that act as calcium channel antagonists and agonists. SUMMARY OF THE INVENTION Isolated and purified nucleic acid fragments that encode human calcium channel subunits are provided. DNA encoding α. subunits of a human calcium channel, and RNA, encoding such subunits, made upon transcription of such DNA are provided. In particular, DNA fragments encoding or. subunits of voltage- dependent human calcium channels (VDCCs) type A, type B (also referred to as VDCC IV) , type C (also referred to as VDCC II) type D (also referred to as VDCC III) and type E are provided. DNA encoding α 1A , a 1B , α ιc , α 1D and α 1E subunits is provided. DNA encoding an α 1D subunit that includes the amino acids substantially as set forth as residues 10-2161 of SEQ ID No. 1 is provided. DNA encoding an o. 1D subunit that includes substantially the amino acids set forth as amino acids 1-34 in SEQ ID No. 2 in place of amino acids 373-406 of SEQ ID No. 1 is also provided. DNA encoding an α lc subunit that includes the amino acids substantially as set forth in SEQ ID No. 3 or SEQ ID No. 6 and DNA encoding an α 1B subunit that includes an amino acid sequence substantially as set forth in SEQ ID No. 7 or in SEQ ID No. 8 is also provided. DNA encoding α 1A subunits is also provided. Such DNA includes DNA encoding an α 1A subunit that has substantially the same sequence of amino acids as encoded by the DNA set forth in SEQ ID No. 22 or No. 23 or other splice variants of α. 1A that include all or part of the sequence set forth in SEQ ID No. 22 or 23. The sequence set forth in SEQ ID NO. 22 is a splice variant designated a 1Α _ 1 ; and the sequence set forth in SEQ ID NO. 23 is a splice variant designated cκ 1A . 2 . DNA encoding or 1A subunits also include DNA encoding subunits that can be isolated using all or a portion of the DNA having SEQ ID NO. 21, 22 or 23 or DNA obtained from the phage lysate of an E. coli host containing DNA encoding an α. 1A subunit that has been deposited in the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under Accession No. 75293 in accord with the Budapest Treaty. The DNA in such phage includes a DNA fragment having the sequence set forth in SEQ ID No. 21. This fragment selectively hybridizes under conditions of high stringency to DNA encoding c_ 1A but not to DNA encoding c_ 1B and, thus, can be used to isolate DNA that encodes α. 1A subunits. DNA encoding α. 1E subunits of a human calcium channel is also provided. This DNA includes DNA that encodes- an α 1E splice variant designated α 1E _. encoded by the DNA set forth in SEQ ID No. 24, and a variant designated α 1E _ 3 encoded by SEQ ID No. 25. This DNA also includes other splice variants thereof that encodes sequences of amino acids encoded by all or a portion of the sequences of nucleotides set forth in SEQ ID Nos. 24 and 25 and DNA that hybridizes under conditions of high stringency to the DNA of SEQ ID. No. 24 or 25 and that encodes an α 1E splice variant. DNA encoding 2 subunits of a human calcium channel, and RNA encoding such subunits, made upon transcription of such a DNA are provided. DNA encoding splice variants of the a 2 subunit, including tissue-specific splice variants, are also provided. In particular, DNA encoding the α. 2a -α. 2e subunit subtypes is provided. In particularly preferred embodiments, the DNA encoding the a 2 subunit that is produced by alternative processing of a primary transcript that includes DNA encoding the amino acids set forth in SEQ ID 11 and the DNA of SEQ ID No. 13 inserted between nucleotides 1624 and 1625 of SEQ ID No. 11 is provided. The DNA and amino acid sequences of α. 2a - a 2e are set forth in SEQ. ID Nos. 11 and 29-32, respectively. Isolated and purified DNA fragments encoding human calcium channel β subunits, including DNA encoding /?., β 2 , β 3 and β 4 subunits, and splice variants of the β subunits are provided. RNA encoding β subunits, made upon transcription of the DNA is also provided. DNA encoding a β. subunit that is produced by alternative processing of a primary transcript that includes DNA encoding the amino acids set forth in SEQ ID No. 9, but including the DNA set forth in SEQ ID No. 12 inserted in place of nucleotides 615-781 of SEQ ID No. 9 is also provided. DNA encoding /β. subunits that are encoded by transcripts that have the sequence set forth in SEQ ID No. 9 including the DNA set forth in SEQ ID No. 12 inserted in place of nucleotides 615- 781 of SEQ ID No. 9, but that lack one or more of the following sequences of nucleotides: nucleotides 14-34 of SEQ ID No. 12, nucleotides 13-34 of SEQ ID No. 12, nucleotides 35- 55 of SEQ ID No 12, nucleotides 56-190 of SEQ ID No. 12 and nucleotides 191-271 of SEQ ID No. 12 are also provided. In particular, β λ subunit splice variants β 1 . 1 -β 1 _ 5 (see, SEQ ID Nos. 9, 10 and 33-35) described below, are provided. B 2 subunit splice variants β 2c -β e > that include all or a portion of SEQ ID Nos. 26, 29 and 30 are provided; β 3 subunit splice variants, including β 3 subunit splice variants that have the sequences set forth in SEQ ID Nos 19 and 20, and DNA encoding the β 4 subunit that includes DNA having the sequence set forth in SEQ ID No. 27 and the amino acid sequence set forth in SEQ ID No. 28 are provided. Also Escherichia coli {E. coli ) host cells harboring plasmids containing DNA encoding β 3 have been deposited in accord with the Budapest Treaty under Accession No. 69048 at the American Type Culture Collection. The deposited clone encompasses nucleotides 122-457 in SEQ ID No. 19 and 107-443 in SEQ ID No. 20. DNA encoding β subunits that are produced by alternative processing of a primary transcript encoding a β subunit, including a transcript that includes DNA encoding the amino acids set forth in SEQ ID No. 9 or including a primary transcript that encodes β 3 as deposited under ATCC Accession No. 69048, but lacking and including alternative exons are provided or may be constructed from the DNA provided herein. DNA encoding γ subunits of human calcium channels is also provided. RNA, encoding γ subunits, made upon transcription of the DNA are also provided. In particular, DNA containing the sequence of nucleotides set forth in SEQ ID No. 14 is provided. Full-length DNA clones and corresponding RNA transcripts, encoding α.., including splice variants of α 1A , 1D , a 1B , < ιc , and α 1E , C-2 and β subunits, including β 1 . 1 -β 1 _ s , β 2 c> β 2 D< β 2 E< 0 3 -i and β t of human calcium channels are provided. Also provided are DNA clones encoding a substantial portions of the certain c. ιc subtype subunits and γ subunits of voltage-dependent human calcium channels for the preparation of full-length DNA clones encoding the corresponding full-length subunits. Full-length clones may be readily obtained using the disclosed DNA as a probe as described herein. The the a 1A subunit, α. ιc subunit, α 1E subunit and splice variants thereof, the /3 2D , jS 2C and β 2E subunits and S 4 subunits and nucleic acids encoding these subunits are of particular interest herein. Eukaryotic cells containing heterologous DNA encoding one or more calcium channel subunits, particularly human calcium channel subunits, or containing RNA transcripts of DNA clones encoding one or more of the subunits are provided. A single α.. subunit can form a channel. The requisite combination of siibunits for formation of active channels in selected cells, however, can be determined empirically using the methods herein. For example, if a selected α. subtype or variant does not form an active channel in a selected cell line, an additional subunit or subunits can be added until an active channel is formed. In preferred embodiments, the cells contain DNA or RNA encoding a human α. subunit, preferably at least an cv 1D , α 1B , α 1A or α 1E subunit. In more preferred embodiments, the cells contain DNA or RNA encoding additional heterologous subunits, including at least one β, 2 or γ subunit. In such embodiments, eukaryotic cells stably or transiently transfected with any combination of one, two, three or four of the subunit-encoding DNA clones, such as DNA encoding any of α-, α. + β , a 1 + β + α 2 , are provided. The eukaryotic cells provided herein contain heterologous DNA that encodes an c_. subunit or heterologous DNA that encodes an α. subunit and heterologous DNA that encodes a β subunit. At least one subunit is selected c_ 1A _-, - 1A _ 2. c_ lc _ 2 , C. IE - 1 . α 1E _ 3 , β 2C , β 2D , β 2 , a β 3 _ 1 , β 3 _ 2 subunit or a β subunit. Si preferred embodiments, the cells express such heterologous calcium channel subunits and include one or more of the subunits in membrane-spanning heterologous calcium channels. In more preferred embodiments, the eukaryotic cells express functional, heterologous calcium channels that are capable of gating the passage of calcium channel-selective ions and/or binding compounds that, at physiological concentrations, modulate the activity of the heterologous calcium channel. In certain embodiments, the heterologous calcium channels include at least one heterologous calcium channel subunit. In most preferred embodiments, the calcium channels that are expressed on the surface of the eukaryotic cells are composed substantially or entirely of subunits encoded by the heterologous DNA or RNA. In preferred embodiments, the heterologous calcium channels of such cells are distinguishable from any endogenous calcium channels of the host cell. Such cells provide a means to obtain homogeneous populations of calcium channels. Typically, the cells contain the selected calcium channel as the only heterologous ion channel expressed.by the cell. In certain embodiments the recombinant eukaryotic cells that contain the heterologous DNA encoding the calcium channel subunits are produced by transfection with DNA encoding one or more of the subunits or are injected with RNA transcripts of DNA encoding one or more of the calcium channel subunits. The DNA may be introduced as a linear DNA fragment or may be included in an expression vector for stable or transient expression of the subunit-encoding DNA. Vectors containing DNA encoding human calcium channel subunits are also provided. The eukaryotic cells that express heterologous calcium channels may be used in assays for calcium channel function or, in the case of cells transformed with fewer subunit- encoding nucleic acids than necessary to constitute a functional recombinant human calcium channel, such cells may be used to assess the effects of additional subunits on calcium channel activity. The additional subunits can be provided by subsequently transfecting such a cell with one or more DNA clones or RNA transcripts encoding human calcium channel subunits. The recombinant eukaryotic cells that express membrane spanning heterologous calcium channels may be used in methods for identifying compounds that modulate calcium channel activity. In particular, the cells are used in assays that identify agonists and antagonists of calcium channel activity in humans and/or assessing the contribution of the various calcium channel subunits to the transport and regulation of transport of calcium ions. Because the cells constitute homogeneous populations of calcium channels, they provide a means to identify agonists or antagonists of calcium channel activity that are specific for each such population. The assays that use the eukaryotic cells for identifying compounds that modulate calcium channel activity are also provided. In practicing these assays the eukaryotic cell that expresses a heterologous calcium channel, containing at least on subunit encoded by the DNA provided herein, is in a solution containing a test compound and a calcium channel selective ion, the cell membrane is depolarized, and current flowing into the cell is detected. If the test compound is one that modulates calcium channel activity, the current that is detected is different from that produced by depolarizing the same or a substantially identical cell in the presence of the same calcium channel-selective ion but in the absence of the compound. In preferred embodiments, prior to the depolarization step, the cell is maintained at a holding potential which substantially inactivates calcium channels which are endogenous to the cell. Also in preferred embodiments, the cells are mammalian cells, most preferably HEK cells, or amphibian oδcytes. Nucleic acid probes, typically labeled for detection, containing at least about 14, preferably 16, or, if desired, 20 or 30 or more, contiguous nucleotides of 1D , a ιc , a 1B , lh and α 1E , 2 , β, including β λ , β 2 , β 3 and β 4 splice variants and γ subunit-encoding DNA are provided. Methods using the probes for the isolation and cloning of calcium channel subunit- encoding DNA, including splice variants within tissues and inter-tissue variants are also provided. Purified human calcium channel subunits and purified human calcium channels are provided. The subunits and channels can be isolated from a eukaryotic cell transfected with DNA that encodes the subunit. In another embodiment, immunoglobulins or antibodies obtained from the serum of an animal immunized with a substantially pure preparation of a human calcium channel, human calcium channel subunit or epitope-containing fragment of a human calcium subunit are provided. Monoclonal antibodies produced using a human calcium channel, human calcium channel subunit or epitope-containing fragment thereof as an immunogen are also provided. E. coli fusion proteins including a fragment of a human calcium channel subunit may also be used as immunogen. Such fusion proteins may contain a bacterial protein or portion thereof, such as the E. coli TrpE protein, fused to a calcium channel subunit peptide. The immunoglobulins that are produced using the calcium channel subunits or purified calcium channels as immunogens have, among other properties, the ability to specifically and preferentially bind to and/or cause the immunoprecipitation of a human calcium channel or a subunit thereof which may be present in a biological sample or a solution derived from such a biological sample. Such antibodies may also be used to selectively isolate cells that express calcium channels that contain the subunit for which the antibodies are specific. Methods for modulating the activity of ion channels by contacting the calcium channels with an effective amount of the above-described antibodies are also provided. A diagnostic method for determining the presence of Lambert Eaton Syndrome (LES) in a human based on immunological reactivity of LES immunoglobulin G (IgG) with a human calcium channel subunit or a eukaryotic cell which expresses a recombinant human calcium channel or a subunit thereof is also provided. In particular, an immunoassay method for diagnosing Lamber -Eaton Syndrome in a person by combining serum or an IgG fraction from the person (test serum) with calcium channel proteins, including the and β subunits, and ascertaining whether antibodies in the test serum react with one or more of the subunits, or a recombinant cell which expresses one or more of the subunits to a greater extent than antibodies in control serum, obtained from a person or group of persons known to be free of the Syndrome, is provided. Any immunoassay procedure known in the art for detecting antibodies against a given antigen in serum can be employed in the method. DETAILED DESCRIPTION OF THE INVENTION Definitions: Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference herein. Reference to each of the calcium channel subunits includes the subunits that are specifically disclosed herein and human calcium channel subunits encoded by DNA that can be isolated by using the DNA disclosed as probes and screening an appropriate human cDNA or genomic library under at least low stringency. Such DNA also includes DNA that encodes proteins that have about 40% homology to any of the subunits proteins described herein or DNA that hybridizes under conditions of at least low stringency to the DNA provided herein and the protein encoded by such DNA exhibits additional identifying characteristics, such as function or molecular weight. It is understood that subunits that are encoded by transcripts that represent splice variants of the disclosed subunits or other such subunits may exhibit less than 40% overall homology to any single subunit, but will include regions of such homology to one or more such subunits. It is also understood that 40% homology refers to proteins that share approximately 40% of their amino acids in common or that share somewhat less, but include conservative amino acid substitutions, whereby the activity of the protein is not substantially altered. As used herein, the α. subunits types, encoded by different genes, are designated as type α. 1A , α. 1B , α. ιc , α 1D and α; 1E . These types have also been referred to as VDCC IV for α 1B , VDCC II for α. ιc and VDCC III for α. 1D . Subunit subtypes, which are splice variants, are referred to, for example as a 1B _ l t CΪ 1B _ 2 ^ιc-ι etc. Thus, as used herein, DNA encoding the α. subunit refers to DNA that hybridizes to the DNA provided herein under conditions of at least low stringency or encodes a subunit that has at least about 40% homology to protein encoded by DNA disclosed herein that encodes an c.. subunit of a human calcium. An subunit may be identified by its ability to form a calcium channel. Typically, α. subunits have molecular masses greater than at least about 120 kD. Also, hydropathy plots of deduced α. subunit amino acid sequences indicate that the α- subunits contain four internal repeats, each containing six putative transmembrane domains. The activity of a calcium channel may be assessed in vi tro by methods known to those of skill in the art, including the electrophysiological and other methods described herein. Typically, α. subunits include regions to which one or more modulators of calcium channel activity, such as a 1,4-DHP or ω-CgTx, interact directly or indirectly. Types of α. subunits may be distinguished by any method known to those of skill in the art, including on the basis of binding specificity. For example, it has been found herein that α. 1B subunits participate in the formation channels that have previously been referred to as N-type channels, or 1D subunits participate in the formation of channels that had previously been referred to as L-type channels, and α. 1A subunits appear to participate in the formation of channels that exhibit characteristics typical of channels that had previously been designated P-type channels. Thus, for example, the activity of channels that contain the α 1B subunit are insensitive to 1,4-DHPs,- whereas the activity of channels that contain the α 1D subunit are modulated or altered by a 1,4-DHP. It is presently preferable to refer to calcium channels based on pharmacological characteristics and current kinetics and to avoid historical designations. Types and subtypes of ot. subunits may be characterized on the basis of the effects of such modulators on the subunit or a channel containing the subunit as well as differences in currents and current kinetics produced by calcium channels containing the subunit. As used herein, an α 2 subunit is encoded by DNA that hybridizes to the DNA provided herein under conditions of low stringency or encodes a protein that has at least about 40% homology with that disclosed herein. Such DNA encodes a protein that typically has a molecular mass greater than about 120 kD, but does not form a calcium channel in the absence of an α. subunit, and may alter the activity of a calcium channel that contains an α. subunit. Subtypes of the 2 subunit that arise as splice variants are designated by lower case letter, such as α 2a , . . . c. 2e . In addition, the α 2 subunit and the large fragment produced when the protein is subjected to reducing conditions appear to be glycosylated with at least N-linked sugars and do not specifically bind to the 1,4-DHPs and phenylalkylamines that specifically bind to the α. subunit. The smaller fragment, the C-terminal fragment, is referred to as the δ subunit and includes amino acids from about 946 (SEQ ID No. 11) through about the C-terminus. This fragment may dissociate from the remaining portion of 2 when the α.- subunit is exposed to reducing conditions. As used herein, a β subunit is encoded by DNA that hybridizes to the DNA provided herein under conditions of low stringency or encodes a protein that has at least about 40% homology with that disclosed herein and is a protein that typically has a molecular mass lower than the a subunits and on the order of about 50-80 kD, does not form a detectable calcium channel in the absence of an α. subunit, but may alter the activity of a calcium channel that contains an α- subunit or that contains an α. and a 2 subunit. Types of the β subunit that are encoded by different genes are designated with subscripts, such as β , β 2 , β 3 and β 4 . Subtypes of β subunits that arise as splice variants of a particular type are designated with a numerical subscript referring to the type and to the variant. Such subtypes include, but are not limited to the β. splice variants, including β'■._.-S.. 5 and β 2 variants, including β 2C -β 2E . As used herein, a γ subunit is a subunit encoded by DNA disclosed herein as encoding the γ subunit and may be isolated and identified using the DNA disclosed herein as a probe by hybridization or other such method known to those of skill in the art, whereby full-length clones encoding a γ subunit may be isolated or constructed. A γ subunit will be encoded by DNA that hybridizes to the DNA provided herein under conditions of low stringency or exhibits sufficient sequence homology to encode a protein that has at least about 40% homology with the γ subunit described herein. Thus, one of skill in the art, in light of the disclosure herein, can identify DNA encoding α., c_ 2 , β , δ and γ calcium channel subunits, including types encoded by different genes and subtypes that represent splice variants. For example, DNA probes based on the DNA disclosed herein may be used to screen an appropriate library, including a genomic or cDNA library, for hybridization to the probe and obtain DNA in one or more clones that includes an open reading fragment that encodes an entire protein. Subsequent to screening an appropriate library with the DNA disclosed herein, the isolated DNA can be examined for the presence of an open reading frame from which the sequence of the encoded protein may be deduced. Determination of the molecular weight and comparison with the sequences herein should reveal the identity of the subunit as an α., a 2 etc. subunit. Functional assays may, if necessary, be used to determine whether the subunit is an α.., α 2 subunit or β subunit. For example, DNA encoding an α 1A subunit may be isolated by screening an appropriate library with DNA, encoding all or a portion of the human α. 1A subunit. Such DNA includes the DNA in the phage deposited under ATCC Accession No. 75293 that encodes a portion of an α. subunit. DNA encoding an α 1A subunit may obtained from an appropriate library by screening with an oligonucleotide having all or a portion of the sequence set forth in SEQ ID No. 21, 22 and/or 23 or with the DNA in the deposited phage. Alternatively, such DNA may have a sequence that encodes an α 1A subunit that is encoded by SEQ ID NO. 22 or 23. Similarly, DNA encoding β 3 may be isolated by screening a human cDNA library with DNA probes prepared from the plasmid Si.42 deposited under ATCC Accession No. 69048 or obtained from an appropriate library using probes having sequences prepared according to the sequences set forth in SEQ ID Nos. 19 and/or 20. Also, DNA encoding β 4 may be isolated by screening a human cDNA library with DNA _ probes prepared according to DNA set forth in SEQ ID No. 27, which sets forth the DNA sequence of a clone encoding a β 4 subunit. The amino acid sequence is set forth in SEQ ID No. 28. Any method known to those of skill in the art for isolation and identification of DNA and preparation of full-length genomic or cDNA clones, including methods exemplified herein, may be used. DNA encoding The subunit encoded by isolated DNA may be identified by comparison with the DNA and amino acid sequences of the subunits provided herein. Splice variants share extensive regions of homology, but include non-homologous regions, subunits encoded by different genes share a uniform distribution of non-homologous sequences. As used herein, a splice variant refers to a variant produced by differential processing of a primary transcript of genomic DNA that results in more than one type of mRNA. Splice variants may occur within a single tissue type or among tissues (tissue-specific variants) . Thus, cDNA clones that encode calcium channel subunit subtypes that have regions of identical amino acids and regions of different amino acid sequences are referred to herein as "splice variants". As used herein, a "calcium channel-selective ion" is an ion that is capable of flowing through, or being blocked from flowing through, a calcium channel which spans a cellular membrane under conditions which would substantially similarly permit or block the flow of Ca 2+ . Ba 2+ is an example of an ion which is a calcium channel-selective ion. As used herein, a compound that modulates calcium channel activity is one that affects the ability of the calcium channel to pass calcium channel-selective ions or affects other detectable calcium channel features, such as current kinetics. Such compounds include calcium channel antagonists and agonists and compounds that exert their effect on the activity of the calcium channel directly or indirectly. As used herein, a "substantially pure" subunit or protein is a subunit or protein that is sufficiently free of other polypeptide contaminants to appear homogeneous by SDS-PAGE or to be unambiguously sequenced. As used herein, selectively hybridize means that a DNA fragment hybridizes to a second fragment with sufficient specificity to permit the second fragment to be identified or isolated from among a plurality of fragments. In general, selective hybridization occurs at conditions of high stringency. As used herein, heterologous or foreign DNA and RNA are used interchangeably and refer to DNA or RNA that does not occur naturally as part of the genome in which it is present or which is found in a location or locations in the genome that differ from that in which it occurs in nature. It is DNA or RNA that is not endogenous to the cell and has been artificially introduced into the cell. Examples of heterologous DNA include, but are not limited to, DNA that encodes a calcium channel subunit and DNA that encodes RNA or proteins that mediate or alter expression of endogenous DNA by affecting transcription, translation, or other regulatable biochemical processes. The cell that expresses the heterologous DNA, such as DNA encoding a calcium channel subunit, may contain DNA encoding the same or different calcium channel subunits. The heterologous DNA need not be expressed and may be introduced in a manner such that it is integrated into the host cell genome or is maintained episomally. As used herein, operative linkage of heterologous DNA to regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences, refers to the functional relationship between such DNA and such sequences of nucleotides. For example, operative linkage of heterologous DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA in reading frame. As used herein, isolated, substantially pure DNA refers to DNA fragments purified according to standard techniques employed by those skilled in the art [see, e.g., Maniatis et al . (1982) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY] . As used herein, expression refers to the process by which nucleic acid is transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the nucleic acid is derived from genomic DNA, expression may, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA. As used herein, vector or plasmid refers to discrete elements that are used to introduce heterologous DNA into cells for either expression of the heterologous DNA or for replication of the cloned heterologous DNA. Selection and use of such vectors and plasmids are well within the level of skill of the art. As used herein, expression vector includes vectors capable of expressing DNA fragments that are in operative linkage with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or may integrate into the host cell genome. As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be cis acting or may be responsive to trans acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated. As used herein, a recombinant eukaryotic cell is a eukaryotic cell that contains heterologous DNA or RNA. As used herein, a recombinant or heterologous calcium channel refers to a calcium channel that contains one or more subunits that are encoded by heterologous DNA that has been introduced into and expressed in a eukaryotic cells that expresses the recombinant calcium channel. A recombinant calcium channel may also include subunits that are produced by DNA endogenous to the cell. In certain embodiments, the recombinant or heterologous calcium channel may contain only subunits that are encoded by heterologous DNA. As used herein, "functional" with respect to a recombinant or heterologous calcium channel means that the channel is able to provide for and regulate entry of calcium channel-selective ions, including, but not limited to, Ca 2+ or Ba 2+ , in response to a stimulus and/or bind ligands with affinity for the channel. Preferably such calcium channel activity is distinguishable, such as electrophysiological, pharmacological and other means known to those of skill in the art, from any endogenous calcium channel activity that in the host cell. As used herein, a peptide having an amino acid sequence substantially as set forth in a particular SEQ ID No. includes peptides that have the same function but may include minor variations in sequence, such as conservative amino acid changes or minor deletions or insertions that do not alter the activity of the peptide. The activity of a calcium channel receptor subunit peptide refers to its ability to form functional calcium channels with other such subunits. As used herein, a physiological concentration of a compound is that which is necessary and sufficient for a biological process to occur. For example, a physiological concentration of a calcium channel-selective ion is a concentration of the calcium channel-selective ion necessary and sufficient to provide an inward current when the channels open. As used herein, activity of a calcium channel refers to the movement of a calcium channel-selective ion through a calcium channel. Such activity may be measured by any method known to those of skill in the art, including, but not limited to, measurement of the amount of current which flows through the recombinant channel in response to a stimulus. As used herein, a "functional assay" refers to an assay that identifies functional calcium channels. A functional assay, thus, is an assay to assess function. As understood by those skilled in the art, assay methods for identifying compounds, such as antagonists and agonists, that modulate calcium channel activity, generally requires comparison to a control. One type of a "control" cell or "control" culture is a cell or culture that is treated substantially the same as the cell or culture exposed to the test compound except that the control culture is not exposed to the test compound. Another type of a "control" cell or "control" culture may be a cell or a culture of cells which are identical to the transfected cells except the cells employed for the control culture do not express functional calcium channels. In this situation, the response of test cell to the test compound is compared to the response (or lack of response) of the calcium channel-negative cell to the test compound, when cells or cultures of each type of cell are exposed to substantially the same reaction conditions in the presence of the compound being assayed. For example, in methods that use patch clamp electrophysiological procedures, the same cell can be tested in the presence and absence of the test compound, by changing the external solution bathing the cell as known in the art. It is also understood that each of the subunits disclosed herein may be modified by making conservative amino acid substitutions and the resulting modified subunits are contemplated herein. Suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non- essential regions of a polypeptide do not substantially alter biological activity (see, e.g. , Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p.224) . Such substitutions are preferably, although not exclusively, made in accordance with those set forth in TABLE 1 as follows: TABLE 1 Original residue Conservative substitution Ala (A) Gly; Ser Arg (R) Lys Asn (N) Gin; His Cys (C) Ser Gin (Q) Asn Glu (E) Asp Gly (G) Ala; Pro His (H) Asn; Gin lie (I) Leu; Val Leu (L) lie; Val Lys (K) Arg; Gin; Glu Met (M) Leu; Tyr; lie Phe (F) Met; Leu; Tyr Ser (S) Thr Thr (T) Ser Trp (W) Tyr Tyr (Y) Trp; Phe Val (V) He; Leu Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions. Any such modification of the polypeptide may be effected by any means known to those of skill in this art. Mutation may be effected by any method known to those of skill in the art, including site-specific or site-directed mutagenesis of DNA encoding the protein and the use of DNA amplification methods using primers to introduce and amplify alterations in the DNA template. Identification and isolation of DNA encoding human calcium channel subunits Methods for identifying and isolating DNA encoding α., α. 2 , β and γ subunits of human calcium channels are provided. Identification and isolation of such DNA may be accomplished by hybridizing, under appropriate conditions, at least low stringency whereby DNA that encodes the desired subunit is isolated, restriction enzyme-digested human DNA with a labeled probe having at least 14, preferably 16 or more nucleotides and derived from any contiguous portion of DNA having a sequence of nucleotides set forth herein by sequence identification number. Once a hybridizing fragment is identified in the hybridization reaction, it can be cloned employing standard cloning techniques known to those of skill in the art. Full-length clones may be identified by the presence of a complete open reading frame and the identity of the encoded protein verified by sequence comparison with the subunits provided herein and by functional assays to assess calcium channel- forming ability or other function. This method can be used to identify genomic DNA encoding the subunit or cDNA encoding splice variants of human calcium channel subunits generated by alternative splicing of the primary transcript of genomic subunit DNA. For instance, DNA, cDNA or genomic DNA, encoding a calcium channel subunit may be identified by hybridization to a DNA probe and characterized by methods known to those of skill in the art, such as restriction mapping and DNA sequencing, and compared to the DNA provided herein in order to identify heterogeneity or divergence in the sequences of the DNA. Such sequence differences may indicate that the transcripts from which the cDNA was produced result from alternative splicing of a primary transcript, if the non-homologous and homologous regions are clustered, or from a different gene if the non- homologous regions are distributed throughout the cloned DNA. Any suitable method for isolating genes using the DNA provided herein may be used. For example, oligonucleotides corresponding to regions of sequence differences have been used to isolate, by hybridization, DNA encoding the full- length splice variant and can be used to isolate genomic clones. A probe, based on a nucleotide sequence disclosed herein, which encodes at least a portion of a subunit of a human calcium channel, such as a tissue-specific exon, may be used as a probe to clone related DNA, to clone a full-length cDNA clone or genomic clone encoding the human calcium channel subunit. Labeled, including, but not limited to, radioactively or enzymatically labeled, RNA or single-stranded DNA of at least 14 substantially contiguous bases, preferably 16 or more, generally at least 30 contiguous bases of a nucleic acid which encodes at least a portion of a human calcium channel subunit, the sequence of which nucleic acid corresponds to a segment of a nucleic acid sequence disclosed herein by reference to a SEQ ID No. are provided. Such nucleic acid segments may be used as probes in the methods provided herein for cloning DNA encoding calcium channel subunits. See, generally, Sambrook et al . (1989) Molecular Cloning: A Laboratory Manual , 2nd Edition, Cold Spring Harbor Laboratory Press. In addition, nucleic acid amplification techniques, which are well known in the art, can be used to locate splice variants of calcium channel subunits by employing oligonucleotides based on DNA sequences surrounding the divergent sequence primers for amplifying human RNA or genomic DNA. Size and sequence determinations of the amplification products can reveal splice variants. Furthermore, isolation of human genomic DNA sequences by hybridization can yield DNA containing multiple exons, separated by introns, that correspond to different splice variants of transcripts encoding human calcium channel subunits. DNA encoding types and subtypes of each of the or., α 2 l β and γ subunit of voltage-dependent human calcium channels has been cloned herein by nucleic acid amplication of cDNA from selected tissues or by screening human cDNA libraries prepared from isolated poly A+ mRNA from cell lines or tissue of human origin having such calcium channels. Among the sources of such cells or tissue for obtaining mRNA are human brain tissue or a human cell line of neural origin, such as a neuroblastoma cell line, human skeletal muscle or smooth muscle cells, and the like. Methods of preparing cDNA libraries are well known in the art [see generally Ausubel et al . (1987) Current Protocols in Molecular Biology, Wiley-Interscience, New York; and Davis et al . (1986) Basic Methods in Molecular Biology, Elsevier Science Publishing Co., New York] . Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode transmembrane domains, sequences predicted to encode cytoplasmic loops, signal sequences, ligand-binding sites, and other functionally significant sequences (see Table, below) . Either the full-length subunit-encoding DNA or fragments thereof can be used as probes, preferably labeled with suitable label means for ready detection. When fragments are used as probes, preferably the DNA sequences will be typically from the carboxyl-end-encoding portion of the DNA, and most preferably will include predicted transmembrane domain- encoding portions based on hydropathy analysis of the deduced amino acid sequence [see, e.g. , Kyte and Doolittle [(1982) J. Mol . Biol . 117:105] . Riboprobes that specific for human calcium channel subunit types or subtypes have been prepared. These probes are useful for identifying expression of particular subunits in selected tissues and cells. The regions from which the probes were prepared were identified by comparing the DNA and amino acid sequences of all known α or β subunit subtypes. Regions of least homology, preferably human-derived sequences, and generally about 250 to about 600 nucleotides were selected. Numerous riboprobes for and β subunits have been prepared; some of these are listed in the following Table. TABLE 2 SUMMARY OF RNA PROBES * The pGEM series are avai a e rom Promega, Ma ison WI; see a so, U.S. Patent No. 4,766,072. The above-noted nucleotide regions are also useful in selecting regions of the protein for preparation of subunit- specific antibodies, discussed below. The DNA clones and fragments thereof provided herein thus can be used to isolate genomic clones encoding each subunit and to isolate any splice variants by hybridization screening of libraries prepared from different human tissues. Nucleic acid amplification techniques, which are well known in the art, can also be used to locate DNA encoding splice variants of human calcium channel subunits. This is accomplished by employing oligonucleotides based on DNA sequences surrounding divergent sequence(s) as primers for amplifying human RNA or genomic DNA. Size and sequence determinations of the amplification products can reveal the existence of splice variants. Furthermore, isolation of human genomic DNA sequences by hybridization can yield DNA containing multiple exons, separated by introns, that correspond to different splice variants of transcripts encoding human calcium channel subunits. Once DNA encoding a calcium channel subunit is isolated, ribonuclease (RNase) protection assays can be employed to determine which tissues express mRNA encoding a particular calcium channel subunit or variant. These assays provide a sensitive means for detecting and quantitating an RNA species in a complex mixture of total cellular RNA. The subunit DNA is labeled and hybridized with cellular RNA. If complementary mRNA is present in the cellular RNA, a DNA-RNA hybrid results. The RNA sample is then treated with RNase, which degrades single-stranded RNA. Any RNA-DNA hybrids are protected from RNase degradation and can be visualized by gel electrophoresis and autoradiography. In situ hybridization techniques can also be used to determine which tissues express mRNA encoding a particular calcium channel subunit. The labeled subunit DNAs are hybridized to different tissue slices to visualize subunit mRNA expression. With respect to each of the respective subunits (α., a 2 , β or γ) of human calcium channels, once the DNA encoding the channel subunit was identified by a nucleic acid screening method, the isolated clone was used for further screening to identify overlapping clones. Some of the cloned DNA fragments can and have been subcloned into an appropriate vector such as pIBI24/25 (IBI, New Haven, CT) , M13mpl8/19, pGEM4, pGEM3, pGEM7Z, pSP72 and other such vectors known to those of skill in this art, and characterized by DNA sequencing and restriction enzyme mapping. A sequential series of overlapping clones may thus be generated for each of the subunits until a full-length clone can be prepared by methods, known to those of skill in the art, that include identification of translation initiation (start) and translation termination (stop) codons. For expression of the cloned DNA, the 5' noncoding region and other transcriptional and translational control regions of such a clone may be replaced with an efficient ribosome binding site and other regulatory regions as known in the art. Other modifications of the 5' end, known to those of skill in the art, that may be required to optimize translation and/or transcription efficiency may also be effected, if deemed necessary. Examples II-VIIII, below, describe in detail the cloning of each of the various subunits of a human calcium channel as well as subtypes and splice variants, including tissue- specific variants thereof. In the few instances in which partial sequences of a subunit are disclosed, it is well within the skill of the art, in view of the teaching herein, to obtain the corresponding full-length clones and sequence thereof encoding the subunit, subtype or splice variant thereof using the methods described above and exemplified below. Identification and isolation of DNA encoding __. subunits A number of voltage-dependent calcium channel α- subunit genes, which are expressed in the human CNS and in other tissues, have been identified and have been designated as α 1A , α 1B (or VDCC IV), <_.. < - (or VDCC II), α 1D (or VDCC III) and α 1E . DNA, isolated from a human neural cDNA library, that encodes each of the subunit types has been isolated. DNA encoding subtypes of each of the types, which arise as splice variants are also provided. Subtypes are herein designated, for example, as a 1B . l f _ 1B _ 2 . The α. subunits types A B, C, D and E of voltage- dependent calcium channels, and subtypes thereof, differ with respect to sensitivity to known classes of calcium channel agonists and antagonists, such as DHPs, phenylalkylammes, omega conotoxin (ω-CgTx) , the funnel web spider toxin ω-Aga- IV, and pyrazonoylguanidines. These subunit types also appear to differ in the holding potential and in the kinetics of currents produced upon depolarization of cell membranes containing calcium channels that include different types of α. subunits. DNA that encodes an of. subunit that binds to at least one compound selected from among dihydropyridines, phenylalkylammes, ω-CgTx, components of funnel web spider toxin, and pyrazonoylguanidines is provided. For example, the α 1B subunit provided herein appears to specifically interact with ω-CgTx in N-type channels, and the α 1D subunit provided herein specifically interacts with DHPs in L-type channels. Identification and isolation of DNA encoding the c_- D human calcium channel subunit The or 1D subunit cDNA has been isolated using fragments of the rabbit skeletal muscle calcium channel α. subunit cDNA as a probe to screen a cDNA library of a human neuroblastoma cell line, IMR32, to obtain clone αl.36. This clone was used as a probe to screen additional IMR32 cell cDNA libraries to obtain overlapping clones, which were then employed for screening until a sufficient series of clones to span the length of the nucleotide sequence encoding the human c_ 1D subunit was obtained. Full-length clones encoding α. 1D were constructed by ligating portions of partial cv 1D clones as described in Example II. SEQ ID No. 1 shows the 7,635 nucleotide sequence of the cDNA encoding the α XD subunit. There is a 6,483 nucleotide sequence reading frame which encodes a sequence of 2,161 amino acids (as set forth in SEQ ID No. 1) . SEQ ID No. 2 provides the sequence of an alternative exon encoding the IS6 transmembrane domain [see Tanabe, T. , et al . (1987) Nature 328:313-318 for a description of transmembrane domain terminology] of the α 1D subunit. SEQ ID No. 1 also shows the 2,161 amino acid sequence deduced from the human neuronal calcium channel α 1D subunit DNA. Based on the amino acid sequence, the c. 1D protein has a calculated Mr of 245,163. The α 1D subunit of the calcium channel contains four putative internal repeated sequence regions. Four internally repeated regions represent 24 putative transmembrane segments, and the amino- and carboxyl-termini extend intracellularly. The α. 1D subunit has been shown to mediate DHP-sensitive, high-voltage-activated, long-lasting calcium channel activity. This calcium channel activity was detected when oόcytes were co-injected with RNA transcripts encoding an α 1D and β^_ 2 or α 1D , 2b and 3._ 2 subunits. This activity was distinguished from Ba + currents detected when oόcytes were injected with RNA transcripts encoding the jβ.. 2 ± 2b subunits. These currents pharmacologically and biophysically resembled Ca 2+ currents reported for uninjected oόcytes. Identification and isolation of DNA encoding the α u human calcium channel subunit Biological material containing DNA encoding a portion of the α 1A subunit had been deposited in the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under the terms of the Budapest Treaty on the International Recognition of Deposits of Microorganisms for Purposes of Patent Procedure and the Regulations promulgated under this Treaty. Samples of the deposited material are and will be available to industrial property offices and other persons legally entitled to receive them under the terms of the Treaty and Regulations and otherwise in compliance with the patent laws and regulations of the United States of America and all other nations or international organizations in which this application, or an application claiming priority of this application, is filed or in which any patent granted on any such application is granted. A portion of an α 1A subunit is encoded by an approximately 3 kb insert in λgtlO phage designated αl.254 in E. coli host strain NM514. A phage lysate of this material has been deposited as at the American Type Culture Collection under ATCC Accession No. 75293, as described above. DNA encoding α 1A may also be identified by screening with a probe prepared from DNA that has SEQ ID No. 21: 5' CTCAGTACCATCTCTGATACCAGCCCCA 3' . α. 1A splice variants have been obtained. The sequences of two α. 1A splice variants, Q!^.. and α la _ 2 are set forth in SEQ. ID Nos. 22 and 23. Other splice variants may be obtained by screening a human library as described above or using all or a portion of the sequences set forth in SEQ ID Nos. 22 and 23. Identification and isolation of DNA encoding the α 1B human calcium channel subunit DNA encoding the α 1B subunit was isolated by screening a human basal ganglia cDNA library with fragments of the rabbit skeletal muscle calcium channel α- subunit-encoding cDNA. A portion of one of the positive clones was used to screen an IMR32 cell cDNA library. Clones that hybridized to the basal ganglia DNA probe were used to further screen an IMR32 cell cDNA library to identify overlapping clones that in turn were used to screen a human hippocampus cDNA library. In this way, a sufficient series of clones to span nearly the entire length of the nucleotide sequence encoding the human 1B subunit was obtained. Nucleic acid amplification of specific regions of the IMR32 cell α 1B mRNA yielded additional segments of the α 1B coding sequence. A full-length a 1B DNA clone was constructed by ligating portions of the partial cDNA clones as described in Example II.C. SEQ ID Nos. 7 and 8 show the nucleotide sequences of DNA clones encoding the α 1B subunit as well as the deduced amino acid sequences. The α 1B subunit encoded by SEQ ID No. 7 is referred to as the α 1B .. subunit to distinguish it from another α. 1B subunit, α 1B . 2 , encoded by the nucleotide sequence shown as SEQ ID No. 8, which is derived from alternative splicing of the α 1B subunit transcript. Nucleic acid amplification of IMR32 cell mRNA using oligonucleotide primers designed according to nucleotide sequences within the α. 1B _.-encoding DNA has identified variants of the C- 1B transcript that appear to be splice variants because they contain divergent coding sequences. Identification and isolation of DNA encoding the __ 1C human calcium channel subunit Numerous α.-.-specific DNA clones were isolated. Characterization of the sequence revealed the α ιc coding sequence, the α ιc initiation of translation sequence, and an alternatively spliced region of α ιc . Alternatively spliced variants of the α ιc subunit have been identified. SEQ ID No. 3 sets forth DNA encoding a substantial protion of an __ 1C subunit. The DNA sequences set forth in SEQ ID No. 4 and No. 5 encode two possible amino terminal ends of the ιc protein. SEQ ID No. 6 encodes an alternative exon for the IV S3 transmembrane domain. The sequences of substantial portions of two α lc splice variants, designated α.-... and c. ιc _ 2 , are set forth in SEQ ID NOs. 3 and 36, respectively. The isolation and identification of DNA clones encoding portions of the α. ιc subunit is described in detail in Example II. Identification and isolation of DNA encoding the α 1E human calcium channel subunit DNA encoding α 1E human calcium channel subunits have been isolated from an oligo dT-primed human hippocampus library. The resulting clones, which are splice variants, were designated 1E . and α 1E _ 3 . The subunit designated Q.. J ... has the amino acid sequence set forth in SEQ ID No. 24, and a subunit designated α 1E . 3 has the amino acid sequence set forth in SEQ ID No. 25. These splice variants differ by virtue of a 57 base pair insert between nucleotides 2405 and 2406 of SEQ. ID No. 24. The c. 1E subunits provided herein appear to participate in the formation of calcium channels that have properties of high-voltage activated calcium channels and low-voltage activated channels. These channels are rapidly inactivating compared to other high voltage-activated calcium channels. In addition these channels exhibit pharmacological profiles that are similar to voltage-activated channels, but are also sensitive to DHPs and ω-Aga-lVA, which block certain high voltage activated channels. Additional details regarding the electrophysiology and pharmacology of channels containing α 1E subunits is provided in Example VII. F. Identification and isolation of DNA encoding encoding additional α. human calcium channel subunit types and subtypes DNA encoding additional c.. subunits can be isolated and identified using the DNA provided herein as described for the a iA' ^ IB / ι c iΩ an< ^ α i E subunits or using other methods known to those of skill in the art. In particular, the DNA provided herein may be used to screen appropriate libraries to isolate related DNA. Full-length clones can be constructed using methods, such as those described herein, and the resulting subunits characterized by comparison of their sequences and electrophysiological and pharmacological properties with the subunits exemplified herein. Identification and isolation of DNA encoding β human calcium channel subunits DNA encoding jS. To isolate DNA encoding the β subunit, a human hippocampus cDNA library was screened by hybridization to a DNA fragment encoding a rabbit skeletal muscle calcium channel β subunit. A hybridizing clone was selected and was in turn used to isolate overlapping clones until the overlapping clones encompassing DNA encoding the entire the human calcium channel β subunit were isolated and sequenced. Five alternatively spliced forms of the human calcium channel /?. subunit have been identified and DNA encoding a number of forms have been isolated. These forms are designated ?. . ., expressed in skeletal muscle, /3-_ 2 , expressed in the CNS, also expressed in the in the CNS, β__. 4 , expressed in aorta tissue and HEK 293 cells, and j6.. s , expressed in HEK 293 cells. Full-length DNA clones encoding the jS., 2 and /3._ 3 subunits have been constructed. The subunits βi-i- > β__ . an< β . s have been identified by nucleic acid amplification analysis as alternatively spliced forms of the β subunit. Sequences of the β. splice variants are set forth in SEQ ID Nos. 9, 10 and 33-35. DNA encoding β 2 DNA encoding the β 2 splice variants has been obtained. These splice variants include β 2C -β 2E - Splice variants β 2C -β 2Ε, include all of sequence set forth in SEQ ID No. 26, except for the portion at the 5' end (up to nucleotide 182) , which differs among splice variants. The sequence set forth in SEQ ID No. 26 encodes β ∞ . Additional splice variants may be isolated using the methods described herein and oligonucleotides including all or portions of the DNA set forth in SEQ ID. No. 26 or may be prepared or obtained as described in the Examples. The sequences of β 2 splice variants β 2C and β 2E are set forth in SEQ ID Nos. 37 and 38, respectively. DNA encoding β 3 DNA encoding the β 3 subunit and any splice variants thereof may be isolated by screening a library, as described above for the /3. subunit, using DNA probes prepared according to SEQ ID Nos. 19, 20 or using all or a portion of the deposited β 3 clone plasmid βl.42 (ATCC Accession No. 69048) . The E. coli host containing plasmid 01.42 that includes DNA encoding a β 3 subunit has been deposited as ATCC Accession No. 69048 in the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under the terms of the Budapest Treaty on the International Recognition of Deposits of Microorganisms for Purposes of Patent Procedure and the Regulations promulgated under this Treaty. Samples of the deposited material are and will be available to industrial property offices and other persons legally entitled to receive them under the terms of the Treaty and Regulations and otherwise in compliance with the patent laws and regulations of the United States of America and all other nations or international organizations in which this application, or an application claiming priority of this application, is filed or in which any patent granted on any such application is granted. The β 3 encoding plasmid is designated βl . A2 . The plasmid contains a 2.5 kb JEcoRI fragment encoding β 3 inserted into vector pGem Φ 7zF(+) and has been deposited in E. coli host strain DH5α. The sequences of β 3 splice variants, designated β 3 . 1 and β 3 _ 2 are set forth in SEQ ID Nos. 19 and 20, respectively. Identification and isolation of DNA encoding the α2 human calcium channel subunit DNA encoding a human neuronal calcium channel 2 subunit was isolated in a manner substantially similar to that used for isolating DNA encoding an α. subunit, except that a human genomic DNA library was probed under low and high stringency conditions with a fragment of DNA encoding the rabbit skeletal muscle calcium channel 2 subunit. The fragment included nucleotides having a sequence corresponding to the nucleotide sequence between nucleotides 43 and 272 inclusive of rabbit back skeletal muscle calcium channel 2 subunit cDNA as disclosed in PCT International Patent Application Publication No. WO 89/09834, which corresponds to U.S. Application Serial No. 07/620,520 (now allowed U.S. Application Serial No. 07/914,231), which is a continuation-in-part of United States Serial No. 176,899, filed April 4, 1988. Example IV describes the isolation of DNA clones encoding α 2 subunits of a human calcium channel from a human DNA library using genomic DNA and cDNA clones, identified by hybridization to the genomic DNA, as probes. SEQ ID Nos. 11 and 29-32 show the sequence of DNA encoding 2 subunits. As described in Example V, nucleic acid amplification analysis of RNA from human skeletal muscle, brain tissue and aorta using oligonucleotide primers specific for a region of the human neuronal c_ 2 subunit cDNA that diverges from the rabbit skeletal muscle calcium channel a 2 subunit cDNA identified splice variants of the human calcium channel 2 subunit transcript. Identification and isolation of DNA encoding γ human calcium channel subunits DNA encoding a portion of a human neuronal calcium channel γ subunit has been isolated as described in detail in Example VI. SEQ ID No. 14 shows the nucleotide sequence at the 3' -end of this DNA which includes a reading frame encoding a sequence of 43 amino acid residues. Since the portion that has been obtained is homologous to the rabbit clone, described in allowed co-owned U.S. Application Serial No. 07/482,384, the remainder of the clone can be obtained using routine methods. Antibodies Antibodies, monoclonal or polyclonal, specific for calcium channel subunit subtypes or for calcium channel types can be prepared employing standard techniques, known to those of skill in the art, using the subunit proteins or portions thereof as antigens. Anti-peptide and anti-fusion protein antibodies can be used [see, for example, Bahouth et al. (1991) Trends Pharmacol . Sci . .12:338-343; Current Protocols in Molecular Biology (Ausubel et al. , eds. ) John Wiley and Sons, New York (1984)] . Factors to consider in selecting portions of the calcium channel subunits for use as immunogens (as either a synthetic peptide or a recombinantly produced bacterial fusion protein) include antigenicity accessibility (i.e., extracellular and cytoplasmic domains), uniqueness to the particular subunit, and other factors known to those of skill in this art. The availability of subunit-specific antibodies makes possible the application of the technique of immunohistochemistry to monitor the distribution and expression density of various subunits (e.g. , in normal vs diseased brain tissue) . Such antibodies could also be employed in diagnostic, such as LES diagnosis, and therapeutic applications, such as using antibodies that modulate activities of calcium channels. The antibodies can be administered to a subject employing standard methods, such as, for example, by intraperitoneal, intramuscular, intravenous, or subcutaneous injection, implant or transdermal modes of administration, and the like. One of skill in the art can empirically determine dose forms, treatment regiments, etc., depending on the mode of administration employed. Subunit-specific monoclonal antibodies and polyclonal antisera have been prepared. The regions from which the antigens were identified by comparing the DNA and amino acid sequences of all known or β subunit subtypes. Regions of least homology, preferably human-derived sequences were selected. The selected regions or fusion proteins containing the selected regions are used as immunogens. Hydrophobicity analyses of residues in selected protein regions and fusion proteins are also performed; regions of high hydrophobicity are avoided. Also, and more importantly, when preparing fusion proteins in bacterial hosts, rare codons are avoided. In particular, inclusion of 3 or more successive rare codons in a selected host is avoided. Numerous antibodies, polyclonal and monoclonal, specific for a or β subunits types or subtypes have been prepared; some of these are listed in the following Table. Exemplary antibodies and peptide antigens used to prepare the antibodies are set forth in the following Table: TABLE 3 * GST gene fusion system is ava lable from Pharmac a; see also, Sm th et al. (1988) Gene £7:31. The system provides pGEX plasmids that are designed for inducible, high-level expression of genes or gene fragments as fusions with Schistosoma japonicum GST. Upon expression in a bacterial host, the resulting fusion proteins are purified from bacterial lysates by affinity chromatography. The GST fusion proteins are each specific for the cytoplasmic loop region IIS6-IIS1, which is a region of low subtype homology for all subtypes, including α ιc and 1D , for which similar fusions and antisera can be prepared. Preparation of recombinant eukaryotic cells containing DNA encoding heterologous calcium channel subunits DNA encoding one or more of the calcium channel subunits or a portion of a calcium channel subunit may be introduced into a host cell for expression or replication of the DNA. Such DNA may be introduced using methods described in the following examples or using other procedures well known to those skilled in the art. Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are also well known in the art [see, e. g. , Sambrook et al . (1989) Molecular Cloning: A Laboratory Manual , Second Edi tion, Cold Spring Harbor Laboratory Press] . Cloned full-length DNA encoding any of the subunits of a human calcium channel may be introduced into a plasmid vector for expression in a eukaryotic cell. Such DNA may be genomic DNA or cDNA. Host cells may be transfected with one or a combination of the plasmids, each of which encodes at least one calcium channel subunit. Alternatively, host cells may be transfected with linear DNA using methods well known to those of skill in the art. While the DNA provided herein may be expressed in any eukaryotic cell, including yeast cells such as P. pastoriε [see, e . g. , Cregg et al . (1987) Bio/Technology 5:479], mammalian expression systems for expression of the DNA encoding the human calcium channel subunits provided herein are preferred. The heterologous DNA may be introduced by any method known to those of skill in the art, such as transfection with a vector encoding the heterologous DNA. Particularly preferred vectors for transfection of mammalian cells are the pSV2dhfr expression vectors, which contain the SV40 early promoter, mouse dhfr gene, SV40 polyadenylation and splice sites and sequences necessary for maintaining the vector in bacteria, cytomegalovirus (CMV) promoter-based vectors such as pCDNAl, or pcDNA-amp and MMTV promoter-based vectors. DNA encoding the human calcium channel subunits has been inserted in the vector pCDNAl at a position immediately following the CMV promoter. The vector pCDNAl is presently preferred. Stably or transiently transfected mammalian cells may be prepared by methods known in the art by transfecting cells with an expression vector having a selectable marker gene such as the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance or the like, and, for transient transfection, growing the transfected cells under conditions selective for cells expressing the marker gene. Functional voltage-dependent calcium channels have been produced in HEK 293 cells transfected with a derivative of the vector pCDNAl that contains DNA encoding a human calcium channel subunit. The heterologous DNA may be maintained in the cell as an episomal element or may be integrated into chromosomal DNA of the cell. The resulting recombinant cells may then be cultured or subcultured (or passaged, in the case of mammalian cells) from such a culture or a subculture thereof. Methods for transfection, injection and culturing recombinant cells are known to the skilled artisan. Eukaryotic cells in which DNA or RNA may be introduced, include any cells that are transfectable by such DNA or RNA or into which such DNA may be injected. Virtually any eukaryotic cell can serve as a vehicle for heterologous DNA. Preferred cells are those that can also express the DNA and RNA and most preferred cells are those that can form recombinant or heterologous calcium channels that include one or more subunits encoded by the heterologous DNA. Such cells may be identified empirically or selected from among those known to be readily transfected or injected. Preferred cells for introducing DNA include those that can be transiently or stably transfected and include, but are not limited to, cells of mammalian origin, such as COS cells, mouse L cells, CHO cells, human embryonic kidney cells, African green monkey cells and other such cells known to those of skill in the art, amphibian cells, such as Xenopus laeviε oόcytes, or those of yeast such as Saccharomyceε cerevisiae or Pichia pastoriε . Preferred cells for expressing injected RNA transcripts or cDNA include Xenopus laeviε oόcytes. Cells that are preferred for transfection of DNA are those that can be readily and efficiently transfected. Such cells are known to those of skill in the art or may be empirically identified. Preferred cells include DG44 cells and HEK 293 cells, particularly HEK 293 cells that can be frozen in liquid nitrogen and then thawed and regrown. Such HEK 293 cells are described, for example in U.S. Patent No. 5,024,939 to Gorman [see, also Stillman et al . (1985) Mol . Cell .Biol . 5:2051- 2060] . The cells may be used as vehicles for replicating heterologous DNA introduced therein or for expressing the heterologous DNA introduced therein. In certain embodiments, the cells are used as vehicles for expressing the heterologous DNA as a means to produce substantially pure human calcium channel subunits or heterologous calcium channels. Host cells containing the heterologous DNA may be cultured under conditions whereby the calcium channels are expressed. The calcium channel subunits may be purified using protein purification methods known to those of skill in the art. For example, antibodies, such as those provided herein, that specifically bind to one or more of the subunits may be used for affinity purification of the subunit or calcium channels containing the subunits. Substantially pure subunits of a human calcium channel ofj , subunits of a human calcium channel, a 2 subunits of a human calcium channel, β subunits of a human calcium channel and γ subunits of a human calcium channel are provided. Substantially pure isolated calcium channels that contain at least one of the human calcium channel subunits are also provided. Substantially pure calcium channels that contain a mixture of one or more subunits encoded by the host cell and one or more subunits encoded by heterologous DNA or RNA that has been introduced into the cell are also provided. Substantially pure subtype- or tissue-type specific calcium channels are also provided. In other embodiments, eukaryotic cells that contain heterologous DNA encoding at least one of an a λ subunit of a human calcium channel , an c_ 2 subunit of a human calcium channel, a β subunit of a human calcium channel and a y subunit of a human calcium channel are provided. In accordance with one preferred embodiment, the heterologous DNA is expressed in the eukaryotic cell and preferably encodes a human calcium channel α- subunit. Expression of heterologous calcium channels: electrophysiology and pharmacology Electrophysiological methods for measuring calcium channel activity are kwown to those of skill in the art and are exemplified herein. Any such methods may be used in order to detect the formation of functional calcium channels and to characterize the kinetics and other characteristics of the resulting currents. Pharmacological studies may be combined with the electrophysiological measurements in order to further characterize the calcium channels. With respect to measurement of the activity of functional heterologous calcium channels, preferably, endogenous ion channel activity and, if desired, heterologous channel activity of channels that do not contain the desired subunits, of a host cell can be inhibited to a significant extent by chemical, pharmacological and electrophysiological means, including the use of differential holding potential, to increase the S/N ratio of the measured heterologous calcium channel activity. Thus, various combinations of subunits encoded by the DNA provided herein are introduced into eukaryotic cells. The resulting cells can be examined to ascertain whether functional channels are expressed and to determine the properties of the channels. In particularly preferred aspects, the eukaryotic cell which contains the heterologous DNA expresses it and forms a recombinant functional calcium channel activity. In more preferred aspects, the recombinant calcium channel activity is readily detectable because it is a type that is absent from the untransfected host cell or is of a magnitude and/or pharmacological properties or exhibits biophysical properties not exhibited in the untransfected cell. The eukaryotic cells can be transfected with various combinations of the subunit subtypes provided herein. The resulting cells will provide a uniform population of calcium channels for study of calcium channel activity and for use in the drug screening assays provided herein. Experiments that have been performed have demonstrated the inadequacy of prior classification schemes. Preferred among transfected cells is a recombinant eukaryotic cell with a functional heterologous calcium channel. The recombinant cell can be produced by introduction of and expression of heterologous DNA or RNA transcripts encoding an cv. subunit of a human calcium channel, more preferably also expressing, a heterologous DNA encoding a β subunit of a human calcium channel and/or heterologous DNA encoding an a 2 subunit of a human calcium channel. Especially preferred is the expression in such a recombinant cell of each of the α., β and at 2 subunits encoded by such heterologous DNA or RNA transcripts, and optionally expression of heterologous DNA or an RNA transcript encoding a γ subunit of a human calcium channel. The functional calcium channels may preferably include at least an α. subunit and a β subunit of a human calcium channel. Eukaryotic cells expressing these two subunits and also cells expressing additional subunits, have been prepared by transfection of DNA and by injection of RNA transcripts. Such cells have exhibited voltage-dependent calcium channel activity attributable to calcium channels that contain one or more of the heterologous human calcium channel subunits. For example, eukaryotic cells expressing heterologous calcium channels containing an 2 subunit in addition to the α. subunit and a β subunit have been shown to exhibit increased calcium selective ion flow across the cellular membrane in response to depolarization, indicating that the a 2 subunit may potentiate calcium channel function. Cells that have been co-transfected with increasing ratios of c_ 2 to α. and the activity of the resulting calcium channels has been measured. The results indicate that 2 increasing the amount of c_ 2 -encoding DNA relative to the other transfected subunits increases calcium channel activity. Eukaryotic cells which express heterologous calcium channels containing at least a human c*. subunit, a human β subunit and a human 2 subunit are preferred. Eukaryotic cells transformed with a composition containing cDNA or an RNA transcript that encodes an α. subunit alone or in combination with a β and/or an o_ 2 subunit may be used to produce cells that express functional calcium channels. Since recombinant cells expressing human calcium channels containing all of the human subunits encoded by the heterologous cDNA or RNA are especially preferred, it is desirable to inject or transfect such host cells with a sufficient concentration of the subunit-encoding nucleic acids to form calcium channels that contain the human subunits encoded by heterologous DNA or RNA. The precise amounts and ratios of DNA or RNA encoding the subunits may be empirically determined and optimized for a particular combination of subunits, cells and assay conditions. In particular, mammalian cells have been transiently and stably tranfected with DNA encoding one or more human calcium channel subunits. Such cells express heterologous calcium channels that exhibit pharmacological and electrophysiological properties that can be ascribed to human calcium channels. Such cells, however, represent homogeneous populations and the pharmacological and electrophysiological data provides insights into human calcium channel activity heretofore unattainable. For example, HEK cells that have been transiently transfected with DNA encoding the α- E .., α 2b , and / β._ 3 subunits. The resulting cells transiently express these subunits, which form calcium channels that have properties that appear to be a pharmacologically distinct class of voltage-activated calcium channels distinct from those of L-, N-, T- and P-type channels. The observed 1E currents were insensitive to drugs and toxins previously used to define other classes of voltage-activated calcium channels. HEK cells that have been transfiently transfected with DNA encoding α. 1B _ 1# α 2b , and / β._ 2 express heterologous calcium channels that exhibt sensitivity to ω-conotoxin and currents typical of N-type channels. It has been found that alteration of the molar raios of α.^.-, α 2b and β x _ 2 introduced into the cells into to achieve equivalent mRNA levels significantly increased the number of receptors per cell, the current density, and affected the K d for ω-conotoxin. The electrophyiological properties of these channels produced from _- 1B _ 1# α 2b , and ?._- was compared with those of channels produced by transiently transfecting HEK cells with DNA encoding 1B . ι r 2b and S.. 3 . The channels exhibited similar voltage dependence of activation, substantially identical voltage dependence, similar kinetics of activation and tail currents that could be fit by a single exponential. The voltage dependence of the kinetics of inactivation was significantly different at all voltages examined. In certain embodiments, the eukaryotic cell with a heterologous calcium channel is produced by introducing into the cell a first composition, which contains at least one RNA transcript that is translated in the cell into a subunit of a human calcium channel. In preferred embodiments, the subunits that are translated include an a λ subunit of a human calcium channel. More preferably, the composition that is introduced contains an RNA transcript which encodes an α. subunit of a human calcium channel and also contains (1) an RNA transcript which encodes a β subunit of a human calcium channel and/or (2) an RNA transcript which encodes an a 2 subunit of a human calcium channel. Especially preferred is the introduction of RNA encoding an a x , a β and an a 2 human calcium channel subunit, and, optionally, a γ subunit of a human calcium channel. Methods for in vitro transcription of a cloned DNA and injection of the resulting RNA into eukaryotic cells are well known in the art. Transcripts of any of the full- length DNA encoding any of the subunits of a human calcium channel may be injected alone or in combination with other transcripts into eukaryotic cells for expression in the cells. Amphibian oόcytes are particularly preferred for expression of in vi tro transcripts of the human calcium channel subunit cDNA clones provided herein. Amphibian oocytes that express functional heterologous calcium channels have been produced by this method. Assays and Clinical uses of the cells and calcium channels Assays Assays for identifying compounds that modulate calcium channel activity Among the uses for eukaryotic cells which recombinantly express one or more subunits are assays for determining whether a test compound has calcium channel agonist or antagonist activity. These eukaryotic cells may also be used to select from among known calcium channel agonists and antagonists those exhibiting a particular calcium channel subtype specificity and to thereby select compounds that have potential as disease- or tissue-specific therapeutic agents. In vitro methods for identifying compounds, such as calcium channel agonist and antagonists, that modulate the activity of calcium channels using eukaryotic cells that express heterologous human calcium channels are provided. In particular, the assays use eukaryotic celTs that express heterologous human calcium channel subunits encoded by heterologous DNA provided herein, for screening potential calcium channel agonists and antagonists which are specific for human calcium channels and particularly for screening for compounds that are specific for particular human calcium channel subtypes. Such assays may be used in conjunction with methods of rational drug design to select among agonists and antagonists, which differ slightly in structure, those particularly useful for modulating the activity of human calcium channels, and to design or select compounds that exhibit subtype- or tissue- specific calcium channel antagonist and agonist activities. These assays should accurately predict the relative therapeutic efficacy of a compound for the treatment of certain disorders in humans. In addition, since subtype-and tissue-specific calcium channel subunits are provided, cells with tissue- specific or subtype- specific recombinant calcium channels may be prepared and used in assays for identification of human calcium channel tissue- or subtype-specific drugs. Desirably, the host cell for the expression of calcium channel subunits does not produce endogenous calcium channel subunits of the type or in an amount that substantially interferes with the detection of heterologous calcium channel subunits in ligand binding assays or detection of heterologous calcium channel function, such as generation of calcium current, in functional assays. Also, the host cells preferably should not produce endogenous calcium channels which detectably interact with compounds having, at physiological concentrations (generally nanomolar or picomolar concentrations) , affinity for calcium channels that contain one or all of the human calcium channel subunits provided herein. With respect to ligand binding assays for identifying a compound which has affinity for calcium channels, cells are employed which express, preferably, at least a heterologous α. subunit. Transfected eukaryotic cells which express at least an α. subunit may be used to determine the ability of a test compound to specifically bind to heterologous calcium channels by, for example, evaluating the ability of the test compound to inhibit the interaction of a labeled compound known to specifically interact with calcium channels. Such ligand binding assays may be performed on intact transfected cells or membranes prepared therefrom. The capacity of a test compound to bind to or otherwise interact with membranes that contain heterologous calcium channels or subunits thereof may be determined by using any appropriate method, such as competitive binding analysis, such as Scatchard plots, in which the binding capacity of such membranes is determined in the presence and absence of one or more concentrations of a compound having known affinity for the calcium channel. Where necessary, the results may be compared to a control experiment designed in accordance with methods known to those of skill in the art. For example, as a negative control, the results may be compared to those of assays of an identically treated membrane preparation from host cells which have not been transfected with one or more subunit-encoding nucleic acids. The assays involve contacting the cell membrane of a recombinant eukaryotic cell which expresses at least one subunit of a human calcium channel, preferably at least an α. subunit of a human calcium channel, with a test compound and measuring the ability of the test compound to specifically bind to the membrane or alter or modulate the activity of a heterologous calcium channel on the membrane. In preferred embodiments, the assay uses a recombinant cell that has a calcium channel containing an α. subunit of a human calcium channel in combination with a β subunit of a human calcium channel and/or an a 2 subunit of a human calcium channel. Recombinant cells expressing heterologous calcium channels containing each of the a 1 , β and 2 human subunits, and, optionally, a γ subunit of a human calcium channel are especially preferred for use in such assays. In certain embodiments, the assays for identifying compounds that modulate calcium channel activity are practiced by measuring the calcium channel activity of a eukaryotic cell having a heterologous, functional calcium channel when such cell is exposed to a solution containing the test compound and a calcium channel-selective ion and comparing the measured calcium channel activity to the calcium channel activity of the same cell or a substantially identical control cell in a solution not containing the test compound. The cell is maintained in a solution having a concentration of calcium channel-selective ions sufficient to provide an inward current when the channels open. Rcombinant cells expressing calcium channels that include each of the α., β and a 2 human subunits, and, optionally, a γ subunit of a human calcium channel, are especially preferred for use in such assays. Methods for practicing such assays are known to those of skill in the art. For example, for similar methods applied with Xenopus laeviε oόcytes and acetylcholine receptors, see, Mishina et al . [(1985) Nature 313:364] and, with such oόcytes and sodium channels [see, Νoda et al . (1986) Nature 322:826-828] . For similar studies which have been carried out with the acetylcholine receptor, see, e.g., Claudio et al . [(1987) Science 235:1688-1694] . Functional recombinant or heterologous calcium channels may be identified by any method known to those of skill in the art. For example, electrophysiological procedures for measuring the current across an ion-selective membrane of a cell, which are well known, may be used. The amount and duration of the flow of calcium-selective ions through heterologous calcium channels of a recombinant cell containing DNA encoding one or more of the subunits provided herein has been measured using electrophysiological recordings using a two electrode and the whole-cell patch clamp techniques. In order to improve the sensitivity of the assays, known methods can be used to eliminate or reduce non-calcium currents and calcium currents resulting from endogenous calcium channels, when measuring calcium currents through recombinant channels. For example, the DHP Bay K 8644 specifically enhances L-type calcium channel function by increasing the duration of the open state of the channels [see, e. g. , Hess, J.B., et al. (1984) Nature 311:538-544] . Prolonged opening of the channels results in calcium currents of increased magnitude and duration. Tail currents can be observed upon repolarization of the cell membrane after activation of ion channels by a depolarizing voltage command. The opened channels require a finite time to close or "deactivate" upon repolarization, and the current that flows through the channels during this period is referred to as a tail current. Because Bay K 8644 prolongs opening events in calcium channels, it tends to prolong these tail currents and make them more pronounced. In practicing these assays, stably or transiently transfected cells or injected cells that express voltage- dependent human calcium channels containing one or more of the subunits of a human calcium channel desirably may be used in assays to identify agents, such as calcium channel agonists and antagonists, that modulate calcium channel activity. Functionally testing the activity of test compounds, including compounds having unknown activity, for calcium channel agonist or antagonist activity to determine if the test compound potentiates, inhibits or otherwise alters the flow of calcium ions or other ions through a human calcium channel can be accomplished by (a) maintaining a eukaryotic cell which is transfected or injected to express a heterologous functional calcium channel capable of regulating the flow of calcium channel-selective ions into the cell in a medium containing calcium channel-selective ions (i) in the presence of and (ii) in the absence of a test compound; (b) maintaining the cell under conditions such that the heterologous calcium channels are substantially closed and endogenous calcium channels of the cell are substantially inhibited (c) depolarizing the membrane of the cell maintained in step (b) to an extent and for an amount of time sufficient to cause (preferably, substantially only) the heterologous calcium channels to become permeable to the calcium channel-selective ions; and (d) comparing the amount and duration of current flow into the cell in the presence of the test compound to that of the current flow into the cell, or a substantially similar cell, in the absence of the test compound. The assays thus use cells, provided herein, that express heterologous functional calcium channels and measure functionally, such as electrophysiologically, the ability of a test compound to potentiate, antagonize or otherwise modulate the magnitude and duration of the flow of calcium channel-selective ions, such as Ca ++ or Ba ++ , through the heterologous functional channel. The amount of current which flows through the recombinant calcium channels of a cell may be determined directly, such as electrophysiologically, or by monitoring an independent reaction which occurs intracellularly and which is directly influenced in a calcium (or other) ion dependent manner. Any method for assessing the activity of a calcium channel may be used in conjunction with the cells and assays provided herein. For example, in one embodiment of the method for testing a compound for its ability to modulate calcium channel activity, the amount of current is measured by its modulation of a reaction which is sensitive to calcium channel-selective ions and uses a eukaryotic cell which expresses a heterologous calcium channel and also contains a transcriptional control element operatively linked for expression to a structural gene that encodes an indicator protein. The transcriptional control element used for transcription of the indicator gene is responsive in the cell to a calcium channel-selective ion, such as Ca 2+ and Ba + . The details of such transcriptional based assays are described in commonly owned PCT International Patent Application No. PCT/US91/5625, filed August 7, 1991, which claims priority to copending commonly owned allowed U.S. Application Serial No. 07/563,751, filed August 7, 1990; see also, commonly owned published PCT International Patent Application PCT US92/11090, which corresponds to co-pending U.S. Applications Serial Nos. 08/229,150 and 08/244,985. Assays for diagnosis of LES LES is an autoimmune disease characterized by an insufficient release of acetylcholine from motor nerve terminals which normally are responsive to nerve impulses. Immunoglobulins (IgG) from LES patients block individual voltage-dependent calcium channels and thus inhibit calcium channel activity [Kim and Neher, Science 235:405-408 (1988)] . A diagnostic assay for Lambert Eaton Syndrome (LES) is provided herein. The diagnostic assay for LES relies on the immunological reactivity of LES IgG with the human calcium channels or particular subunits alone or in combination or expressed on the surface of recombinant cells. For example, such an assay may be based on immunoprecipitation of LES IgG by the human calcium channel subunits and cells that express such subunits provided herein. Clinical applications In relation to therapeutic treatment of various disease states, the availability of DNA encoding human calcium channel subunits permits identification of any alterations in such genes (e.g. , mutations) which may correlate with the occurrence of certain disease states. In addition, the creation of animal models of such disease states becomes possible, by specifically introducing such mutations into synthetic DNA fragments can then be introduced into laboratory animals or in vi tro assay systems to determine the effects thereof. Also, genetic screening can be carried out using the nucleotide sequences as probes. Thus, nucleic acid samples from subjects having pathological conditions suspected of involving alteration/modification of any one or more of the calcium channel subunits can be screened with appropriate probes to determine if any abnormalities exist with respect to any of the endogenous calcium channels. Similarly, subjects having a family history of disease states related to calcium channel dysfunction can be screened to determine if they are also predisposed to such disease states. EXAMPLES The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention. EXAMPLE I: PREPARATION OF LIBRARIES USED FOR ISOLATION OF DNA ENCODING HUMAN NEURONAL VOLTAGE- DEPENDENT CALCIUM CHANNEL SUBUNITS A. RNA Isolation 1. IMR32 cells IMR32 cells were obtained from the American Type Culture Collection (ATCC Accession No. CCL127, Rockville, MD) and grown in DMEM, 10% fetal bovine serum, 1% penicillin/streptomycin (GIBCO, Grand Island, NY) plus 1.0 mM dibutyryl cAMP (dbcAMP) for ten days. Total RNA was isolated from the cells according to the procedure described by H.C. Birnboim [(1988) Nucleic Acids Research 16:1487-1497] . Poly(A + ) RNA was selected according to standard procedures [see, e . g. , Sambrook et al . (1989) Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory Press; pg. 7.26-7.29] . 2. Human thalamus tissue Human thalamus tissue (2.34 g) , obtained from the National Neurological Research Bank, Los Angeles, CA, that had been stored frozen at -70°C was pulverized using a mortar and pestle in the presence of liquid nitrogen and the cells were lysed in 12 ml of lysis buffer (5 M guanidinium isothiocyanate, 50 mM TRIS, pH 7.4, 10 mM EDTA, 5% β- mercaptoethanol) . Lysis buffer was added to the lysate to yield a final volume of 17 ml. N-laurylsarcosine and CsCl were added to the mixture to yield final concentrations of 4% and 0.01 g/ml, respectively, in a final volume of 18 ml. The sample was centrifuged at 9,000 rpm in a Sorvall SS34 rotor for 10 min at room temperature to remove the insoluble material as a pellet. The supernatant was divided into two equal portions and each was layered onto a 2-ml cushion of a solution of 5.7 M CsCl, 0.1 M EDTA contained in separate centrifuge tubes to yield approximately 9 ml per tube. The samples were centrifuged in an SW41 rotor at 37,000 rpm for 24 h at 20°C. After centrifugation, each RNA pellet was resuspended in 3 ml ETS (10 mM TRIS, pH 7.4, 10 mM EDTA, 0.2% SDS) and combined into a single tube. The RNA was precipitated with 0.25 M NaCl and two volumes of 95% ethanol. The precipitate was collected by centrifugation and resuspended in 4 ml PK buffer (0.05 M TRIS, pH 8.4, 0.14 M NaCl, 0.01 M EDTA, 1% SDS). Proteinase K was added to the sample to a final concentration of 200 μg/ml. The sample was incubated at 22°C for 1 h, followed by extraction with an equal volume of phenol:chloroform:isoamylalcohol (50:48:2) two times, followed by one extraction with an equal volume of chloroform: isoamylalcohol (24:1). The RNA was precipitated with ethanol and NaCl. The precipitate was resuspended in 400 μl of ETS buffer. The yield of total RNA was approximately 1.0 mg. Poly A + RNA (30 μg) was isolated from the total RNA according to standard methods as stated in Example I.A.I. B. Library Construction Double-stranded cDNA was synthesized according to standard methods [see, e.g. , Sambrook et al . (1989) IN: Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory Press, Chapter 8] . Each library was prepared in substantially the same manner except for differences in: 1) the oligonucleotide used to prime the first strand cDNA synthesis, 2) the adapters that were attached to the double- stranded cDNA, 3) the method used to remove the free or unused adapters, and 4) the size of the fractionated cDNA ligated into the λ phage vector. 1. IMR32 cDNA library #1 Single-stranded cDNA was synthesized using IMR32 poly(A + ) RNA (Example I.A.l.) as a template and was primed using oligo (dT) 12 . 1B (Collaborative Research Inc., Bedford, MA) : The single-stranded cDNA was converted to double-stranded cDNA and the yield was approximately 2μg. Ecol adapters: 5'-AATTCGGTACGTACACTCGAGC-3' = 22-mer (SEQ ID No.15) 3'- GCCATGCATGTGAGCTCG-5' = 18-mer (SEQ ID No.16) also containing SnaBI and Xhol restriction sites were then added to the double-stranded cDNA according to the following procedure. a. Phosphorylation of 18-mer The 18-mer was phosphorylated using standard methods [see, e.g., Sambrook et al . (1989) IN: Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory Press, Chapter 8] by combining in a 10 μl total volume the 18-mer (225 pmoles) with [ 32 P]γ-ATP (7000 Ci/mmole; 1.0 μl) and kinase (2 U) and incubating at 37° C for 15 minutes. After incubation, 1 μl 10 mM ATP and an additional 2 U of kinase were added and incubated at 37°C for 15 minutes. Kinase was then inactivated by boiling for 10 minutes. b. Hybridization of 22-mer The 22-mer was hybridized to the phosphorylated 18-mer by addition of 225 pmoles of the 22-mer (plus water to bring volume to 15 μl) , and incubation at 65°C for 5 minutes. The reaction was then allowed to slow cool to room temperature. The adapters were thus present at a concentration of 15 pmoles/μl, and were ready for cDNA-adapter ligation. c. Ligation of adapters to cDNA After the EcόRI , SnaBI, Xhol adapters were ligated to the double-stranded cDNA using a standard protocol [see, e.g., Sambrook et al . (1989) IN: Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory Press, Chapter 8] , the ligase was inactivated by heating the mixture to 72°C for 15 minutes. The following reagents were added to the cDNA ligation reaction and heated at 37°C for 30 minutes: cDNA ligation reaction (20 μl) , water (24 μl) , lOx kinase buffer (3 μl), 10 mM ATP (1 μl) and kinase (2μl of 2 U/μl) . The reaction was stopped by the addition of 2 μl 0.5M EDTA, followed by one phenol/chloroform extraction and one chloroform extraction. d. Size Selection and Packaging of cDNA The double-stranded cDNA with the EcoRI, SnaBI, Xhol adapters ligated was purified away from the free or unligated adapters using a 5 ml Sepharose CL-4B column (Sigma, St. Louis, MO) . 100 μl fractions were collected and those containing the cDNA, determined by monitoring the radioactivity, were pooled, ethanol precipitated, resuspended in TE buffer and loaded onto a 1% agarose gel. After the electrophoresis, the gel was stained with ethidium bromide and the 1 to 3 kb fraction was cut from the gel. The cDNA embedded in the agarose was eluted using the "Geneluter Electroelution System" (Invitrogen, San Diego, CA) . The eluted cDNA was collected by ethanol precipitation and resuspended in TE buffer at 0.10 pmol/μl. The cDNA was ligated to 1 μg of EcoRI digested, dephosphorylated λgtll in a 5 μl reaction volume at a 2- to 4- fold molar excess ratio of cDNA over the λgtll vector. The ligated λgtll containing the cDNA insert was packaged into λ phage virions in vi tro using the Gigapack (Stratagene, La Jolla, CA) kit. The packaged phage were plated on an E. coli Y1088 bacterial lawn in preparation for screening. 2. IMR32 cDNA library #2 This library was prepared as described (Example I.B.I.) with the exception that 3 to 9 kb cDNA fragments were ligated into the λgtll phage vector rather than the 1 to 3 kb fragments. 3. IMR32 cDNA library #3 IMR32 cell poly(A + ) RNA (Example I.A.I.) was used as a template to synthesize single-stranded cDNA. The primers for the first strand cDNA synthesis were random primers (hexadeoxy-nucleotides [pd(N) Cat #5020-1, Clontech, Palo Alto, CA) . The double-stranded cDNA was synthesized, .EcoRI, SnaBI , Xhol adapters were added to the cDNA, the unligated adapters were removed, and the double-stranded cDNA with the ligated adapters was fractionated on an agarose gel, as described in Example I.B.I. The cDNA fraction greater than 1.8 kb was eluted from the agarose, ligated into λgtll, packaged, and plated into a bacterial lawn of Y1088 (as described in Example I.B.I.) . 4. IMR32 cDNA library #4 IMR32 cell poly(A + ) RNA (Example I.A.I.) was used as a template to synthesize single-stranded cDNA. The primers for the first strand cDNA synthesis were oligonucleotides: 89-365a specific for the α 1D (VDCC III) type α.-subunit (see Example II.A.) coding sequence (the complementary sequence of nt 2927 to 2956, SEQ ID No. 1), 89-495 specific for the α. lc (VDCC II) type of.-subunit (see Example II.B.) coding sequence (the complementary sequence of nt 852 to 873, SEQ ID No. 3), and 90-12 specific for the α ιc -subunit coding sequence (the complementary sequence of nt 2496 to 2520, SEQ ID No. 3) . The cDNA library was then constructed as described (Example I.B.3) , except that the cDNA size-fraction greater than 1.5 kb was eluted from the agarose rather than the greater than 1.8 kb fraction. 5. IMR32 cDNA library #5 The cDNA library was constructed as described (Example I.B.3.) with the exception that the size-fraction greater than 1.2 kb was eluted from the agarose rather than the greater than 1.8 kb fraction. 6. Human thalamus cDNA library #6 Human thalamus poly (A + ) RNA (Example I.A.2.) was used as a template to synthesize single-stranded cDNA. Oligo (dT) was used to prime the first strand synthesis (Example I.B.I.) . The double-stranded cDNA was synthesized (Example I.B.I.) and EcoRI, Kpnl , Ncol adapters of the following sequence: 5' CCATGGTACCTTCGTTGACG 3'= 20-mer (SEQ ID NO. 17) 3' GGTACCATGGAAGCAACTGCTTAA 5'= 24-mer (SEQ ID NO. 18) were ligated to the double-stranded cDNA as described (Example I.B.I.) with the 20-mer replacing the 18-mer and the 24-mer replacing the 22-mer. The unligated adapters were removed by passing the cDNA-adapter mixture through a 1 ml Bio Gel A-50 (Bio-Rad Laboratories, Richmond, CA) column. Fractions (30 μl) were collected and 1 μl of each fraction in the first peak of radioactivity was electrophoresed on a 1% agarose gel. After electrophoresis, the gel was dried on a vacuum gel drier and exposed to x-ray film. The fractions containing cDNA fragments greater than 600 bp were pooled, ethanol precipitated, and ligated into λgtll (Example I.B.I.) . The construction of the cDNA library was completed as described (Example I.B.I. ) . C. Hybridization and Washing Conditions Hybridization of radiolabelled nucleic acids to immobilized DNA for the purpose of screening cDNA libraries, DNA Southern transfers, or northern transfers was routinely performed in standard hybridization conditions [hybridization: 50% deionized formamide, 200 μg/ml sonicated herring sperm DNA (Cat #223646, Boehringer Mannheim Biochemicals, Indianapolis, IN), 5 x SSPE, 5 x Denhardt's, 42° C; wash :0.2 x SSPE, 0.1% SDS, 65° C] . The recipes for SSPE and Denhardt's and the preparation of deionized formamide are described, for example, in Sambrook et al . (1989) Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory Press, Chapter 8) . In some hybridizations, lower stringency conditions were used in that 10% deionized formamide replaced 50% deionized formamide described for the standard hybridization conditions. The washing conditions for removing the non-specific probe from the filters was either high, medium, or low stringency as described below: 1) high stringency: 0.1 x SSPE, 0.1% SDS, 65°C 2) medium stringency: 0.2 x SSPE, 0.1% SDS, 50°C 3) low stringency: 1.0 x SSPE, 0.1% SDS, 50°C. It is understood that equivalent stringencies may be achieved using alternative buffers, salts and temperatures. EXAMPLE II: ISOLATION OF DNA ENCODING THE HUMAN NEURONAL CALCIUM CHANNEL α. SUBUNIT A. Isolation of DNA encoding the c_ 1D subunit 1. Reference list of partial α 1D cDNA clones Numerous α. 1D -specific cDNA clones were isolated in order to characterize the complete 1D coding sequence plus portions of the 5' and 3' untranslated sequences. SEQ ID No. 1 shows the complete α 1D DNA coding sequence, plus 510 nucleotides of α 1D 5' untranslated sequence ending in the guanidine nucleotide adjacent to the adenine nucleotide of the proposed initiation of translation as well as 642 nucleotides of 3' untranslated sequence. Also shown in SEQ ID No. 1 is the deduced amino acid sequence. A list of partial cDNA clones used to characterize the α 1D sequence and the nucleotide position of each clone relative to the full-length α. 1D cDNA sequence, which is set forth in SEQ ID No. 1, is shown below. The isolation and characterization of these clones are described below (Example II.A.2.) . IMR32 1.144 nt 1 to 510 of SEQ ID No. 1 5' untranslated sequence, nt 511 to 2431, SEQ ID No. 1 IMR32 * 1.136 nt 1627 to 2988, SEQ ID No. 1 nt 1 to 104 of SEQ ID No. 2 additional exon, nt 2083 to 6468, SEQ ID No. 1 nt 2857 to 4281, SEQ ID No. 1 nt 5200 to 7635, SEQ ID No. 1 * 5' of nt 1627, IMR32 1.136 encodes an intron and an additional exon described in Example II.A.2.d. @ IMR32 1.80 contains two deletions, nt 2984 to 3131 and nt 5303 to 5349 (SEQ ID No. 1) . The 148 nt deletion (nt 2984 to 3131) was corrected by performing a polymerase chain reaction described in Example II.A.3.b. # IMR32 1.36 contains a 132 nt deletion (nt 3081 to 3212) . 2. Isolation and characterization of individual clones listed in Example II.A.1. a. IMR32 1.36 Two million recombinants of the IMR32 cDNA library #1 (Example I.B.I.) were screened in duplicate at a density of approximately 200,000 plaques per 150 mm plate using a mixture of radiolabelled fragments of the coding region of the rabbit skeletal muscle calcium channel α- cDNA [for the sequence of the rabbit skeletal muscle calcium channel α. subunit cDNA, see, Tanabe et al . (1987) . Nature 328 : 313 - 318] : Fragment Nucleotides KpnI -EcόRI -78 to 1006 EcoRI-XhoI 1006 to 2653 Apal-Apal 3093 to 4182 Bglll-SacI 4487 to 5310 The hybridization was performed using low stringency hybridization conditions (Example I.e.) and the filters were washed under low stringency (Example I.e.) . Only one α 1D - specific recombinant (IMR32 1.36) of the 2 x 10 e screened was identified. IMR32 1.36 was plaque purified by standard methods (J. Sambrook et al . (1989) Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory Press, Chapter 8) subcloned into pGEM3 (Promega, Madison, WI) and characterized by DNA sequencing. b. IMR32 1.80 Approximately 1 x 10 6 recombinants of the IMR32 cDNA library #2 (Example I.B.2.) were screened in duplicate at a density of approximately 100,000 plaques per 150 mm plate using the IMR32 1.36 cDNA fragment (Example II.A.1) as a probe. Standard hybridization conditions were used, and the filters were washed under high stringency (Example I.e.) . Three positive plaques were identified one of which was IMR32 1.80. IMR32 1.80 was plaque purified by standard methods, restriction mapped, subcloned, and characterized by DNA sequencing. c. IMR32 1.144 Approximately 1 x 10 6 recombinants of the IMR32 cDNA library #3 (Example I.B.3) were screened with the EcόRI-PvuII fragment (nt 2083 to 2518, SEQ ID No. 1) of IMR32 1.80. The hybridization was performed using standard hybridization conditions (Example I.C.) and the filters were washed under high stringency (Example I.e.) . Three positive plagues were identified one of which was IMR32 1.144. IMR32 1.144 was plaque purified, restriction mapped, and the cDNA insert was subcloned into pGEM7Z (Promega, Madison, WI) and characterized by DNA sequencing. This characterization revealed that IMR32 1.144 has a series of ATG codons encoding seven possible initiating methionines (nt 511 to 531, SEQ ID No. 1) . Nucleic acid amplification analysis, and DNA sequencing of cloned nucleic acid amplification analysis products encoding these seven ATG codons confirmed that this sequence is present in the α 1D transcript expressed in dbcAMP-induced IMR32 cells. d. IMR32 1.136 Approximately 1 x 10 6 recombinants of the IMR32 cDNA library #4 (Example I.B.4) were screened with the EcoRl-Pvull fragment (nt 2083 to 2518, SEQ ID No. 1) of IMR32 1.80 (Example II. .1.) . The hybridization was performed using standard hybridization conditions (Example I.C.) and the filters were washed under high stringency (Example I.C.) . Six positive plaques were identified one of which was IMR32 1.136. IMR32 1.136 was plaque purified, restriction mapped, and the cDNA insert was subcloned into a standard plasmid vector, pSP72 (Promega, Madison, WI. ) , and characterized by DNA sequencing. This characterization revealed that IMR32 1.136 encodes an incompletely spliced α 1D transcript. The clone contains nucleotides 1627 to 2988 of SEQ ID No. 1 preceded by an approximate 640 bp intron. This intron is then preceded by a 104 nt exon (SEQ ID No. 2) which is an alternative exon encoding the IS6 transmembrane domain [see, e. g. , Tanabe et al . (1987) Nature 325:313-318 for a description of the IS1 to IVS6 transmembrane terminology] of the α. 1D subunit and can replace nt 1627 to 1730, SEQ ID No. 1, to produce a completely spliced α 1D transcript. e. IMR32 1.163 Approximately 1 x 10 6 recombinants of the IMR32 cDNA library #3 (Example I.B.3.) were screened with the Ncol-Xhol fragment of IMR32 1.80 (Example II.A.1.) containing nt 5811 to 6468 (SEQ ID No. 1) . The hybridization was performed using standard hybridization conditions (Example I.C.) and the filters were washed under high stringency (Example I.C) . Three positive plaques were identified one of which was IMR32 1.163. IMR32 1.163 was plaque purified, restriction mapped, and the cDNA insert was subcloned into a standard plasmid vector, pSP72 (Promega, Madison, WI. ) , and characterized by DNA sequencing. This characterization revealed that IMR32 1.163 contains the α 1D termination codon, nt 6994 to 6996 (SEQ ID No. 1) . 3. Construction of a full-length α 1D cDNA [pVDCCIII(A)] α. 1D cDNA clones IMR32 1.144, IMR32 1.136, IMR32 1.80, and IMR32 1.163 (Example II.A.2.) overlap and include the entire c_ 1D coding sequence, nt 511 to 6993 (SEQ ID No. 1) , with the exception of a 148 bp deletion, nt 2984 to 3131 (SEQ ID No. 1) . Portions of these partial cDNA clones were ligated to generate a full-length α 1D cDNA in a eukaryotic expression vector. The resulting vector was called pVDCCIII (A) . The construction of pVDCCIII (A) was performed in four steps described in detail below: (1) the construction of pVDCCIIl/5' using portions of IMR32 1.144, IMR32 1.136, and IMR32 1.80, (2) the construction of pVDCCIIl/5' .3 that corrects the 148 nt deletion in the IMR32 1.80 portion of pVDCCIIl/5', (3) the construction of pVDCCIII/3' .1 using portions of IMR32 1.80 and IMR32 1.163, and (4) the ligation of a portion of the pVDCCIII/5' .3 insert, the insert of pVDCCIII/3' .1, and pcDNAl (Invitrogen, San Diego, CA) to form pVDCCIII (A) . The vector pcDNAl is a eukaryotic expression vector containing a cytomegalovirus (CMV) promoter which is a constitutive promoter recognized by mammalian host cell RNA polymerase II. Each of the DNA fragments used in preparing the full- length construct was purified by electrophoresis through an agarose gel onto DE81 filter paper (Whatman, Clifton, NJ) and elution from the filter paper using 1.0 M NaCl, 10 mM TRIS, pH 8.0, 1 mM EDTA. The ligations typically were performed in a 10 μl reaction volume with an equal molar ratio of insert fragment and a two-fold molar excess of the total insert relative to the vector. The amount of DNA used was normally about 50 ng to 100 ng. a. pVDCC II/5' To construct pVDCCIII/5', IMR321.144 (Example II.A.2.C.) was digested with Xhol and BcoRI and the fragment containing the vector (pGEM7Z) , α 1D nt 1 to 510 (SEQ ID No. 1) , and α 1D nt 511 to 1732 (SEQ ID No. 1) was isolated by gel electrophoresis. The EcoRI-Apal fragment of IMR32 1.136 (Example II.A.2.d.) nucleotides 1733 to 2671 (SEQ ID No. 1) was isolated, and the Apal-Hindlll fragment of IMR32 1.80 (Example II.A.2.b.), nucleotides 2672 to 4492 (SEQ ID No. 1) was isolated. The three DNA clones were ligated to form pVDCCIII/5' containing nt 1 to 510 (5' untranslated sequence; SEQ ID No. 1) and nt 511 to 4492 (SEQ ID No. 1) . b. pVDCCIII/5' .3 Comparison of the IMR32 1.36 and IMR32 1.80 DNA sequences revealed that these two cDNA clones differ through the α 1D coding sequence, nucleotides 2984 to 3212. nucleic acid amplification analysis of IMR32 1.80 and dbcAMP-induced (1.0 mM, 10 days) IMR32 cytoplasmic RNA (isolated according to Ausubel, F.M. et al . (Eds) (1988) Current Protocols in Molecular Biology, John Wiley and Sons, New York) revealed that IMR32 1.80 had a 148 nt deletion, nt 2984 to 3131 (SEQ ID No. 1), and that IMR32 1.36 had a 132 nt deletion, nt 3081 to 3212. To perform the nucleic acid amplification analysis, the amplification reaction was primed with α 1D -specific oligonucleotides 112 (nt 2548 to 2572, SEQ ID No. 1) and 311 (the complementary sequence of nt 3928 to 3957, SEQ ID No. 1) . These products were then reamplified using α 1D -specific oligonucleotides 310 (nt 2583 to 2608 SEQ ID No. 1) and 312 (the complementary sequence of nt 3883 to 3909) . This reamplified product, which contains AccI and Bglll restriction sites, was digested with AccI and Bglll and the Accl-Bglll fragment, nt 2765 to 3890 (SEQ ID No. 1) was cloned into Accl- Bgrlll digested pVDCCIII/5' to replace the Accl-Bglll pVDCCIII/5' fragment that had the deletion. This new construct was named pVDCCIII/5' .3. DNA sequence determination of pVDCCIII/5' .3 through the amplified region confirmed the 148 nt deletion in IMR32 1.80. c. pVDCCIIl/3' .1 To construct pVDCCIIl/3' .1, the cDNA insert of IMR32 1.163 (Example II.A.2.e.) was subcloned into pBluescript II (Stratagene, La Jolla, CA) as an Xhol fragment. The Xhol sites on the cDNA fragment were furnished by the adapters used to construct the cDNA library (Example I.B.3.) . The insert was oriented such that the translational orientation of the insert of IMR32 1.163 was opposite to that of the lacZ gene present in the plasmid, as confirmed by analysis of restriction enzyme digests of the resulting plasmid. This was done to preclude the possibility of expression of α 1D sequences in DH5α cells transformed with this plasmid due to fusion with the lacZ gene. This plasmid was then digested with Hindlll and Bglll and the Hindlll - Bglll fragment (the Hindlll site comes from the vector and the Bglll site is at nt 6220, SEQ ID No. 1) was eliminated, thus deleting nt 5200 to 6220 (SEQ ID No. 1) of the IMR32 1.163 clone and removing this sequence from the remainder of the plasmid which contained the 3' Bglll Xhol fragment, nt 6221 to 7635 (SEQ ID No. 1) . pVDCCIIl/3' .1 was then made by splicing together the Hindlll- PvuII fragment from IMR32 1.80 (nucleotides 4493-5296, SEQ ID No. 1), the PvuII - Bglll fragment of IMR32 1.163 (nucleotides 5294 to 6220, SEQ ID No. 1) and the Hindi11-Bglll-digested pBluescript plasmid containing the 3' Bglll/Xhol IMR32 1.163 fragment (nt 6221 to 7635, SEQ ID No. 1) . d. pVDCCIII(A): the full-length α 1D construct To construct pVDCCIII (A) , the Dral-Hindlll fragment (5' untranslated sequence nt 330 to 510, SEQ ID No. 1 and coding sequence nt 511 to 4492, SEQ ID No. 1) of pVDCCIII/5' .3 (Example II.A.3.b.) was isolated; the Hindlll-Xhol fragment of pVDCCIIl/3' .1 (containing nt 4493 to 7635, SEQ ID No. 1, plus the Xhol site of the adapter) (Example II.A.3.C.) was isolated; and the plasmid vector, pcDNAl, was digested with EcόRV and Xhol and isolated on an agarose gel. The three DNA fragments were ligated and MC1061-P3 (Invitrogen, San Diego, CA) was transformed. Isolated clones were analyzed by restriction mapping and DNA sequencing and pVDCCIII (A) was identified which had the fragments correctly ligated together: Oral-Hindlll, Hindlll-Xhol, XhoI-EcoRV with the blunt-end Dral and EcόRV site ligating together to form the circular plasmid. The amino-terminus of the α 1D subunit is encoded by the seven consecutive 5' methionine codons (nt 511 to 531, SEQ ID No. 1) . This 5' portion plus nt 532 to 537, encoding two lysine residues, were deleted from pVDCCIII (A) and replaced with an efficient ribosomal binding site (5'- ACCACC-3') to form pVDCCIII.RBS (A) . Expression experiments in which transcripts of this construct were injected into Xenopuε laeviε oόcytes did not result in an enhancement in the recombinant voltage-dependent calcium channel expression level relative to the level of expression in oόcytes injected with transcripts of pVDCCIII (A) . B. Isolation of DNA encoding the α lc subunit 1. Reference List of Partial lc cDNA clones Numerous α. ιc -specific cDNA clones were isolated in order to characterize the α lc coding sequence, the α: lc initiation of translation, and an alternatively spliced region of o; lc . SEQ ID No. 3 sets forth one α. lc coding sequence (a.-...) and deduced amino acid sequence; SEQ ID No. 36 sets forth another splice variant designated c_ lc _ 2 . SEQ ID No. 4 and No. 5 encode two possible amino terminal ends of an c_ ιc splice variant. SEQ ID No. 6 encodes an alternative exon for the IV S3 transmembrane domain. Other α. ιc variants can be constructed by selecting the alternative amino terminal ends in place of the ends in SEQ ID No. 3 or 36 and/or inserting the alternative exon (SEQ ID No. 6) in the appropriate location, such as in SEQ ID NO. 3 in place of nucleotides 3904-3987. In addition, the 75 nucleotide sequence (nucleotides 1391-1465 in SEQ ID No. 3) can be deleted or inserted to produce an alternative α ιc splice variant. Shown below is a list of clones used to characterize the G.. sequence and the nucleotide position of each clone relative to the characterized α. ιc sequence (SEQ ID No. 3) . The isolation and characterization of these cDNA clones are described below (Example II.B.2) . IMR32 1.66 nt 1 to 916, SEQ ID No. 3 nt 1 to 132, SEQ ID No. 4 IMR32 1.157 nt 1 to 873, SEQ ID No. 3 nt 1 to 89, SEQ ID No. 5 nt 50 to 1717, SEQ ID No. 3 nt 1366 to 2583, SEQ ID No. 3 nt 758 to 867, SEQ ID No. 3 nt 2804 to 5904, SEQ ID No. 3 nt 2199 to 3903, SEQ ID No. 3 nt 1 to 84 of alternative exon, SEQ ID No. 6 IMR32 1.38 nt 2448 to 4702, SEQ ID No. 3 nt 1 to 84 of alternative exon, SEQ ID No. 6 * IMR32 1.86 has a 73 nt deletion compared to the rabbit cardiac muscle calcium channel α. subunit cDNA sequence. Θ 1.16G is an a ιc genomic clone. 2. Isolation and characterization of clones described in Example II.B.l. a. CNS 1.30 Approximately 1 x 10 6 recombinants of the human thalamus cDNA library No. 6 (Example I.B.6.) were screened with fragments of the rabbit skeletal muscle calcium channel α^ cDNA described in Example II.A.2.a. The hybridization was performed using standard hybridization conditions (Example I.C.) and the filters were washed under low stringency (Example I.C) . Six positive plaques were identified, one of which was CNS 1.30. CNS 1.30 was plaque purified, restriction mapped, subcloned, and characterized by DNA sequencing. CNS 1.30 encodes α ιc -specific sequence nt 2199 to 3903 (SEQ ID No. 3) followed by nt 1 to 84 of one of two identified alternative α lc exons (SEQ ID No. 6). 3' of SEQ ID No. 6, CNS 1.30 contains an intron and, thus, CNS 1.30 encodes a partially spliced α. ιc transcript. b. 1.160 Approximately 1 x 10 6 recombinants of a λEMBL3-based human genomic DNA library (Cat # HL1006d Clontech Corp., Palo Alto, CA) were screened using a rabbit skeletal muscle cDNA fragment (nt -78 to 1006, Example II.A.2.a.) . The hybridization was performed using standard hybridization conditions (Example I.C.) and the filters were washed under low stringency (Example I.C.) . Fourteen positive plaques were identified, one of which was 1.16G. Clone 1.16G was plaque purified, restriction mapped, subcloned, and portions were characterized by DNA sequencing. DNA sequencing revealed that 1.16G encodes α. ιc -specific sequence as described in Example II.B.l. c. IMR32 1.66 and IMR32 1.67 Approximately 1 x 10 6 recombinants of IMR32 cDNA library #5 (Example I.B.5.) were screened with a 151 bp Kpnl-Sacl fragment of 1.16G (Example II.B.2.b.) encoding lc sequence (nt 758 to 867, SEQ ID No. 3) . The hybridization was performed using standard hybridization conditions (Example I.e.) . The filters were then washed in 0.5 x SSPE at 65°C Of the positive plaques, IMR32 1.66 and IMR32 1.67 were identified. The hybridizing plaques were purified, restriction mapped, subcloned, and characterized by DNA sequencing. Two of these cDNA clones, IMR32 1.66 and 1.67, encode α lc subunits as described (Example II.B.l.) . In addition, IMR32 1.66 encodes a partially spliced o; lc transcript marked by a GT splice donor dinucleotide beginning at the nucleotide 3' of nt 916 (SEQ ID No. 3) . The intron sequence within 1.66 is 101 nt long. IMR32 1.66 encodes the α ιc initiation of translation, nt 1 to 3 (SEQ ID No. 3) and 132 nt of 5' untranslated sequence (SEQ ID No. 4) precede the start codon in IMR32 1.66. d. IMR32 1.37 and IMR32 1.38 Approximately 2 x 10 6 recombinants of IMR32 cDNA library #1 (Example I.B.I.) were screened with the CNS 1.30 cDNA fragment (Example II.B.2.a.) . The hybridization was performed using low stringency hybridization conditions (Example I.C.) and the filters were washed under low stringency (Example I.C) . Four positive plaques were identified, plaque purified, restriction mapped, subcloned, and characterized by DNA sequencing. Two of the clones, IMR32 1.37 and IMR32 1.38 encode α. ιc -specific sequences as described in Example II.B.l. DNA sequence comparison of IMR32 1.37 and IMR32 1.38 revealed that the __ 1C transcript includes two exons that encode the IVS3 transmembrane domain. IMR32 1.37 has a single exon, nt 3904 to 3987 (SEQ ID No. 3) and IMR32 1.38 appears to be anomalously spliced to contain both exons juxtaposed, nt 3904 to 3987 (SEQ ID No. 3) followed by nt 1 to 84 (SEQ ID No. 6) . The alternative splice of the α ιc transcript to contain either of the two exons encoding the IVS3 region was confirmed by comparing the CNS 1.30 sequence to the IMR32 1.37 sequence. CNS 1.30 contains nt 1 to 84 (SEQ ID No. 6) preceded by the identical sequence contained in IMR32 1.37 for nt 2199 to 3903 (SEQ ID No. 3) . As described in Example II.B.2.a., an intron follows nt 1 to 84 (SEQ ID No. 6) . Two alternative exons have been spliced adjacent to nt 3903 (SEQ ID No. 3) represented by CNS 1.30 and IMR32 1.37. e. IMR32 1.86 IMR32 cDNA library #1 (Example I.B.I.) was screened in duplicate using oligonucleotide probes 90-9 (nt 1462 to 1491, SEQ ID No. 3) and 90-12 (nt 2496 to 2520, SEQ ID No. 3) . These oligonucleotide probes were chosen in order to isolate a clone that encodes the α lc subunit between the 3' end of IMR32 1.67 (nt 1717, SEQ ID No. 3) and the 5' end of CNS 1.30 (nt 2199, SEQ ID No. 3) . The hybridization conditions were standard hybridization conditions (Example I.C.) with the exception that the 50% deionized formamide was reduced to 20%. The filters were washed under low stringency (Example I.C) . Three positive plaques were identified one of which was IMR32 1.86. IMR32 1.86 was plaque purified, subcloned, and characterized by restriction mapping and DNA sequencing. IMR32 1.86 encodes a ιc sequences as described in Example II.B.l. Characterization by DNA sequencing revealed that IMR32 1.86 contains a 73 nt deletion compared to the DNA encoding rabbit cardiac muscle calcium channel α. subunit [Mikami et al . (1989) Nature 340:230], nt 2191 to 2263. These missing nucleotides correspond to nt 2176-2248 of SEQ ID No. 3. Because the 5' -end of CNS 1.30 overlaps the 3'-end of IMR32 1.86, some of these missing nucleotides, i.e., nt 2205- 2248 of SEQ ID No. 3, are accounted for by CNS 1.30. The remaining missing nucleotides of the 73 nucleotide deletion in IMR32 1.86 (i.e., nt 2176-2204 SEQ ID No. 3) were determined by nucleic acid amplification analysis of dbcAMP-induced IMR32 cell RNA. The 73 nt deletion is a frame-shift mutation and, thus, needs to be corrected. The exact human sequence through this region, (which has been determined by the DNA sequence of CNS 1.30 and nucleic acid amplification analysis of IMR32 cell RNA) can be inserted into IMR32 1.86 by standard methods, e. g. , replacement of a restriction fragment or site-directed mutagenesis. f. IMR32 1.157 One million recombinants of IMR32 cDNA library #4 (Example I.B.4.) were screened with an XhoI-EcoRI fragment of IMR32 1.67 encoding α ιc nt 50 to 774 (SEQ ID No. 3) . The hybridization was performed using standard hybridization conditions (Example I.C.) . The filters were washed under high stringency (Example I.C) . One of the positive plaques identified was IMR32 1.157. This plaque was purified, the insert was restriction mapped and subcloned to a standard plasmid vector pGEM7Z (Promega, Madison, WI) . The DNA was characterized by sequencing. IMR32 1.157 appears to encodes an alternative 5' portion of the α ιc sequence beginning with nt 1 to 89 (SEQ ID No. 5) and followed by nt 1 to 873 (SEQ ID No. 3) . Analysis of the 1.66 and 1.157 5' sequence is described below (Example II.B.3.) . 3. Characterization of the α lc initiation of translation site Portions of the sequences of IMR32 1.157 (nt 57 to 89, SEQ ID No. 5; nt 1 to 67, SEQ ID No. 3), IMR32 1.66 (nt 100 to 132, SEQ ID No. 4; nt 1 to 67, SEQ ID No. 3) , were compared to the rabbit lung CaCB-receptor cDNA sequence, nt -33 to 67 [Biel et al . (1990) FEBS Lett . 269:409] . The human sequences are possible alternative 5' ends of the α ιc transcript encoding the region of initiation of translation. IMR32 1.66 closely matches the CaCB receptor cDNA sequence and diverges from the CaCB receptor cDNA sequence in the 5' direction beginning at nt 122 (SEQ ID No. 4) . The start codon identified in the CaCB receptor cDNA sequence is the same start codon used to describe the α ιc coding sequence, nt 1 to 3 (SEQ ID No. 3) . The sequences of α ιc splice variants, designated α.,... and α ιc _, are set forth in SEQ ID NOs. 3 and 36. C. Isolation of partial cDNA clones encoding the α 1B subunit and construction of a full-length clone A human basal ganglia cDNA library was screened with the rabbit skeletal muscle α. subunit cDNA fragments (see Example II.A.2.a for description of fragments) under low stringency conditions. One of the hybridizing clones was used to screen an IMR32 cell cDNA library to obtain additional partial α 1B cDNA clones, which were in turn used to further screen an IMR32 cell cDNA library for additional partial cDNA clones. One of the partial IMR32 α. 1B clones was used to screen a human hippocampus library to obtain a partial α 1B clone encoding the 3' end of the α 1B coding sequence. The sequence of some of the regions of the partial cDNA clones was compared to the sequence of products of nucleic acid amplification analysis of IMR32 cell RNA to determine the accuracy of the cDNA sequences. Nucleic acid amplification analysis analysis of IMR32 cell RNA and genomic DNA using oligonucleotide primers corresponding to sequences located 5' and 3' of the STOP codon of the DNA encoding the α 1B subunit revealed an alternatively spliced α. 1B -encoding mRNA in IMR32 cells. This second mRNA product is the result of differential splicing of the α. αB subunit transcript to include another exon that is not present in the mRNA corresponding to the other 3' α 1B cDNA sequence that was initially isolated. To distinguish these splice variants of the α 1B subunit, the subunit encoded by a DNA sequence corresponding to the form containing the additional exon is referred to as α 1B .. (SEQ ID No. 7) , whereas the subunit encoded by a DNA sequence corresponding to the form lacking the additional exon is referred to as α 1B . 2 (SEQ ID No. 8) . The sequence of Q. 1B _. diverges from that of α 1B _ 2 beginning at nt 6633 (SEQ ID No. 7) . Following the sequence of the additional exon in α 1B _ j. (nt 6633-6819; SEQ ID No. 7), the α 1B _. and a 1B _ 2 sequences are identical (i.e., nt 6820-7362 in SEQ ID No. 7 and nt 6633-7175 in SEQ ID No. 8) . SEQ ID No. 7 and No. 8 set forth 143 nt of 5' untranslated sequence (nt 1-143) as well as 202 nt of 3' untranslated sequence (nt 7161-7362, SEQ ID No. 7) of the DNA encoding α.g.- and 321 nt of 3' untranslated sequence (nt 6855-7175, SEQ ID No. 8) of the DNA encoding α 1B _ 2 . Nucleic acid amplification analysis analysis of the IS6 region of the α 1B transcript revealed what appear to be additional splice variants based on multiple fragment sizes seen on an ethidium bromide-stained agarose gel containing the products of the amplification reaction. A full-length a 1B _ x cDNA clone designated pcDNA-a.j,.. was prepared in an eight-step process as follows. STEP 1: The Sacl restriction site of pGEM3 (Promega, Madison, WI) was destroyed by digestion at the SacI site, producing blunt ends by treatment with T4 DNA polymerase, and religation. The new vector was designated pGEMΔSac. STEP 2: Fragment 1 (Hindlll/Kpnl; nt 2337 to 4303 of SEQ ID No. 7) was ligated into Hindlll/Kpnl digested pGEM3ΔSac to produce pαl.l77HK. STEP 3: Fragment 1 has a 2 nucleotide deletion (nt 3852 and 3853 of SEQ ID No. 7) . The deletion was repaired by inserting an amplfied fragment (fragment 2) of IMR32 RNA into pαl.l77HK. Thus, fragment 2 (Narl/Kpnl ; nt 3828 to 4303 of SEQ ID No. 7) was inserted into Narl/Kpnl digested pαl.l77HK replacing the Narl/Kpnl portion of fragment 1 and producing pal.177HK/PCR. STEP 4: Fragment 3 (Kpnl/Kpnl ; nt 4303 to 5663 of SEQ ID No. 7) was ligated into .Kpnl digested pal.177HK/PCR to produce palB5'K. STEP 5: Fragment 4 (EcoRI/Hindlll; EcoRI adaptor plus nt 1 to 2337 of SEQ ID No. 7) and fragment 5 (Hindlll/Xhol fragment of pαlB5'K; nt 2337 to 5446 of SEQ ID No. 7) were ligated together into EcoRl/Xhol digested pcDNAl (Invitrogen, San Diego, CA) to produce pαlB5' . STEP 6: Fragment 6 (EcoRl/EcoRI; EcoRI adapters on both ends plus nt 5749 to 7362 of SEQ ID No. 7) was ligated into EcoRI digested pBluescript II KS (Stratagene, La Jolla, CA) with the 5' end of the fragment proximal to the Kpnl site in the polylinker to produce p l.230. STEP 7: Fragment 7 (Kpnl/Xhol ; nt 4303 to 5446 of SEQ ID No. 7), and fragment 8 (Xhol/Cεpl ; nt 5446 to 6259 of SEQ ID No. 7) were ligated into Kpnl/Cspl digested p l.230 (removes nt 5749 to 6259 of SEQ ID No. 7 that was encoded in pal.230 and maintains nt 6259 to 7362 of SEQ ID No. 7) to produce pαlB3' . STEP 8: Fragment 9 (Sphl/Xhol ; nt 4993 to 5446 of SEQ ID No. 7) and fragment 10 (Xhol/Xbal of pαlB3' ; nt 5446 to 7319 of SEQ ID No. 7) were ligated into Sphl/Xbal digested pαlB5' (removes nt 4993 to 5446 of SEQ ID No. 7 that were encoded in pαlB5' and maintains nt 1 to 4850 of SEQ ID No. 7) to produce pcDNAα- D ... The resulting construct, pcDNAα 1B _ 1( contains, in pCDNAl, a full-length coding region encoding α 1B _. (nt 144-7362, SEQ ID No. 7), plus 5' untranslated sequence (nt 1-143, SEQ ID No. 7) and 3' untranslated sequence (nt 7161-7319, SEQ ID No. 7) under the transcriptional control of the CMV promoter. D. Isolation of DNA encoding human calcium channel α 1A subunits 1. Isolation of partial clones DNA clones encoding portions of human calcium channel α 1A subunits were obtained by hybridization screening of human cerebellum cDNA libraries and nucleic acid amplification of human cerebellum RNA. Clones corresponding to the 3' end of the α 1A coding sequence were isolated by screening 1 x 10 6 recombinants of a randomly primed cerebellum cDNA library (size-selected for inserts greater than 2.8 kb in length) under low stringency conditions (6X SSPE, 5X Denhart's solution, 0.2% SDS, 200 μg/ml sonicated herring sperm DNA, 42°C) with oligonucleotide 704 containing nt 6190-6217 of the rat α 1A coding sequence [Starr et al . (1992) Proc. Natl . Acad. Sci . U. S.A. 85:5621-5625] . Washes were performed under low stringency conditions. Several clones that hybridized to the probe (clones αl.251-αl.259 and αl.244) were purified and characterized by restriction enzyme mapping and DNA sequence analysis. At least two of the clones, αl.244 and αl.254, contained a translation termination codon. Although clones αl.244 and αl.254 are different lengths, they both contain a sequence of nucleotides that corresponds to the extreme 3' end of the α 1A transcript, i.e., the two clones overlap. These two clones are identical in the region of overlap, except, clone αl.244 contains a sequence of 5 and a sequence of 12 nucleotides that are not present in αl.254. To obtain additional α 1A -encoding clones, 1 x 10 6 recombinants of a randomly primed cerebellum cDNA library (size-selected for inserts ranging from 1.0 to 2.8 kb in length) was screened for hybridization to three oligonucleotides: oligonucleotide 701 (containing nucleotides 2288-2315 of the rat α 1A coding sequence) , oligonucleotide 702 (containing nucleotides 3559-3585 of the rat α 1A coding sequence) and oligonucleotide 703 (containing nucleotides 4798-4827 of the rat α 1A coding sequence) . Hybridization and washes were performed using the same conditions as used for the first screening with oligonucleotide 704, except that washes were conducted at 45°C Twenty clones (clones αl.269- αl.288) hybridized to the probe. Several clones were plaque- purified and characterized by restriction enzyme mapping and DNA sequence analysis. One clone, αl.279, contained a sequence of about 170 nucleotides that is not present in other clones corresponding to the same region of the coding sequence. This region may be present in other splice variants. None of the clones contained a translation intiation codon. To obtain clones corresponding to the 5' end of the human α 1A coding sequence, another cerebellum cDNA library was prepared using oligonucleotide 720 (containing nucleotides 2485-2510 of SEQ ID No. 22) to specifically prime first-strand cDNA synthesis. The library (8 x 10 5 recombinants) was screened for hybridization to three oligonucleotides: oligonucleotide 701, oligonucleotide 726 (containing nucleotides 2333-2360 of the rat α 1A coding sequence) and oligonucleotide 700 (containing nucleotides 767-796 of the rat α 1A coding sequence) under low stringency hybridization and washing conditions. Approximately 50 plaques hybridized to the probe. Hybridizing clones αl.381-αl.390 were plaque- purified and characterized by restriction enzyme maping and DNA sequence analysis. At least one of the clones, αl.381, contained a translation initiation codon. Alignment of the sequences of the purified clones revealed that the sequences overlapped to comprise the entire α 1A coding sequence. However, not all the overlapping sequences of partial clones contained convenient enzyme restriction sites for use in ligating partial clones to construct a full-length α 1A coding sequence. To obtain DNA fragments containing convenient restriction enzyme sites that could be used in constructing a full-length α 1A DNA, cDNA was synthesized from RNA isolated from human cerebellum tissue and subjected to nucleic acid amplification. The oligonucleotides used as primers corresponded to human α 1A coding sequence located 5' and 3' of selected restriction enzyme sites. Thus, in the first amplification reaction, oligonucleotides 753 (containing nucleotides 2368-2391 of SEQ ID No. 22) and 728 (containing nucleotides 3179-3202 of SEQ ID No. 22) were used as the primer pair. To provide a sufficient amount of the desired DNA fragment, the product of this amplification was reamplified using oligonucleotides 753 and 754 (containing nucleotides 3112-3135 of SEQ ID No. 22 as the primer pair. The resulting product was 768 bp in length. In the second amplification reaction, oligonucleotides 719 (containing nucleotides 4950-4975 of SEQ ID No. 22 and 752 (containing nucleotides 5647-5670 of SEQ ID No. 22) were used as the primer pair. To provide a sufficient amount of the desired second DNA fragment, the product of this amplification was reamplified using oligonucleotides 756 (containing nucleotides 5112-5135 of SEQ ID No. 22) and 752 as the primer pair. The resulting product was 559 bp in length. 2. Construction of full-Length α 1A coding sequences Portions of clone αl.381, the 768-bp nucleic acid amplification product, clone αl.278, the 559-bp nucleic acid amplification product, and clone αl.244 were ligated at convenient restriction sites to generate a full-length α 1A coding sequence referred to as α 1A ... Comparison of the results of sequence analysis of clones αl.244 and αl.254 indicated that the primary transcript of the α 1A subunit gene is alternatively spliced to yield at least two variant mRNAs encoding different forms of the α 1A subunit. One form, a lh . l t is encoded by the sequence shown in SEQ ID No. 22. The sequence encoding a second form, α 1A _ 2 , differs from the α 1A . --encoding sequence at the 3' end in that it lacks a 5-nt sequence found in clone αl.244 (nucleotides 7035-7039 of SEQ ID No. 22) . This deletion shifts the reading frame and introduces a translation termination codon resulting in an α 1A _ 2 coding sequence that encodes a shorter α 1A subunit than that encoded by the α 1A .. splice variant. Consequently, a portion of the 3' end of the α 1A _- coding sequence is actually 3' untranslated sequence in the α 1A _ 2 DNA. The complete sequence °f a i fκ - 2 > which can be constructed by ligating portions of clone αl.38l, the 768-bp nucleic acid amplification product, clone αl.278, the 559-bp nucleic acid amplification product and clone αl.254, is set forth in SEQ ID No. 23. E. Isolation of DNA Encoding the α 1E Subunit DNA encoding α 1E subunits of the human calcium channel were isolated from human hippocampus libraries. The selected clones sequenced. DNA sequence analysis of DNA clones encoding the α 1E subunit indicated that at least two alternatively spliced forms of the same α 1E subunit primary transcript are expressed. One form has the sequence set forth in SEQ ID No. 24 and was designated α 1E _. and the other was designated α 1E _ 3 , which has the sequence obtained by inserting a 57 base pair fragment between nucleotides 2405 and 2406 of SEQ ID No. 24. The resulting sequence is set forth in SEQ ID No. 25. The subunit designated α 1E _. has a calculated molecular weight of 254,836 and the subunit designated α 1E _ 3 has a calculated molecular weight of 257,348. α 1E _ 3 has a 19 amino acid insertion (encoded by SEQ ID No. 25) relative to α 1E _. in the region that appears to be the cytoplasmic loop between transmembrane domains IIS6 and IIIS1. EXAMPLE III: ISOLATION OF CDNA CLONES ENCODING THE HUMAN NEURONAL CALCIUM CHANNEL jS. subunit A. Isolation of partial cDNA clones encoding the β subunit and construction of a full-length clone encoding the 3. subunit A human hippocampus cDNA library was screened with the rabbit skeletal muscle calcium channel β. subunit cDNA fragment (nt 441 to 1379) [for isolation and sequence of the rabbit skeletal muscle calcium channel 0. subunit cDNA, see U.S. Patent Application Serial NO. 482,384 or Ruth et al . (1989) Science 245:1115] using standard hybridization conditions (Example I.e.) . A portion of one of the hybridizing clones was used to rescreen the hippocampus library to obtain additional cDNA clones. The cDNA inserts of hybridizing clones were characterized by restriction mapping and DNA sequencing and compared to the rabbit skeletal muscle calcium channel /?. subunit cDNA sequence. Portions of the partial jβ. subunit cDNA clones were ligated to generate a full-length clone encoding the entire β λ subunit. SEQ ID No. 9 shows the β- subunit coding sequence (nt 1-1434) as well as a portion of the 3' untranslated sequence (nt 1435-1546) . The deduced amino acid sequence is also provided in SEQ ID No. 9. In order to perform expression experiments, full-length β-_ subunit cDNA clones were constructed as follows. Step 1: DNA fragment 1 (-800 bp of 5' untranslated sequence plus nt 1-277 of SEQ ID No. 9) was ligated to DNA fragment 2 (nt 277-1546 of SEQ ID No. 9 plus 448 bp of intron sequence) and cloned into pGEM7Z. The resulting plasmid, pSl- 1.18, contained a full-length /?. subunit clone that included a 448-bp intron. Step 2: To replace the 5' untranslated sequence of pβl- 1.18 with a ribosome binding site, a double-stranded adapter was synthesized that contains an .EcoRI site, sequence encoding a ribosome binding site (5' -ACCACC-3' ) and nt 1-25 of SEQ ID No. 9. The adapter was ligated to Smal-digested p?l-1.18, and the products of the ligation reaction were digested with .EcoRI. Step 3: The .EcoRI fragment from step 2 containing the .EcoRI adapter, efficient ribosome binding site and nt 1-1546 of SEQ ID No. 9 plus intron sequence was cloned into a plasmid vector and designated p/31-1.18RBS. The EcoRI fragment of pSl- 1.18RBS was subcloned into JScoRI-digested pcDNAl with the initiation codon proximal to CMV promoter to form pHBCaCH/3 la RBS (A) . Step 4: To generate a full-length clone encoding the S. subunit lacking intron sequence, DNA fragment 3 (nt 69-1146 of SEQ ID No. 9 plus 448 bp of intron sequence followed by nt 1147-1546 of SEQ ID No. 9) , was subjected to site-directed mutagenesis to delete the intron sequence, thereby yielding pjSl(-). The EcoRI-XhoI fragment of p?l-1.18RBS (containing of the ribosome binding site and nt 1-277 of SEQ ID No. 9) was ligated to the XhoI-EcoRI fragment of p3l(-) (containing of nt 277-1546 of SEQ ID No. 9) and cloned into pcDNAl with the initiation of translation proximal to the CMV promoter. The resulting expression plasmid was designated pHBCaCH? lb RBS (A) . B. Splice Variant S.. 3 DNA sequence analysis of the DNA clones encoding the ?. subunit indicated that in the CNS at least two alternatively spliced forms of the same human S. subunit primary transcript are expressed. One form is represented by the sequence shown in SEQ ID No. 9 and is referred to as β 1 _ 2 . The sequences of β x _ 2 and the alternative form, β 1 _ 3 , diverge at nt 1334 (SEQ ID No. 9) . The complete β 1 _ 3 sequence (nt 1-1851) , including 3' untranslated sequence (nt 1795-1851), is set forth in SEQ ID No. 10. EXAMPLE IV: ISOLATION OF CDNA CLONES ENCODING THE HUMAN NEURONAL CALCIUM CHANNEL α. 2 -subunit A. Isolation of cDNA clones The complete human neuronal α 2 coding sequence (nt 35- 3310) plus a portion of the 5' untranslated sequence (nt 1 to 34) as well as a portion of the 3' untranslated sequence (nt 3311-3600) is set forth in SEQ ID No. 11. To isolate DNA encoding the human neuronal α 2 subunit, human α 2 genomic clones first were isolated by probing human genomic Southern blots using a rabbit skeletal muscle calcium channel α 2 subunit cDNA fragment [nt 43 to 272, Ellis et al . (1988) Science 240:1661] . Human genomic DNA was digested with EcoRI, electrophoresed, blotted, and probed with the rabbit skeletal muscle probe using standard hybridization conditions (Example I.C.) and low stringency washing conditions (Example I.C) . Two restriction fragments were identified, 3.5 kb and 3.0 kb. These EcoRI restriction fragments were cloned by preparing a λgtll library containing human genomic EcoRI fragments ranging from 2.2 kb to 4.3 kb. The library was screened as described above using the rabbit α 2 probe, hybridizing clones were isolated and characterized by DNA sequencing. HGCaCHα2.20 contained the 3.5 kb fragment and HGCaCHα2.9 contained the 3.0 kb fragment. Restriction mapping and DNA sequencing revealed that HGCaCHα2.20 contains an 82 bp exon (nt 130 to 211 of the human α 2 coding sequence, SEQ ID No. 11) on a 650 bp Pstl-Xbal restriction fragment and that HGCaCHα2.9 contains 105 bp of an exon (nt 212 to 316 of the coding sequence, SEQ ID No. 11) on a 750 bp Xbal-Bglll restriction fragment. These restriction fragments were used to screen the human basal ganglia cDNA library (Example II.C2.a.) . HBCaCHα2.1 was isolated (nt 29 to 1163, SEQ ID No. 11) and used to screen a human brain stem cDNA library (ATCC Accession No. 37432) obtained from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD. 20852. Two clones were isolated, HBCaCHα2.5 (nt 1 to 1162, SEQ ID No. 11) and HBCaCHα2.8 (nt 714 to 1562, SEQ ID No. 11, followed by 1600 nt of intervening sequence) . A 2400 bp fragment of HBCaCHα2.8 (beginning at nt 759 of SEQ ID No. 11 and ending at a Smal site in the intron) was used to rescreen the brain stem library and to isolate HBCaCHα2.11 (nt 879 to 3600, SEQ ID No. 11). Clones HBCaCHα2.5 and HBCaCHα2.11 overlap to encode an entire human brain α 2 protein. B. Construction of pHBCaCHα-A To construct pHBCaCHα 2 A containing DNA encoding a full- length human calcium channel α 2 subunit, an (EcoRI) -PvuII fragment of HBCaCHα2.5 (nt 1 to 1061, SEQ ID No. 11, EcoRI adapter, PvuII partial digest) and a PvuII-PstI fragment of HBCaCHα2.11 (nt 1061 to 2424 SEQ ID No. 11; PvuII partial digest) were ligated into EcoRI-PstI-digested pIBI24 (Stratagene, La Jolla, CA) . Subsequently, an (EcoRI) -PstI fragment (nt 1 to 2424 SEQ ID No. 11) was isolated and ligated to a PstI- (EcoRI) fragment (nt 2424 to 3600 SEQ ID No. 11) of HBCaCHα2.11 in EcoRI-digested pIBI24 to produce DNA, HBCaCHα2, encoding a full-length human brain α 2 subunit. The 3600 bp EcoRI insert of HBCaCHα2 (nt 1 to 3600, SEQ ID No. 11) was subcloned into pcDNAl (pHBCaCHα2A) with the methionine initiating codon proximal to the CMV promoter. The 3600 bp EcoRI insert of HBCaCHα2 was also subcloned into pSV2dHFR [Subramani et al . (1981) . Mol . Cell . Biol . 1:854-864] which contains the SV40 early promoter, mouse dihydrofolate reductase (dhfr) gene, SV40 polyadenylation and splice sites and sequences required for maintenance of the vector in bacteria. EXAMPLE V. DIFFERENTIAL PROCESSING OF THE HUMAN / S. TRANSCRIPT AND THE HUMAN a 2 TRANSCRIPT A. Differential processing of the jS. transcript Nucleic acid amplification analysis of the human β x transcript present in skeletal muscle, aorta, hippocampus and basal ganglia, and HEK 293 cells revealed differential processing of the region corresponding to nt 615-781 of SEQ ID No. 9 in each of the tissues. Four different sequences that result in five different processed J- transcripts through this region were identified. The β x transcripts from the different tissues contained different combinations of the four sequences, except for one of the β x transcripts expressed in HEK 293 cells (jβ j. . 5 ) which lacked all four sequences. None of the β transcripts contained each of the four sequences; however, for ease of reference, all four sequences are set forth end-to-end as a single long sequence in SEQ ID No. 12. The four sequences that are differentially processed are sequence 1 (nt 14-34 in SEQ ID No. 12) , sequence 2 (nt 35- 55 in SEQ ID No. 12), sequence 3 (nt 56-190 in SEQ ID No. 12) and sequence 4 (nt 191-271 in SEQ ID No. 12) . The forms of the β transcript that have been identified include: (1) a form that lacks sequence 1 called S... (expressed in skeletal muscle) , (2) a form that lacks sequences 2 and 3 called / S._ 2 (expressed in CNS) , (3) a form that lacks sequences 1, 2 and 3 called /S-_ 4 (expressed in aorta and HEK cells) and (4) a form that lacks sequences 1-4 called β 1 _ s (expressed in HEK cells) . Additionally, the jβ^ and β . s contain a guanine nucleotide (nt 13 in SEQ ID No. 12) that is absent in the ?..- and /_.._- forms. The sequences of / S. splice variants are set forth in SEQ ID Nos. 9, 10 and 33-35. B. Differential processing of transcripts encoding the 2 subunit. The complete human neuronal α 2 coding sequence (nt 35- 3307) plus a portion of the 5' untranslated sequence (nt 1 to 34) as well as a portion of the 3' untranslated sequence (nt 3308-3600) is set forth as SEQ ID No. 11. Nucleic acid amplification analysis of the human α 2 transcript present in skeletal muscle, aorta, and CNS revealed differential processing of the region corresponding to nt 1595-1942 of SEQ ID No. 11 in each of the tissues. The analysis indicated that the primary transcript of the genomic DNA that includes the nucleotides corresponding to nt 1595-1942 also includes an additional sequence (SEQ ID No. 13 : 5 ' CCTATTGGTGTAGGTATACCAACAATTAATTT AAGAAAAAGGAGACCCAATATCCAG 3' ) inserted between nt 1624 and 1625 of SEQ ID No. 11. Five alternatively spliced variant transcripts that differ in the presence or absence of one to three different portions of the region of the primary transcript that includes the region of nt 1595-1942 of SEQ ID No. 11 plus SEQ ID No. 13 inserted between nt 1624 and 1625 have been identified. The five α 2 -encoding transcripts from the different tissues include different combinations of the three sequences, except for one of the α 2 transcripts expressed in aorta which lacks all three sequences. None of the α 2 transcripts contained each of the three sequences. The sequences of the three regions that are differentially processed are sequence 1 (SEQ ID No. 13) , sequence 2 ( 5' AACCCCAAATCTCAG 3', which is nt 1625-1639 of SEQ ID No. 11), and sequence 3 ( 5' CAAAAAAGGGCAAAATGAAGG 3', which is nt 1908-1928 of SEQ ID No. 11) . The five α 2 forms identified are (1) a form that lacks sequence 3 called α 2a (expressed in skeletal muscle) , (2) a form that lacks sequence 1 called α 2b (expressed in CNS) , (3) a form that lacks sequences 1 and 2 called α 2c expressed in aorta) , (4) a form that lacks sequences 1, 2 and 3 called α 2d (expressed in aorta) and (5) a form that lacks sequences 1 and 3 called α 2e (expressed in aorta) . The sequences of α 2a - α 2e are set forth in SEQ. ID Nos. 29 - 32, respectively. EXAMPLE VI: ISOLATION OF DNA ENCODING A CALCIUM CHANNEL γ SUBUNIT FROM A HUMAN BRAIN CDNA LIBRARY A. Isolation of DNA encoding the γ subunit Approximately 1 x 10 6 recombinants from a λgtll-based human hippocampus cDNA library (Clontech catalog #HL1088b, Palo Alto, CA) were screened by hybridization to a 484 bp sequence of the rabbit skeletal muscle calcium channel γ subunit cDNA (nucleotides 621-626 of the coding sequence plus 438 nucleotides of 3' -untranslated sequence) contained in vector γJlO [Jay, S. et al . (1990) . Science 245:490-492] . Hybridization was performed using moderate stringency conditions (20% deionized formamide, 5x Denhardt's, 6 x SSPE, 0.2% SDS, 20 μg/ml herring sperm DNA, 42°C) and the filters were washed under low stringency (see Example I.C.) . A plaque that hybridized to this probe was purified and insert DNA was subcloned into pGEM7Z. This cDNA insert was designated γl.4. B. Characterization of γl.4 γl.4 was confirmed by DNA hybridization and characterized by DNA sequencing. The 1500 bp Sstl fragment of γl.4 hybridized to the rabbit skeletal muscle calcium channel γ subunit cDNA γJlO on a Southern blot. SEQ analysis of this fragment revealed that it contains of approximately 500 nt of human DNA sequence and -1000 nt of λgtll sequence (included due to apparent destruction of one of the EcoRI cloning sites in λgtll) . The human DNA sequence contains of 129 nt of coding sequence followed immediately by a translational STOP codon and 3' untranslated sequence (SEQ ID No. 14) . To isolate the remaining 5' sequence of the human γ subunit cDNA, human CNS cDNA libraries and/or preparations of mRNA from human CNS tissues can first be assayed by nucleic acid amplification analysis methods using oligonucleotide primers based on the γ cDNA-specific sequence of γl.4. Additional human neuronal γ subunit-encoding DNA can be isolated from cDNA libraries that, based on the results of the nucleic acid amplification analysis assay, contain γ-specific amplifiable cDNA. Alternatively, cDNA libraries can be constructed from mRNA preparations that, based on the results of the nucleic acid amplification analysis assays, contain γ- specific amplifiable transcripts. Such libraries are constructed by standard methods using oligo dT to prime first- strand cDNA synthesis from poly A + RNA (see Example I.B.) . Alternatively, first-strand cDNA can be specified by priming first-strand cDNA synthesis with a γ cDNA-specific oligonucleotide based on the human DNA sequence in γl.4. A cDNA library can then be constructed based on this first- strand synthesis and screened with the γ-specific portion of γl.4. EXAMPLE VII: ISOLATION OF CDNA CLONES ENCODING THE HUMAN NEURONAL Ca CHANNEL β 2 SUBUNIT Isolation of DNA Encoding human calcium channel β 2 subunits Sequencing of clones isolated as described in Example III revealed a clone encoding a human neuronal calcium channel β 2 subunit (designated β 2D see, SEQ ID No. 26) . An oligonucleotide based on the 5' end of this clone was used to prime a human hippocampus cDNA library. The library was screened with this β 2 clone under conditions of low to medium stringency (final wash 0.5 X SSPE, 50° C) . Several hybridizing clones were isolated and sequenced. Among these clones were those that encode β 2C , β 2D and β 2E . For example, the sequence of β 2C is set forth in SEQ ID NO. 37, and the sequeence of β 2E is set forth in SEQ ID No. 38. A randomly primed hippocampus library was then screened using a combination of the clone encoding β 2τ> and a portion of the β 3 clone deposited under ATCC Accession No. 69048. Multiple hybridizing clones were isolated. Among these were clones designated 0101, 0102 and 0104. jδlOl appears to encodes the 5' end of a splice variant of β 2 , designated β 2E . 0102 and 0104 encode portions of the 3' end of β 2 . It appears that the β 2 splice variants include nucleotides 182-2294 of SEQ ID No. 26 and differ only between the start codon and nucleotides that correspond to 212 of SEQ. ID No. 26. EXAMPLE VIII: ISOLATION OF cDNA CLONES ENCODING HUMAN CALCIUM CHANNEL β 4 and β 3 SUBUNITS A. Isolation of cDNA Clones Encoding a Human β 4 Subunit A clone containing a translation initiation codon and approximately 60% of the β 4 coding sequence was obtained from a human cerebellum cDNA library (see nucleotides 1-894 of Sequence ID No. 27) . To obtain DNA encoding the remaining 3' portion of the β 4 coding sequence, a human cerebellum cDNA library was screened for hybridization a nucleic acid amplification product under high stringency hybridization and wash conditions. Hybridizing clones are purified and characterized by restriction enzyme mapping and DNA sequence analysis to identify those that contain sequence corresponding to the 3' end of the β 4 subunit coding sequence and a termination codon. Selected clones are ligated to the clone containing the 5' half of the β 4 coding sequence at convenient restriction sites to generate a full-length cDNA encoding a β 4 subunit. The sequence of a full-length β 4 clone is set forth in SEQ ID No. 27; the amino acid sequence is set forth in SEQ ID No. 28. B. Isolation of cDNA Clones Encoding a Human 03 Subunit Sequencing of clones isolated as described in Example III also revealed a clone encoding a human neuronal calcium channel 0 3 subunit. This clone has been deposited as plasmid 01.42 (ATCC Accession No. 69048). To isolate a full-length cDNA clone encoding a complete 0 3 subunit, a human hippocampus cDNA library (Stratagene, La Jolla, CA) was screened for hybridization to a 5' EcoRI-PstI fragment of the cDNA encoding βχ__ 2 using lower stringency hybridization conditions (20% deionized formamide, 200 μg/ml sonicated herring sperm DNA, 5X SSPE, 5X Denhardt's solution, 42° C) and wash conditions. One of the hybridizing clones contained both translation initiation and termination codons and encodes a complete 0 3 subunit designated 0 3 _. (Sequence ID No. 19) . In vi tro transcripts of the cDNA were prepared and injected into Xenopus oocytes along with transcripts of the - 1B _ ι and α 2b cDNAs using methods similiar to those described in Example IX.D. Two-electrode voltage clamp recordings of the oocytes revealed significant voltage-dependent inward Ba 2+ currents. An additional 0 3 subunit-encoding clone, designated 0 3 _ 2 , was obtained by screening a human cerebellum cDNA library for hybridization to the nucleic acid amplification product referred to in Example VIII.A. under lower stringency (20% deionized formamide, 200 μg/ml sonicated herring sperm DNA, 5X SSPE, 5X Denhardt's solution, 42° C) hybridization and wash conditions. The 5' ends of this clone (Sequence ID No. 20, 0 3 . 2 ) and the first 0 3 subunit, designated 0 3 _ ι; (Sequence ID No. 19) differ at their 5' ends and are splice variants of the 0 3 gene. EXAMPLE IX: RECOMBINANT EXPRESSION OF HUMAN NEURONAL CALCIUM CHANNEL SUBUNIT-ENCODING cDNA AND RNA TRANSCRIPTS IN MAMMALIAN CELLS A. Recombinant Expression of the Human Neuronal Calcium Channel a 2 subunit cDNA in DG44 Cells 1. Stable transfection of DG44 cells DG44 cells [dhfr " Chinese hamster ovary cells; see, e. g. , Urlaub, G. et al . (1986) Som. Cell Molec. Genet . 12:555-566] obtained from Lawrence Chasin at Columbia University were stably transfected by CaP0 4 precipitation methods [Wigler et al . (1979) Proc . Natl . Acad. Sci . USA 76:1373-1376] with pSV2dhfr vector containing the human neuronal calcium channel α 2 -subunit cDNA (see Example IV) for polycistronic expression/selection in transfected cells. Transfectants were grown on 10% DMEM medium without hypoxanthine or thymidine in order to select cells that had incorporated the expression vector. Twelve transfectant cell lines were established as indicated by their ability to survive on this medium. 2. Analysis of 2 subunit cDNA expression in transfected DG44 cells Total RNA was extracted according to the method of Birnboim [(1988) Nuc. Acidε Reε . 16:1487-1497] from four of the DG44 cell lines that had been stably transfected with pSV2dhfr containing the human neuronal calcium channel α 2 subunit cDNA. RNA (-15 μg per lane) was separated on a 1% agarose formaldehyde gel, transferred to nitrocellulose and hybridized to the random-primed human neuronal calcium channel α 2 cDNA (hybridization: 50% formamide, 5 x SSPE, 5 x Denhardt's, 42° C; wash :0.2 x SSPE, 0.1% SDS, 65° C) . Northern blot analysis of total RNA from four of the DG44 cell lines that had been stably transfected with pSV2dhfr containing the human neuronal calcium channel α 2 subunit cDNA revealed that one of the four cell lines contained hybridizing mRNA the size expected for the transcript of the α 2 subunit cDNA (5000 nt based on the size of the cDNA) when grown in the presence of 10 mM sodium butyrate for two days. Butyrate nonspecifically induces transcription and is often used for inducing the SV40 early promoter [Gorman, C and Howard, B. (1983) Nucleic Acidε Reε. 11:1631] . This cell line, 44α 2 -9, also produced mRNA species smaller (several species) and larger (6800 nt) than the size expected for the transcript of the α 2 cDNA (5000 nt) that hybridized to the α 2 cDNA-based probe. The 5000- and 6800-nt transcripts produced by this transfectant should contain the entire α 2 subunit coding sequence and therefore should yield a full-length α 2 subunit protein. A weakly hybridizing 8000-nucleotide transcript was present in untransfected and transfected DG44 cells. Apparently, DG44 cells transcribe a calcium channel α 2 subunit or similar gene at low levels. The level of expression of this endogenous α 2 subunit transcript did not appear to be affected by exposing the cells to butyrate before isolation of RNA for northern analysis. Total protein was extracted from three of the DG44 cell lines that had been stably transfected with pSV2dhfr containing the human neuronal calcium channel α 2 subunit cDNA. Approximately 10 7 cells were sonicated in 300 μl of a solution containing 50 mM HEPES, 1 mM EDTA, 1 mM PMSF. An equal volume of 2x loading dye [Laemmli, U.K. (1970) . Nature 227:680] was added to the samples and the protein was subjected to electrophoresis on an 8% polyacrylamide gel and then electrotransferred to nitrocellulose. The nitrocellulose was incubated with polyclonal guinea pig antisera (1:200 dilution) directed against the rabbit skeletal muscle calcium channel α 2 subunit (obtained from K. Campbell, University of Iowa) followed by incubation with [ 125 I] -protein A. The blot was exposed to X-ray film at -70° C. Reduced samples of protein from the transfected cells as well as from untransfected DG44 cells contained immunoreactive protein of the size expected for the α 2 subunit of the human neuronal calcium channel (130- 150 kDa) . The level of this immunoreactive protein was higher in 44α 2 -9 cells that had been grown in the presence of 10 mM sodium butyrate than in 44α 2 -9 cells that were grown in the absence of sodium butyrate. These data correlate well with those obtained in northern analyses of total RΝA from 44α 2 -9 and untransfected DG44 cells. Cell line 44α 2 -9 also produced a 110 kD immunoreactive protein that may be either a product of proteolytic degradation of the full-length α 2 subunit or a product of translation of one of the shorter (<5000 nt) πtRΝAs produced in this cell line that hybridized to the α 2 subunit cDΝA probe. B. Expression of DΝA encoding human neuronal calcium channel α., 2 and 0. subunits in HEK cells Human embryonic kidney cells (HEK 293 cells) were transiently and stably transfected with human neuronal DΝA encoding calcium channel subunits. Individual transfectants were analyzed electrophysiologically for the presence of voltage-activated barium currents and functional recombinant voltage-dependent calcium channels were. 1. Transfection of HEK 293 cells Separate expression vectors containing DNA encoding human neuronal calcium channel α 1D , α 2 and 0. subunits, plasmids pVDCCIII (A), pHBCaCHα 2 A, and pHBCaCH0 Za RBS(A) , respectively, were constructed as described in Examples II.A.3, IV.B. and III.B.3., respectively. These three vectors were used to transiently co-transfect HEK 293 cells. For stable transfection of HEK 293 cells, vector pHBCaCH0 lb RBS(A) (Example III.B.3.) was used in place of pHBCaCH0 la RBS (A) to introduce the DNA encoding the 0- subunit into the cells along with pVDCCIII (A) and pHBCaCHα 2 A. a. Transient transfection Expression vectors pVDCCIII (A) , pHBCaCHα 2 A and pHBCaCH0 la RBS (A) were used in two sets of transient transfections of HEK 293 cells (ATCC Accession No. CRL1573) . In one transfection procedure, HEK 293 cells were transiently cotransfected with the α. subunit cDNA expression plasmid, the α 2 subunit cDNA expression plasmid, the β x subunit cDNA expression plasmid and plasmid pCMVøgal (Clontech Laboratories, Palo Alto, CA) . Plasmid pCMVøgal contains the lacZ gene (encoding E. coli 0-galactosidase) fused to the cytomegalovirus (CMV) promoter and was included in this transfection as a marker gene for monitoring the efficiency of transfection. In the other transfection procedure, HEK 293 cells were transiently co-transfected with the α. subunit cDNA expression plasmid pVDCCIII (A) and pCMVøgal. In both transfections, 2-4 x 10 6 HEK 293 cells in a 10-cm tissue culture plate were transiently co-transfected with 5 μg of each of the plasmids included in the experiment according to standard CaP0 4 precipitation transfection procedures (Wigler et al . (1979) Proc . Natl . Acad . Sci . USA 76:1373-1376) . The transfectants were analyzed for 0-galactosidase expression by direct staining of the product of a reaction involving 0- galactosidase and the X-gal substrate [Jones, J.R. (1986) EMBO 5:3133-3142] and by measurement of 0-galactosidase activity [Miller, J.H. (1972) Experiments in Molecular Genetics, pp. 352-355, Cold Spring Harbor Press] . To evaluate subunit cDNA expression in these transfectants, the cells were analyzed for subunit transcript production (northern analysis) , subunit protein production (immunoblot analysis of cell lysates) and functional calcium channel expression (electrophysiological analysis) . b. Stable transfection HEK 293 cells were transfected using the calcium phosphate transfection procedure [Current Protocolε in Molecular Biology, Vol. 1, Wiley Inter-Science, Supplement 14, Unit 9.1.1-9.1.9 (1990)] . Ten-cm plates, each containing one- to-two million HEK 293 cells, were transfected with 1 ml of DNA/calcium phosphate precipitate containing 5 μg pVDCCIII (A) , 5 μg pHBCaCHα 2 A, 5μg pHBCaCH0 lb RBS (A) , 5 μg pCMVBgal and 1 μg pSV2neo (as a selectable marker) . After 10-20 days of growth in media containing 500 μg G418, colonies had formed and were isolated using cloning cylinders. 2. Analysis of HEK 293 cells transiently transfected with DNA encoding human neuronal calcium channel subunits a. Analysis of 0-galactoβidase expression Transient transfectants were assayed for 0-galactosidase expression by 0-galactosidase activity assays (Miller, J.H., (1972) Experiments in Molecular Genetics, pp. 352-355, Cold Spring Harbor Press) of cell lysates (prepared as described in Example VII.A.2) and staining of fixed cells (Jones, J.R. (1986) EMBO 5:3133-3142) . The results of these assays indicated that approximately 30% of the HEK 293 cells had been transfected. b. Northern analysis PolyA+ RNA was isolated using the Invitrogen Fast Trak Kit (InVitrogen, San Diego, CA) from HEK 293 cells transiently transfected with DNA encoding each of the α., α 2 and 0. subunits and the lacZ gene or the α- subunit and the lacZ gene. The RNA was subjected to electrophoresis on an agarose gel and transferred to nitrocellulose. The nitrocellulose was then hybridized with one or more of the following radiolabeled probes: the lacZ gene, human neuronal calcium channel α 1D subunit-encoding cDNA, human neuronal calcium channel α 2 subunit-encoding cDNA or human neuronal calcium channel 0. subunit-encoding cDNA. Two transcripts that hybridized with the α. subunit-encoding cDNA were detected in HEK 293 cells transfected with the DNA encoding the α-, α 2 , and 0. subunits and the lacZ gene as well as in HEK 293 cells transfected with the α. subunit cDNA and the lacZ gene. One mRNA species was the size expected for the transcript of the α. subunit cDNA (8000 nucleotides) . The second RNA species was smaller (4000 nucleotides) than the size expected for this transcript. RNA of the size expected for the transcript of the lacZ gene was detected in cells transfected with the α., α 2 and 0. subunit- encoding cDNA and the lacZ gene and in cells transfected with the α. subunit cDNA and the lacZ gene by hybridization to the lacZ gene sequence. RNA from cells transfected with the α., α 2 and 0. subunit- encoding cDNA and the lacZ gene was also hybridized with the α 2 and 0. subunit cDNA probes. Two mRNA species hybridized to the α 2 subunit cDNA probe. One species was the size expected for the transcript of the α 2 subunit cDNA (4000 nucleotides) . The other species was larger (6000 nucleotides) than the expected size of this transcript. Multiple RNA species in the cells co-transfected with α-, α 2 and 0 X subunit-encoding cDNA and the lacZ gene hybridized to the 0. subunit cDNA probe. Multiple 0 subunit transcripts of varying sizes were produced since the 0 subunit cDNA expression vector contains two potential polyA* addition sites. c. Electrophysiological analysis Individual transiently transfected HEK 293 cells were assayed for the presence of voltage-dependent barium currents using the whole-cell variant of the patch clamp technique [Hamill et al. (1981) . Pflugerε Arch. 391:85-100] . HEK 293 cells transiently transfected with pCMVøgal only were assayed for barium currents as a negative control in these experiments. The cells were placed in a bathing solution that contained barium ions to serve as the current carrier. Choline chloride, instead of NaCl or KCl, was used as the major salt component of the bath solution to eliminate currents through sodium and potassium channels. The bathing solution contained 1 mM MgCl 2 and was buffered at pH 7.3 with 10 mM HEPES (pH adjusted with sodium or tetraethylammonium hydroxide) . Patch pipettes were filled with a solution containing 135 mM CsCl, 1 mM MgCl 2 , 10 mM glucose, 10 mM EGTA, 4 mM ATP and 10 mM HEPES (pH adjusted to 7.3 with tetraethylammonium hydroxide) . Cesium and tetraethylammonium ions block most types of potassium channels. Pipettes were coated with Sylgard (Dow-Corning, Midland, MI) and had resistances of 1-4 megohm. Currents were measured through a 500 megohm headstage resistor with the Axopatch IC (Axon Instruments, Foster City, CA) amplifier, interfaced with a Labmaster (Scientific Solutions, Solon, OH) data acquisition board in an IBM-compatible PC. PClamp (Axon Instruments) was used to generate voltage commands and acquire data. Data were analyzed with pClamp or Quattro Professional (Borland International, Scotts Valley, CA) programs. To apply drugs, "puffer" pipettes positioned within several micrometers of the cell under study were used to apply solutions by pressure application. The drugs used for pharmacological characterization were dissolved in a solution identical to the bathing solution. Samples of a 10 mM stock solution of Bay K 8644 (RBI, Natick, MA), which was prepared in DMSO, were diluted to a final concentration of 1 μM in 15 mM Ba + -containing bath solution before they were applied. Twenty-one negative control HEK 293 cells (transiently transfected with the lacZ gene expression vector pCMVøgal only) were analyzed by the whole-cell variant of the patch clamp method for recording currents. Only one cell displayed a discernable inward barium current; this current was not affected by the presence of 1 μM Bay K 8644. In addition, application of Bay K 8644 to four cells that did not display Ba 2+ currents did not result in the appearance of any currents. Two days after transient transfection of HEK 293 cells with α-, α 2 and 0. subunit-encoding cDNA and the lacZ gene, individual transfectants were assayed for voltage-dependent barium currents. The currents in nine transfectants were recorded. Because the efficiency of transfection of one cell can vary from the efficiency of transfection of another cell, the degree of expression of heterologous proteins in individual transfectants varies and some cells do not incorporate or express the foreign DNA. Inward barium currents were detected in two of these nine transfectants. In these assays, the holding potential of the membrane was -90 mV. The membrane was depolarized in a series of voltage steps to different test potentials and the current in the presence and absence of 1 μM Bay K 8644 was recorded. The inward barium current was significantly enhanced in magnitude by the addition of Bay K 8644. The largest inward barium current (-160 pA) was recorded when the membrane was depolarized to 0 mV in the presence of 1 μM Bay K 8644. A comparison of the I-V curves, generated by plotting the largest current recorded after each depolarization versus the depolarization voltage, corresponding to recordings conducted in the absence and presence of Bay K 8644 illustrated the enhancement of the voltage-activated current in the presence of Bay K 8644. Pronounced tail currents were detected in the tracings of currents generated in the presence of Bay K 8644 in HEK 293 cells transfected with α., α 2 and 0. subunit-encoding cDNA and the lacZ gene, indicating that the recombinant calcium channels responsible for the voltage-activated barium currents recorded in this transfected appear to be DHP-sensitive. The second of the two transfected cells that displayed inward barium currents expressed a -50 pA current when the membrane was depolarized from -90 mV. This current was nearly completely blocked by 200 μM cadmium, an established calcium channel blocker. Ten cells that were transiently transfected with the DNA encoding the α. subunit and the lacZ gene were analyzed by whole-cell patch clamp methods two days after transfection. One of these cells displayed a 30 pA inward barium current. This current amplified 2-fold in the presence of 1 μM Bay K 8644. Furthermore, small tail currents were detected in the presence of Bay K 8644. These data indicate that expression of the human neuronal calcium channel α 1D subunit-encoding cDNA in HEK 293 yields a functional DHP-sensitive calcium channel. 3. Analysis of HEK 293 cells stably transfected with DNA encoding human neuronal calcium channel subunits Individual stably transfected HEK 293 cells were assayed electrophysiologically for the presence of voltage-dependent barium currents as described for electrophysiological analysis of transiently transfected HEK 293 cells (see Example VII.B.2.c) . In an effort to maximize calcium channel activity via cyclic-AMP-dependent kinase-mediated phosphorylation [Pelzer, et al. (1990) .Rev. Phyεiol . Biochem. Pharmacol . 114:107-207] , cAMP (Na salt, 250 μM) was added to the pipet solution and forskolin (10 μM) was added to the bath solution in some of the recordings. Qualitatively similar results were obtained whether these compounds were present or not. Barium currents were recorded from stably transfected cells in the absence and presence of Bay K 8644 (1 μM) . When the cell was depolarized to -10 mV from a holding potential of -90 mV in the absence of Bay K 8644, a current of approximately 35pA with a rapidly deactivating tail current was recorded. During application of Bay K 8644, an identical depolarizing protocol elicited a current of approximately 75 pA, accompanied by an augmented and prolonged tail current. The peak magnitude of currents recorded from this same cell as a function of a series of depolarizing voltages were assessed. The responses in the presence of Bay K 8644 not only increased, but the entire current-voltage relation shifted about -10 mV. Thus, three typical hallmarks of Bay K 8644 action, namely increased current magnitude, prolonged tail currents, and negatively shifted activation voltage, were observed, clearly indicating the expression of a DHP-sensitive calcium channel in these stably transfected cells. No such effects of Bay K 8644 were observed in untransfected HEK 293 cells, either with or without cAMP or forskolin. C. Use of pCMV-based vectors and pcDNAl-based vectors for expression of DNA encoding human neuronal calcium channel subunits 1. Preparation of constructs Additional expression vectors were constructed using pCMV. The full-length α 1D cDNA from pVDCCIII (A) (see Example II.A.3.d), the full-length α 2 cDNA, contained on a 3600 bp EcoRI fragment from HBCaCHα 2 (see Example IV.B) and a full- length 0. subunit cDNA from pHBCaCH0 lb RBS(A) (see Example III.B.3) were separately subcloned into plasmid pCMVøgal. Plasmid pCMVøgal was digested with NotI to remove the lacZ gene. The remaining vector portion of the plasmid, referred to as pCMV, was blunt-ended at the NotI sites. The full- length α 2 -encoding DΝA and øi-encoding DΝA, contained on separate EcoRI fragments, were isolated, blunt-ended and separately ligated to the blunt-ended vector fragment of pCMV locating the cDΝAs between the CMV promoter and SV40 polyadenylation sites in pCMV. To ligate the α 1D -encoding cD A with pCMV, the restriction sites in the polylinkers immediately 5' of the CMV promoter and immediately 3' of the SV40 polyadenylation site were removed from pCMV. A polylinker was added at the NotI site. The polylinker had the following sequence of restriction enzyme recognition sites: Hindlll Xball GT site site CACCGG NotI Destroys Not The α 1D -encoding DΝA, isolated as a BamHl/Xhol fragment from pVDCCIII (A), was then ligated to Xball/Sall-digested pCMV to place it between the CMV promoter and SV40 polyadenylation site. Plasmid pCMV contains the CMV promoter as does pcDNAl, but differs from pcDNAl in the location of splice donor/splice acceptor sites relative to the inserted subunit-encoding DΝA. After inserting the subunit-encoding DΝA into pCMV, the splice donor/splice acceptor sites are located 3' of the CMV promoter and 5' of the subunit-encoding DΝA start codon. After inserting the subunit-encoding DΝA into pcDNAl, the splice donor/splice acceptor sites are located 3' of the subunit cDΝA stop codon. 2. Transfection of HEK 293 cells HEK 293 cells were .transiently co-transfected with the α 1D , α 2 and 0. subunit-encoding DΝA in pCMV or with the α 1D α 2 and 0 subunit-encoding DΝA in pcDNAl (vectors pVDCCIII (A) , pHBCaCHα 2 A and pHBCaCH0 lb RBS (A) , respectively) , as described in Example VII.B.l.a. Plasmid pCMVøgal was included in each transfection as a measure of transfection efficiency. The results of 0-galactosidase assays of the transfectants (see Example VII.B.2.), indicated that HEK 293 cells were transfected equally efficiently with pCMV- and pcDΝAl-based plasmids. The pcDNAl-based plasmids, however, are presently preferred for expression of calcium channel receptors. D. Expression in Xenopus laevis oόcytes of R A encoding human neuronal calcium channel subunits Various combinations of the transcripts of DΝA encoding the human neuronal α. α. and 0. subunits prepared in vi tro were injected into Xenopuε laeviε oόcytes. Those injected with combinations that included a 1D exhibited voltage-activated barium currents. 1. Preparation of transcripts Transcripts encoding the human neuronal calcium channel α 1D , α 2 and 0. subunits were synthesized according to the instructions of the mCAP mRNA CAPPING KIT (Strategene, La Jolla, CA catalog #200350) . Plasmids pVDCC III.RBS(A), containing pcDNAl and the α 1D cDNA that begins with a ribosome binding site and the eighth ATG codon of the coding sequence (see Example III.A.3.d), plasmid pHBCaCHαiA containing pcDNAl and an α 2 subunit cDNA (see Example IV) , and plasmid pHBCaCH0 lb RBS (A) containing pcDNAl and the 0. DNA lacking intron sequence and containing a ribosome binding site (see Example III) , were linearized by restriction digestion. The α 1D cDNA- and α 2 subunit-encoding plasmids were digested with Xhol, and the 0. subunit- encoding plasmid was digested with EcoRV. The DNA insert was transcribed with T7 RNA polymerase. 2. Injection of oόcytes Xenopuε laeviε oόcytes were isolated and defolliculated by collagenase treatment and maintained in 100 mM NaCl, 2 mM KC1, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, pH 7.6, 20 μg/ml ampicillin and 25 μg/ml streptomycin at 19-25°C for 2 to 5 days after injection and prior to recording. For each transcript that was injected into the oόcyte, 6 ng of the specific mRNA was injected per cell in a total volume of 50 nl. 3. Intracellular voltage recordings Injected oόcytes were examined for voltage-dependent barium currents using two-electrode voltage clamp methods [Dascal, N. (1987) CRC Crit . Rev. Biochem. 22:317] . The pClamp (Axon Instruments) software package was used in conjunction with a Labmaster 125 kHz data acquisition interface to generate voltage commands and to acquire and analyze data. Quattro Professional was also used in this analysis. Current signals were digitized at 1-5 kHz, and filtered appropriately. The bath solution contained of the following: 40 mM BaCl 2 , 36 mM tetraethylammonium chloride (TEA-C1) , 2 mM KC1, 5 mM 4-aminopyridine, 0.15 mM niflumic acid, 5 mM HEPES, pH 7.6. a. Electrophysiological analysis of oόcytes injected with transcripts encoding the human neuronal calcium channel l t 2 and 0.-subunits Uninjected oόcytes were examined by two-electrode voltage clamp methods and a very small (25 nA) endogenous inward Ba 2+ current was detected in only one of seven analyzed cells. Oόcytes coinjected with α. D , α 2 and 0. subunit transcripts expressed sustained inward barium currents upon depolarization of the membrane from a holding potential of -90 mV or -50 mV (154 ± 129 nA, n=21) . These currents typically showed little inactivation when test pulses ranging from 140 to 700 msec, were administered. Depolarization to a series of voltages revealed currents that first appeared at approximately -30 mV and peaked at approximately 0 mV. Application of the DHP Bay K 8644 increased the magnitude of the currents, prolonged the tail currents present upon repolarization of the cell and induced a hyperpolarizing shift in current activation. Bay K 8644 was prepared fresh from a stock solution in DMSO and introduced as a lOx concentrate directly into the 60 μl bath while the perfusion pump was turned off. The DMSO concentration of the final diluted drug solutions in contact with the cell never exceeded 0.1%. Control experiments showed that 0.1% DMSO had no effect on membrane currents. Application of the DHP antagonist nifedipine (stock solution prepared in DMSO and applied to the cell as described for application of Bay K 8644) blocked a substantial fraction (91 ± 6%, n=7) of the inward barium current in oόcytes coinjected with transcripts of the α 1D , α 2 and 0. subunits. A residual inactivating component of the inward barium current typically remained after nifedipine application. The inward barium current was blocked completely by 50 μM Cd 2+ , but only approximately 15% by 100 μM Ni 2+ . The effect of ωCgTX on the inward barium currents in oόcytes co-injected with transcripts of the α 1D , α 2 , and 0. subunits was investigated. ωCgTX (Bachem, Inc., Torrance CA) was prepared in the 15 mM BaCl 2 bath solution plus 0.1% cytochrome C (Sigma) to serve as a carrier protein. Control experiments showed that cytochrome C had no effect on currents. A series of voltage pulses from a -90 mV holding potential to 0 mV were recorded at 20 msec, intervals. To reduce the inhibition of ωCgTX binding by divalent cations, recordings were made in 15 mM BaCl 2 , 73.5 mM tetraethylammonium chloride, and the remaining ingredients identical to the 40 mM Ba 2+ recording solution. Bay K 8644 was applied to the cell prior to addition to ωCgTX in order to determine the effect of ωCgTX on the DHP-sensitive current component that was distinguished by the prolonged tail currents. The inward barium current was blocked weakly (54 ± 29%, n=7) and reversibly by relatively high concentrations (10-15 μM) of ωCgTX. The test currents and the accompanying tail currents were blocked progressively within two to three minutes after application of ωCgTX, but both recovered partially as the ωCgTX was flushed from the bath. b. Analysis of oόcytes injected with only a transcripts encoding the human neuronal calcium channel α 1D or transcripts encoding an α 1D and other subunits The contribution of the α 2 and 0. subunits to the inward barium current in oόcytes injected with transcripts encoding the α 1D , α 2 and 0. subunits was assessed by expression of the α 1D subunit alone or in combination with either the 0. subunit or the α 2 subunit. In oόcytes injected with only the transcript of a α 1D cDNA, no Ba 2+ currents were detected (n=3) . In oόcytes injected with transcripts of α 1D and 0. cDNAs, small (108 ± 39 nA) Ba + currents were detected upon depolarization of the membrane from a holding potential of -90 mV that resembled the currents observed in cells injected with transcripts of α 1D , α 2 and 0. cDNAs, although the magnitude of the current was less. In two of the four oόcytes injected with transcripts of the α 1D -encoding and 0.-encoding DNA, the Ba 2+ currents exhibited a sensitivity to Bay K 8644 that was similar to the Bay K 8644 sensitivity of Ba 2+ currents expressed in oόcytes injected with transcripts encoding the α 1D α.-, α 2 _ and 0. subunits. Three of five oόcytes injected with transcripts encoding the α 1D and α 2 subunits exhibited very small Ba 2+ currents (15- 30 nA) upon depolarization of the membrane from a holding potential of -90 mV. These barium currents showed little or no response to Bay K 8644. c. Analysis of oόcytes injected with transcripts encoding the human neuronal calcium channel 2 and/or 0. subunit To evaluate the contribution of the α 1D α.-subunit to the inward barium currents detected in oόcytes co-injected with transcripts encoding the α 1D , α 2 and 0. subunits, oόcytes injected with transcripts encoding the human neuronal calcium channel α 2 and/or 0. subunits were assayed for barium currents. Oόcytes injected with transcripts encoding the α 2 subunit displayed no detectable inward barium currents (n=5) . Oόcytes injected with transcripts encoding a β-, subunit displayed measurable (54 ± 23 nA, n=5) inward barium currents upon depolarization and oόcytes injected with transcripts encoding the α 2 and 0. subunits displayed inward barium currents that were approximately 50% larger (80 ± 61 nA, n=18) than those detected in oόcytes injected with transcripts of the 0.-encoding DNA only. The inward barium currents in oόcytes injected with transcripts encoding the 0. subunit or α 2 and 0- subunits typically were first observed when the membrane was depolarized to -30 mV from a holding potential of -90 mV and peaked when the membrane was depolarized to 10 to 20 mV. Macroscopically, the currents in oόcytes injected with transcripts encoding the α 2 and 0. subunits or with transcripts encoding the 0. subunit were indistinguishable. In contrast to the currents in oόcytes co-injected with transcripts of α 1D , α 2 and 0. subunit cDNAs, these currents showed a significant inactivation during the test pulse and a strong sensitivity to the holding potential. The inward barium currents in oόcytes co-injected with transcripts encoding the α 2 and 0. subunits usually inactivated to 10-60% of the peak magnitude during a 140-msec pulse and were significantly more sensitive to holding potential than those in oόcytes co-injected with transcripts encoding the α 1D , α 2 and 0. subunits. Changing the holding potential of the membranes of oόcytes co-injected with transcripts encoding the α 2 and 0. subunits from -90 to -50 mV resulted in an approximately 81% (n__ll) reduction in the magnitude of the inward barium current of these cells. In contrast, the inward barium current measured in oόcytes co¬ injected with transcripts encoding the α 1D , α 2 and 0. subunits were reduced approximately 24% (n=ll) when the holding potential was changed from -90 to -50 mV. The inward barium currents detected in oόcytes injected with transcripts encoding the α 2 and 0. subunits were pharmacologically distinct from those observed in oόcytes co¬ injected with transcripts encoding the α 1D , α 2 and 0. subunits. Oόcytes injected with transcripts encoding the α 2 and 0. subunits displayed inward barium currents that were insensitive to Bay K 8644 (n=ll) . Nifedipine sensitivity was difficult to measure because of the holding potential sensitivity of nifedipine and the current observed in oόcytes injected with transcripts encoding the α 2 and 0. subunits. Nevertheless, two oόcytes that were co-injected with transcripts encoding the α 2 and 0. subunits displayed measurable (25 to 45 nA) inward barium currents when depolarized from a holding potential of -50 mV. These currents were insensitive to nifedipine (5 to 10 μM) . The inward barium currents in oocytes injected with transcripts encoding the α 2 and 0. subunits showed the same sensitivity to heavy metals as the currents detected in oόcytes injected with transcripts encoding the α 1D , α 2 and 0 ! subunits. The inward barium current detected in oόcytes injected with transcripts encoding the human neuronal α 2 and 0. subunits has pharmacological and biophysical properties that resemble calcium currents in uninjected Xenopus oόcytes. Because the amino acids of this human neuronal calcium channel 0. subunit lack hydrophobic segments capable of forming transmembrane domains, it is unlikely that recombinant β t subunits alone can form an ion channel. It is more probable that a homologous endogenous α. subunit exists in oόcytes and that the activity mediated by such an α- subunit is enhanced by expression of a human neuronal 0 X subunit. E. Expression of DNA encoding human neuronal calcium channel α 1B , α 2B and 0._ 2 subunits in HEK cells 1. Transfection of HEK cells The transient expression of the human neuronal α 1B _ 1# α 2b and 0._ 2 subunits was studied in HEK293 cells. The HEK293 cells were grown as a monolayer culture in Dulbecco's modified Eagle's medium (Gibco) containing 5% defined-supplemented bovine calf serum (Hyclone) plus penicillin G (100 U/ml) and steptomycin sulfate (100 μg/ml) . HEK293 cell transfections were mediated by calcium phosphate as described above. Transfected cells were examined for inward Ba 2+ currents (J Ba ) mediated by voltage-dependent Ca + channels. Cells were transfected (2 x 10 6 per polylysine-coated plate. Standard transfections (10-cm dish) contained 8 μg of pcDNAα 1B . 1# 5 μg of pHBCaCHα 2 A, 2 μg pHBCaCH0 lb RBS(A) (see, Examples II.A.3, IV.B. and III) and 2 μg of CMV0 (Clontech) 0- glactosidase expression plasmid, and pUClβ to maintain a constant mass of 20 μg/ml. Cells were analyzed 48 to 72 hours after transfection. Transfection efficiencies (±10%) , which were determined by in situ histochemical staining for 0-galactosidase activity (Sanes et al . (1986) EMBO J. , 5:3133), generally were greater than 50%. 2. Electrophysiological analysis of transfectant currents a. Materials and methods Properties of recombinantly expressed Ca 2+ channels were studied by whole cell patch-clamp techniques. Recordings were performed on transfected HEK293 cells 2 to 3 days after transfection. Cells were plated at 100,000 to 300,000 cells per polylysine-coated, 35-mm tissue culture dishes (Falcon, Oxnard, CA) 24 hours before recordings. Cells were perfused with 15 mM BaCl 2 , 125 mM choline chloride, 1 mM MgCl 2 , and 10 mM Hepes (pH = 7.3) adjusted with tetraethylammonium hydroxide (bath solution) . Pipettes were filled with 135 mM CsCl, 10 mM EGTA, 10 mM Hepes, 4 mM Mg-adenosine triphosphate (pH = 7.5) adjusted with tetraethylammonium hydroxide. Sylgard (Dow-Corning, Midland, MI) -coated, fire-polished, and filled pipettes had resistances of 1 to 2 megohm before gigohm seals were established to cells. Bay K 8644 and nifedipine (Research Biochemicals, Natick, MA) were prepared from stock solutions (in dimethyl sulfoxide) and diluted into the bath solution. The dimethyl sulfoxide concentration in the final drug solutions in contact with the cells never exceeded 0.1%. Control experiments showed that 0.1% dimethyl sulfoxide had no efect on membrane currents. ωCgTX (Bachem, Inc., Torrance CA) was prepared in the 15 mM BaCl 2 bath solution plus 0.1% cytochrome C (Sigma, St. Louis MO) to serve as a carrier protein. Control experiments showed that cytochrome C had no effect on currents. These drugs were dissolved in bath solution, and continuously applied by means of puffer pipettes as required for a given experiment. Recordings were performed at room temperature (22° to 25°C) . Series resistance compensation (70 to 85%) was employed to minimize voltage error that resulted from pipette access resistance, typically 2 to 3.5 megohm. Current signals were filtered (-3 dB, 4-pole Bessel) at a frequency of 1/4 to 1/5 the sampling rate, which ranged from 0.5 to 3 kHz. Voltage commands were generated and data were acquired with CLAMPEX (pClamp, Axon Instruments, Foster City, CA) . All reported data are corrected for linear leak and capacitive components. Exponential fitting of currents was performed with CLAMPFIT (Axon Instruments, Foster City, CA) . b. Results Transfectants were examined for inward Ba 2+ currents (J Ba ) . Cells cotransfected with DNA encoding α 1B .., α 2b , and 0._ 2 subunits expressed high-voltage-activated Ca 2+ channels. J B,a first appeared when the membrane was depolarized from a holding potential of -90 mV to -20 mV and peaked in magnitude at 10 V. Thirty-nine of 95 cells (12 independent transfections) had J Ba that ranged from 30 to 2700 pA, with a mean of 433 pA. The mean current density was 26 pA/pF, and the highest density was 150 pA/pF. The I Ba typically increased by 2- to 20-fold during the first 5 minutes of recording. Repeated depolarizations during long records often revealed rundown of J Ba usually not exceeding 20% within 10 min. J Ba typically activated within 10 ms and inactivated with both a fast time constant ranging from 46 to 105 ms and a slow time constant ranging from 291 to 453 ms [n = 3) . Inactivation showed a complex voltage dependence, such that J Ba elicited at ≥20 mV inactivated more slowly than I Ba elicited at lower test voltages, possibly a result of an increase in the magnitude of slow compared to fast inactivation components at higher test voltages. Recombinant c_ 1B _ 1 α 2b 0 1 _ 2 channels were sensitive to holding potential. Steady-state inactivation of I Ba , measured after a 30- to 60-s conditioning at various holding potentials, was approximately 50% at holding potential between -60 and -70 mV and approximately 90% at -40 mV. Recovery of J Ba from inactivation was usually incomplete, measuring 55 to 75% of the original magnitude within 1 min. after the holding potential was returned to more negative potentials, possibly indicating some rundown or a slow recovery rate. Recombinant o 1B . 1 α 2b 0 1 . 2 channels were also blocked irreversibly by ω-CgTx concentrations ranging from 0.5 to 10 μM during the time scale of the experiments. Application of 5 μM toxin (n = 7) blocked the activity completely within 2 min. , and no recovery of I Ba was observed after washing ω-CgTx from the bath for up to 15 min. d 2+ blockage (50 μM) was rapid, complete, and reversible; the DHPs Bay K 8644 (1 μM; n = 4) or nifedipine (5 μM; n = 3) had no discernable effect. Cells cotransfected with DNA encoding α 1B .., α 2b , and β x _ 2 subunits predominantly displayed a single class of saturable, high-affinity ω-CgTx binding sites. The determined dissociation constant (K d ) value was 54.6 ± 14.5 pM (n = 4) . Cells transfected with the vector containing only 0-galactosidase-encoding DNA or α 2b 0-encoding DNA showed no specific binding. The binding capacity (B max ) of the α 1B . 1 α 2b 0-transfected cells was 28,710 ± 11,950 sites per cell (n = 4) . These results demonstrate that α. B . 1 α 2b 0 1 _ 2 -transfected cells express high-voltage-activated, inactivating Ca 2+ channel activity that is irreversibly blocked by ω-CgTx, insensitive to DHPs, and sensitive to holding potential. The activation and inactivation kinetics and voltage sensitivity of the channel formed in these cells are generally consistent with previous characterizations of neuronal N-type Ca 2+ channels. F. Expression of DNA encoding human neuronal calcium channel α 1B _ x , _- 1B _ 2 . anc ι-ι subunits in HEK cells Significant Ba 2+ currents were not detected in untransfected HEK293 cells. Furthermore, untransfected HEK293 cells do not express detectable ω-CgTx GVIA binding sites. In order to approximate the expression of a homogeneous population of trimeric α 1B , α 2b and β. protein complexes in transfected HEK293 cells, the α 1B , α 2b and β. expression levels were altered. The efficiency of expression and assembly of channel complexes at the cell surface were optimized by adjusting the molar ratio of α 1B , α 2b and β χ expression plasmids used in the transfections. The transfectants were analyzed for mRNA levels, ω-CgTx GVIA binding and Ca 2+ channel current density in order to determine near optimal channel expression in the absence of immunological reagents for evaluating protein expression. Higher molar ratios of α 2b appeared to increase calcium channel activity. 1. Transfections HEK293 cells were maintained in DMEM (Gibco #320-1965AJ) , 5.5% Defined/Supplemented bovine calf serum (Hyclone #A-2151- L) , 100 U/ml penicillin G and 100 μg/ml streptomycin. Ca 2+ - phosphate based transient transfections were performed and analyzed as described above. Cells were co-transfected with either 8 μg pcDNAlα 1B _. (described in Example II.C), 5 μg pHBCaCHα 2 A (see, Example IV.B.), 2 μg pHBCaCH0 lb RBS(A) (0-.- expression plasmid; see Examples III.A. and IX.E.), and 2 μg pCMVø-gal [Clontech, Palo Alto, CA] (2:1.8:1 molar ratio of Ca + channel subunit expression plasmids) or with 3 μg pcDNAlαi B .. or pcDNAlα 1B _ 2 , 11.25 μg pHBCaCHα 2 A, 0.75 or 1.0 μg pHBCaCH0 lb RBS(A) or pcDNA10._ 3 and 2 μg pCMVø-gal (2:10.9:1 molar ratio of Ca 2+ channel subunit expression plasmids) . Plasmid pCMVø-gal, a β-galactosidase expression plasmid, was included in the transfections as a marker to permit transfection efficiency estimates by histochemical staining. When less than three subunits were expressed, pCMVPL2, a pCMV promoter-containing vector that lacks a cDNA insert, was substituted to maintain equal moles of pCMV-based DNA in the transfection. pUC18 DNA was used to maintain the total mass of DNA in the transfection at 20 μg/plate. RNA from the transfected cells was analyzed by Northern blot analysis for calcium channel subunit mRNA expression using random primed 32 P-labeled subunit specific probes. HEK293 cells co-transfected with α 1B . 1# α 2b and 0.. 2 expression plasmids (8, 5 and 2 μg, respectively; molar ratio = 2:1.8:1) did not express equivalent levels of each Ca 2+ channel subunit mRNA. Relatively high levels of α 1B .. and 0._ 2 mRNAs were expressed, but significantly lower levels of α 2b mRNA were expressed. Based on autoradiograph exposures required to produce equivalent signals for all three mRNAs, α 2b transcript levels were estimated to be 5 to 10 times lower than .g.. and 0._ 2 transcript levels. Untransfected HEK293 cells did not express detectable levels of α 1B . 1# α 2b , or 0-_ 2 mRNAs. To achieve equivalent Ca 2+ channel subunit mRNA expression levels, a series of transfections was performed with various amounts of α 1B .., α 2b and 0.. 2 expression plasmids. Because the α 1B .- and β._ 2 mRNAs were expressed at very high levels compared to α 2b mRNA, the mass of α 1B .. and β._ 2 plasmids was lowered and the mass of α 2b plasmid was increased in the transfection experiments. Co-transfection with 3, 11.25 and 0.75 μg of α 1B . ., α 2b and 0-_ 2 expression plasmids, respectively (molar ratio = 2:10.9:1), approached equivalent expression levels of each Ca 2+ channel subunit mRNA. The relative molar quantity of α 2b expression plasmid to α 1B .. and β.. 2 expression plasmids was increased 6-fold. The mass of α 1B . ! and 0._ 2 plasmids in the transfection was decreaεed 2.67-fold and the mass of α 2b plasmid was increaεed 2.25-fold. The 6-fold molar increase of α 2b relative to 1B . x and β._ 2 required to achieve near equal abundance mRNA levels is consistent with the previous 5- to 10-fold lower estimate of relative α 2b mRNA abundance. ω-CgTx GVIA binding to cells transfected with various amounts of expression plasmids indicated that the 3, 11.25 and 0.75 μg of α i B - ι α 2b and 0._ 2 plasmids, respectively, improved the level of cell surface expression of channel complexes. Further increases in the mass of α 2b and β-_ 2 expression plasmids while α 1B _. was held constant, and alterations in the mass of the α 1B .. expression plasmid while α 2b and β._ 2 were held constant, indicated that the cell surface expression of ω-CgTx GVIA binding sites per cell was nearly optimal. All subsequent transfections were performed with 3, 11.25 and 0.75 μg or 1.0 μg of α 1B _- or α 1B _ 2 , α 2b and 0._ 2 or 0.. 3 expression plasmids, respectively. 2. 125 I-ω-CgTx GVIA binding to transfected cells Statistical analysis of the K d and B max values was performed using one-way analysis of variance (ANOVA) followed by the Tukey-Kramer test for multiple pairwise comparisons (p≤0.05) . Combinations of human voltage-dependent Ca 2+ channel subunits, c. 1B _., α 1B . 2 , α 2b , β x _ 2 and 0-_ 3 , were analyzed for saturation binding of 125 I-ω-CgTx GVIA. About 200,000 cells were used per assay, except for the a 1B _ l t α 1B . 2 , α 1B _-α 2b and α 1B . 2 α 2b combinations which were assayed with 1 x 10 6 cells per tube The transfected cells displayed a single-class of saturable, high-affinity binding sites. The values for the dissociation constants (K d ) and binding capacities (B^) were determined for the different combinations . The results are summarized as follows: Subunit Combination K d (pM) B nax (sites/cell) α 1B . 1 α 2b 0 1 _ 2 54.9 ± 11.1 (n=4) 45,324 ± 15,606 5 .2 ± 3.6 (n=3) 91,004 ± 37,654 a- B .-0._ 2 17.9 ± 1.9 (n=3) 5,756 ± 2,163 a. B .-0-_ 3 17.9 ± 1.6 (n=3) 8,729 ± 2,980 ^ lB -i^ ∑b 84. ' 6 + 15.3 (n=3) 2,256 ± 356 a lB _- 31.7 ± 4.2 (n=3) 757 ± 128 53.0 ± 4.8 (n=3) 19,371 ± 3,798 a_ B - 2 a 2b /3_- 3 44.3 ± 8.1 (n=3) 37,652 ± 8,129 a. B - ∑ βi-z 16.4 ± 1.2 (n=3) 2,126 ± 412 a 1B _ 2 0-. 3 22.2 ± 5.8 (n=3) 2,944 ± 1,168 ^ lB -z^ b N.D. * (n=3) N.D. a 1B _ 2 N.D. N.D. * N.D. = not detectable Cells transfected with subunit combinations lacking either the α 1B _- or the α 1B _ 2 subunit did not exhibit any detectable 1 5 I-ω-CgTx GVIA binding (≤ 600 sites/cell) . 1 5 I-ω- CgTx GVIA binding to HEK293 cells transfected with α 1B _ 2 alone or α 1B . 2 α 2b was too low for reliable Scatchard analysis of the data. Comparison of the K d and B^ values revealed several relationships between specific combinations of subunits and the binding affinities and capacities of the transfected cells. In cells transfected with all three subunits, Cα 1B _ ι<2 2b /βι- 2 - / α. B .-α 2b 0._ 3 -, α 1B . 2 α 2b 0-. 2 -, or α- B . 2 α 2b 0-. 3 -transfectants) the K d values were indistinguishable (p>0.05) , ranging from 44.3 ± 8.1 pM to 54.9 ± 11.1 pM. In cells transfected with two- subunit combinations lacking the α 2b subunit .α- B _-0-.. 2 , - g .-ø-. j , α iB-2β__2 or t e κ d values were significantly lower than the three-subunit combinations (p<0.01), ranging from 16.4 ± 1.2 to 22.2 ± 5.8 pM. Cells transfected with only the α 1B. . subunit had a K d value of 31.7 ± 4.2 pM, a value that was not different from the two-subunit combinations lacking α 2b (p<0.05) . As with the comparison between the four α 1B α 2b 0- versus α. 1B 0. combinations, when the α 1B _- was co-expressed with α 2b , the K d increased significantly (p<0.05) from 31.7 + 4.2 to 84.6 ± 5.3 pM. These data demonstrate that co-expression of the α 2b subunit with α 1B _-, α-g.-ø-.-, a XB . 1 β 1 . 3 , oι 1B _ 2 β 1 _ 2 or α 1B . 2 0 α _ 3 subunit combinations results in lower binding affinity of the cell surface receptors for 125 I-ω-CgTx GVIA. The B,^ values of cells transfected with various subunit combinations also differed considerably. Cells transfected with the α 1B _. subunit alone expressed a low but detectable number of binding sites (approximately 750 binding sites/cell) . When the α 1B _. subunit was co-expressed with the α 2b subunit, the binding capacity increased approximately three-fold while co-expression of a 0._ 2 or 0._ 3 subunit with α 1B _. resulted in 8- to 10-fold higher expression of surface binding. Cells transfected with all three subunits expressed the highest number of cell surface receptors. The binding capacities of cells transfected with ff i B -ι α 2b i3 ι - 3 or _-. B . 2 α 2b 0 1 _ 3 combinations were approximately two-fold higher than the corresponding combinations containing the 0-_ 2 subunit. Likewise, cells transfected with oι 1 ^. 1 ! 2b β 1 . 2 σr α 1B .-α 2b 0-_ 3 combinations expressed approximately 2.5-fold more binding sites per cell than the corresponding combinations con¬ taining α 1B _ 2 . In all cases, co-expression of the α 2b subunit with α 1B and 0. increased the surface receptor density compared to cells transfected with only the corresponding α 1B and 0- combinations; approximately 8-fold for Q. 1B _-α 2b 0_,. 2 , 10-fold for α_. B --α 2b /3-- 3 , 9- old for .^α^ø..,, and 13-fold for α 1B . 2 α 2b 0._ 3 . Thus, comparison of the B max values suggests that the toxin-binding subunit, α 1B .- or α 1B . 2 , is more efficiently expressed and assembled on the cell surface when co-ex-pressed with either the α 2b or the 0-_ 2 or 0-_ 3 subunit, and most efficiently expressed when α 2b and 0. subunits are present. 3. Electrophysiology Functional expression of <_- 1B ..α 2b β.. 2 and o. 1B _ 1 β 1 _ 2 subunit combinations was evaluated using the whole-cell recording technique. Transfected cells that had no contacts with surrounding cells and simple morphology were used approximately 48 hours after transfection for recording. The pipette solution was (in mM) 135 CsCl, 10 EGTA, 1 MgCl 2 , 10 HEPES, and 4 mM Mg-ATP (pH 7.3, adjusted with TEA-OH) . The external solution was (in mM) 15 BaCl 2 , 125 Choline Cl, 1 MgCl 2 , and 10 HEPES (pH 7.3, adjusted with TEA-OH) . ω-CgTx GVIA (Bachem) was prepared in the external solution with 0.1% cytochrome C (Sigma) to serve as a carrier. Control experiments showed that cytochrome C had no effect on the Ba 2+ current. The macroscopic electrophysiological properties of Ba 2+ currents in cells transfected with various amounts of the α 2b expression plasmid with the relative amounts of α 1B _. and 0.. 2 plasmids held constant were examined. The amplitudes and densities of the Ba + currents (15 mM BaCl 2 ) recorded from whole cells of these transfectants differed dramatically. The average currents from 7 to 11 cells of three types of transfections (no α 2b ; 2:1.8:1 [α 1B . 1 :α 2b :0 1 _ 2 ] molar ratio; and 2:10.9:1 [α. 1B _- :C- 2b : β_ . . 2 ] molar ratio) were determined. The smallest currents (range: 10 to 205 pA) were recorded when α 2b was not included in the transfection, and the largest currents (range: 50 to 8300 pA) were recorded with the 2:10.9:1 ratio of α 1B.1 α 2b 0 1.2 plasmids, the ratio that resulted in near equivalent mRNA levels for each subunit transcript. When the amount of α 2b plasmid was adjusted to yield approximately an equal abundance of subunit mRNAs, the average peak Ba 2+ current increased from 433 pA to 1,824 pA (4.2-fold) with a corresponding increase in average current density from 26 pA/pF to 127 pA/pF (4.9-fold) . This increase is in the presence of a 2.7-fold decrease in the mass of α 1B .. and 0._ 2 expression plasmids in the transfections. In all transfections, the magnitudes of the Ba 2+ currents did not follow a normal distribution. To compare the subunit combinations and determine the effects of α 2b , the current-voltage properties of cells transfected with α^.-fi.^ or with o: 1B _ 1 ot 2b & 1 _ 2 in either the 2:1.8:1 (α 1B _ 1 :α 2b :0 1 _ 2 ) molar ratio or the 2:10.9:1 (α.g.. :α 2b :0._ 2 ) molar ratio transfectants were examined. The extreme examples of no α 2b and 11.25 μg α 2b (2:10.9:1 molar ratio) showed no significant differences in the current voltage plot at test potentials between 0 mV and +40 mV (p<0.05) . The slight differences observed at either side of the peak region of the current voltage plot were likely due to normalization. The very small currents observed in the' a XB .-ιβ x . 2 transfected cells have a substantially higher component of residual leak relative to the barium current that is activated by the test pulse. When the current voltage plots are normalized, this leak is a much greater component than in the o. 1B _ 1 α 2b 0 1 _ 2 transfected cells and as a result, the current-voltage plot appears broader. This is the most likely explanation of the apparent differences in the current voltage plots, especially given the fact that the current-voltage plot for the α 1B ..0.. 2 transfected cells diverge on both sides of the peak. Typically, when the voltage- dependence activation is shifted, the entire current-voltage plot is shifted, which was not observed. To qualitatively compare the kinetics of each, the average responses of test pulses from -90 mV to 10 mV were normalized and plotted. No significant differences in activation or inactivation kinetics of whole-cell Ba 2+ currents were observed with any combination. G. Expression of DNA encoding human neuronal calcium channel ■_- 1E _ 3 α. 2B 0 1 _ 3 and <_- 1E _ 1 α 2B 0 1 _ 3 subunits in HEK cells Functional expression of the _- IE - I <_- 2B /3 I -3 and < as well as α 1E _ 3 was evaluated using the whole cell recording technique. 1. Methods Recordings were performed on transiently transfected HEK 293 cells two days following the transfection, from cells that had no contacts with surrounding cells and which had simple morphology. The internal solution used to fill pipettes for recording the barium current from the transfected recombinant calcium channels was (in mM) 135 CsCl, 10 EGTA, 1 MgCl 2 , 10 HEPES, and 4 mM Mg-ATP (pH 7.4-7.5, adjusted with TEA-OH) . The external solution for recording the barium current was (in mM) 15 BaCl 2 , 150 Choline Cl, 1 MgCl 2 , and 10 HEPES and 5 TEA-OH (pH 7.3, adjusted with TEA-OH) . In experiments in which Ca 2+ was replaced for Ba 2+ , a Laminar flow chamber was used in order to completely exchange the extracellular solution and prevent any mixing of Ba 2+ and Ca 2+ . ω-CgTx GVIA was prepared in the external solution with 0.1% cytochrome C to serve as a carrier, the toxin was applied by pressurized puffer pipette. Series resistance was compensated 70-85% and currents were analyzed only if the voltage error from series resistance was less than 5 mV. Leak resistance and capacitance was corrected by subtracting the scaled current observed with the P/-4 protocol as implemented by pClamp (Axon Instruments) . 2. Electrophysiology Results Cells transfected with c-iE-ΛbSi-s or Q! _.E-3 Q; 2 i-3 showed strong barium currents with whole cell patch clamp recordings. Cells expressing c. 1E _ 3 α 2B 0._ 3 had larger peak currents than those expressing ■_- 1B _ 1 α 2b 0 1 _ 3 . In addition, the kinetics of activation and inactivation are clearly substantially faster in the cells expressing α 1E calcium channels. HEK 293 cells expressing α 1E _ 3 alone have a significant degree of functional calcium channels, with properties similar to those expressing α. 1E α 2b 0.. 3 but with substantially smaller peak barium currents. Thus, with α 1E , the α 2 and 0. subunits are not required for functional expression of α 1E mediated calcium channels, but do substantially increase the number of functional calcium channels. Examination of the current voltage properties of Qt 1E α 2b 0._ 3 expressing cells indicates that _- 1E - 3 <_- 2 b0_._ 3 is a high-voltage activated calcium channel and the peak current is reached at a potential only slightly less positive than other neuronal calcium channels also expressing α 2b and β x , and α 1B and α 1D . Current voltage properties of and α. 1E _ 3 α 2b 0.. 3 are statistically different from those of ot XB _ x oι 2b β x _ 3 . Current voltage curves for α 1E ..α 2b 0.. 3 and α! :ι.E . 3 α 2b 0 1 _ 3 peak at approximately +5mV, as does the current voltage curve for α 1E _ 3 alone. The kinetics and voltage dependence of inactivation using both prepulse (200 ms) and steady-state inactivation was examined. α 1E mediated calcium channels are rapidly inactivated relative to previously cloned calcium channels and other high voltage-activated calcium channels. <_- 1E _ 3 . 2b 0 1 _ 3 mediated calcium channels are inactivated rapidly and are thus sensitive to relatively brief (200 ms) prepulses as well as long prepulses (>20s steady state inactivation) , but recover rapidly from steady state inactivation. The kinetics of the rapid inactivation has two components, one with a time constant of approximately 25 ms and the other approximately 400 ms. To determine whether α 1E mediated calcium channels have properties of low voltage activated calcium channels, the details of tail currents activated by a test pulse ranging -60 to +90 mV were measured at -60 mV. Tail currents recorded at - 60 mV could be well fit by a single exponential of 150 to 300 μs,- at least an order of magnitude faster than those typically observed with low voltage-activated calcium channels. HEK 293 cells expressing α 1E . 3 - 2b 0 ι - 3 flux more current with Ba 2+ as the charge carrier and currents carried by Ba 2+ and Ca 2+ have different current-voltage properties. Furthermore, the time course of inactivation is slower and the amount of prepulse inactivation less with Ca 2+ as the charge carrier. While the invention has been described with some specificity, modifications apparent to those with ordinary skill in the art may be made without departing from the scope of the invention. Since such modifications will be apparent to those of skill in the art, it is intended that this invention be limited only by the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: THE SALK INSTITUTE BIOTECHNOLY/INDUSTRIAL ASSOCIATES (B) STREET: 505 COAST BLVD SOUTH, SUITE 300 (C) CITY: La Jolla (D) STATE: California (E) COUNTRY: USA (F) POSTAL CODE (ZIP) : 92037 (ii) TITLE OF INVENTION: HUMAN CALCIUM CHANNEL COMPOSITIONS AND METHODS (iii) NUMBER OF SEQUENCES: 38 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/149,097 (B) FILING DATE: 5-NOV-1993 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/105,536 (B) FILING DATE: ll-AUG-1993 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7635 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 511..6996 (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..510 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 6994..7635 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GGGCGAGCGC CTCCGTCCCC GGATGTGAGC TCCGGCTGCC CGCGGTCCCG AGCCAGCGGC 60 GCGCGGGCGG CGGCGGCGGG CACCGGGCAC CGCGGCGGGC GGGCAGACGG GCGGGCATGG 120 GGGGAGCGCC GAGCGGCCCC GGCGGCCGGG CCGGCATCAC CGCGGCGTCT CTCCGCTAGA 180 GGAGGGGACA AGCCAGTTCT CCTTTGCAGC AAAAAATTAC ATGTATATAT TATTAAGATA 240 ATATATACAT TGGATTTTAT TTTTTTAAAA AGTTTATTTT GCTCCATTTT TGAAAAAGAG 300 AGAGCTTGGG TGGCGAGCGG TTTTTTTTTA AAATCAATTA TCCTTATTTT CTGTTATTTG 360 TCCCCGTCCC TCCCCACCCC CCTGCTGAAG CGAGAATAAG GGCAGGGACC GCGGCTCCTA 420 CCTCTTGGTG ATCCCCTTCC CCATTCCGCC CCCGCCCCAA CGCCCAGCAC AGTGCCCTGC 480 ACACAGTAGT CGCTCAATAA ATGTTCGTGG ATG ATG ATG ATG ATG ATG ATG AAA 534 Met Met Met Met Met Met Met Lys 1 5 AAA ATG CAG CAT CAA CGG CAG CAG CAA GCG GAC CAC GCG AAC GAG GCA 582 Lys Met Gin His Gin Arg Gin Gin Gin Ala Asp His Ala Asn Glu Ala 10 15 20 AAC TAT GCA AGA GGC ACC AGA CTT CCT CTT TCT GGT GAA GGA CCA ACT 630 Asn Tyr Ala Arg Gly Thr Arg Leu Pro Leu Ser Gly Glu Gly Pro Thr 25 30 35 40 TCT CAG CCG AAT AGC TCC AAG CAA ACT GTC CTG TCT TGG CAA GCT GCA 678 Ser Gin Pro Asn Ser Ser Lys Gin Thr Val Leu Ser Trp Gin Ala Ala 45 50 55 ATC GAT GCT GCT AGA CAG GCC AAG GCT GCC CAA ACT ATG AGC ACC TCT 726 lie Asp Ala Ala Arg Gin Ala Lys Ala Ala Gin Thr Met Ser Thr Ser 60 65 70 GCA CCC CCA CCT GTA GGA TCT CTC TCC CAA AGA AAA CGT CAG CAA TAC 774 Ala Pro Pro Pro Val Gly Ser Leu Ser Gin Arg Lys Arg Gin Gin Tyr 75 80 85 GCC AAG AGC AAA AAA CAG GGT AAC TCG TCC AAC AGC CGA CCT GCC CGC 822 Ala Lys Ser Lys Lys Gin Gly Asn Ser Ser Asn Ser Arg Pro Ala Arg 90 95 100 GCC CTT TTC TGT TTA TCA CTC AAT AAC CCC ATC CGA AGA GCC TGC ATT 870 Ala Leu Phe Cys Leu Ser Leu Asn Asn Pro lie Arg Arg Ala Cys lie 105 110 115 120 AGT ATA GTG GAA TGG AAA CCA TTT GAC ATA TTT ATA TTA TTG GCT ATT 918 Ser lie Val Glu Trp Lys Pro Phe Asp lie Phe lie Leu Leu Ala lie 125 130 135 TTT GCC AAT TGT GTG GCC TTA GCT ATT TAC ATC CCA TTC CCT GAA GAT 966 Phe Ala Asn Cys Val Ala Leu Ala lie Tyr lie Pro Phe Pro Glu Asp 140 145 150 GAT TCT AAT TCA ACA AAT CAT AAC TTG GAA AAA GTA GAA TAT GCC TTC 1014 Asp Ser Asn Ser Thr Asn His Asn Leu Glu Lys Val Glu Tyr Ala Phe 155 160 165 CTG ATT ATT TTT ACA GTC GAG ACA TTT TTG AAG ATT ATA GCG TAT GGA 1062 Leu He He Phe Thr Val Glu Thr Phe Leu Lys He He Ala Tyr Gly 170 175 180 TTA TTG CTA CAT CCT AAT GCT TAT GTT AGG AAT GGA TGG AAT TTA CTG 1110 Leu Leu Leu His Pro Asn Ala Tyr Val Arg Asn Gly Trp Asn Leu Leu 185 190 195 200 GAT TTT GTT ATA GTA ATA GTA GGA TTG TTT AGT GTA ATT TTG GAA CAA 1158 Asp Phe Val He Val He Val Gly Leu Phe Ser Val He Leu Glu Gin 205 210 215 TTA ACC AAA GAA ACA GAA GGC GGG AAC CAC TCA AGC GGC AAA TCT GGA 1206 Leu Thr Lys Glu Thr Glu Gly Gly Asn His Ser Ser Gly Lys Ser Gly 220 225 230 GGC TTT GAT GTC AAA GCC CTC CGT GCC TTT CGA GTG TTG CGA CCA CTT 1254 Gly Phe Asp Val Lys Ala Leu Arg Ala Phe Arg Val Leu Arg Pro Leu 235 240 245 CGA CTA GTG TCA GGA GTG CCC AGT TTA CAA GTT GTC CTG AAC TCC ATT 1302 Arg Leu Val Ser Gly Val Pro Ser Leu Gin Val Val Leu Asn Ser He 250 255 260 ATA AAA GCC ATG GTT CCC CTC CTT CAC ATA GCC CTT TTG GTA TTA TTT 1350 He Lys Ala Met Val Pro Leu Leu His He Ala Leu Leu Val Leu Phe 265 270 275 280 GTA ATC ATA ATC TAT GCT ATT ATA GGA TTG GAA CTT TTT ATT GGA AAA 1398 Val He He He Tyr Ala He He Gly Leu Glu Leu Phe He Gly Lys 285 290 295 ATG CAC AAA ACA TGT TTT TTT GCT GAC TCA GAT ATC GTA GCT GAA GAG 1446 Met His Lys Thr Cys Phe Phe Ala Asp Ser Asp He Val Ala Glu Glu 300 305 310 GAC CCA GCT CCA TGT GCG TTC TCA GGG AAT GGA CGC CAG TGT ACT GCC 1494 Asp Pro Ala Pro Cys Ala Phe Ser Gly Asn Gly Arg Gin Cys Thr Ala 315 320 325 AAT GGC ACG GAA TGT AGG AGT GGC TGG GTT GGC CCG AAC GGA GGC ATC 1542 Asn Gly Thr Glu Cys Arg Ser Gly Trp Val Gly Pro Asn Gly Gly He 330 335 340 ACC AAC TTT GAT AAC TTT GCC TTT GCC ATG CTT ACT GTG TTT CAG TGC 1590 Thr Asn Phe Asp Asn Phe Ala Phe Ala Met Leu Thr Val Phe Gin Cys 345 350 355 360 ATC ACC ATG GAG GGC TGG ACA GAC GTG CTC TAC TGG ATG AAT GAT GCT 1638 He Thr Met Glu Gly Trp Thr Asp Val Leu Tyr Trp Met Asn Asp Ala 365 370 375 ATG GGA TTT GAA TTG CCC TGG GTG TAT TTT GTC AGT CTC GTC ATC TTT 1686 Met Gly Phe Glu Leu Pro Trp Val Tyr Phe Val Ser Leu Val He Phe 380 385 390 GGG TCA TTT TTC GTA CTA AAT CTT GTA CTT GGT GTA TTG AGC GGA GAA 1734 Gly Ser Phe Phe Val Leu Asn Leu Val Leu Gly Val Leu Ser Gly Glu 395 400 405 TTC TCA AAG GAA AGA GAG AAG GCA AAA GCA CGG GGA GAT TTC CAG AAG 1782 Phe Ser Lys Glu Arg Glu Lys Ala Lys Ala Arg Gly Asp Phe Gin Lys 410 415 420 CTC CGG GAG AAG CAG CAG CTG GAG GAG GAT CTA AAG GGC TAC TTG GAT 1830 Leu Arg Glu Lys Gin Gin Leu Glu Glu Asp Leu Lys Gly Tyr Leu Asp 425 430 435 440 TGG ATC ACC CAA GCT GAG GAC ATC GAT CCG GAG AAT GAG GAA GAA GGA 1878 Trp He Thr Gin Ala Glu Asp He Asp Pro Glu Asn Glu Glu Glu Gly 445 450 455 GGA GAG GAA GGC AAA CGA AAT ACT AGC ATG CCC ACC AGC GAG ACT GAG 1926 Gly Glu Glu Gly Lys Arg Asn Thr Ser Met Pro Thr Ser Glu Thr Glu 460 465 470 TCT GTG AAC ACA GAG AAC GTC AGC GGT GAA GGC GAG AAC CGA GGC TGC 1974 Ser Val Asn Thr Glu Asn Val Ser Gly Glu Gly Glu Asn Arg Gly Cys 475 480 485 TGT GGA AGT CTC TGT CAA GCC ATC TCA AAA TCC AAA CTC AGC CGA CGC 2022 Cys Gly Ser Leu Cys Gin Ala He Ser Lys Ser Lys Leu Ser Arg Arg 490 495 500 TGG CGT CGC TGG AAC CGA TTC AAT CGC AGA AGA TGT AGG GCC GCC GTG 2070 Trp Arg Arg Trp Asn Arg Phe Asn Arg Arg Arg Cys Arg Ala Ala Val 505 510 515 520 AAG TCT GTC ACG TTT TAC TGG CTG GTT ATC GTC CTG GTG TTT CTG AAC 2118 Lys Ser Val Thr Phe Tyr Trp Leu Val He Val Leu Val Phe Leu Asn 525 530 535 ACC TTA ACC ATT TCC TCT GAG CAC TAC AAT CAG CCA GAT TGG TTG ACA 2166 Thr Leu Thr He Ser Ser Glu His Tyr Asn Gin Pro Asp Trp Leu Thr 540 545 550 CAG ATT CAA GAT ATT GCC AAC AAA GTC CTC TTG GCT CTG TTC ACC TGC 2214 Gin He Gin Asp He Ala Asn Lys Val Leu Leu Ala Leu Phe Thr Cys 555 560 565 GAG ATG CTG GTA AAA ATG TAC AGC TTG GGC CTC CAA GCA TAT TTC GTC 2262 Glu Met Leu Val Lys Met Tyr Ser Leu Gly Leu Gin Ala Tyr Phe Val 570 575 580 TCT CTT TTC AAC CGG TTT GAT TGC TTC GTG GTG TGT GGT GGA ATC ACT 2310 Ser Leu Phe Asn Arg Phe Asp Cys Phe Val Val Cys Gly Gly He Thr 585 590 595 600 GAG ACG ATC TTG GTG GAA CTG GAA ATC ATG TCT CCC CTG GGG ATC TCT 2358 Glu Thr He Leu Val Glu Leu Glu He Met Ser Pro Leu Gly He Ser 605 610 615 GTG TTT CGG TGT GTG CGC CTC TTA AGA ATC TTC AAA GTG ACC AGG CAC 2406 Val Phe Arg Cys Val Arg Leu Leu Arg He Phe Lys Val Thr Arg His 620 625 630 TGG ACT TCC CTG AGC AAC TTA GTG GCA TCC TTA TTA AAC TCC ATG AAG 2454 Trp Thr Ser Leu Ser Asn Leu Val Ala Ser Leu Leu Asn Ser Met Lys 635 640 645 TCC ATC GCT TCG CTG TTG CTT CTG CTT TTT CTC TTC ATT ATC ATC TTT 2502 Ser He Ala Ser Leu Leu Leu Leu Leu Phe Leu Phe He He He Phe 650 655 660 TCC TTG CTT GGG ATG CAG CTG TTT GGC GGC AAG TTT AAT TTT GAT GAA 2550 Ser Leu Leu Gly Met Gin Leu Phe Gly Gly Lys Phe Asn Phe Asp Glu 665 670 675 680 ACG CAA ACC AAG CGG AGC ACC TTT GAC AAT TTC CCT CAA GCA CTT CTC 2598 Thr Gin Thr Lys Arg Ser Thr Phe Asp Asn Phe Pro Gin Ala Leu Leu 685 690 695 ACA GTG TTC CAG ATC CTG ACA GGC GAA GAC TGG AAT GCT GTG ATG TAC 2646 Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp Asn Ala Val Met Tyr 700 705 710 GAT GGC ATC ATG GCT TAC GGG GGC CCA TCC TCT TCA GGA ATG ATC GTC 2694 Asp Gly He Met Ala Tyr Gly Gly Pro Ser Ser Ser Gly Met He Val 715 720 725 TGC ATC TAC TTC ATC ATC CTC TTC ATT TGT GGT AAC TAT ATT CTA CTG 2742 Cys He Tyr Phe He He Leu Phe He Cys Gly Asn Tyr He Leu Leu 730 735 740 AAT GTC TTC TTG GCC ATC GCT GTA GAC AAT TTG GCT GAT GCT GAA AGT 2790 Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala Asp Ala Glu Ser 745 750 755 760 CTG AAC ACT GCT CAG AAA GAA GAA GCG GAA GAA AAG GAG AGG AAA AAG 2838 Leu Asn Thr Ala Gin Lys Glu Glu Ala Glu Glu Lys Glu Arg Lys Lys 765 770 775 ATT GCC AGA AAA GAG AGC CTA GAA AAT AAA AAG AAC AAC AAA CCA GAA 2886 He Ala Arg Lys Glu Ser Leu Glu Asn Lys Lys Asn Asn Lys Pro Glu 780 785 790 GTC AAC CAG ATA GCC AAC AGT GAC AAC AAG GTT ACA ATT GAT GAC TAT 2934 Val Asn Gin He Ala Asn Ser Asp Asn Lys Val Thr He Asp Asp Tyr 795 800 805 AGA GAA GAG GAT GAA GAC AAG GAC CCC TAT CCG CCT TGC GAT GTG CCA 2982 Arg Glu Glu Asp Glu Asp Lys Asp Pro Tyr Pro Pro Cys Asp Val Pro 810 815 820 GTA GGG GAA GAG GAA GAG GAA GAG GAG GAG GAT GAA CCT GAG GTT CCT 3030 Val Gly Glu Glu Glu Glu Glu Glu Glu Glu Asp Glu Pro Glu Val Pro 825 830 835 840 GCC GGA CCC CGT CCT CGA AGG ATC TCG GAG TTG AAC ATG AAG GAA AAA 3078 Ala Gly Pro Arg Pro Arg Arg He Ser Glu Leu Asn Met Lys Glu Lys 845 850 855 ATT GCC CCC ATC CCT GAA GGG AGC GCT TTC TTC ATT CTT AGC AAG ACC 3126 He Ala Pro He Pro Glu Gly Ser Ala Phe Phe He Leu Ser Lys Thr 860 865 870 AAC CCG ATC CGC GTA GGC TGC CAC AAG CTC ATC AAC CAC CAC ATC TTC 3174 Asn Pro He Arg Val Gly Cys His Lys Leu He Asn His His He Phe 875 880 885 ACC AAC CTC ATC CTT GTC TTC ATC ATG CTG AGC AGT GCT GCC CTG GCC 3222 Thr Asn Leu He Leu Val Phe He Met Leu Ser Ser Ala Ala Leu Ala 890 895 900 GCA GAG GAC CCC ATC CGC AGC CAC TCC TTC CGG AAC ACG ATA CTG GGT 3270 Ala Glu Asp Pro He Arg Ser His Ser Phe Arg Asn Thr He Leu Gly 905 910 915 920 TAC TTT GAC TAT GCC TTC ACA GCC ATC TTT ACT GTT GAG ATC CTG TTG 3318 Tyr Phe Asp Tyr Ala Phe Thr Ala He Phe Thr Val Glu He Leu Leu 925 930 935 AAG ATG ACA ACT TTT GGA GCT TTC CTC CAC AAA GGG GCC TTC TGC AGG 3366 Lys Met Thr Thr Phe Gly Ala Phe Leu His Lys Gly Ala Phe Cys Arg 940 945 950 AAC TAC TTC AAT TTG CTG GAT ATG CTG GTG GTT GGG GTG TCT CTG GTG 3414 Asn Tyr Phe Asn Leu Leu Asp Met Leu Val Val Gly Val Ser Leu Val 955 960 965 TCA TTT GGG ATT CAA TCC AGT GCC ATC TCC GTT GTG AAG ATT CTG AGG 3462 Ser Phe Gly He Gin Ser Ser Ala He Ser Val Val Lys He Leu Arg 970 975 980 GTC TTA AGG GTC CTG CGT CCC CTC AGG GCC ATC AAC AGA GCA AAA GGA 3510 Val Leu Arg Val Leu Arg Pro Leu Arg Ala He Asn Arg Ala Lys Gly 985 990 995 1000 CTT AAG CAC GTG GTC CAG TGC GTC TTC GTG GCC ATC CGG ACC ATC GGC 3558 Leu Lys His Val Val Gin Cys Val Phe Val Ala He Arg Thr He Gly 1005 1010 1015 AAC ATC ATG ATC GTC ACC ACC CTC CTG CAG TTC ATG TTT GCC TGT ATC 3606 Asn He Met He Val Thr Thr Leu Leu Gin Phe Met Phe Ala Cys He 1020 1025 1030 GGG GTC CAG TTG TTC AAG GGG AAG TTC TAT CGC TGT ACG GAT GAA GCC 3654 Gly Val Gin Leu Phe Lys Gly Lys Phe Tyr Arg Cys Thr Asp Glu Ala 1035 1040 1045 AAA AGT AAC CCT GAA GAA TGC AGG GGA CTT TTC ATC CTC TAC AAG GAT 3702 Lys Ser Asn Pro Glu Glu Cys Arg Gly Leu Phe He Leu Tyr Lys Asp 1050 1055 1060 GGG GAT GTT GAC AGT CCT GTG GTC CGT GAA CGG ATC TGG CAA AAC AGT 3750 Gly Asp Val Asp Ser Pro Val Val Arg Glu Arg He Trp Gin Asn Ser 1065 1070 1075 1080 GAT TTC AAC TTC GAC AAC GTC CTC TCT GCT ATG ATG GCG CTC TTC ACA 3798 Asp Phe Asn Phe Asp Asn Val Leu Ser Ala Met Met Ala Leu Phe Thr 1085 1090 1095 GTC TCC ACG TTT GAG GGC TGG CCT GCG TTG CTG TAT AAA GCC ATC GAC 3846 Val Ser Thr Phe Glu Gly Trp Pro Ala Leu Leu Tyr Lys Ala He Asp 1100 1105 1110 TCG AAT GGA GAG AAC ATC GGC CCA ATC TAC AAC CAC CGC GTG GAG ATC 3894 Ser Asn Gly Glu Asn He Gly Pro He Tyr Asn His Arg Val Glu He 1115 1120 1125 TCC ATC TTC TTC ATC ATC TAC ATC ATC ATT GTA GCT TTC TTC ATG ATG 3942 Ser He Phe Phe He He Tyr He He He Val Ala Phe Phe Met Met 1130 1135 1140 AAC ATC TTT GTG GGC TTT GTC ATC GTT ACA TTT CAG GAA CAA GGA GAA 3990 Asn He Phe Val Gly Phe Val He Val Thr Phe Gin Glu Gin Gly Glu 1145 1150 1155 1160 AAA GAG TAT AAG AAC TGT GAG CTG GAC AAA AAT CAG CGT CAG TGT GTT 4038 Lys Glu Tyr Lys Asn Cys Glu Leu Asp Lys Asn Gin Arg Gin Cys Val 1165 1170 1175 GAA TAC GCC TTG AAA GCA CGT CCC TTG CGG AGA TAC ATC CCC AAA AAC 4086 Glu Tyr Ala Leu Lys Ala Arg Pro Leu Arg Arg Tyr He Pro Lys Asn 1180 1185 1190 CCC TAC CAG TAC AAG TTC TGG TAC GTG GTG AAC TCT TCG CCT TTC GAA 4134 Pro Tyr Gin Tyr Lys Phe Trp Tyr Val Val Asn Ser Ser Pro Phe Glu 1195 1200 1205 TAC ATG ATG TTT GTC CTC ATC ATG CTC AAC ACA CTC TGC TTG GCC ATG 4182 Tyr Met Met Phe Val Leu He Met Leu Asn Thr Leu Cys Leu Ala Met 1210 1215 1220 CAG CAC TAC GAG CAG TCC AAG ATG TTC AAT GAT GCC ATG GAC ATT CTG 4230 Gin His Tyr Glu Gin Ser Lys Met Phe Asn Asp Ala Met Asp lie Leu 1225 1230 1235 1240 AAC ATG GTC TTC ACC GGG GTG TTC ACC GTC GAG ATG GTT TTG AAA GTC 4278 Asn Met Val Phe Thr Gly Val Phe Thr Val Glu Met Val Leu Lys Val 1245 1250 1255 ATC GCA TTT AAG CCT AAG GGG TAT TTT AGT GAC GCC TGG AAC ACG TTT 4326 He Ala Phe Lys Pro Lys Gly Tyr Phe Ser Asp Ala Trp Asn Thr Phe 1260 1265 1270 GAC TCC CTC ATC GTA ATC GGC AGC ATT ATA GAC GTG GCC CTC AGC GAA 4374 Asp Ser Leu He Val He Gly Ser He He Asp Val Ala Leu Ser Glu 1275 1280 1285 GCA GAC CCA ACT GAA AGT GAA AAT GTC CCT GTC CCA ACT GCT ACA CCT 4422 Ala Asp Pro Thr Glu Ser Glu Asn Val Pro Val Pro Thr Ala Thr Pro 1290 1295 1300 GGG AAC TCT GAA GAG AGC AAT AGA ATC TCC ATC ACC TTT TTC CGT CTT 4470 Gly Asn Ser Glu Glu Ser Asn Arg He Ser He Thr Phe Phe Arg Leu 1305 1310 1315 1320 TTC CGA GTG ATG CGA TTG GTG AAG CTT CTC AGC AGG GGG GAA GGC ATC 4518 Phe Arg Val Met Arg Leu Val Lys Leu Leu Ser Arg Gly Glu Gly He 1325 1330 1335 CGG ACA TTG CTG TGG ACT TTT ATT AAG TTC TTT CAG GCG CTC CCG TAT 4566 Arg Thr Leu Leu Trp Thr Phe He Lys Phe Phe Gin Ala Leu Pro Tyr 1340 1345 1350 GTG GCC CTC CTC ATA GCC ATG CTG TTC TTC ATC TAT GCG GTC ATT GGC 4614 Val Ala Leu Leu He Ala Met Leu Phe Phe He Tyr Ala Val He Gly 1355 1360 1365 ATG CAG ATG TTT GGG AAA GTT GCC ATG AGA GAT AAC AAC CAG ATC AAT 4662 Met Gin Met Phe Gly Lys Val Ala Met Arg Asp Asn Asn Gin He Asn 1370 1375 1380 AGG AAC AAT AAC TTC CAG ACG TTT CCC CAG GCG GTG CTG CTG CTC TTC 4710 Arg Asn Asn Asn Phe Gin Thr Phe Pro Gin Ala Val Leu Leu Leu Phe 1385 1390 1395 1400 AGG TGT GCA ACA GGT GAG GCC TGG CAG GAG ATC ATG CTG GCC TGT CTC 4758 Arg Cys Ala Thr Gly Glu Ala Trp Gin Glu He Met Leu Ala Cys Leu 1405 1410 1415 CCA GGG AAG CTC TGT GAC CCT GAG TCA GAT TAC AAC CCC GGG GAG GAG 4806 Pro Gly Lys Leu Cys Asp Pro Glu Ser Asp Tyr Asn Pro Gly Glu Glu 1420 1425 1430 CAT ACA TGT GGG AGC AAC TTT GCC ATT GTC TAT TTC ATC AGT TTT TAC 4854 His Thr Cys Gly Ser Asn Phe Ala He Val Tyr Phe He Ser Phe Tyr 1435 1440 1445 ATG CTC TGT GCA TTT CTG ATC ATC AAT CTG TTT GTG GCT GTC ATC ATG 4902 Met Leu Cys Ala Phe Leu He He Asn Leu Phe Val Ala Val He Met 1450 1455 1460 GAT AAT TTC GAC TAT CTG ACC CGG GAC TGG TCT ATT TTG GGG CCT CAC 4950 Asp Asn Phe Asp Tyr Leu Thr Arg Asp Trp Ser He Leu Gly Pro His 1465 1470 1475 1480 CAT TTA GAT GAA TTC AAA AGA ATA TGG TCA GAA TAT GAC CCT GAG GCA 4998 His Leu Asp Glu Phe Lys Arg He Trp Ser Glu Tyr Asp Pro Glu Ala 1485 1490 1495 AAG GGA AGG ATA AAA CAC CTT GAT GTG GTC ACT CTG CTT CGA CGC ATC 5046 Lys Gly Arg He Lys His Leu Asp Val Val Thr Leu Leu Arg Arg He 1500 1505 1510 CAG CCT CCC CTG GGG TTT GGG AAG TTA TGT CCA CAC AGG GTA GCG TGC 5094 Gin Pro Pro Leu Gly Phe Gly Lys Leu Cys Pro His Arg Val Ala Cys 1515 1520 1525 AAG AGA TTA GTT GCC ATG AAC ATG CCT CTC AAC AGT GAC GGG ACA GTC 5142 Lys Arg Leu Val Ala Met Asn Met Pro Leu Asn Ser Asp Gly Thr Val 1530 1535 1540 ATG TTT AAT GCA ACC CTG TTT GCT TTG GTT CGA ACG GCT CTT AAG ATC 5190 Met Phe Asn Ala Thr Leu Phe Ala Leu Val Arg Thr Ala Leu Lys He 1545 1550 1555 1560 AAG ACC GAA GGG AAC CTG GAG CAA GCT AAT GAA GAA CTT CGG GCT GTG 5238 Lys Thr Glu Gly Asn Leu Glu Gin Ala Asn Glu Glu Leu Arg Ala Val 1565 1570 1575 ATA AAG AAA ATT TGG AAG AAA ACC AGC ATG AAA TTA CTT GAC CAA GTT 5286 He Lys Lys He Trp Lys Lys Thr Ser Met Lys Leu Leu Asp Gin Val 1580 1585 1590 GTC CCT CCA GCT GGT GAT GAT GAG GTA ACC GTG GGG AAG TTC TAT GCC 5334 Val Pro Pro Ala Gly Asp Asp Glu Val Thr Val Gly Lys Phe Tyr Ala 1595 1600 1605 ACT TTC CTG ATA CAG GAC TAC TTT AGG AAA TTC AAG AAA CGG AAA GAA 5382 Thr Phe Leu He Gin Asp Tyr Phe Arg Lys Phe Lys Lys Arg Lys Glu 1610 1615 1620 CAA GGA CTG GTG GGA AAG TAC CCT GCG AAG AAC ACC ACA ATT GCC CTA 5430 Gin Gly Leu Val Gly Lys Tyr Pro Ala Lys Asn Thr Thr He Ala Leu 1625 1630 1635 1640 CAG GCG GGA TTA AGG ACA CTG CAT GAC ATT GGG CCA GAA ATC CGG CGT 5478 Gin Ala Gly Leu Arg Thr Leu His Asp He Gly Pro Glu He Arg Arg 1645 1650 1655 GCT ATA TCG TGT GAT TTG CAA GAT GAC GAG CCT GAG GAA ACA AAA CGA 5526 Ala He Ser Cys Asp Leu Gin Asp Asp Glu Pro Glu Glu Thr Lys Arg 1660 1665 1670 GAA GAA GAA GAT GAT GTG TTC AAA AGA AAT GGT GCC CTG CTT GGA AAC 5574 Glu Glu Glu Asp Asp Val Phe Lys Arg Asn Gly Ala Leu Leu Gly Asn 1675 1680 1685 CAT GTC AAT CAT GTT AAT AGT GAT AGG AGA GAT TCC CTT CAG CAG ACC 5622 His Val Asn His Val Asn Ser Asp Arg Arg Asp Ser Leu Gin Gin Thr 1690 1695 1700 AAT ACC ACC CAC CGT CCC CTG CAT GTC CAA AGG CCT TCA ATT CCA CCT 5670 Asn Thr Thr His Arg Pro Leu His Val Gin Arg Pro Ser He Pro Pro 1705 1710 1715 1720 GCA AGT GAT ACT GAG AAA CCG CTG TTT CCT CCA GCA GGA AAT TCG GTG 5718 Ala Ser Asp Thr Glu Lys Pro Leu Phe Pro Pro Ala Gly Asn Ser Val 1725 1730 1735 TGT CAT AAC CAT CAT AAC CAT AAT TCC ATA GGA AAG CAA GTT CCC ACC 5766 Cys His Asn His His Asn His Asn Ser He Gly Lys Gin Val Pro Thr 1740 1745 1750 TCA ACA AAT GCC AAT CTC AAT AAT GCC AAT ATG TCC AAA GCT GCC CAT 5814 Ser Thr Asn Ala Asn Leu Asn Asn Ala Asn Met Ser Lys Ala Ala His 1755 1760 1765 GGA AAG CGG CCC AGC ATT GGG AAC CTT GAG CAT GTG TCT GAA AAT GGG 5862 Gly Lys Arg Pro Ser He Gly Asn Leu Glu His Val Ser Glu Asn Gly 1770 1775 1780 CAT CAT TCT TCC CAC AAG CAT GAC CGG GAG CCT CAG AGA AGG TCC AGT 5910 His His Ser Ser His Lys His Asp Arg Glu Pro Gin Arg Arg Ser Ser 1785 1790 1795 1800 GTG AAA AGA ACC CGC TAT TAT GAA ACT TAC ATT AGG TCC GAC TCA GGA 5958 Val Lys Arg Thr Arg Tyr Tyr Glu Thr Tyr He Arg Ser Asp Ser Gly 1805 1810 1815 GAT GAA CAG CTC CCA ACT ATT TGC CGG GAA GAC CCA GAG ATA CAT GGC 6006 Asp Glu Gin Leu Pro Thr He Cys Arg Glu Asp Pro Glu He His Gly 1820 1825 1830 TAT TTC AGG GAC CCC CAC TGC TTG GGG GAG CAG GAG TAT TTC AGT AGT 6054 Tyr Phe Arg Asp Pro His Cys Leu Gly Glu Gin Glu Tyr Phe Ser Ser 1835 1840 1845 GAG GAA TGC TAC GAG GAT GAC AGC TCG CCC ACC TGG AGC AGG CAA AAC 6102 Glu Glu Cys Tyr Glu Asp Asp Ser Ser Pro Thr Trp Ser Arg Gin Asn 1850 1855 1860 TAT GGC TAC TAC AGC AGA TAC CCA GGC AGA AAC ATC GAC TCT GAG AGG 6150 Tyr Gly Tyr Tyr Ser Arg Tyr Pro Gly Arg Asn He Asp Ser Glu Arg 1865 1870 1875 1880 CCC CGA GGC TAC CAT CAT CCC CAA GGA TTC TTG GAG GAC GAT GAC TCG 6198 Pro Arg Gly Tyr His His Pro Gin Gly Phe Leu Glu Asp Asp Asp Ser 1885 1890 1895 CCC GTT TGC TAT GAT TCA CGG AGA TCT CCA AGG AGA CGC CTA CTA CCT 6246 Pro Val Cys Tyr Asp Ser Arg Arg Ser Pro Arg Arg Arg Leu Leu Pro 1900 1905 1910 CCC ACC CCA GCA TCC CAC CGG AGA TCC TCC TTC AAC TTT GAG TGC CTG 6294 Pro Thr Pro Ala Ser His Arg Arg Ser Ser Phe Asn Phe Glu Cys Leu 1915 1920 1925 CGC CGG CAG AGC AGC CAG GAA GAG GTC CCG TCG TCT CCC ATC TTC CCC 6342 Arg Arg Gin Ser Ser Gin Glu Glu Val Pro Ser Ser Pro He Phe Pro 1930 1935 1940 CAT CGC ACG GCC CTG CCT CTG CAT CTA ATG CAG CAA CAG ATC ATG GCA 6390 His Arg Thr Ala Leu Pro Leu His Leu Met Gin Gin Gin He Met Ala 1945 1950 1955 1960 GTT GCC GGC CTA GAT TCA AGT AAA GCC CAG AAG TAC TCA CCG AGT CAC 6438 Val Ala Gly Leu Asp Ser Ser Lys Ala Gin Lys Tyr Ser Pro Ser His 1965 1970 1975 TCG ACC CGG TCG TGG GCC ACC CCT CCA GCA ACC CCT CCC TAC CGG GAC 6486 Ser Thr Arg Ser Trp Ala Thr Pro Pro Ala Thr Pro Pro Tyr Arg Asp 1980 1985 1990 TGG ACA CCG TGC TAC ACC CCC CTG ATC CAA GTG GAG CAG TCA GAG GCC 6534 Trp Thr Pro Cys Tyr Thr Pro Leu He Gin Val Glu Gin Ser Glu Ala 1995 2000 2005 CTG GAC CAG GTG AAC GGC AGC CTG CCG TCC CTG CAC CGC AGC TCC TGG 6582 Leu Asp Gin Val Asn Gly Ser Leu Pro Ser Leu His Arg Ser Ser Trp 2010 2015 2020 TAC ACA GAC GAG CCC GAC ATC TCC TAC CGG ACT TTC ACA CCA GCC AGC 6630 Tyr Thr Asp Glu Pro Asp He Ser Tyr Arg Thr Phe Thr Pro Ala Ser 2025 2030 2035 2040 CTG ACT GTC CCC AGC AGC TTC CGG AAC AAA AAC AGC GAC AAG CAG AGG 6678 Leu Thr Val Pro Ser Ser Phe Arg Asn Lys Asn Ser Asp Lys Gin Arg 2045 2050 2055 AGT GCG GAC AGC TTG GTG GAG GCA GTC CTG ATA TCC GAA GGC TTG GGA 6726 Ser Ala Asp Ser Leu Val Glu Ala Val Leu He Ser Glu Gly Leu Gly 2060 2065 2070 CGC TAT GCA AGG GAC CCA AAA TTT GTG TCA GCA ACA AAA CAC GAA ATC 6774 Arg Tyr Ala Arg Asp Pro Lys Phe Val Ser Ala Thr Lys His Glu He 2075 2080 2085 GCT GAT GCC TGT GAC CTC ACC ATC GAC GAG ATG GAG AGT GCA GCC AGC 6822 Ala Asp Ala Cys Asp Leu Thr He Asp Glu Met Glu Ser Ala Ala Ser 2090 2095 2100 ACC CTG CTT AAT GGG AAC GTG CGT CCC CGA GCC AAC GGG GAT GTG GGC 6870 Thr Leu Leu Asn Gly Asn Val Arg Pro Arg Ala Asn Gly Asp Val Gly 2105 2110 2115 2120 CCC CTC TCA CAC CGG CAG GAC TAT GAG CTA CAG GAC TTT GGT CCT GGC 6918 Pro Leu Ser His Arg Gin Asp Tyr Glu Leu Gin Asp Phe Gly Pro Gly 2125 2130 2135 TAC AGC GAC GAA GAG CCA GAC CCT GGG AGG GAT GAG GAG GAC CTG GCG 6966 Tyr Ser Asp Glu Glu Pro Asp Pro Gly Arg Asp Glu Glu Asp Leu Ala 2140 2145 2150 GAT GAA ATG ATA TGC ATC ACC ACC TTG TAGCCCCCAG CGAGGGGCAG 7013 Asp Glu Met He Cys He Thr Thr Leu 2155 2160 ACTGGCTCTG GCCTCAGGTG GGGCGCAGGA GAGCCAGGGG AAAAGTGCCT CATAGTTAGG 7073 AAAGTTTAGG CACTAGTTGG GAGTAATATT CAATTAATTA GACTTTTGTA TAAGAGATGT 7133 CATGCCTCAA GAAAGCCATA AACCTGGTAG GAACAGGTCC CAAGCGGTTG AGCCTGGCAG 7193 AGTACCATGC GCTCGGCCCC AGCTGCAGGA AACAGCAGGC CCCGCCCTCT CACAGAGGAT 7253 GGGTGAGGAG GCCAGACCTG CCCTGCCCCA TTGTCCAGAT GGGCACTGCT GTGGAGTCTG 7313 CTTCTCCCAT GTACCAGGGC ACCAGGCCCA CCCAACTGAA GGCATGGCGG CGGGGTGCAG 7373 GGGAAAGTTA AAGGTGATGA CGATCATCAC ACCTGTGTCG TTACCTCAGC CATCGGTCTA 7433 GCATATCAGT CACTGGGCCC AACATATCCA TTTTTAAACC CTTTCCCCCA AATACACTGC 7493 GTCCTGGTTC CTGTTTAGCT GTTCTGAAAT ACGGTGTGTA AGTAAGTCAG AACCCAGCTA 7553 CCAGTGATTA TTGCGAGGGC AATGGGACCT CATAAATAAG GTTTTCTGTG ATGTGACGCC 7613 AGTTTACATA AGAGAATATC AC 7635 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 104 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..102 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..104 (D) OTHER INFORMATION: /note= "A 104-nucleotide alternative exon of alpha-ID." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GTA AAT GAT GCG ATA GGA TGG GAA TGG CCA TGG GTG TAT TTT GTT AGT 48 Val Asn Asp Ala He Gly Trp Glu Trp Pro Trp Val Tyr Phe Val Ser 1 5 10 15 CTG ATC ATC CTT GGC TCA TTT TTC GTC CTT AAC CTG GTT CTT GGT GTC 96 Leu He He Leu Gly Ser Phe Phe Val Leu Asn Leu Val Leu Gly Val 20 25 30 CTT AGT GG 104 Leu Ser (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6575 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..6492 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATG GTC AAT GAG AAT ACG AGG ATG TAC ATT CCA GAG GAA AAC CAC CAA 48 Met Val Asn Glu Asn Thr Arg Met Tyr He Pro Glu Glu Asn His Gin 1 5 10 15 GGT TCC AAC TAT GGG AGC CCA CGC CCC GCC CAT GCC AAC ATG AAT GCC 96 Gly Ser Asn Tyr Gly Ser Pro Arg Pro Ala His Ala Asn Met Asn Ala 20 25 30 AAT GCG GCA GCG GGG CTG GCC CCT GAG CAC ATC CCC ACC CCG GGG GCT 144 Asn Ala Ala Ala Gly Leu Ala Pro Glu His He Pro Thr Pro Gly Ala 35 40 45 GCC CTG TCG TGG CAG GCG GCC ATC GAC GCA GCC CGG CAG GCT AAG CTG 192 Ala Leu Ser Trp Gin Ala Ala He Asp Ala Ala Arg Gin Ala Lys Leu 50 55 60 ATG GGC AGC GCT GGC AAT GCG ACC ATC TCC ACA GTC AGC TCC ACG CAG 240 Met Gly Ser Ala Gly Asn Ala Thr He Ser Thr Val Ser Ser Thr Gin 65 70 75 80 CGG AAG CGC CAG CAA TAT GGG AAA CCC AAG AAG CAG GGC AGC ACC ACG 288 Arg Lys Arg Gin Gin Tyr Gly Lys Pro Lys Lys Gin Gly Ser Thr Thr 85 90 95 GCC ACA CGC CCG CCC CGA GCC CTG CTC TGC CTG ACC CTG AAG AAC CCC 336 Ala Thr Arg Pro Pro Arg Ala Leu Leu Cys Leu Thr Leu Lys Asn Pro 100 105 110 ATC CGG AGG GCC TGC ATC AGC ATT GTC GAA TGG AAA CCA TTT GAA ATA 384 He Arg Arg Ala Cys He Ser He Val Glu Trp Lys Pro Phe Glu He 115 120 125 ATT ATT TTA CTG ACT ATT TTT GCC AAT TGT GTG GCC TTA GCG ATC TAT 432 He He Leu Leu Thr He Phe Ala Asn Cys Val Ala Leu Ala He Tyr 130 135 140 ATT CCC TTT CCA GAA GAT GAT TCC AAC GCC ACC AAT TCC AAC CTG GAA 480 He Pro Phe Pro Glu Asp Asp Ser Asn Ala Thr Asn Ser Asn Leu Glu 145 150 155 160 CGA GTG GAA TAT CTC TTT CTC ATA ATT TTT ACG GTG GAA GCG TTT TTA 528 Arg Val Glu Tyr Leu Phe Leu He He Phe Thr Val Glu Ala Phe Leu 165 170 175 AAA GTA ATC GCC TAT GGA CTC CTC TTT CAC CCC AAT GCC TAC CTC CGC 576 Lys Val He Ala Tyr Gly Leu Leu Phe His Pro Asn Ala Tyr Leu Arg 180 185 190 AAC GGC TGG AAC CTA CTA GAT TTT ATA ATT GTG GTT GTG GGG CTT TTT 624 Asn Gly Trp Asn Leu Leu Asp Phe He He Val Val Val Gly Leu Phe 195 200 205 AGT GCA ATT TTA GAA CAA GCA ACC AAA GCA GAT GGG GCA AAC GCT CTC 672 Ser Ala He Leu Glu Gin Ala Thr Lys Ala Asp Gly Ala Asn Ala Leu 210 215 220 GGA GGG AAA GGG GCC GGA TTT GAT GTG AAG GCG CTG AGG GCC TTC CGC 720 Gly Gly Lys Gly Ala Gly Phe Asp Val Lys Ala Leu Arg Ala Phe Arg 225 230 235 240 GTG CTG CGC CCC CTG CGG CTG GTG TCC GGA GTC CCA AGT CTC CAG GTG 768 Val Leu Arg Pro Leu Arg Leu Val Ser Gly Val Pro Ser Leu Gin Val 245 250 255 GTC CTG AAT TCC ATC ATC AAG GCC ATG GTC CCC CTG CTG CAC ATC GCC 816 Val Leu Asn Ser He He Lys Ala Met Val Pro Leu Leu His He Ala 260 265 270 CTG CTT GTG CTG TTT GTC ATC ATC ATC TAC GCC ATC ATC GGC TTG GAG 864 Leu Leu Val Leu Phe Val He He He Tyr Ala He He Gly Leu Glu 275 280 285 CTC TTC ATG GGG AAG ATG CAC AAG ACC TGC TAC AAC CAG GAG GGC ATA 912 Leu Phe Met Gly Lys Met His Lys Thr Cys Tyr Asn Gin Glu Gly He 290 295 300 GCA GAT GTT CCA GCA GAA GAT GAC CCT TCC CCT TGT GCG CTG GAA ACG 960 Ala Asp Val Pro Ala Glu Asp Asp Pro Ser Pro Cys Ala Leu Glu Thr 305 310 315 320 GGC CAC GGG CGG CAG TGC CAG AAC GGC ACG GTG TGC AAG CCC GGC TGG 1008 Gly His Gly Arg Gin Cys Gin Asn Gly Thr Val Cys Lys Pro Gly Trp 325 330 335 GAT GGT CCC AAG CAC GGC ATC ACC AAC TTT GAC AAC TTT GCC TTC GCC 1056 Asp Gly Pro Lys His Gly He Thr Asn Phe Asp Asn Phe Ala Phe Ala 340 345 350 ATG CTC ACG GTG TTC CAG TGC ATC ACC ATG GAG GGC TGG ACG GAC GTG 1104 Met Leu Thr Val Phe Gin Cys He Thr Met Glu Gly Trp Thr Asp Val 355 360 365 CTG TAC TGG GTC AAT GAT GCC GTA GGA AGG GAC TGG CCC TGG ATC TAT 1152 Leu Tyr Trp Val Asn Asp Ala Val Gly Arg Asp Trp Pro Trp He Tyr 370 375 380 TTT GTT ACA CTA ATC ATC ATA GGG TCA TTT TTT GTA CTT AAC TTG GTT 1200 Phe Val Thr Leu He He He Gly Ser Phe Phe Val Leu Asn Leu Val 385 390 395 400 CTC GGT GTG CTT AGC GGA GAG TTT TCC AAA GAG AGG GAG AAG GCC AAG 1248 Leu Gly Val Leu Ser Gly Glu Phe Ser Lys Glu Arg Glu Lys Ala Lys 405 410 415 GCC CGG GGA GAT TTC CAG AAG CTG CGG GAG AAG CAG CAG CTA GAA GAG 1296 Ala Arg Gly Asp Phe Gin Lys Leu Arg Glu Lys Gin Gin Leu Glu Glu 420 425 430 GAT CTC AAA GGC TAC CTG GAT TGG ATC ACT CAG GCC GAA GAC ATC GAT 1344 Asp Leu Lys Gly Tyr Leu Asp Trp He Thr Gin Ala Glu Asp He Asp 435 440 445 CCT GAG AAT GAG GAC GAA GGC ATG GAT GAG GAG AAG CCC CGA AAC AGA 1392 Pro Glu Asn Glu Asp Glu Gly Met Asp Glu Glu Lys Pro Arg Asn Arg 450 455 460 GGC ACT CCG GCG GGC ATG CTT GAT CAG AAG AAA GGG AAG TTT GCT TGG 1440 Gly Thr Pro Ala Gly Met Leu Asp Gin Lys Lys Gly Lys Phe Ala Trp 465 470 475 480 TTT AGT CAC TCC ACA GAA ACC CAT GTG AGC ATG CCC ACC AGT GAG ACC 1488 Phe Ser His Ser Thr Glu Thr His Val Ser Met Pro Thr Ser Glu Thr 485 490 495 GAG TCC GTC AAC ACC GAA AAC GTG GCT GGA GGT GAC ATC GAG GGA GAA 1536 Glu Ser Val Asn Thr Glu Asn Val Ala Gly Gly Asp He Glu Gly Glu 500 505 510 AAC TGC GGG GCC AGG CTG GCC CAC CGG ATC TCC AAG TCA AAG TTC AGC 1584 Asn Cys Gly Ala Arg Leu Ala His Arg He Ser Lys Ser Lys Phe Ser 515 520 525 CGC TAC TGG CGC CGG TGG AAT CGG TTC TGC AGA AGG AAG TGC CGC GCC 1632 Arg Tyr Trp Arg Arg Trp Asn Arg Phe Cys Arg Arg Lys Cys Arg Ala 530 535 540 GCA GTC AAG TCT AAT GTC TTC TAC TGG CTG GTG ATT TTC CTG GTG TTC 1680 Ala Val Lys Ser Asn Val Phe Tyr Trp Leu Val He Phe Leu Val Phe 545 550 555 560 CTC AAC ACG CTC ACC ATT GCC TCT GAG CAC TAC AAC CAG CCC AAC TGG 1728 Leu Asn Thr Leu Thr He Ala Ser Glu His Tyr Asn Gin Pro Asn Trp 565 570 575 CTC ACA GAA GTC CAA GAC ACG GCA AAC AAG GCC CTG CTG GCC CTG TTC 1776 Leu Thr Glu Val Gin Asp Thr Ala Asn Lys Ala Leu Leu Ala Leu Phe 580 585 590 ACG GCA GAG ATG CTC CTG AAG ATG TAC AGC CTG GGC CTG CAG GCC TAC 1824 Thr Ala Glu Met Leu Leu Lys Met Tyr Ser Leu Gly Leu Gin Ala Tyr 595 600 605 TTC GTG TCC CTC TTC AAC CGC TTT GAC TGC TTC GTC GTG TGT GGC GGC 1872 Phe Val Ser Leu Phe Asn Arg Phe Asp Cys Phe Val Val Cys Gly Gly 610 615 620 ATC CTG GAG ACC ATC CTG GTG GAG ACC AAG ATC ATG TCC CCA CTG GGC 1920 He Leu Glu Thr He Leu Val Glu Thr Lys He Met Ser Pro Leu Gly 625 630 635 640 ATC TCC GTG CTC AGA TGC GTC CGG CTG CTG AGG ATT TTC AAG ATC ACG 1968 He Ser Val Leu Arg Cys Val Arg Leu Leu Arg He Phe Lys He Thr 645 650 655 AGG TAC TGG AAC TCC TTG AGC AAC CTG GTG GCA TCC TTG CTG AAC TCT 2016 Arg Tyr Trp Asn Ser Leu Ser Asn Leu Val Ala Ser Leu Leu Asn Ser 660 665 670 GTG CGC TCC ATC GCC TCC CTG CTC CTT CTC CTC TTC CTC TTC ATC ATC 2064 Val Arg Ser He Ala Ser Leu Leu Leu Leu Leu Phe Leu Phe He He 675 680 685 ATC TTC TCC CTC CTG GGG ATG CAG CTC TTT GGA GGA AAG TTC AAC TTT 2112 He Phe Ser Leu Leu Gly Met Gin Leu Phe Gly Gly Lys Phe Asn Phe 690 695 700 GAT GAG ATG CAG ACC CGG AGG AGC ACA TTC GAT AAC TTC CCC CAG TCC 2160 Asp Glu Met Gin Thr Arg Arg Ser Thr Phe Asp Asn Phe Pro Gin Ser 705 710 715 720 CTC CTC ACT GTG TTT CAG ATC CTG ACC GGG GAG GAC TGG AAT TCG GTG 2208 Leu Leu Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp Asn Ser Val 725 730 735 ATG TAT GAT GGG ATC ATG GCT TAT GGG GGC CCC TCT TTT CCA GGG ATG 2256 Met Tyr Asp Gly He Met Ala Tyr Gly Gly Pro Ser Phe Pro Gly Met 740 745 750 TTA GTC TGT ATT TAC TTC ATC ATC CTC TTC ATC TGT GGA AAC TAT ATC 2304 Leu Val Cys He Tyr Phe He He Leu Phe He Cys Gly Asn Tyr He 755 760 765 CTA CTG AAT GTG TTC TTG GCC ATT GCT GTG GAC AAC CTG GCT GAT GCT 2352 Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala Asp Ala 770 775 780 GAG AGC CTC ACA TCT GCC CAA AAG GAG GAG GAA GAG GAG AAG GAG AGA 2400 Glu Ser Leu Thr Ser Ala Gin Lys Glu Glu Glu Glu Glu Lys Glu Arg 785 790 795 800 AAG AAG CTG GCC AGG ACT GCC AGC CCA GAG AAG AAA CAA GAG TTG GTG 2448 Lys Lys Leu Ala Arg Thr Ala Ser Pro Glu Lys Lys Gin Glu Leu Val 805 810 815 GAG AAG CCG GCA GTG GGG GAA TCC AAG GAG GAG AAG ATT GAG CTG AAA 2496 Glu Lys Pro Ala Val Gly Glu Ser Lys Glu Glu Lys He Glu Leu Lys 820 825 830 TCC ATC ACG GCT GAC GGA GAG TCT CCA CCC GCC ACC AAG ATC AAC ATG 2544 Ser He Thr Ala Asp Gly Glu Ser Pro Pro Ala Thr Lys He Asn Met 835 840 845 GAT GAC CTC CAG CCC AAT GAA AAT GAG GAT AAG AGC CCC TAC CCC AAC 2592 Asp Asp Leu Gin Pro Asn Glu Asn Glu Asp Lys Ser Pro Tyr Pro Asn 850 855 860 CCA GAA ACT ACA GGA GAA GAG GAT GAG GAG GAG CCA GAG ATG CCT GTC 26 0 Pro Glu Thr Thr Gly Glu Glu Asp Glu Glu Glu Pro Glu Met Pro Val 865 870 875 880 GGC CCT CGC CCA CGA CCA CTC TCT GAG CTT CAC CTT AAG GAA AAG GCA 2688 Gly Pro Arg Pro Arg Pro Leu Ser Glu Leu His Leu Lys Glu Lys Ala 885 890 895 GTG CCC ATG CCA GAA GCC AGC GCG TTT TTC ATC TTC AGC TCT AAC AAC 2736 Val Pro Met Pro Glu Ala Ser Ala Phe Phe He Phe Ser Ser Asn Asn 900 905 910 AGG TTT CGC CTC CAG TGC CAC CGC ATT GTC AAT GAC ACG ATC TTC ACC 2784 Arg Phe Arg Leu Gin Cys His Arg He Val Asn Asp Thr He Phe Thr 915 920 925 AAC CTG ATC CTC TTC TTC ATT CTG CTC AGC AGC ATT TCC CTG GCT GCT 2832 Asn Leu He Leu Phe Phe He Leu Leu Ser Ser He Ser Leu Ala Ala 930 935 940 GAG GAC CCG GTC CAG CAC ACC TCC TTC AGG AAC CAT ATT CTG TTT TAT 2880 Glu Asp Pro Val Gin His Thr Ser Phe Arg Asn His He Leu Phe Tyr 945 950 955 960 TTT GAT ATT GTT TTT ACC ACC ATT TTC ACC ATT GAA ATT GCT CTG AAG 2928 Phe Asp He Val Phe Thr Thr He Phe Thr He Glu He Ala Leu Lys 965 970 975 ATG ACT GCT TAT GGG GCT TTC TTG CAC AAG GGT TCT TTC TGC CGG AAC 2976 Met Thr Ala Tyr Gly Ala Phe Leu His Lys Gly Ser Phe Cys Arg Asn 980 985 990 TAC TTC AAC ATC CTG GAC CTG CTG GTG GTC AGC GTG TCC CTC ATC TCC 3024 Tyr Phe Asn He Leu Asp Leu Leu Val Val Ser Val Ser Leu He Ser 995 1000 1005 TTT GGC ATC CAG TCC AGT GCA ATC AAT GTC GTG AAG ATC TTG CGA GTC 3072 Phe Gly He Gin Ser Ser Ala He Asn Val Val Lys He Leu Arg Val 1010 1015 1020 CTG CGA GTA CTC AGG CCC CTG AGG GCC ATC AAC AGG GCC AAG GGG CTA 3120 Leu Arg Val Leu Arg Pro Leu Arg Ala He Asn Arg Ala Lys Gly Leu 1025 1030 1035 1040 AAG CAT GTG GTT CAG TGT GTG TTT GTC GCC ATC CGG ACC ATC GGG AAC 3168 Lys His Val Val Gin Cys Val Phe Val Ala He Arg Thr He Gly Asn 1045 1050 1055 ATC GTG ATT GTC ACC ACC CTG CTG CAG TTC ATG TTT GCC TGC ATC GGG 3216 He Val He Val Thr Thr Leu Leu Gin Phe Met Phe Ala Cys He Gly 1060 1065 1070 GTC CAG CTC TTC AAG GGA AAG CTG TAC ACC TGT TCA GAC AGT TCC AAG 3264 Val Gin Leu Phe Lys Gly Lys Leu Tyr Thr Cys Ser Asp Ser Ser Lys 1075 1080 1085 CAG ACA GAG GCG GAA TGC AAG GGC AAC TAC ATC ACG TAC AAA GAC GGG 3312 Gin Thr Glu Ala Glu Cys Lys Gly Asn Tyr He Thr Tyr Lys Asp Gly 1090 1095 1100 GAG GTT GAC CAC CCC ATC ATC CAA CCC CGC AGC TGG GAG AAC AGC AAG 3360 Glu Val Asp His Pro He He Gin Pro Arg Ser Trp Glu Asn Ser Lys 1105 1110 1115 1120 TTT GAC TTT GAC AAT GTT CTG GCA GCC ATG ATG GCC CTC TTC ACC GTC 3408 Phe Asp Phe Asp Asn Val Leu Ala Ala Met Met Ala Leu Phe Thr Val 1125 1130 1135 TCC ACC TTC GAA GGG TGG CCA GAG CTG CTG TAC CGC TCC ATC GAC TCC 3456 Ser Thr Phe Glu Gly Trp Pro Glu Leu Leu Tyr Arg Ser He Asp Ser 1140 1145 1150 CAC ACG GAA GAC AAG GGC CCC ATC TAC AAC TAC CGT GTG GAG ATC TCC 3504 His Thr Glu Asp Lys Gly Pro He Tyr Asn Tyr Arg Val Glu He Ser 1155 1160 1165 ATC TTC TTC ATC ATC TAC ATC ATC ATC ATC GCC TTC TTC ATG ATG AAC 3552 He Phe Phe He He Tyr He He He He Ala Phe Phe Met Met Asn 1170 1175 1180 ATC TTC GTG GGC TTC GTC ATC GTC ACC TTT CAG GAG CAG GGG GAG CAG 3600 He Phe Val Gly Phe Val He Val Thr Phe Gin Glu Gin Gly Glu Gin 1185 1190 1195 1200 GAG TAC AAG AAC TGT GAG CTG GAC AAG AAC CAG CGA CAG TGC GTG GAA 3648 Glu Tyr Lys Asn Cys Glu Leu Asp Lys Asn Gin Arg Gin Cys Val Glu 1205 1210 1215 TAC GCC CTC AAG GCC CGG CCC CTG CGG AGG TAC ATC CCC AAG AAC CAG 3696 Tyr Ala Leu Lys Ala Arg Pro Leu Arg Arg Tyr He Pro Lys Asn Gin 1220 1225 1230 CAC CAG TAC AAA GTG TGG TAC GTG GTC AAC TCC ACC TAC TTC GAG TAC 3744 His Gin Tyr Lys Val Trp Tyr Val Val Asn Ser Thr Tyr Phe Glu Tyr 1235 1240 1245 CTG ATG TTC GTC CTC ATC CTG CTC AAC ACC ATC TGC CTG GCC ATG CAG 3792 Leu Met Phe Val Leu He Leu Leu Asn Thr He Cys Leu Ala Met Gin 1250 1255 1260 CAC TAC GGC CAG AGC TGC CTG TTC AAA ATC GCC ATG AAC ATC CTC AAC 3840 His Tyr Gly Gin Ser Cys Leu Phe Lys He Ala Met Asn He Leu Asn 1265 1270 1275 1280 ATG CTC TTC ACT GGC CTC TTC ACC GTG GAG ATG ATC CTG AAG CTC ATT 3888 Met Leu Phe Thr Gly Leu Phe Thr Val Glu Met He Leu Lys Leu He 1285 1290 1295 GCC TTC AAA CCC AAG GGT TAC TTT AGT GAT CCC TGG AAT GTT TTT GAC 3936 Ala Phe Lys Pro Lys Gly Tyr Phe Ser Asp Pro Trp Asn Val Phe Asp 1300 1305 1310 TTC CTC ATC GTA ATT GGC AGC ATA ATT GAC GTC ATT CTC AGT GAG ACT 3984 Phe Leu He Val He Gly Ser He He Asp Val He Leu Ser Glu Thr 1315 1320 1325 AAT CCA GCT GAA CAT ACC CAA TGC TCT CCC TCT ATG AAC GCA GAG GAA 4032 Asn Pro Ala Glu His Thr Gin Cys Ser Pro Ser Met Asn Ala Glu Glu 1330 1335 1340 AAC TCC CGC ATC TCC ATC ACC TTC TTC CGC CTG TTC CGG GTC ATG CGT 4080 Asn Ser Arg He Ser He Thr Phe Phe Arg Leu Phe Arg Val Met Arg 1345 1350 1355 1360 CTG GTG AAG CTG CTG AGC CGT GGG GAG GGC ATC CGG ACG CTG CTG TGG 4128 Leu Val Lys Leu Leu Ser Arg Gly Glu Gly He Arg Thr Leu Leu Trp 1365 1370 1375 ACC TTC ATC AAG TCC TTC CAG GCC CTG CCC TAT GTG GCC CTC CTG ATC 4176 Thr Phe He Lys Ser Phe Gin Ala Leu Pro Tyr Val Ala Leu Leu He 1380 1385 1390 GTG ATG CTG TTC TTC ATC TAC GCG GTG ATC GGG ATG CAG GTG TTT GGG 4224 Val Met Leu Phe Phe He Tyr Ala Val He Gly Met Gin Val Phe Gly 1395 1400 1405 AAA ATT GCC CTG AAT GAT ACC ACA GAG ATC AAC CGG AAC AAC AAC TTT 4272 Lys He Ala Leu Asn Asp Thr Thr Glu He Asn Arg Asn Asn Asn Phe 1410 1415 1420 CAG ACC TTC CCC CAG GCC GTG CTG CTC CTC TTC AGG TGT GCC ACC GGG 4320 Gin Thr Phe Pro Gin Ala Val Leu Leu Leu Phe Arg Cys Ala Thr Gly 1425 1430 1435 1440 GAG GCC TGG CAG GAC ATC ATG CTG GCC TGC ATG CCA GGC AAG AAG TGT 4368 Glu Ala Trp Gin Asp He Met Leu Ala Cys Met Pro Gly Lys Lys Cys 1445 1450 1455 GCC CCA GAG TCC GAG CCC AGC AAC AGC ACG GAG GGT GAA ACA CCC TGT 4416 Ala Pro Glu Ser Glu Pro Ser Asn Ser Thr Glu Gly Glu Thr Pro Cys 1460 1465 1470 GGT AGC AGC TTT GCT GTC TTC TAC TTC ATC AGC TTC TAC ATG CTC TGT 4464 Gly Ser Ser Phe Ala Val Phe Tyr Phe He Ser Phe Tyr Met Leu Cys 1475 1480 1485 GCC TTC CTG ATC ATC AAC CTC TTT GTA GCT GTC ATC ATG GAC AAC TTT 4512 Ala Phe Leu He He Asn Leu Phe Val Ala Val He Met Asp Asn Phe 1490 1495 1500 GAC TAC CTG ACA AGG GAC TGG TCC ATC CTT GGT CCC CAC CAC CTG GAT 4560 Asp Tyr Leu Thr Arg Asp Trp Ser He Leu Gly Pro His His Leu Asp 1505 1510 1515 1520 GAG TTT AAA AGA ATC TGG GCA GAG TAT GAC CCT GAA GCC AAG GGT CGT 4608 Glu Phe Lys Arg He Trp Ala Glu Tyr Asp Pro Glu Ala Lys Gly Arg 1525 1530 1535 ATC AAA CAC CTG GAT GTG GTG ACC CTC CTC CGG CGG ATT CAG CCG CCA 4656 He Lys His Leu Asp Val Val Thr Leu Leu Arg Arg He Gin Pro Pro 1540 1545 1550 CTA GGT TTT GGG AAG CTG TGC CCT CAC CGC GTG GCT TGC AAA CGC CTG 4704 Leu Gly Phe Gly Lys Leu Cys Pro His Arg Val Ala Cys Lys Arg Leu 1555 1560 1565 GTC TCC ATG AAC ATG CCT CTG AAC AGC GAC GGG ACA GTC ATG TTC AAT 4752 Val Ser Met Asn Met Pro Leu Asn Ser Asp Gly Thr Val Met Phe Asn 1570 1575 1580 GCC ACC CTG TTT GCC CTG GTC AGG ACG GCC CTG AGG ATC AAA ACA GAA 4800 Ala Thr Leu Phe Ala Leu Val Arg Thr Ala Leu Arg He Lys Thr Glu 1585 1590 1595 1600 GGG AAC CTA GAA CAA GCC AAT GAG GAG CTG CGG GCG ATC ATC AAG AAG 48 8 Gly Asn Leu Glu Gin Ala Asn Glu Glu Leu Arg Ala He He Lys Lys 1605 1610 1615 ATC TGG AAG CGG ACC AGC ATG AAG CTG CTG GAC CAG GTG GTG CCC CCT 4896 He Trp Lys Arg Thr Ser Met Lys Leu Leu Asp Gin Val Val Pro Pro 1620 1625 1630 GCA GGT GAT GAT GAG GTC ACC GTT GGC AAG TTC TAC GCC ACG TTC CTG 4944 Ala Gly Asp Asp Glu Val Thr Val Gly Lys Phe Tyr Ala Thr Phe Leu 1635 1640 1645 ATC CAG GAG TAC TTC CGG AAG TTC AAG AAG CGC AAA GAG CAG GGC CTT 4992 He Gin Glu Tyr Phe Arg Lys Phe Lys Lys Arg Lys Glu Gin Gly Leu 1650 1655 1660 GTG GGC AAG CCC TCC CAG AGG AAC GCG CTG TCT CTG CAG GCT GGC TTG 5040 Val Gly Lys Pro Ser Gin Arg Asn Ala Leu Ser Leu Gin Ala Gly Leu 1665 1670 1675 1680 CGC ACA CTG CAT GAC ATC GGG CCT GAG ATC CGA CGG GCC ATC TCT GGA 5088 Arg Thr Leu His Asp He Gly Pro Glu He Arg Arg Ala He Ser Gly 1685 1690 1695 GAT CTC ACC GCT GAG GAG GAG CTG GAC AAG GCC ATG AAG GAG GCT GTG 5136 Asp Leu Thr Ala Glu Glu Glu Leu Asp Lys Ala Met Lys Glu Ala Val 1700 1705 1710 TCC GCT GCT TCT GAA GAT GAC ATC TTC AGG AGG GCC GGT GGC CTG TTC 5184 Ser Ala Ala Ser Glu Asp Asp He Phe Arg Arg Ala Gly Gly Leu Phe 1715 1720 1725 GGC AAC CAC GTC AGC TAC TAC CAA AGC GAC GGC CGG AGC GCC TTC CCC 5232 Gly Asn His Val Ser Tyr Tyr Gin Ser Asp Gly Arg Ser Ala Phe Pro 1730 1735 1740 CAG ACC TTC ACC ACT CAG CGC CCG CTG CAC ATC AAC AAG GCG GGC AGC 5280 Gin Thr Phe Thr Thr Gin Arg Pro Leu His He Asn Lys Ala Gly Ser 1745 1750 1755 1760 AGC CAG GGC GAC ACT GAG TCG CCA TCC CAC GAG AAG CTG GTG GAC TCC 5328 Ser Gin Gly Asp Thr Glu Ser Pro Ser His Glu Lys Leu Val Asp Ser 1765 1770 1775 ACC TTC ACC CCG AGC AGC TAC TCG TCC ACC GGC TCC AAC GCC AAC ATC 5376 Thr Phe Thr Pro Ser Ser Tyr Ser Ser Thr Gly Ser Asn Ala Asn He 1780 1785 1790 AAC AAC GCC AAC AAC ACC GCC CTG GGT CGC CTC CCT CGC CCC GCC GGC 5424 Asn Asn Ala Asn Asn Thr Ala Leu Gly Arg Leu Pro Arg Pro Ala Gly 1795 1800 1805 TAC CCC AGC ACA GTC AGC ACT GTG GAG GGC CAC GGG CCC CCC TTG TCC 5472 Tyr Pro Ser Thr Val Ser Thr Val Glu Gly His Gly Pro Pro Leu Ser 1810 1815 1820 CCT GCC ATC CGG GTG CAG GAG GTG GCG TGG AAG CTC AGC TCC AAC AGG 5520 Pro Ala He Arg Val Gin Glu Val Ala Trp Lys Leu Ser Ser Asn Arg 1825 1830 1835 1840 TGC CAC TCC CGG GAG AGC CAG GCA GCC ATG GCG CGT CAG GAG GAG ACG 5568 Cys His Ser Arg Glu Ser Gin Ala Ala Met Ala Arg Gin Glu Glu Thr 1845 1850 1855 TCT CAG GAT GAG ACC TAT GAA GTG AAG ATG AAC CAT GAC ACG GAG GCC 5616 Ser Gin Asp Glu Thr Tyr Glu Val Lys Met Asn His Asp Thr Glu Ala 1860 1865 1870 TGC AGT GAG CCC AGC CTG CTC TCC ACA GAG ATG CTC TCC TAC CAG GAT 5664 Cys Ser Glu Pro Ser Leu Leu Ser Thr Glu Met Leu Ser Tyr Gin Asp 1875 1880 1885 GAC GAA AAT CGG CAA CTG ACG CTC CCA GAG GAG GAC AAG AGG GAC ATC 5712 Asp Glu Asn Arg Gin Leu Thr Leu Pro Glu Glu Asp Lys Arg Asp He 1890 1895 1900 CGG CAA TCT CCG AAG AGG GGT TTC CTC CGC TCT GCC TCA CTA GGT CGA 5760 Arg Gin Ser Pro Lys Arg Gly Phe Leu Arg Ser Ala Ser Leu Gly Arg 1905 1910 1915 1920 AGG GCC TCC TTC CAC CTG GAA TGT CTG AAG CGA CAG AAG GAC CGA GGG 5808 Arg Ala Ser Phe His Leu Glu Cys Leu Lys Arg Gin Lys Asp Arg Gly 1925 1930 1935 GGA GAC ATC TCT CAG AAG ACA GTC CTG CCC TTG CAT CTG GTT CAT CAT 5856 Gly Asp He Ser Gin Lys Thr Val Leu Pro Leu His Leu Val His His 1940 1945 1950 CAG GCA TTG GCA GTG GCA GGC CTG AGC CCC CTC CTC CAG AGA AGC CAT 5904 Gin Ala Leu Ala Val Ala Gly Leu Ser Pro Leu Leu Gin Arg Ser His 1955 1960 1965 TCC CCT GCC TCA TTC CCT AGG CCT TTT GCC ACC CCA CCA GCC ACA CCT 5952 Ser Pro Ala Ser Phe Pro Arg Pro Phe Ala Thr Pro Pro Ala Thr Pro 1970 1975 1980 GGC AGC CGA GGC TGG CCC CCA CAG CCC GTC CCC ACC CTG CGG CTT GAG 6000 Gly Ser Arg Gly Trp Pro Pro Gin Pro Val Pro Thr Leu Arg Leu Glu 1985 1990 1995 2000 GGG GTC GAG TCC AGT GAG AAA CTC AAC AGC AGC TTC CCA TCC ATC CAC 6048 Gly Val Glu Ser Ser Glu Lys Leu Asn Ser Ser Phe Pro Ser He His 2005 2010 2015 TGC GGC TCC TGG GCT GAG ACC ACC CCC GGT GGC GGG GGC AGC AGC GCC 6096 Cys Gly Ser Trp Ala Glu Thr Thr Pro Gly Gly Gly Gly Ser Ser Ala 2020 2025 2030 GCC CGG AGA GTC CGG CCC GTC TCC CTC ATG GTG CCC AGC CAG GCT GGG 6144 Ala Arg Arg Val Arg Pro Val Ser Leu Met Val Pro Ser Gin Ala Gly 2035 2040 2045 GCC CCA GGG AGG CAG TTC CAC GGC AGT GCC AGC AGC CTG GTG GAA GCG 6192 Ala Pro Gly Arg Gin Phe His Gly Ser Ala Ser Ser Leu Val Glu Ala 2050 2055 2060 GTC TTG ATT TCA GAA GGA CTG GGG CAG TTT GCT CAA GAT CCC AAG TTC 6240 Val Leu He Ser Glu Gly Leu Gly Gin Phe Ala Gin Asp Pro Lys Phe 2070 2075 2080 2085 ATC GAG GTC ACC ACC CAG GAG CTG GCC GAC GCC TGC GAC ATG ACC ATA 6288 He Glu Val Thr Thr Gin Glu Leu Ala Asp Ala Cys Asp Met Thr He 2090 2095 2100 GAG GAG ATG GAG AGC GCG GCC GAC AAC ATC CTC AGC GGG GGC GCC CCA 6336 Glu Glu Met Glu Ser Ala Ala Asp Asn He Leu Ser Gly Gly Ala Pro 2105 2110 2115 CAG AGC CCC AAT GGC GCC CTC TTA CCC TTT GTG AAC TGC AGG GAC GCG 6384 Gin Ser Pro Asn Gly Ala Leu Leu Pro Phe Val Asn Cys Arg Asp Ala 2120 2125 2130 GGG CAG GAC CGA GCC GGG GGC GAA GAG GAC GCG GGC TGT GTG CGC GCG 6432 Gly Gin Asp Arg Ala Gly Gly Glu Glu Asp Ala Gly Cys Val Arg Ala 2135 2135 2140 CGG GGT CGA CCG AGT GAG GAG GAG CTC CAG GAC AGC AGG GTC TAC GTC 6480 Arg Gly Arg Pro Ser Glu Glu Glu Leu Gin Asp Ser Arg Val Tyr Val 2145 2150 2155 2160 AGC AGC CTG TAGTGGGCGC TGCCAGATGC GGGCTTTTTT TTATTTGTTT CAATGTTCCT 6539 Ser Ser Leu AATGGGTTCG TTTCAGAAGT GCCTCACTGT TCTCGT 6575 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 133 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: AGACCACGGC TTCCTCGAAT CTTGCGCGAA GCCGCCGGCCA TCGGAGGAG GGATTAATCC 60 AGACCCGCCG GGGGGTGTTT TCACATTTCT TCCTCTTCGTG GCTGCTCCT CCTATTAAAA 120 CCATTTTTGG TCC 133 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 89 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: CGCTGAGGGC CTTCCGCGTG CTGCGCCCCC TGCGGCTGGT GTCCGGAGTC CCAAGTCTCC 60 AGGTGGTCCT GAATTCCATC ATCAAGGCC 89 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 84 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..84 (D) OTHER INFORMATION: /note= "An alternative exon of alpha-IC." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: CAC TAT TTC TGT GAT GCA TGG AAT ACA TTT GAC GCC TTG ATT GTT GTG 48 His Tyr Phe Cys Asp Ala Trp Asn Thr Phe Asp Ala Leu He Val Val 1 5 10 15 GGT AGC ATT GTT GAT ATA GCA ATC ACC GAG GTA AAC 84 Gly Ser He Val Asp He Ala He Thr Glu Val Asn 20 25 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7362 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 144..7163 (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..143 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 7161..7362 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GCGGCGGCGG CTGCGGCGGT GGGGCCGGGC GAGGTCCGTG CGGTCCCGGC GGCTCCGTGG 60 CTGCTCCGCT CTGAGCGCCT GCGCGCCCCG CGCCCTCCCT GCCGGGGCCG CTGGGCCGGG 120 GATGCACGCG GGGCCCGGGA GCC ATG GTC CGC TTC GGG GAC GAG CTG GGC 170 Met Val Arg Phe Gly Asp Glu Leu Gly 1 5 GGC CGC TAT GGA GGC CCC GGC GGC GGA GAG CGG GCC CGG GGC GGC GGG 218 Gly Arg Tyr Gly Gly Pro Gly Gly Gly Glu Arg Ala Arg Gly Gly Gly 10 15 20 25 GCC GGC GGG GCG GGG GGC CCG GGT CCC GGG GGG CTG CAG CCC GGC CAG 266 Ala Gly Gly Ala Gly Gly Pro Gly Pro Gly Gly Leu Gin Pro Gly Gin 30 35 40 CGG GTC CTC TAC AAG CAA TCG ATC GCG CAG CGC GCG CGG ACC ATG GCG 314 Arg Val Leu Tyr Lys Gin Ser He Ala Gin Arg Ala Arg Thr Met Ala 45 50 55 CTG TAC AAC CCC ATC CCG GTC AAG CAG AAC TGC TTC ACC GTC AAC CGC 362 Leu Tyr Asn Pro He Pro Val Lys Gin Asn Cys Phe Thr Val Asn Arg 60 65 70 TCG CTC TTC GTC TTC AGC GAG GAC AAC GTC GTC CGC AAA TAC GCG AAG 410 Ser Leu Phe Val Phe Ser Glu Asp Asn Val Val Arg Lys Tyr Ala Lys 75 80 85 CGC ATC ACC GAG TGG CCT CCA TTC GAG AAT ATG ATC CTG GCC ACC ATC 458 Arg He Thr Glu Trp Pro Pro Phe Glu Asn Met He Leu Ala Thr He 90 95 100 105 ATC GCC AAC TGC ATC GTG CTG GCC CTG GAG CAG CAC CTC CCT GAT GGG 506 He Ala Asn Cys He Val Leu Ala Leu Glu Gin His Leu Pro Asp Gly 110 115 120 GAC AAA ACG CCC ATG TCC GAG CGG CTG GAC GAC ACG GAG CCC TAT TTC 554 Asp Lys Thr Pro Met Ser Glu Arg Leu Asp Asp Thr Glu Pro Tyr Phe 125 130 135 ATC GGG ATC TTT TGC TTC GAG GCA GGG ATC AAA ATC ATC GCT CTG GGC 602 He Gly He Phe Cys Phe Glu Ala Gly He Lys He He Ala Leu Gly 140 145 150 TTT GTC TTC CAC AAG GGC TCT TAC CTG CGG AAC GGC TGG AAC GTC ATG 650 Phe Val Phe His Lys Gly Ser Tyr Leu Arg Asn Gly Trp Asn Val Met 155 160 165 GAC TTC GTG GTC GTC CTC ACA GGG ATC CTT GCC ACG GCT GGA ACT GAC 698 Asp Phe Val Val Val Leu Thr Gly He Leu Ala Thr Ala Gly Thr Asp 170 175 180 185 TTC GAC CTG CGA ACA CTG AGG GCT GTG CGT GTG CTG AGG CCC CTG AAG 746 Phe Asp Leu Arg Thr Leu Arg Ala Val Arg Val Leu Arg Pro Leu Lys 190 195 200 CTG GTG TCT GGG ATT CCA AGT TTG CAG GTG GTG CTC AAG TCC ATC ATG 794 Leu Val Ser Gly He Pro Ser Leu Gin Val Val Leu Lys Ser He Met 205 210 215 AAG GCC ATG GTT CCA CTC CTG CAG ATT GGG CTG CTT CTC TTC TTT GCC 842 Lys Ala Met Val Pro Leu Leu Gin He Gly Leu Leu Leu Phe Phe Ala 220 225 230 ATC CTC ATG TTT GCC ATC ATT GGC CTG GAG TTC TAC ATG GGC AAG TTC 890 He Leu Met Phe Ala He He Gly Leu Glu Phe Tyr Met Gly Lys Phe 235 240 245 CAC AAG GCC TGT TTC CCC AAC AGC ACA GAT GCG GAG CCC GTG GGT GAC 938 His Lys Ala Cys Phe Pro Asn Ser Thr Asp Ala Glu Pro Val Gly Asp 250 255 260 265 TTC CCC TGT GGC AAG GAG GCC CCA GCC CGG CTG TGC GAG GGC GAC ACT 986 Phe Pro Cys Gly Lys Glu Ala Pro Ala Arg Leu Cys Glu Gly Asp Thr 270 275 280 GAG TGC CGG GAG TAC TGG CCA GGA CCC AAC TTT GGC ATC ACC AAC TTT 1034 Glu Cys Arg Glu Tyr Trp Pro Gly Pro Asn Phe Gly He Thr Asn Phe 285 290 295 GAC AAT ATC CTG TTT GCC ATC TTG ACG GTG TTC CAG TGC ATC ACC ATG 1082 Asp Asn He Leu Phe Ala He Leu Thr Val Phe Gin Cys He Thr Met 300 305 310 GAG GGC TGG ACT GAC ATC CTC TAT AAT ACA AAC GAT GCG GCC GGC AAC 1130 Glu Gly Trp Thr Asp He Leu Tyr Asn Thr Asn Asp Ala Ala Gly Asn 315 320 325 ACC TGG AAC TGG CTC TAC TTC ATC CCT CTC ATC ATC ATC GGC TCC TTC 1178 Thr Trp Asn Trp Leu Tyr Phe He Pro Leu He He He Gly Ser Phe 330 335 340 345 TTC ATG CTC AAC CTG GTG CTG GGC GTG CTC TCG GGG GAG TTT GCC AAG 1226 Phe Met Leu Asn Leu Val Leu Gly Val Leu Ser Gly Glu Phe Ala Lys 350 355 360 GAG CGA GAG AGG GTG GAG AAC CGC CGC GCC TTC CTG AAG CTG CGC CGG 1274 Glu Arg Glu Arg Val Glu Asn Arg Arg Ala Phe Leu Lys Leu Arg Arg 365 370 375 CAG CAG CAG ATC GAG CGA GAG CTC AAC GGG TAC CTG GAG TGG ATC TTC 1322 Gin Gin Gin He Glu Arg Glu Leu Asn Gly Tyr Leu Glu Trp He Phe 380 385 390 AAG GCG GAG GAA GTC ATG CTG GCC GAG GAG GAC AGG AAT GCA GAG GAG 1370 Lys Ala Glu Glu Val Met Leu Ala Glu Glu Asp Arg Asn Ala Glu Glu 395 400 405 AAG TCC CCT TTG GAC GTG CTG AAG AGA GCG GCC ACC AAG AAG AGC AGA 1418 Lys Ser Pro Leu Asp Val Leu Lys Arg Ala Ala Thr Lys Lys Ser Arg 410 415 420 425 AAT GAC CTG ATC CAC GCA GAG GAG GGA GAG GAC CGG TTT GCA GAT CTC 1466 Asn Asp Leu He His Ala Glu Glu Gly Glu Asp Arg Phe Ala Asp Leu 430 435 440 TGT GCT GTT GGA TCC CCC TTC GCC CGC GCC AGC CTC AAG AGC GGG AAG 1514 Cys Ala Val Gly Ser Pro Phe Ala Arg Ala Ser Leu Lys Ser Gly Lys 445 450 455 ACA GAG AGC TCG TCA TAC TTC CGG AGG AAG GAG AAG ATG TTC CGG TTT 1562 Thr Glu Ser Ser Ser Tyr Phe Arg Arg Lys Glu Lys Met Phe Arg Phe 460 465 470 TTT ATC CGG CGC ATG GTG AAG GCT CAG AGC TTC TAC TGG GTG GTG CTG 1610 Phe He Arg Arg Met Val Lys Ala Gin Ser Phe Tyr Trp Val Val Leu 475 480 485 TGC GTG GTG GCC CTG AAC ACA CTG TGT GTG GCC ATG GTG CAT TAC AAC 1658 Cys Val Val Ala Leu Asn Thr Leu Cys Val Ala Met Val His Tyr Asn 490 495 500 505 CAG CCG CGG CGG CTT ACC ACG ACC CTG TAT TTT GCA GAG TTT GTT TTC 1706 Gin Pro Arg Arg Leu Thr Thr Thr Leu Tyr Phe Ala Glu Phe Val Phe 510 515 520 CTG GGT CTC TTC CTC ACA GAG ATG TCC CTG AAG ATG TAT GGC CTG GGG 1754 Leu Gly Leu Phe Leu Thr Glu Met Ser Leu Lys Met Tyr Gly Leu Gly 525 530 535 CCC AGA AGC TAC TTC CGG TCC TCC TTC AAC TGC TTC GAC TTT GGG GTC 1802 Pro Arg Ser Tyr Phe Arg Ser Ser Phe Asn Cys Phe Asp Phe Gly Val 540 545 550 ATC GTG GGG AGC GTC TTT GAA GTG GTC TGG GCG GCC ATC AAG CCG GGA 1850 He Val Gly Ser Val Phe Glu Val Val Trp Ala Ala He Lys Pro Gly 555 560 565 AGC TCC TTT GGG ATC AGT GTG CTG CGG GCC CTC CGC CTG CTG AGG ATC 1898 Ser Ser Phe Gly He Ser Val Leu Arg Ala Leu Arg Leu Leu Arg He 570 575 580 585 TTC AAA GTC ACG AAG TAC TGG AGC TCC CTG CGG AAC CTG GTG GTG TCC 1946 Phe Lys Val Thr Lys Tyr Trp Ser Ser Leu Arg Asn Leu Val Val Ser 590 595 600 CTG CTG AAC TCC ATG AAG TCC ATC ATC AGC CTG CTC TTC TTG CTC TTC 1994 Leu Leu Asn Ser Met Lys Ser He He Ser Leu Leu Phe Leu Leu Phe 605 610 615 CTG TTC ATT GTG GTC TTC GCC CTG CTG GGG ATG CAG CTG TTT GGG GGA 2042 Leu Phe He Val Val Phe Ala Leu Leu Gly Met Gin Leu Phe Gly Gly 620 625 630 CAG TTC AAC TTC CAG GAT GAG ACT CCC ACA ACC AAC TTC GAC ACC TTC 2090 Gin Phe Asn Phe Gin Asp Glu Thr Pro Thr Thr Asn Phe Asp Thr Phe 635 640 645 CCT GCC GCC ATC CTC ACT GTC TTC CAG ATC CTG ACG GGA GAG GAC TGG 2138 Pro Ala Ala He Leu Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp 650 655 660 665 AAT GCA GTG ATG TAT CAC GGG ATC GAA TCG CAA GGC GGC GTC AGC AAA 2186 Asn Ala Val Met Tyr His Gly He Glu Ser Gin Gly Gly Val Ser Lys 670 675 680 GGC ATG TTC TCG TCC TTT TAC TTC ATT GTC CTG ACA CTG TTC GGA AAC 2234 Gly Met Phe Ser Ser Phe Tyr Phe He Val Leu Thr Leu Phe Gly Asn 685 690 695 TAC ACT CTG CTG AAT GTC TTT CTG GCC ATC GCT GTG GAC AAC CTG GCC 2282 Tyr Thr Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala 700 705 710 AAC GCC CAA GAG CTG ACC AAG GAT GAA GAG GAG ATG GAA GAA GCA GCC 2330 Asn Ala Gin Glu Leu Thr Lys Asp Glu Glu Glu Met Glu Glu Ala Ala 715 720 725 AAT CAG AAG CTT GCT CTG CAA AAG GCC AAA GAA GTG GCT GAA GTC AGC 2378 Asn Gin Lys Leu Ala Leu Gin Lys Ala Lys Glu Val Ala Glu Val Ser 730 735 740 745 CCC ATG TCT GCC GCG AAC ATC TCC ATC GCC GCC AGG CAG CAG AAC TCG 2426 Pro Met Ser Ala Ala Asn He Ser He Ala Ala Arg Gin Gin Asn Ser 750 755 760 GCC AAG GCG CGC TCG GTG TGG GAG CAG CGG GCC AGC CAG CTA CGG CTG 2474 Ala Lys Ala Arg Ser Val Trp Glu Gin Arg Ala Ser Gin Leu Arg Leu 765 770 775 CAG AAC CTG CGG GCC AGC TGC GAG GCG CTG TAC AGC GAG ATG GAC CCC 2522 Gin Asn Leu Arg Ala Ser Cys Glu Ala Leu Tyr Ser Glu Met Asp Pro 780 785 790 GAG GAG CGG CTG CGC TTC GCC ACT ACG CGC CAC CTG CGG CCC GAC ATG 2570 Glu Glu Arg Leu Arg Phe Ala Thr Thr Arg His Leu Arg Pro Asp Met 795 800 805 AAG ACG CAC CTG GAC CGG CCG CTG GTG GTG GAG CTG GGC CGC GAC GGC 2618 Lys Thr His Leu Asp Arg Pro Leu Val Val Glu Leu Gly Arg Asp Gly 810 815 820 825 GCG CGG GGG CCC GTG GGA GGC AAA GCC CGA CCT GAG GCT GCG GAG GCC 2666 Ala Arg Gly Pro Val Gly Gly Lys Ala Arg Pro Glu Ala Ala Glu Ala 830 835 840 CCC GAG GGC GTC GAC CCT CCG CGC AGG CAC CAC CGG CAC CGC GAC AAG 2714 Pro Glu Gly Val Asp Pro Pro Arg Arg His His Arg His Arg Asp Lys 845 850 855 GAC AAG ACC CCC GCG GCG GGG GAC CAG GAC CGA GCA GAG GCC CCG AAG 2762 Asp Lys Thr Pro Ala Ala Gly Asp Gin Asp Arg Ala Glu Ala Pro Lys 860 865 870 GCG GAG AGC GGG GAG CCC GGT GCC CGG GAG GAG CGG CCG CGG CCG CAC 2810 Ala Glu Ser Gly Glu Pro Gly Ala Arg Glu Glu Arg Pro Arg Pro His 875 880 885 CGC AGC CAC AGC AAG GAG GCC GCG GGG CCC CCG GAG GCG CGG AGC GAG 2858 Arg Ser His Ser Lys Glu Ala Ala Gly Pro Pro Glu Ala Arg Ser Glu 890 895 900 905 CGC GGC CGA GGC CCA GGC CCC GAG GGC GGC CGG CGG CAC CAC CGG CGC 2906 Arg Gly Arg Gly Pro Gly Pro Glu Gly Gly Arg Arg His His Arg Arg 910 915 920 GGC TCC CCG GAG GAG GCG GCC GAG CGG GAG CCC CGA CGC CAC CGC GCG 2954 Gly Ser Pro Glu Glu Ala Ala Glu Arg Glu Pro Arg Arg His Arg Ala 925 930 935 CAC CGG CAC CAG GAT CCG AGC AAG GAG TGC GCC GGC GCC AAG GGC GAG 3002 His Arg His Gin Asp Pro Ser Lys Glu Cys Ala Gly Ala Lys Gly Glu 940 945 950 CGG CGC GCG CGG CAC CGC GGC GGC CCC CGA GCG GGG CCC CGG GAG GCG 3050 Arg Arg Ala Arg His Arg Gly Gly Pro Arg Ala Gly Pro Arg Glu Ala 955 960 965 GAG AGC GGG GAG GAG CCG GCG CGG CGG CAC CGG GCC CGG CAC AAG GCG 3098 Glu Ser Gly Glu Glu Pro Ala Arg Arg His Arg Ala Arg His Lys Ala 970 975 980 985 CAG CCT GCT CAC GAG GCT GTG GAG AAG GAG ACC ACG GAG AAG GAG GCC 3146 Gin Pro Ala His Glu Ala Val Glu Lys Glu Thr Thr Glu Lys Glu Ala 990 995 1000 ACG GAG AAG GAG GCT GAG ATA GTG GAA GCC GAC AAG GAA AAG GAG CTC 3194 Thr Glu Lys Glu Ala Glu He Val Glu Ala Asp Lys Glu Lys Glu Leu 1005 1010 1015 CGG AAC CAC CAG CCC CGG GAG CCA CAC TGT GAC CTG GAG ACC AGT GGG 3242 Arg Asn His Gin Pro Arg Glu Pro His Cys Asp Leu Glu Thr Ser Gly 1020 1025 1030 ACT GTG ACT GTG GGT CCC ATG CAC ACA CTG CCC AGC ACC TGT CTC CAG 3290 Thr Val Thr Val Gly Pro Met His Thr Leu Pro Ser Thr Cys Leu Gin 1035 1040 1045 AAG GTG GAG GAA CAG CCA GAG GAT GCA GAC AAT CAG CGG AAC GTC ACT 3338 Lys Val Glu Glu Gin Pro Glu Asp Ala Asp Asn Gin Arg Asn Val Thr 1050 1055 1060 1065 CGC ATG GGC AGT CAG CCC CCA GAC CCG AAC ACT ATT GTA CAT ATC CCA 3386 Arg Met Gly Ser Gin Pro Pro Asp Pro Asn Thr He Val His He Pro 1070 1075 1080 GTG ATG CTG ACG GGC CCT CTT GGG GAA GCC ACG GTC GTT CCC AGT GGT 3434 Val Met Leu Thr Gly Pro Leu Gly Glu Ala Thr Val Val Pro Ser Gly 1085 1090 1095 AAC GTG GAC CTG GAA AGC CAA GCA GAG GGG AAG AAG GAG GTG GAA GCG 3482 Asn Val Asp Leu Glu Ser Gin Ala Glu Gly Lys Lys Glu Val Glu Ala 1100 1105 1110 GAT GAC GTG ATG AGG AGC GGC CCC CGG CCT ATC GTC CCA TAC AGC TCC 3530 Asp Asp Val Met Arg Ser Gly Pro Arg Pro He Val Pro Tyr Ser Ser 1115 1120 1125 ATG TTC TGT TTA AGC CCC ACC AAC CTG CTC CGC CGC TTC TGC CAC TAC 3578 Met Phe Cys Leu Ser Pro Thr Asn Leu Leu Arg Arg Phe Cys His Tyr 1130 1135 1140 1145 ATC GTG ACC ATG AGG TAC TTC GAG GTG GTC ATT CTC GTG GTC ATC GCC 3626 He Val Thr Met Arg Tyr Phe Glu Val Val He Leu Val Val He Ala 1150 1155 1160 TTG AGC AGC ATC GCC CTG GCT GCT GAG GAC CCA GTG CGC ACA GAC TCG 3674 Leu Ser Ser He Ala Leu Ala Ala Glu Asp Pro Val Arg Thr Asp Ser 1165 1170 1175 CCC AGG AAC AAC GCT CTG AAA TAC CTG GAT TAC ATT TTC ACT GGT GTC 3722 Pro Arg Asn Asn Ala Leu Lys Tyr Leu Asp Tyr He Phe Thr Gly Val 1180 1185 1190 TTT ACC TTT GAG ATG GTG ATA AAG ATG ATC GAC TTG GGA CTG CTG CTT 3770 Phe Thr Phe Glu Met Val He Lys Met He Asp Leu Gly Leu Leu Leu 1195 1200 1205 CAC CCT GGA GCC TAT TTC CGG GAC TTG TGG AAC ATT CTG GAC TTC ATT 3818 His Pro Gly Ala Tyr Phe Arg Asp Leu Trp Asn He Leu Asp Phe He 1210 1215 1220 1225 GTG GTC AGT GGC GCC CTG GTG GCG TTT GCT TTC TCA GGA TCC AAA GGG 3866 Val Val Ser Gly Ala Leu Val Ala Phe Ala Phe Ser Gly Ser Lys Gly 1230 1235 1240 AAA GAC ATC AAT ACC ATC AAG TCT CTG AGA GTC CTT CGT GTC CTG CGG 3914 Lys Asp He Asn Thr He Lys Ser Leu Arg Val Leu Arg Val Leu Arg 1245 1250 1255 CCC CTC AAG ACC ATC AAA CGG CTG CCC AAG CTC AAG GCT GTG TTT GAC 3962 Pro Leu Lys Thr He Lys Arg Leu Pro Lys Leu Lys Ala Val Phe Asp 1260 1265 1270 TGT GTG GTG AAC TCC CTG AAG AAT GTC CTC AAC ATC TTG ATT GTC TAC 4010 Cys Val Val Asn Ser Leu Lys Asn Val Leu Asn He Leu He Val Tyr 1275 1280 1285 ATG CTC TTC ATG TTC ATA TTT GCC GTC ATT GCG GTG CAG CTC TTC AAA 4058 Met Leu Phe Met Phe He Phe Ala Val He Ala Val Gin Leu Phe Lys 1290 1295 1300 1305 GGG AAG TTT TTC TAC TGC ACA GAT GAA TCC AAG GAG CTG GAG AGG GAC 4106 Gly Lys Phe Phe Tyr Cys Thr Asp Glu Ser Lys Glu Leu Glu Arg Asp 1310 1315 1320 TGC AGG GGT CAG TAT TTG GAT TAT GAG AAG GAG GAA GTG GAA GCT CAG 4154 Cys Arg Gly Gin Tyr Leu Asp Tyr Glu Lys Glu Glu Val Glu Ala Gin 1325 1330 1335 CCC AGG CAG TGG AAG AAA TAC GAC TTT CAC TAC GAC AAT GTG CTC TGG 4202 Pro Arg Gin Trp Lys Lys Tyr Asp Phe His Tyr Asp Asn Val Leu Trp 1340 1345 1350 GCT CTG CTG ACG CTG TTC ACA GTG TCC ACG GGA GAA GGC TGG CCC ATG 4250 Ala Leu Leu Thr Leu Phe Thr Val Ser Thr Gly Glu Gly Trp Pro Met 1355 1360 1365 GTG CTG AAA CAC TCC GTG GAT GCC ACC TAT GAG GAG CAG GGT CCA AGC 4298 Val Leu Lys His Ser Val Asp Ala Thr Tyr Glu Glu Gin Gly Pro Ser 1370 1375 1380 1385 CCT GGG TAC CGC ATG GAG CTG TCC ATC TTC TAC GTG GTC TAC TTT GTG 4346 Pro Gly Tyr Arg Met Glu Leu Ser He Phe Tyr Val Val Tyr Phe Val 1390 1395 1400 GTC TTT CCC TTC TTC TTC GTC AAC ATC TTT GTG GCT TTG ATC ATC ATC 4394 Val Phe Pro Phe Phe Phe Val Asn He Phe Val Ala Leu He He He 1405 1410 1415 ACC TTC CAG GAG CAG GGG GAC AAG GTG ATG TCT GAA TGC AGC CTG GAG 4442 Thr Phe Gin Glu Gin Gly Asp Lys Val Met Ser Glu Cys Ser Leu Glu 1420 1425 1430 AAG AAC GAG AGG GCT TGC ATT GAC TTC GCC ATC AGC GCC AAA CCC CTG 4490 Lys Asn Glu Arg Ala Cys He Asp Phe Ala He Ser Ala Lys Pro Leu 1435 1440 1445 ACA CGG TAC ATG CCC CAA AAC CGG CAG TCG TTC CAG TAT AAG ACG TGG 4538 Thr Arg Tyr Met Pro Gin Asn Arg Gin Ser Phe Gin Tyr Lys Thr Trp 1450 1455 1460 1465 ACA TTT GTG GTC TCC CCG CCC TTT GAA TAC TTC ATC ATG GCC ATG ATA 4586 Thr Phe Val Val Ser Pro Pro Phe Glu Tyr Phe He Met Ala Met He 1470 1475 1480 GCC CTC AAC ACT GTG GTG CTG ATG ATG AAG TTC TAT GAT GCA CCC TAT 4634 Ala Leu Asn Thr Val Val Leu Met Met Lys Phe Tyr Asp Ala Pro Tyr 1485 1490 1495 GAG TAC GAG CTG ATG CTG AAA TGC CTG AAC ATC GTG TTC ACA TCC ATG 4682 Glu Tyr Glu Leu Met Leu Lys Cys Leu Asn He Val Phe Thr Ser Met 1500 1505 1510 TTC TCC ATG GAA TGC GTG CTG AAG ATC ATC GCC TTT GGG GTG CTG AAC 4730 Phe Ser Met Glu Cys Val Leu Lys He He Ala Phe Gly Val Leu Asn 1515 1520 1525 TAT TTC AGA GAT GCC TGG AAT GTC TTT GAC TTT GTC ACT GTG TTG GGA 4778 Tyr Phe Arg Asp Ala Trp Asn Val Phe Asp Phe Val Thr Val Leu Gly 1530 1535 1540 1545 AGT ATT ACT GAT ATT TTA GTA ACA GAG ATT GCG GAA ACG AAC AAT TTC 4826 Ser He Thr Asp He Leu Val Thr Glu He Ala Glu Thr Asn Asn Phe 1550 1555 1560 ATC AAC CTC AGC TTC CTC CGC CTC TTT CGA GCT GCG CGG CTG ATC AAG 4874 He Asn Leu Ser Phe Leu Arg Leu Phe Arg Ala Ala Arg Leu He Lys 1565 1570 1575 CTG CTC CGC CAG GGC TAC ACC ATC CGC ATC CTG CTG TGG ACC TTT GTC 4922 Leu Leu Arg Gin Gly Tyr Thr He Arg He Leu Leu Trp Thr Phe Val 1580 1585 1590 CAG TCC TTC AAG GCC CTG CCC TAC GTG TGT CTG CTC ATT GCC ATG CTG 4970 Gin Ser Phe Lys Ala Leu Pro Tyr Val Cys Leu Leu He Ala Met Leu 1595 1600 1605 TTC TTC ATC TAC GCC ATC ATC GGC ATG CAG GTG TTT GGG AAT ATT GCC 5018 Phe Phe He Tyr Ala He He Gly Met Gin Val Phe Gly Asn He Ala 1610 1615 1620 1625 CTG GAT GAT GAC ACC AGC ATC AAC CGC CAC AAC AAC TTC CGG ACG TTT 5066 Leu Asp Asp Asp Thr Ser He Asn Arg His Asn Asn Phe Arg Thr Phe 1630 1635 1640 TTG CAA GCC CTG ATG CTG CTG TTC AGG AGC GCC ACG GGG GAG GCC TGG 5114 Leu Gin Ala Leu Met Leu Leu Phe Arg Ser Ala Thr Gly Glu Ala Trp 1645 1650 1655 CAC GAG ATC ATG CTG TCC TGC CTG AGC AAC CAG GCC TGT GAT GAG CAG 5162 His Glu He Met Leu Ser Cys Leu Ser Asn Gin Ala Cys Asp Glu Gin 1660 1665 1670 GCC AAT GCC ACC GAG TGT GGA AGT GAC TTT GCC TAC TTC TAC TTC GTC 5210 Ala Asn Ala Thr Glu Cys Gly Ser Asp Phe Ala Tyr Phe Tyr Phe Val 1675 1680 1685 TCC TTC ATC TTC CTG TGC TCC TTT CTG ATG TTG AAC CTC TTT GTG GCT 5258 Ser Phe He Phe Leu Cys Ser Phe Leu Met Leu Asn Leu Phe Val Ala 1690 1695 1700 1705 GTG ATC ATG GAC AAT TTT GAG TAC CTC ACG CGG GAC TCT TCC ATC CTA 5306 Val He Met Asp Asn Phe Glu Tyr Leu Thr Arg Asp Ser Ser He Leu 1710 1715 1720 GGT CCT CAC CAC TTG GAT GAG TTC ATC CGG GTC TGG GCT GAA TAC GAC 5354 Gly Pro His His Leu Asp Glu Phe He Arg Val Trp Ala Glu Tyr Asp 1725 1730 1735 CCG GCT GCG TGT GGG CGC ATC AGT TAC AAT GAC ATG TTT GAG ATG CTG 5402 Pro Ala Ala Cys Gly Arg He Ser Tyr Asn«Asp Met Phe Glu Met Leu 1740 1745 1750 AAA CAC ATG TCC CCG CCT CTG GGG CTG GGG AAG AAA TGC CCT GCT CGA 5450 Lys His Met Ser Pro Pro Leu Gly Leu Gly Lys Lys Cys Pro Ala Arg 1755 1760 1765 GTT GCT TAC AAG CGC CTG GTT CGC ATG AAC ATG CCC ATC TCC AAC GAG 5498 Val Ala Tyr Lys Arg Leu Val Arg Met Asn Met Pro He Ser Asn Glu 1770 1775 1780 1785 GAC ATG ACT GTT CAC TTC ACG TCC ACG CTG ATG GCC CTC ATC CGG ACG 5546 Asp Met Thr Val His Phe Thr Ser Thr Leu Met Ala Leu He Arg Thr 1790 1795 1800 GCA CTG GAG ATC AAG CTG GCC CCA GCT GGG ACA AAG CAG CAT CAG TGT 5594 Ala Leu Glu He Lys Leu Ala Pro Ala Gly Thr Lys Gin His Gin Cys 1805 1810 1815 GAC GCG GAG TTG AGG AAG GAG ATT TCC GTT GTG TGG GCC AAT CTG CCC 5642 Asp Ala Glu Leu Arg Lys Glu He Ser Val Val Trp Ala Asn Leu Pro 1820 1825 1830 CAG AAG ACT TTG GAC TTG CTG GTA CCA CCC CAT AAG CCT GAT GAG ATG 5690 Gin Lys Thr Leu Asp Leu Leu Val Pro Pro His Lys Pro Asp Glu Met 1835 1840 1845 ACA GTG GGG AAG GTT TAT GCA GCT CTG ATG ATA TTT GAC TTC TAC AAG 5738 Thr Val Gly Lys Val Tyr Ala Ala Leu Met He Phe Asp Phe Tyr Lys 1850 1855 1860 1865 CAG AAC AAA ACC ACC AGA GAC CAG ATG CAG CAG GCT CCT GGA GGC CTC 5786 Gin Asn Lys Thr Thr Arg Asp Gin Met Gin Gin Ala Pro Gly Gly Leu 1870 1875 1880 TCC CAG ATG GGT CCT GTG TCC CTG TTC CAC CCT CTG AAG GCC ACC CTG 5834 Ser Gin Met Gly Pro Val Ser Leu Phe His Pro Leu Lys Ala Thr Leu 1885 1890 1895 GAG CAG ACA CAG CCG GCT GTG CTC CGA GGA GCC CGG GTT TTC CTT CGA 5882 Glu Gin Thr Gin Pro Ala Val Leu Arg Gly Ala Arg Val Phe Leu Arg 1900 1905 1910 CAG AAG AGT TCC ACC TCC CTC AGC AAT GGC GGG GCC ATA CAA AAC CAA 5930 Gin Lys Ser Ser Thr Ser Leu Ser Asn Gly Gly Ala He Gin Asn Gin 1915 1920 1925 GAG AGT GGC ATC AAA GAG TCT GTC TCC TGG GGC ACT CAA AGG ACC CAG 5978 Glu Ser Gly He Lys Glu Ser Val Ser Trp Gly Thr Gin Arg Thr Gin 1930 1935 1940 1945 GAT GCA CCC CAT GAG GCC AGG CCA CCC CTG GAG CGT GGC CAC TCC ACA 6026 Asp Ala Pro His Glu Ala Arg Pro Pro Leu Glu Arg Gly His Ser Thr 1950 1955 1960 GAG ATC CCT GTG GGG CGG TCA GGA GCA CTG GCT GTG GAC GTT CAG ATG 6074 Glu He Pro Val Gly Arg Ser Gly Ala Leu Ala Val Asp Val Gin Met 1965 1970 1975 CAG AGC ATA ACC CGG AGG GGC CCT GAT GGG GAG CCC CAG CCT GGG CTG 6122 Gin Ser He Thr Arg Arg Gly Pro Asp Gly Glu Pro Gin Pro Gly Leu 1980 1985 1990 GAG AGC CAG GGT CGA GCG GCC TCC ATG CCC CGC CTT GCG GCC GAG ACT 6170 Glu Ser Gin Gly Arg Ala Ala Ser Met Pro Arg Leu Ala Ala Glu Thr 1995 2000 2005 CAG CCC GTC ACA GAT GCC AGC CCC ATG AAG CGC TCC ATC TCC ACG CTG 6218 Gin Pro Val Thr Asp Ala Ser Pro Met Lys Arg Ser He Ser Thr Leu 2010 2015 2020 2025 GCC CAG CGG CCC CGT GGG ACT CAT CTT TGC AGC ACC ACC CCG GAC CGC 6266 Ala Gin Arg Pro Arg Gly Thr His Leu Cys Ser Thr Thr Pro Asp Arg 2030 2035 2040 CCA CCC CCT AGC CAG GCG TCG TCG CAC CAC CAC CAC CAC CGC TGC CAC 6314 Pro Pro Pro Ser Gin Ala Ser Ser His His His His His Arg Cys His 2045 2050 2055 CGC CGC AGG GAC AGG AAG CAG AGG TCC CTG GAG AAG GGG CCC AGC CTG 6362 Arg Arg Arg Asp Arg Lys Gin Arg Ser Leu Glu Lys Gly Pro Ser Leu 2060 2065 2070 TCT GCC GAT ATG GAT GGC GCA CCA AGC AGT GCT GTG GGG CCG GGG CTG 6410 Ser Ala Asp Met Asp Gly Ala Pro Ser Ser Ala Val Gly Pro Gly Leu 2075 2080 2085 CCC CCG GGA GAG GGG CCT ACA GGC TGC CGG CGG GAA CGA GAG CGC CGG 6458 Pro Pro Gly Glu Gly Pro Thr Gly Cys Arg Arg Glu Arg Glu Arg Arg 2090 2095 2100 2105 CAG GAG CGG GGC CGG TCC CAG GAG CGG AGG CAG CCC TCA TCC TCC TCC 6506 Gin Glu Arg Gly Arg Ser Gin Glu Arg Arg Gin Pro Ser Ser Ser Ser 2110 2115 2120 TCG GAG AAG CAG CGC TTC TAC TCC TGC GAC CGC TTT GGG GGC CGT GAG 6554 Ser Glu Lys Gin Arg Phe Tyr Ser Cys Asp Arg Phe Gly Gly Arg Glu 2125 2130 2135 CCC CCG AAG CCC AAG CCC TCC CTC AGC AGC CAC CCA ACG TCG CCA ACA 6602 Pro Pro Lys Pro Lys Pro Ser Leu Ser Ser His Pro Thr Ser Pro Thr 2140 2145 2150 GCT GGC CAG GAG CCG GGA CCC CAC CCA CAG GGC AGT GGT TCC GTG AAT 6650 Ala Gly Gin Glu Pro Gly Pro His Pro Gin Gly Ser Gly Ser Val Asn 2155 2160 2165 GGG AGC CCC TTG CTG TCA ACA TCT GGT GCT AGC ACC CCC GGC CGC GGT 6698 Gly Ser Pro Leu Leu Ser Thr Ser Gly Ala Ser Thr Pro Gly Arg Gly 2170 2175 2180 2185 GGG CGG AGG CAG CTC CCC CAG ACG CCC CTG ACT CCC CGC CCC AGC ATC 6746 Gly Arg Arg Gin Leu Pro Gin Thr Pro Leu Thr Pro Arg Pro Ser He 2190 2195 2200 ACC TAC AAG ACG GCC AAC TCC TCA CCC ATC CAC TTC GCC GGG GCT CAG 6794 Thr Tyr Lys Thr Ala Asn Ser Ser Pro He His Phe Ala Gly Ala Gin 2205 2210 2215 ACC AGC CTC CCT GCC TTC TCC CCA GGC CGG CTC AGC CGT GGG CTT TCC 6842 Thr Ser Leu Pro Ala Phe Ser Pro Gly Arg Leu Ser Arg Gly Leu Ser 2220 2225 2230 GAA CAC AAC GCC CTG CTG CAG AGA GAC CCC CTC AGC CAG CCC GTG GCC 6890 Glu His Asn Ala Leu Leu Gin Arg Asp Pro Leu Ser Gin Pro Leu Ala 2235 2240 2245 CCT GGC TCT CGA ATT GGC TCT GAC CCT TAC CTG GGG CAG CGT CTG GAC 6938 Pro Gly Ser Arg He Gly Ser Asp Pro Tyr Leu Gly Gin Arg Leu Asp 2250 2255 2260 2265 AGT GAG GCC TCT GTC CAC GCC CTG CCT GAG GAC ACG CTC ACT TTC GAG 6986 Ser Glu Ala Ser Val His Ala Leu Pro Glu Asp Thr Leu Thr Phe Glu 2270 2275 2280 GAG GCT GTG GCC ACC AAC TCG GGC CGC TCC TCC AGG ACT TCC TAC GTG 7034 Glu Ala Val Ala Thr Asn Ser Gly Arg Ser Ser Arg Thr Ser Tyr Val 2285 2290 2295 TCC TCC CTG ACC TCC CAG TCT CAC CCT CTC CGC CGC GTG CCC AAC GGT 7082 Ser Ser Leu Thr Ser Gin Ser His Pro Leu Arg Arg Val Pro Asn Gly 2300 2305 2310 TAC CAC TGC ACC CTG GGA CTC AGC TCG GGT GGC CGA GCA CGG CAC AGC 7130 Tyr His Cys Thr Leu Gly Leu Ser Ser Gly Gly Arg Ala Arg His Ser 2315 2320 2325 TAC CAC CAC CCT GAC CAA GAC CAC TGG TGC TAGCTGCACC GTGACCGCTC 7180 Tyr His His Pro Asp Gin Asp His Trp Cys 2330 2335 234 AGACGCCTGC ATGCAGCAGG CGTGTGTTCC AGTGGATGAG TTTTATCATC CACACGGGGC 7240 AGTCGGCCCT CGGGGGAGGC CTTGCCCACC TTGGTGAGGC TCCTGTGGCC CCTCCCTCCC 7300 CCTCCTCCCC TCTTTTACTC TAGACGACGA ATAAAGCCCT GTTGCTTGAG TGTACGTACC 7360 GC 7362 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7175 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 144..6857 (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..143 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 6855..7175 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: GCGGCGGCGG CTGCGGCGGT GGGGCCGGGC GAGGTCCGTG CGGTCCCGGC GGCTCCGTGG 60 CTGCTCCGCT CTGAGCGCCT GCGCGCCCCG CGCCCTCCCT GCCGGGGCCG CTGGGCCGGG 120 GATGCACGCG GGGCCCGGGA GCC ATG GTC CGC TTC GGG GAC GAG CTG GGC 170 Met Val Arg Phe Gly Asp Glu Leu Gly 1 5 GGC CGC TAT GGA GGC CCC GGC GGC GGA GAG CGG GCC CGG GGC GGC GGG 218 Gly Arg Tyr Gly Gly Pro Gly Gly Gly Glu Arg Ala Arg Gly Gly Gly 10 15 20 25 GCC GGC GGG GCG GGG GGC CCG GGT CCC GGG GGG CTG CAG CCC GGC CAG 266 Ala Gly Gly Ala Gly Gly Pro Gly Pro Gly Gly Leu Gin Pro Gly Gin 30 35 40 CGG GTC CTC TAC AAG CAA TCG ATC GCG CAG CGC GCG CGG ACC ATG GCG 314 Arg Val Leu Tyr Lys Gin Ser He Ala Gin Arg Ala Arg Thr Met Ala 45 50 55 CTG TAC AAC CCC ATC CCG GTC AAG CAG AAC TGC TTC ACC GTC AAC CGC 362 Leu Tyr Asn Pro He Pro Val Lys Gin Asn Cys Phe Thr Val Asn Arg 60 65 70 TCG CTC TTC GTC TTC AGC GAG GAC AAC GTC GTC CGC AAA TAC GCG AAG 410 Ser Leu Phe Val Phe Ser Glu Asp Asn Val Val Arg Lys Tyr Ala Lys 75 80 85 CGC ATC ACC GAG TGG CCT CCA TTC GAG AAT ATG ATC CTG GCC ACC ATC 458 Arg He Thr Glu Trp Pro Pro Phe Glu Asn Met He Leu Ala Thr He 90 95 100 105 ATC GCC AAC TGC ATC GTG CTG GCC CTG GAG CAG CAC CTC CCT GAT GGG 506 He Ala Asn Cys He Val Leu Ala Leu Glu Gin His Leu Pro Asp Gly 110 115 120 GAC AAA ACG CCC ATG TCC GAG CGG CTG GAC GAC ACG GAG CCC TAT TTC 554 Asp Lys Thr Pro Met Ser Glu Arg Leu Asp Asp Thr Glu Pro Tyr Phe 125 130 135 ATC GGG ATC TTT TGC TTC GAG GCA GGG ATC AAA ATC ATC GCT CTG GGC 602 He Gly He Phe Cys Phe Glu Ala Gly He Lys He He Ala Leu Gly 140 145 150 TTT GTC TTC CAC AAG GGC TCT TAC CTG CGG AAC GGC TGG AAC GTC ATG 650 Phe Val Phe His Lys Gly Ser Tyr Leu Arg Asn Gly Trp Asn Val Met 155 160 165 GAC TTC GTG GTC GTC CTC ACA GGG ATC CTT GCC ACG GCT GGA ACT GAC 698 Asp Phe Val Val Val Leu Thr Gly He Leu Ala Thr Ala Gly Thr Asp 170 175 180 185 TTC GAC CTG CGA ACA CTG AGG GCT GTG CGT GTG CTG AGG CCC CTG AAG 746 Phe Asp Leu Arg Thr Leu Arg Ala Val Arg Val Leu Arg Pro Leu Lys 190 195 200 CTG GTG TCT GGG ATT CCA AGT TTG CAG GTG GTG CTC AAG TCC ATC ATG 794 Leu Val Ser Gly He Pro Ser Leu Gin Val Val Leu Lys Ser He Met 205 210 215 AAG GCC ATG GTT CCA CTC CTG CAG ATT GGG CTG CTT CTC TTC TTT GCC 842 Lys Ala Met Val Pro Leu Leu Gin He Gly Leu Leu Leu Phe Phe Ala 220 225 230 ATC CTC ATG TTT GCC ATC ATT GGC CTG GAG TTC TAC ATG GGC AAG TTC 890 He Leu Met Phe Ala He He Gly Leu Glu Phe Tyr Met Gly Lys Phe 235 240 245 CAC AAG GCC TGT TTC CCC AAC AGC ACA GAT GCG GAG CCC GTG GGT GAC 938 His Lys Ala Cys Phe Pro Asn Ser Thr Asp Ala Glu Pro Val Gly Asp 250 255 260 265 TTC CCC TGT GGC AAG GAG GCC CCA GCC CGG CTG TGC GAG GGC GAC ACT 986 Phe Pro Cys Gly Lys Glu Ala Pro Ala Arg Leu Cys Glu Gly Asp Thr 270 275 280 GAG TGC CGG GAG TAC TGG CCA GGA CCC AAC TTT GGC ATC ACC AAC TTT 1034 Glu Cys Arg Glu Tyr Trp Pro Gly Pro Asn Phe Gly He Thr Asn Phe 285 290 295 GAC AAT ATC CTG TTT GCC ATC TTG ACG GTG TTC CAG TGC ATC ACC ATG 1082 Asp Asn He Leu Phe Ala He Leu Thr Val Phe Gin Cys He Thr Met 300 305 310 GAG GGC TGG ACT GAC ATC CTC TAT AAT ACA AAC GAT GCG GCC GGC AAC 1130 Glu Gly Trp Thr Asp He Leu Tyr Asn Thr Asn Asp Ala Ala Gly Asn 315 320 325 ACC TGG AAC TGG CTC TAC TTC ATC CCT CTC ATC ATC ATC GGC TCC TTC 1178 Thr Trp Asn Trp Leu Tyr Phe He Pro Leu He He He Gly Ser Phe 330 335 340 345 TTC ATG CTC AAC CTG GTG CTG GGC GTG CTC TCG GGG GAG TTT GCC AAG 1226 Phe Met Leu Asn Leu Val Leu Gly Val Leu Ser Gly Glu Phe Ala Lys 350 355 360 GAG CGA GAG AGG GTG GAG AAC CGC CGC GCC TTC CTG AAG CTG CGC CGG 1 74 Glu Arg Glu Arg Val Glu Asn Arg Arg Ala Phe Leu Lys Leu Arg Arg 365 370 375 CAG CAG CAG ATC GAG CGA GAG CTC AAC GGG TAC CTG GAG TGG ATC TTC 1322 Gin Gin Gin He Glu Arg Glu Leu Asn Gly Tyr Leu Glu Trp He Phe 380 385 390 AAG GCG GAG GAA GTC ATG CTG GCC GAG GAG GAC AGG AAT GCA GAG GAG 1370 Lys Ala Glu Glu Val Met Leu Ala Glu Glu Asp Arg Asn Ala Glu Glu 395 400 405 AAG TCC CCT TTG GAC GTG CTG AAG AGA GCG GCC ACC AAG AAG AGC AGA 1418 Lys Ser Pro Leu Asp Val Leu Lys Arg Ala Ala Thr Lys Lys Ser Arg 410 415 420 425 AAT GAC CTG ATC CAC GCA GAG GAG GGA GAG GAC CGG TTT GCA GAT CTC 1466 Asn Asp Leu He His Ala Glu Glu Gly Glu Asp Arg Phe Ala Asp Leu 430 435 440 TGT GCT GTT GGA TCC CCC TTC GCC CGC GCC AGC CTC AAG AGC GGG AAG 1514 Cys Ala Val Gly Ser Pro Phe Ala Arg Ala Ser Leu Lys Ser Gly Lys 445 450 455 ACA GAG AGC TCG TCA TAC TTC CGG AGG AAG GAG AAG ATG TTC CGG TTT 1562 Thr Glu Ser Ser Ser Tyr Phe Arg Arg Lys Glu Lys Met Phe Arg Phe 460 465 470 TTT ATC CGG CGC ATG GTG AAG GCT CAG AGC TTC TAC TGG GTG GTG CTG 1610 Phe He Arg Arg Met Val Lys Ala Gin Ser Phe Tyr Trp Val Val Leu 475 480 485 TGC GTG GTG GCC CTG AAC ACA CTG TGT GTG GCC ATG GTG CAT TAC AAC 1658 Cys Val Val Ala Leu Asn Thr Leu Cys Val Ala Met Val His Tyr Asn 490 495 500 505 CAG CCG CGG CGG CTT ACC ACG ACC CTG TAT TTT GCA GAG TTT GTT TTC 1706 Gin Pro Arg Arg Leu Thr Thr Thr Leu Tyr Phe Ala Glu Phe Val Phe 510 515 520 CTG GGT CTC TTC CTC ACA GAG ATG TCC CTG AAG ATG TAT GGC CTG GGG 1754 Leu Gly Leu Phe Leu Thr Glu Met Ser Leu Lys Met Tyr Gly Leu Gly 525 530 535 CCC AGA AGC TAC TTC CGG TCC TCC TTC AAC TGC TTC GAC TTT GGG GTC 1802 Pro Arg Ser Tyr Phe Arg Ser Ser Phe Asn Cys Phe Asp Phe Gly Val 540 545 550 ATC GTG GGG AGC GTC TTT GAA GTG GTC TGG GCG GCC ATC AAG CCG GGA 1850 He Val Gly Ser Val Phe Glu Val Val Trp Ala Ala He Lys Pro Gly 555 560 565 AGC TCC TTT GGG ATC AGT GTG CTG CGG GCC CTC CGC CTG CTG AGG ATC 1898 Ser Ser Phe Gly He Ser Val Leu Arg Ala Leu Arg Leu Leu Arg He 570 575 580 585 TTC AAA GTC ACG AAG TAC TGG AGC TCC CTG CGG AAC CTG GTG GTG TCC 1946 Phe Lys Val Thr Lys Tyr Trp Ser Ser Leu Arg Asn Leu Val Val Ser 590 595 600 CTG CTG AAC TCC ATG AAG TCC ATC ATC AGC CTG CTC TTC TTG CTC TTC 1994 Leu Leu Asn Ser Met Lys Ser He He Ser Leu Leu Phe Leu Leu Phe 605 610 615 CTG TTC ATT GTG GTC TTC GCC CTG CTG GGG ATG CAG CTG TTT GGG GGA 2042 Leu Phe He Val Val Phe Ala Leu Leu Gly Met Gin Leu Phe Gly Gly 620 625 630 CAG TTC AAC TTC CAG GAT GAG ACT CCC ACA ACC AAC TTC GAC ACC TTC 2090 Gin Phe Asn Phe Gin Asp Glu Thr Pro Thr Thr Asn Phe Asp Thr Phe 635 640 645 CCT GCC GCC ATC CTC ACT GTC TTC CAG ATC CTG ACG GGA GAG GAC TGG 2138 Pro Ala Ala He Leu Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp 650 655 660 665 AAT GCA GTG ATG TAT CAC GGG ATC GAA TCG CAA GGC GGC GTC AGC AAA 2186 Asn Ala Val Met Tyr His Gly He Glu Ser Gin Gly Gly Val Ser Lys 670 675 680 GGC ATG TTC TCG TCC TTT TAC TTC ATT GTC CTG ACA CTG TTC GGA AAC 2234 Gly Met Phe Ser Ser Phe Tyr Phe He Val Leu Thr Leu Phe Gly Asn 685 690 695 TAC ACT CTG CTG AAT GTC TTT CTG GCC ATC GCT GTG GAC AAC CTG GCC 2282 Tyr Thr Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala 700 705 710 AAC GCC CAA GAG CTG ACC AAG GAT GAA GAG GAG ATG GAA GAA GCA GCC 2330 Asn Ala Gin Glu Leu Thr Lys Asp Glu Glu Glu Met Glu Glu Ala Ala 715 720 725 AAT CAG AAG CTT GCT CTG CAA AAG GCC AAA GAA GTG GCT GAA GTC AGC 2378 Asn Gin Lys Leu Ala Leu Gin Lys Ala Lys Glu Val Ala Glu Val Ser 730 735 740 745 CCC ATG TCT GCC GCG AAC ATC TCC ATC GCC GCC AGG CAG CAG AAC TCG 2426 Pro Met Ser Ala Ala Asn He Ser He Ala Ala Arg Gin Gin Asn Ser 750 755 760 GCC AAG GCG CGC TCG GTG TGG GAG CAG CGG GCC AGC CAG CTA CGG CTG 2474 Ala Lys Ala Arg Ser Val Trp Glu Gin Arg Ala Ser Gin Leu Arg Leu 765 770 775 CAG AAC CTG CGG GCC AGC TGC GAG GCG CTG TAC AGC GAG ATG GAC CCC 2522 Gin Asn Leu Arg Ala Ser Cys Glu Ala Leu Tyr Ser Glu Met Asp Pro 780 785 790 GAG GAG CGG CTG CGC TTC GCC ACT ACG CGC CAC CTG CGG CCC GAC ATG 2570 Glu Glu Arg Leu Arg Phe Ala Thr Thr Arg His Leu Arg Pro Asp Met 795 800 805 AAG ACG CAC CTG GAC CGG CCG CTG GTG GTG GAG CTG GGC CGC GAC GGC 2618 Lys Thr His Leu Asp Arg Pro Leu Val Val Glu Leu Gly Arg Asp Gly 810 815 820 825 GCG CGG GGG CCC GTG GGA GGC AAA GCC CGA CCT GAG GCT GCG GAG GCC 2666 Ala Arg Gly Pro Val Gly Gly Lys Ala Arg Pro Glu Ala Ala Glu Ala 830 835 840 CCC GAG GGC GTC GAC CCT CCG CGC AGG CAC CAC CGG CAC CGC GAC AAG 2714 Pro Glu Gly Val Asp Pro Pro Arg Arg His His Arg His Arg Asp Lys 845 850 855 GAC AAG ACC CCC GCG GCG GGG GAC CAG GAC CGA GCA GAG GCC CCG AAG 2762 Asp Lys Thr Pro Ala Ala Gly Asp Gin Asp Arg Ala Glu Ala Pro Lys 860 865 870 GCG GAG AGC GGG GAG CCC GGT GCC CGG GAG GAG CGG CCG CGG CCG CAC 2810 Ala Glu Ser Gly Glu Pro Gly Ala Arg Glu Glu Arg Pro Arg Pro His 875 880 885 CGC AGC CAC AGC AAG GAG GCC GCG GGG CCC CCG GAG GCG CGG AGC GAG 2858 Arg Ser His Ser Lys Glu Ala Ala Gly Pro Pro Glu Ala Arg Ser Glu 890 895 900 905 CGC GGC CGA GGC CCA GGC CCC GAG GGC GGC CGG CGG CAC CAC CGG CGC 2906 Arg Gly Arg Gly Pro Gly Pro Glu Gly Gly Arg Arg His His Arg Arg 910 915 920 GGC TCC CCG GAG GAG GCG GCC GAG CGG GAG CCC CGA CGC CAC CGC GCG 2954 Gly Ser Pro Glu Glu Ala Ala Glu Arg Glu Pro Arg Arg His Arg Ala 925 930 935 CAC CGG CAC CAG GAT CCG AGC AAG GAG TGC GCC GGC GCC AAG GGC GAG 3002 His Arg His Gin Asp Pro Ser Lys Glu Cys Ala Gly Ala Lys Gly Glu 940 945 950 CGG CGC GCG CGG CAC CGC GGC GGC CCC CGA GCG GGG CCC CGG GAG GCG 3050 Arg Arg Ala Arg His Arg Gly Gly Pro Arg Ala Gly Pro Arg Glu Ala 955 960 965 GAG AGC GGG GAG GAG CCG GCG CGG CGG CAC CGG GCC CGG CAC AAG GCG 3098 Glu Ser Gly Glu Glu Pro Ala Arg Arg His Arg Ala Arg His Lys Ala 970 975 980 985 CAG CCT GCT CAC GAG GCT GTG GAG AAG GAG ACC ACG GAG AAG GAG GCC 3146 Gin Pro Ala His Glu Ala Val Glu Lys Glu Thr Thr Glu Lys Glu Ala 990 995 1000 ACG GAG AAG GAG GCT GAG ATA GTG GAA GCC GAC AAG GAA AAG GAG CTC 3194 Thr Glu Lys Glu Ala Glu He Val Glu Ala Asp Lys Glu Lys Glu Leu 1005 1010 1015 CGG AAC CAC CAG CCC CGG GAG CCA CAC TGT GAC CTG GAG ACC AGT GGG 3242 Arg Asn His Gin Pro Arg Glu Pro His Cys Asp Leu Glu Thr Ser Gly 1020 1025 1030 ACT GTG ACT GTG GGT CCC ATG CAC ACA CTG CCC AGC ACC TGT CTC CAG 3290 Thr Val Thr Val Gly Pro Met His Thr Leu Pro Ser Thr Cys Leu Gin 1035 1040 1045 AAG GTG GAG GAA CAG CCA GAG GAT GCA GAC AAT CAG CGG AAC GTC ACT 3338 Lys Val Glu Glu Gin Pro Glu Asp Ala Asp Asn Gin Arg Asn Val Thr 1050 1055 1060 1065 CGC ATG GGC AGT CAG CCC CCA GAC CCG AAC ACT ATT GTA CAT ATC CCA 3386 Arg Met Gly Ser Gin Pro Pro Asp Pro Asn Thr He Val His He Pro 1070 1075 1080 GTG ATG CTG ACG GGC CCT CTT GGG GAA GCC ACG GTC GTT CCC AGT GGT 3434 Val Met Leu Thr Gly Pro Leu Gly Glu Ala Thr Val Val Pro Ser Gly 1085 1090 1095 AAC GTG GAC CTG GAA AGC CAA GCA GAG GGG AAG AAG GAG GTG GAA GCG 3482 Asn Val Asp Leu Glu Ser Gin Ala Glu Gly Lys Lys Glu Val Glu Ala 1100 1105 1110 GAT GAC GTG ATG AGG AGC GGC CCC CGG CCT ATC GTC CCA TAC AGC TCC 3530 Asp Asp Val Met Arg Ser Gly Pro Arg Pro He Val Pro Tyr Ser Ser 1115 1120 1125 ATG TTC TGT TTA AGC CCC ACC AAC CTG CTC CGC CGC TTC TGC CAC TAC 3578 Met Phe Cys Leu Ser Pro Thr Asn Leu Leu Arg Arg Phe Cys His Tyr 1130 1135 1140 1145 ATC GTG ACC ATG AGG TAC TTC GAG GTG GTC ATT CTC GTG GTC ATC GCC 3626 He Val Thr Met Arg Tyr Phe Glu Val Val He Leu Val Val He Ala 1150 1155 1160 TTG AGC AGC ATC GCC CTG GCT GCT GAG GAC CCA GTG CGC ACA GAC TCG 3674 Leu Ser Ser He Ala Leu Ala Ala Glu Asp Pro Val Arg Thr Asp Ser 1165 1170 1175 CCC AGG AAC AAC GCT CTG AAA TAC CTG GAT TAC ATT TTC ACT GGT GTC 3722 Pro Arg Asn Asn Ala Leu Lys Tyr Leu Asp Tyr He Phe Thr Gly Val 1180 1185 1190 TTT ACC TTT GAG ATG GTG ATA AAG ATG ATC GAC TTG GGA CTG CTG CTT 3770 Phe Thr Phe Glu Met Val He Lys Met He Asp Leu Gly Leu Leu Leu 1195 1200 1205 CAC CCT GGA GCC TAT TTC CGG GAC TTG TGG AAC ATT CTG GAC TTC ATT 3818 His Pro Gly Ala Tyr Phe Arg Asp Leu Trp Asn He Leu Asp Phe He 1210 1215 1220 1225 GTG GTC AGT GGC GCC CTG GTG GCG TTT GCT TTC TCA GGA TCC AAA GGG 3866 Val Val Ser Gly Ala Leu Val Ala Phe Ala Phe Ser Gly Ser Lys Gly 1230 1235 1240 AAA GAC ATC AAT ACC ATC AAG TCT CTG AGA GTC CTT CGT GTC CTG CGG 3914 Lys Asp He Asn Thr He Lys Ser Leu Arg Val Leu Arg Val Leu Arg 1245 1250 1255 CCC CTC AAG ACC ATC AAA CGG CTG CCC AAG CTC AAG GCT GTG TTT GAC 3962 Pro Leu Lys Thr He Lys Arg Leu Pro Lys Leu Lys Ala Val Phe Asp 1260 1265 1270 TGT GTG GTG AAC TCC CTG AAG AAT GTC CTC AAC ATC TTG ATT GTC TAC 4010 Cys Val Val Asn Ser Leu Lys Asn Val Leu Asn He Leu He Val Tyr 1275 1280 1285 ATG CTC TTC ATG TTC ATA TTT GCC GTC ATT GCG GTG CAG CTC TTC AAA 4058 Met Leu Phe Met Phe He Phe Ala Val He Ala Val Gin Leu Phe Lys 1290 1295 1300 1305 GGG AAG TTT TTC TAC TGC ACA GAT GAA TCC AAG GAG CTG GAG AGG GAC 4106 Gly Lys Phe Phe Tyr Cys Thr Asp Glu Ser Lys Glu Leu Glu Arg Asp 1310 1315 1320 TGC AGG GGT CAG TAT TTG GAT TAT GAG AAG GAG GAA GTG GAA GCT CAG 4154 Cys Arg Gly Gin Tyr Leu Asp Tyr Glu Lys Glu Glu Val Glu Ala Gin 1325 1330 1335 CCC AGG CAG TGG AAG AAA TAC GAC TTT CAC TAC GAC AAT GTG CTC TGG 4202 Pro Arg Gin Trp Lys Lys Tyr Asp Phe His Tyr Asp Asn Val Leu Trp 1340 1345 1350 GCT CTG CTG ACG CTG TTC ACA GTG TCC ACG GGA GAA GGC TGG CCC ATG 4250 Ala Leu Leu Thr Leu Phe Thr Val Ser Thr Gly Glu Gly Trp Pro Met 1355 1360 1365 GTG CTG AAA CAC TCC GTG GAT GCC ACC TAT GAG GAG CAG GGT CCA AGC 4298 Val Leu Lys His Ser Val Asp Ala Thr Tyr Glu Glu Gin Gly Pro Ser 1370 1375 1380 1385 CCT GGG TAC CGC ATG GAG CTG TCC ATC TTC TAC GTG GTC TAC TTT GTG 4346 Pro Gly Tyr Arg Met Glu Leu Ser He Phe Tyr Val Val Tyr Phe Val 1390 1395 1400 GTC TTT CCC TTC TTC TTC GTC AAC ATC TTT GTG GCT TTG ATC ATC ATC 4394 Val Phe Pro Phe Phe Phe Val Asn He Phe Val Ala Leu He He He 1405 1410 1415 ACC TTC CAG GAG CAG GGG GAC AAG GTG ATG TCT GAA TGC AGC CTG GAG 4442 Thr Phe Gin Glu Gin Gly Asp Lys Val Met Ser Glu Cys Ser Leu Glu 1420 1425 1430 AAG AAC GAG AGG GCT TGC ATT GAC TTC GCC ATC AGC GCC AAA CCC CTG 4490 Lys Asn Glu Arg Ala Cys He Asp Phe Ala He Ser Ala Lys Pro Leu 1435 1440 1445 ACA CGG TAC ATG CCC CAA AAC CGG CAG TCG TTC CAG TAT AAG ACG TGG 4538 Thr Arg Tyr Met Pro Gin Asn Arg Gin Ser Phe Gin Tyr Lys Thr Trp 1450 1455 1460 1465 ACA TTT GTG GTC TCC CCG CCC TTT GAA TAC TTC ATC ATG GCC ATG ATA 4586 Thr Phe Val Val Ser Pro Pro Phe Glu Tyr Phe He Met Ala Met He 1470 1475 1480 GCC CTC AAC ACT GTG GTG CTG ATG ATG AAG TTC TAT GAT GCA CCC TAT 4634 Ala Leu Asn Thr Val Val Leu Met Met Lys Phe Tyr Asp Ala Pro Tyr 1485 1490 1495 GAG TAC GAG CTG ATG CTG AAA TGC CTG AAC ATC GTG TTC ACA TCC ATG 4682 Glu Tyr Glu Leu Met Leu Lys Cys Leu Asn He Val Phe Thr Ser Met 1500 1505 1510 TTC TCC ATG GAA TGC GTG CTG AAG ATC ATC GCC TTT GGG GTG CTG AAC 4730 Phe Ser Met Glu Cys Val Leu Lys He He Ala Phe Gly Val Leu Asn 1515 1520 1525 TAT TTC AGA GAT GCC TGG AAT GTC TTT GAC TTT GTC ACT GTG TTG GGA 4778 Tyr Phe Arg Asp Ala Trp Asn Val Phe Asp Phe Val Thr Val Leu Gly 1530 1535 1540 1545 AGT ATT ACT GAT ATT TTA GTA ACA GAG ATT GCG GAA ACG AAC AAT TTC 4826 Ser He Thr Asp He Leu Val Thr Glu He Ala Glu Thr Asn Asn Phe 1550 1555 1560 ATC AAC CTC AGC TTC CTC CGC CTC TTT CGA GCT GCG CGG CTG ATC AAG 4874 He Asn Leu Ser Phe Leu Arg Leu Phe Arg Ala Ala Arg Leu He Lys 1565 1570 1575 CTG CTC CGC CAG GGC TAC ACC ATC CGC ATC CTG CTG TGG ACC TTT GTC 4922 Leu Leu Arg Gin Gly Tyr Thr He Arg He Leu Leu Trp Thr Phe Val 1580 1585 1590 CAG TCC TTC AAG GCC CTG CCC TAC GTG TGT CTG CTC ATT GCC ATG CTG 4970 Gin Ser Phe Lys Ala Leu Pro Tyr Val Cys Leu Leu He Ala Met Leu 1595 1600 1605 TTC TTC ATC TAC GCC ATC ATC GGC ATG CAG GTG TTT GGG AAT ATT GCC 5018 Phe Phe He Tyr Ala He He Gly Met Gin Val Phe Gly Asn He Ala 1610 1615 1620 1625 CTG GAT GAT GAC ACC AGC ATC AAC CGC CAC AAC AAC TTC CGG ACG TTT 5066 Leu Asp Asp Asp Thr Ser He Asn Arg His Asn Asn Phe Arg Thr Phe 1630 1635 1640 TTG CAA GCC CTG ATG CTG CTG TTC AGG AGC GCC ACG GGG GAG GCC TGG 5114 Leu Gin Ala Leu Met Leu Leu Phe Arg Ser Ala Thr Gly Glu Ala Trp 1645 1650 1655 CAC GAG ATC ATG CTG TCC TGC CTG AGC AAC CAG GCC TGT GAT GAG CAG 5162 His Glu He Met Leu Ser Cys Leu Ser Asn Gin Ala Cys Asp Glu Gin 1660 1665 1670 GCC AAT GCC ACC GAG TGT GGA AGT GAC TTT GCC TAC TTC TAC TTC GTC 5210 Ala Asn Ala Thr Glu Cys Gly Ser Asp Phe Ala Tyr Phe Tyr Phe Val 1675 1680 1685 TCC TTC ATC TTC CTG TGC TCC TTT CTG ATG TTG AAC CTC TTT GTG GCT 5258 Ser Phe He Phe Leu Cys Ser Phe Leu Met Leu Asn Leu Phe Val Ala 1690 1695 1700 1705 GTG ATC ATG GAC AAT TTT GAG TAC CTC ACG CGG GAC TCT TCC ATC CTA 5306 Val He Met Asp Asn Phe Glu Tyr Leu Thr Arg Asp Ser Ser He Leu 1710 1715 1720 GGT CCT CAC CAC TTG GAT GAG TTC ATC CGG GTC TGG GCT GAA TAC GAC 5354 Gly Pro His His Leu Asp Glu Phe He Arg Val Trp Ala Glu Tyr Asp 1725 1730 1735 CCG GCT GCG TGT GGG CGC ATC AGT TAC AAT GAC ATG TTT GAG ATG CTG 5402 Pro Ala Ala Cys Gly Arg He Ser Tyr Asn Asp Met Phe Glu Met Leu 1740 1745 1750 AAA CAC ATG TCC CCG CCT CTG GGG CTG GGG AAG AAA TGC CCT GCT CGA 5450 Lys His Met Ser Pro Pro Leu Gly Leu Gly Lys Lys Cys Pro Ala Arg 1755 1760 1765 GTT GCT TAC AAG CGC CTG GTT CGC ATG AAC ATG CCC ATC TCC AAC GAG 5498 Val Ala Tyr Lys Arg Leu Val Arg Met Asn Met Pro He Ser Asn Glu 1770 1775 1780 1785 GAC ATG ACT GTT CAC TTC ACG TCC ACG CTG ATG GCC CTC ATC CGG ACG 5546 Asp Met Thr Val His Phe Thr Ser Thr Leu Met Ala Leu He Arg Thr 1790 1795 1800 GCA CTG GAG ATC AAG CTG GCC CCA GCT GGG ACA AAG CAG CAT CAG TGT 5594 Ala Leu Glu He Lys Leu Ala Pro Ala Gly Thr Lys Gin His Gin Cys 1805 1810 1815 GAC GCG GAG TTG AGG AAG GAG ATT TCC GTT GTG TGG GCC AAT CTG CCC 5642 Asp Ala Glu Leu Arg Lys Glu He Ser Val Val Trp Ala Asn Leu Pro 1820 1825 1830 CAG AAG ACT TTG GAC TTG CTG GTA CCA CCC CAT AAG CCT GAT GAG ATG 5690 Gin Lys Thr Leu Asp Leu Leu Val Pro Pro His Lys Pro Asp Glu Met 1835 1840 1845 ACA GTG GGG AAG GTT TAT GCA GCT CTG ATG ATA TTT GAC TTC TAC AAG 5738 Thr Val Gly Lys Val Tyr Ala Ala Leu Met He Phe Asp Phe Tyr Lys 1850 1855 1860 1865 CAG AAC AAA ACC ACC AGA GAC CAG ATG CAG CAG GCT CCT GGA GGC CTC 5786 Gin Asn Lys Thr Thr Arg Asp Gin Met Gin Gin Ala Pro Gly Gly Leu 1870 1875 1880 TCC CAG ATG GGT CCT GTG TCC CTG TTC CAC CCT CTG AAG GCC ACC CTG 5834 Ser Gin Met Gly Pro Val Ser Leu Phe His Pro Leu Lys Ala Thr Leu 1885 1890 1895 GAG CAG ACA CAG CCG GCT GTG CTC CGA GGA GCC CGG GTT TTC CTT CGA 5882 Glu Gin Thr Gin Pro Ala Val Leu Arg Gly Ala Arg Val Phe Leu Arg 1900 1905 1910 CAG AAG AGT TCC ACC TCC CTC AGC AAT GGC GGG GCC ATA CAA AAC CAA 5930 Gin Lys Ser Ser Thr Ser Leu Ser Asn Gly Gly Ala He Gin Asn Gin 1915 1920 1925 GAG AGT GGC ATC AAA GAG TCT GTC TCC TGG GGC ACT CAA AGG ACC CAG 5978 Glu Ser Gly He Lys Glu Ser Val Ser Trp Gly Thr Gin Arg Thr Gin 1930 1935 1940 1945 GAT GCA CCC CAT GAG GCC AGG CCA CCC CTG GAG CGT GGC CAC TCC ACA 6026 Asp Ala Pro His Glu Ala Arg Pro Pro Leu Glu Arg Gly His Ser Thr 1950 1955 1960 GAG ATC CCT GTG GGG CGG TCA GGA GCA CTG GCT GTG GAC GTT CAG ATG 6074 Glu He Pro Val Gly Arg Ser Gly Ala Leu Ala Val Asp Val Gin Met 1965 1970 1975 CAG AGC ATA ACC CGG AGG GGC CCT GAT GGG GAG CCC CAG CCT GGG CTG 6122 Gin Ser He Thr Arg Arg Gly Pro Asp Gly Glu Pro Gin Pro Gly Leu 1980 1985 1990 GAG AGC CAG GGT CGA GCG GCC TCC ATG CCC CGC CTT GCG GCC GAG ACT 6170 Glu Ser Gin Gly Arg Ala Ala Ser Met Pro Arg Leu Ala Ala Glu Thr 1995 2000 2005 CAG CCC GTC ACA GAT GCC AGC CCC ATG AAG CGC TCC ATC TCC ACG CTG 6218 Gin Pro Val Thr Asp Ala Ser Pro Met Lys Arg Ser He Ser Thr Leu 2010 2015 2020 2025 GCC CAG CGG CCC CGT GGG ACT CAT CTT TGC AGC ACC ACC CCG GAC CGC 6266 Ala Gin Arg Pro Arg Gly Thr His Leu Cys Ser Thr Thr Pro Asp Arg 2030 2035 2040 CCA CCC CCT AGC CAG GCG TCG TCG CAC CAC CAC CAC CAC CGC TGC CAC 6314 Pro Pro Pro Ser Gin Ala Ser Ser His His His His His Arg Cys His 2045 2050 2055 CGC CGC AGG GAC AGG AAG CAG AGG TCC CTG GAG AAG GGG CCC AGC CTG 6362 Arg Arg Arg Asp Arg Lys Gin Arg Ser Leu Glu Lys Gly Pro Ser Leu 2060 2065 2070 TCT GCC GAT ATG GAT GGC GCA CCA AGC AGT GCT GTG GGG CCG GGG CTG 6410 Ser Ala Asp Met Asp Gly Ala Pro Ser Ser Ala Val Gly Pro Gly Leu 2075 2080 2085 CCC CCG GGA GAG GGG CCT ACA GGC TGC CGG CGG GAA CGA GAG CGC CGG 6458 Pro Pro Gly Glu Gly Pro Thr Gly Cys Arg Arg Glu Arg Glu Arg Arg 2090 2095 2100 2105 CAG GAG CGG GGC CGG TCC CAG GAG CGG AGG CAG CCC TCA TCC TCC TCC 6506 Gin Glu Arg Gly Arg Ser Gin Glu Arg Arg Gin Pro Ser Ser Ser Ser 2110 2115 2120 TCG GAG AAG CAG CGC TTC TAC TCC TGC GAC CGC TTT GGG GGC CGT GAG 6554 Ser Glu Lys Gin Arg Phe Tyr Ser Cys Asp Arg Phe Gly Gly Arg Glu 2125 2130 2135 CCC CCG AAG CCC AAG CCC TCC CTC AGC AGC CAC CCA ACG TCG CCA ACA 6602 Pro Pro Lys Pro Lys Pro Ser Leu Ser Ser His Pro Thr Ser Pro Thr 2140 2145 2150 GCT GGC CAG GAG CCG GGA CCC CAC CCA CAG GCC GGC TCA GCC GTG GGC 6650 Ala Gly Gin Glu Pro Gly Pro His Pro Gin Ala Gly Ser Ala Val Gly 2155 2160 2165 TTT CCG AAC ACA ACG CCC TGC TGC AGA GAG ACC CCC TCA GCC AGC CCC 6698 Phe Pro Asn Thr Thr Pro Cys Cys Arg Glu Thr Pro Ser Ala Ser Pro 2170 2175 2180 2185 TGG CCC CTG GCT CTC GAA TTG GCT CTG ACC CTT ACC TGG GGC AGC GTC 6746 Trp Pro Leu Ala Leu Glu Leu Ala Leu Thr Leu Thr Trp Gly Ser Val 2190 2195 2200 TGG ACA GTG AGG CCT CTG TCC ACG CCC TGC CTG AGG ACA CGC TCA CTT 6794 Trp Thr Val Arg Pro Leu Ser Thr Pro Cys Leu Arg Thr Arg Ser Leu 2205 2210 2215 TCG AGG AGG CTG TGG CCA CCA ACT CGG GCC GCT CCT CCA GGA CTT CCT 6842 Ser Arg Arg Leu Trp Pro Pro Thr Arg Ala Ala Pro Pro Gly Leu Pro 2220 2225 2230 ACG TGT CCT CCC TGACCTCCCA GTCTCACCCT CTCCGCCGCG TGCCCAACGG 6894 Thr Cys Pro Pro 2235 TTACCACTGC ACCCTGGGAC TCAGCTCGGG TGGCCGAGCA CGGCACAGCT ACCACCACCC 6954 TGACCAAGAC CACTGGTGCT AGCTGCACCG TGACCGCTCA GACGCCTGCA TGCAGCAGGC 7014 GTGTGTTCCA GTGGATGAGT TTTATCATCC ACACGGGGCA GTCGGCCCTC GGGGGAGGCC 7074 TTGCCCACCT TGGTGAGGCT CCTGTGGCCC CTCCCTCCCC CTCCTCCCCT CTTTTACTCT 7134 AGACGACGAA TAAAGCCCTG TTGCTTGAGT GTACGTACCG C 7175 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1546 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1437 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1435..1546 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: ATG GTC CAG AAG ACC AGC ATG TCC CGG GGC CCT TAC CCA CCC TCC CAG 48 Met Val Gin Lys Thr Ser Met Ser Arg Gly Pro Tyr Pro Pro Ser Gin 1 5 10 15 GAG ATC CCC ATG GAG GTC TTC GAC CCC AGC CCG CAG GGC AAA TAC AGC 96 Glu He Pro Met Glu Val Phe Asp Pro Ser Pro Gin Gly Lys Tyr Ser 20 25 30 AAG AGG AAA GGG CGA TTC AAA CGG TCA GAT GGG AGC ACG TCC TCG GAT 144 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gly Ser Thr Ser Ser Asp 35 40 45 ACC ACA TCC AAC AGC TTT GTC CGC CAG GGC TCA GCG GAG TCC TAC ACC 192 Thr Thr Ser Asn Ser Phe Val Arg Gin Gly Ser Ala Glu Ser Tyr Thr 50 55 60 AGC CGT CCA TCA GAC TCT GAT GTA TCT CTG GAG GAG GAC CGG GAA GCC 240 Ser Arg Pro Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala 65 70 75 80 TTA AGG AAG GAA GCA GAG CGC CAG GCA TTA GCG CAG CTC GAG AAG GCC 288 Leu Arg Lys Glu Ala Glu Arg Gin Ala Leu Ala Gin Leu Glu Lys Ala 85 90 95 AAG ACC AAG CCA GTG GCA TTT GCT GTG CGG ACA AAT GTT GGC TAC AAT 336 Lys Thr Lys Pro Val Ala Phe Ala Val Arg Thr Asn Val Gly Tyr Asn 100 105 110 CCG TCT CCA GGG GAT GAG GTG CCT GTG CAG GGA GTG GCC ATC ACC TTC 384 Pro Ser Pro Gly Asp Glu Val Pro Val Gin Gly Val Ala He Thr Phe 115 120 125 GAG CCC AAA GAC TTC CTG CAC ATC AAG GAG AAA TAC AAT AAT GAC TGG 432 Glu Pro Lys Asp Phe Leu His He Lys Glu Lys Tyr Asn Asn Asp Trp 130 135 140 TGG ATC GGG CGG CTG GTG AAG GAG GGC TGT GAG GTT GGC TTC ATT CCC 480 Trp He Gly Arg Leu Val Lys Glu Gly Cys Glu Val Gly Phe He Pro 145 150 155 160 AGC CCC GTC AAA CTG GAC AGC CTT CGC CTG CTG CAG GAA CAG AAG CTG 528 Ser Pro Val Lys Leu Asp Ser Leu Arg Leu Leu Gin Glu Gin Lys Leu 165 170 175 CGC CAG AAC CGC CTC GGC TCC AGC AAA TCA GGC GAT AAC TCC AGT TCC 576 Arg Gin Asn Arg Leu Gly Ser Ser Lys Ser Gly Asp Asn Ser Ser Ser 180 185 190 AGT CTG GGA GAT GTG GTG ACT GGC ACC CGC CGC CCC ACA CCC CCT GCC 624 Ser Leu Gly Asp Val Val Thr Gly Thr Arg Arg Pro Thr Pro Pro Ala 195 200 205 AGT GCC AAA CAG AAG CAG AAG TCG ACA GAG CAT GTG CCC CCC TAT GAC 672 Ser Ala Lys Gin Lys Gin Lys Ser Thr Glu His Val Pro Pro Tyr Asp 210 215 220 GTG GTG CCT TCC ATG AGG CCC ATC ATC CTG GTG GGA CCG TCG CTC AAG 720 Val Val Pro Ser Met Arg Pro He He Leu Val Gly Pro Ser Leu Lys 225 230 235 240 GGC TAC GAG GTT ACA GAC ATG ATG CAG AAA GCT TTA TTT GAC TTC TTG 768 Gly Tyr Glu Val Thr Asp Met Met Gin Lys Ala Leu Phe Asp Phe Leu 245 250 255 AAG CAT CGG TTT GAT GGC AGG ATC TCC ATC ACT CGT GTG ACG GCA GAT 816 Lys His Arg Phe Asp Gly Arg He Ser He Thr Arg Val Thr Ala Asp 260 265 270 ATT TCC CTG GCT AAG CGC TCA GTT CTC AAC AAC CCC AGC AAA CAC ATC 864 He Ser Leu Ala Lys Arg Ser Val Leu Asn Asn Pro Ser Lys His He 275 280 285 ATC ATT GAG CGC TCC AAC ACA CGC TCC AGC CTG GCT GAG GTG CAG AGT 912 He He Glu Arg Ser Asn Thr Arg Ser Ser Leu Ala Glu Val Gin Ser 290 295 300 GAA ATC GAG CGA ATC TTC GAG CTG GCC CGG ACC CTT CAG TTG GTC GCT 960 Glu He Glu Arg He Phe Glu Leu Ala Arg Thr Leu Gin Leu Val Ala 305 310 315 320 CTG GAT GCT GAC ACC ATC AAT CAC CCA GCC CAG CTG TCC AAG ACC TCG 1008 Leu Asp Ala Asp Thr He Asn His Pro Ala Gin Leu Ser Lys Thr Ser 325 330 335 CTG GCC CCC ATC ATT GTT TAC ATC AAG ATC ACC TCT CCC AAG GTA CTT 1056 Leu Ala Pro He He Val Tyr He Lys He Thr Ser Pro Lys Val Leu 340 345 350 CAA AGG CTC ATC AAG TCC CGA GGA AAG TCT CAG TCC AAA CAC CTC AAT 1104 Gin Arg Leu He Lys Ser Arg Gly Lys Ser Gin Ser Lys His Leu Asn 355 360 365 GTC CAA ATA GCG GCC TCG GAA AAG CTG GCA CAG TGC CCC CCT GAA ATG 1152 Val Gin He Ala Ala Ser Glu Lys Leu Ala Gin Cys Pro Pro Glu Met 370 375 380 TTT GAC ATC ATC CTG GAT GAG AAC CAA TTG GAG GAT GCC TGC GAG CAT 1200 Phe Asp He He Leu Asp Glu Asn Gin Leu Glu Asp Ala Cys Glu His 385 390 395 400 CTG GCG GAG TAC TTG GAA GCC TAT TGG AAG GCC ACA CAC CCG CCC AGC 1248 Leu Ala Glu Tyr Leu Glu Ala Tyr Trp Lys Ala Thr His Pro Pro Ser 405 410 415 AGC ACG CCA CCC AAT CCG CTG CTG AAC CGC ACC ATG GCT ACC GCA GCC 1296 Ser Thr Pro Pro Asn Pro Leu Leu Asn Arg Thr Met Ala Thr Ala Ala 420 425 430 CTG GCT GCC AGC CCT GCC CCT GTC TCC AAC CTC CAG GTA CAG GTG CTC 1344 Leu Ala Ala Ser Pro Ala Pro Val Ser Asn Leu Gin Val Gin Val Leu 435 440 445 ACC TCG CTC AGG AGA AAC CTC GGC TTC TGG GGC GGG CTG GAG TCC TCA 1392 Thr Ser Leu Arg Arg Asn Leu Gly Phe Trp Gly Gly Leu Glu Ser Ser 450 455 460 CAG CGG GGC AGT GTG GTG CCC CAG GAG CAG GAA CAT GCC ATG TAGTGGGCGC 1444 Gin Arg Gly Ser Val Val Pro Gin Glu Gin Glu His Ala Met 465 470 475 CCTGCCCGTC TTCCCTCCTG CTCTGGGGTC GGAACTGGAG TGCAGGGAAC ATGGAGGAGG 1504 AAGGGAAGAG CTTTATTTTG TAAAAAAATA AGATGAGCGG CA 1546 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1851 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1797 (D) OTHER INFORMATION: /standard_name= "Betal-3" (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1795..1851 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:10: ATG GTC CAG AAG ACC AGC ATG TCC CGG GGC CCT TAC CCA CCC TCC CAG 48 Met Val Gin Lys Thr Ser Met Ser Arg Gly Pro Tyr Pro Pro Ser Gin 1 5 10 15 GAG ATC CCC ATG GGA GTC TTC GAC CCC AGC CCG CAG GGC AAA TAC AGC 96 Glu He Pro Met Gly Val Phe Asp Pro Ser Pro Gin Gly Lys Tyr Ser 20 25 30 AAG AGG AAA GGG CGA TTC AAA CGG TCA GAT GGG AGC ACG TCC TCG GAT 144 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gly Ser Thr Ser Ser Asp 35 40 45 ACC ACA TCC AAC AGC TTT GTC CGC CAG GGC TCA GCG GAG TCC TAC ACC 192 Thr Thr Ser Asn Ser Phe Val Arg Gin Gly Ser Ala Glu Ser Tyr Thr 50 55 60 AGC CGT CCA TCA GAC TCT GAT GTA TCT CTG GAG GAG GAC CGG GAA GCC 240 Ser Arg Pro Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala 65 70 75 80 TTA AGG AAG GAA GCA GAG CGC CAG GCA TTA GCG CAG CTC GAG AAG GCC 288 Leu Arg Lys Glu Ala Glu Arg Gin Ala Leu Ala Gin Leu Glu Lys Ala 85 90 95 AAG ACC AAG CCA GTG GCA TTT GCT GTG CGG ACA AAT GTT GGC TAC AAT 336 Lys Thr Lys Pro Val Ala Phe Ala Val Arg Thr Asn Val Gly Tyr Asn 100 105 110 CCG TCT CCA GGG GAT GAG GTG CCT GTG CAG GGA GTG GCC ATC ACC TTC 384 Pro Ser Pro Gly Asp Glu Val Pro Val Gin Gly Val Ala He Thr Phe 115 120 125 GAG CCC AAA GAC TTC CTG CAC ATC AAG GAG AAA TAC AAT AAT GAC TGG 432 Glu Pro Lys Asp Phe Leu His He Lys Glu Lys Tyr Asn Asn Asp Trp 130 135 140 TGG ATC GGG CGG CTG GTG AAG GAG GGC TGT GAG GTT GGC TTC ATT CCC 480 Trp He Gly Arg Leu Val Lys Glu Gly Cys Glu Val Gly Phe He Pro 145 150 155 160 AGC CCC GTC AAA CTG GAC AGC CTT CGC CTG CTG CAG GAA CAG AAG CTG 528 Ser Pro Val Lys Leu Asp Ser Leu Arg Leu Leu Gin Glu Gin Lys Leu 165 170 175 CGC CAG AAC CGC CTC GGC TCC AGC AAA TCA GGC GAT AAC TCC AGT TCC 576 Arg Gin Asn Arg Leu Gly Ser Ser Lys Ser Gly Asp Asn Ser Ser Ser 180 185 190 AGT CTG GGA GAT GTG GTG ACT GGC ACC CGC CGC CCC ACA CCC CCT GCC 624 Ser Leu Gly Asp Val Val Thr Gly Thr Arg Arg Pro Thr Pro Pro Ala 195 200 205 AGT GCC AAA CAG AAG CAG AAG TCG ACA GAG CAT GTG CCC CCC TAT GAC 672 Ser Ala Lys Gin Lys Gin Lys Ser Thr Glu His Val Pro Pro Tyr Asp 210 215 220 GTG GTG CCT TCC ATG AGG CCC ATC ATC CTG GTG GGA CCG TCG CTC AAG 720 Val Val Pro Ser Met Arg Pro He He Leu Val Gly Pro Ser Leu Lys 225 230 235 240 GGC TAC GAG GTT ACA GAC ATG ATG CAG AAA GCT TTA TTT GAC TTC TTG 768 Gly Tyr- Glu Val Thr Asp Met Met Gin Lys Ala Leu Phe Asp Phe Leu 245 250 255 AAG CAT CGG TTT GAT GGC AGG ATC TCC ATC ACT CGT GTG ACG GCA GAT 816 Lys His Arg Phe Asp Gly Arg He Ser He Thr Arg Val Thr Ala Asp 260 265 270 ATT TCC CTG GCT AAG CGC TCA GTT CTC AAC AAC CCC AGC AAA CAC ATC 864 He Ser Leu Ala Lys Arg Ser Val Leu Asn Asn Pro Ser Lys His He 275 280 285 ATC ATT GAG CGC TCC AAC ACA CGC TCC AGC CTG GCT GAG GTG CAG AGT 912 He He Glu Arg Ser Asn Thr Arg Ser Ser Leu Ala Glu Val Gin Ser 290 295 300 GAA ATC GAG CGA ATC TTC GAG CTG GCC CGG ACC CTT CAG TTG GTC GCT 960 Glu He Glu Arg He Phe Glu Leu Ala Arg Thr Leu Gin Leu Val Ala 305 310 315 320 CTG GAT GCT GAC ACC ATC AAT CAC CCA GCC CAG CTG TCC AAG ACC TCG 1008 Leu Asp Ala Asp Thr He Asn His Pro Ala Gin Leu Ser Lys Thr Ser 325 330 335 CTG GCC CCC ATC ATT GTT TAC ATC AAG ATC ACC TCT CCC AAG GTA CTT 1056 Leu Ala Pro He He Val Tyr He Lys He Thr Ser Pro Lys Val Leu 340 345 350 CAA AGG CTC ATC AAG TCC CGA GGA AAG TCT CAG TCC AAA CAC CTC AAT 1104 Gin Arg Leu He Lys Ser Arg Gly Lys Ser Gin Ser Lys His Leu Asn 355 360 365 GTC CAA ATA GCG GCC TCG GAA AAG CTG GCA CAG TGC CCC CCT GAA ATG 1152 Val Gin He Ala Ala Ser Glu Lys Leu Ala Gin Cys Pro Pro Glu Met 370 375 380 TTT GAC ATC ATC CTG GAT GAG AAC CAA TTG GAG GAT GCC TGC GAG CAT 1200 Phe Asp He He Leu Asp Glu Asn Gin Leu Glu Asp Ala Cys Glu His 385 390 395 400 CTG GCG GAG TAC TTG GAA GCC TAT TGG AAG GCC ACA CAC CCG CCC AGC 1248 Leu Ala Glu Tyr Leu Glu Ala Tyr Trp Lys Ala Thr His Pro Pro Ser 405 410 415 AGC ACG CCA CCC AAT CCG CTG CTG AAC CGC ACC ATG GCT ACC GCA GCC 1296 Ser Thr Pro Pro Asn Pro Leu Leu Asn Arg Thr Met Ala Thr Ala Ala 420 425 430 CTG GCT GCC AGC CCT GCC CCT GTC TCC AAC CTC CAG GGA CCC TAC CTT 1344 Leu Ala Ala Ser Pro Ala Pro Val Ser Asn Leu Gin Gly Pro Tyr Leu 435 440 445 GCT TCC GGG GAC CAG CCA CTG GAA CGG GCC ACC GGG GAG CAC GCC AGC 1392 Ala Ser Gly Asp Gin Pro Leu Glu Arg Ala Thr Gly Glu His Ala Ser 450 455 460 ATG CAC GAG TAC CCA GGG GAG CTG GGC CAG CCC CCA GGC CTT TAC CCC 1440 Met His Glu Tyr Pro Gly Glu Leu Gly Gin Pro Pro Gly Leu Tyr Pro 465 470 475 480 AGC AGC CAC CCA CCA GGC CGG GCA GGC ACG CTA CGG GCA CTG TCC CGC 1488 Ser Ser His Pro Pro Gly Arg Ala Gly Thr Leu Arg Ala Leu Ser Arg 485 490 495 CAA GAC ACT TTT GAT GCC GAC ACC CCC GGC AGC CGA AAC TCT GCC TAC 1536 Gin Asp Thr Phe Asp Ala Asp Thr Pro Gly Ser Arg Asn Ser Ala Tyr 500 505 510 ACG GAG CTG GGA GAC TCA TGT GTG GAC ATG GAG ACT GAC CCC TCA GAG 1584 Thr Glu Leu Gly Asp Ser Cys Val Asp Met Glu Thr Asp Pro Ser Glu 515 520 525 GGG CCA GGG CTT GGA GAC CCT GCA GGG GGC GGC ACG CCC CCA GCC CGA 1632 Gly Pro Gly Leu Gly Asp Pro Ala Gly Gly Gly Thr Pro Pro Ala Arg 530 535 540 CAG GGA TCC TGG GAG GAC GAG GAA GAA GAC TAT GAG GAA GAG CTG ACC 1680 Gin Gly Ser Trp Glu Asp Glu Glu Glu Asp Tyr Glu Glu Glu Leu Thr 545 550 555 560 GAC AAC CGG AAC CGG GGC CGG AAT AAG GCC CGC TAC TGC GCT GAG GGT 1728 Asp Asn Arg Asn Arg Gly Arg Asn Lys Ala Arg Tyr Cys Ala Glu Gly 565 570 575 GGG GGT CCA GTT TTG GGG CGC AAC AAG AAT GAG CTG GAG GGC TGG GGA 1776 Gly Gly Pro Val Leu Gly Arg Asn Lys Asn Glu Leu Glu Gly Trp Gly 580 585 590 CGA GGC GTC TAC ATT CGC TGAGAGGCAG GGGCCACACG GCGGGAGGAA 1824 Arg Gly Val Tyr He Arg 595 GGGCTCTGAG CCCAGGGGAG GGGAGGG 1851 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3600 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 35..3310 (D) OTHER INFORMATION: /standard_name= "Alpha-2" (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..34 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 3308..3600 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GCGGGGGAGG GGGCATTGAT CTTCGATCGC GAAG ATG GCT GCT GGC TGC CTG 52 Met Ala Ala Gly Cys Leu 1 5 CTG GCC TTG ACT CTG ACA CTT TTC CAA TCT TTG CTC ATC GGC CCC TCG 100 Leu Ala Leu Thr Leu Thr Leu Phe Gin Ser Leu Leu He Gly Pro Ser 10 15 20 TCG GAG GAG CCG TTC CCT TCG GCC GTC ACT ATC AAA TCA TGG GTG GAT 148 Ser Glu Glu Pro Phe Pro Ser Ala Val Thr He Lys Ser Trp Val Asp 25 30 35 AAG ATG CAA GAA GAC CTT GTC ACA CTG GCA AAA ACA GCA AGT GGA GTC 196 Lys Met Gin Glu Asp Leu Val Thr Leu Ala Lys Thr Ala Ser Gly Val 40 45 50 AAT CAG CTT GTT GAT ATT TAT GAG AAA TAT CAA GAT TTG TAT ACT GTG 244 Asn Gin Leu Val Asp He Tyr Glu Lys Tyr Gin Asp Leu Tyr Thr Val 55 60 65 70 GAA CCA AAT AAT GCA CGC CAG CTG GTA GAA ATT GCA GCC AGG GAT ATT 292 Glu Pro Asn Asn Ala Arg Gin Leu Val Glu He Ala Ala Arg Asp He 75 80 85 GAG AAA CTT CTG AGC AAC AGA TCT AAA GCC CTG GTG AGC CTG GCA TTG 340 Glu Lys Leu Leu Ser Asn Arg Ser Lys Ala Leu Val Ser Leu Ala Leu 90 95 100 GAA GCG GAG AAA GTT CAA GCA GCT CAC CAG TGG AGA GAA GAT TTT GCA 388 Glu Ala Glu Lys Val Gin Ala Ala His Gin Trp Arg Glu Asp Phe Ala 105 110 115 AGC AAT GAA GTT GTC TAC TAC AAT GCA AAG GAT GAT CTC GAT CCT GAG 436 Ser Asn Glu Val Val Tyr Tyr Asn Ala Lys Asp Asp Leu Asp Pro Glu 120 125 130 AAA AAT GAC AGT GAG CCA GGC AGC CAG AGG ATA AAA CCT GTT TTC ATT 484 Lys Asn Asp Ser Glu Pro Gly Ser Gin Arg He Lys Pro Val Phe He 135 140 145 150 GAA GAT GCT AAT TTT GGA CGA CAA ATA TCT TAT CAG CAC GCA GCA GTC 532 Glu Asp Ala Asn Phe Gly Arg Gin He Ser Tyr Gin His Ala Ala Val 155 160 165 CAT ATT CCT ACT GAC ATC TAT GAG GGC TCA ACA ATT GTG TTA AAT GAA 580 His He Pro Thr Asp He Tyr Glu Gly Ser Thr He Val Leu Asn Glu 170 175 180 CTC AAC TGG ACA AGT GCC TTA GAT GAA GTT TTC AAA AAG AAT CGC GAG 628 Leu Asn Trp Thr Ser Ala Leu Asp Glu Val Phe Lys Lys Asn Arg Glu 185 190 195 GAA GAC CCT TCA TTA TTG TGG CAG GTT TTT GGC AGT GCC ACT GGC CTA 676 Glu Asp Pro Ser Leu Leu Trp Gin Val Phe Gly Ser Ala Thr Gly Leu 200 205 210 GCT CGA TAT TAT CCA GCT TCA CCA TGG GTT GAT AAT AGT AGA ACT CCA 724 Ala Arg Tyr Tyr Pro Ala Ser Pro Trp Val Asp Asn Ser Arg Thr Pro 215 220 225 230 AAT AAG ATT GAC CTT TAT GAT GTA CGC AGA AGA CCA TGG TAC ATC CAA 772 Asn Lys He Asp Leu Tyr Asp Val Arg Arg Arg Pro Trp Tyr He Gin 235 240 245 GGA GCT GCA TCT CCT AAA GAC ATG CTT ATT CTG GTG GAT GTG AGT GGA 820 Gly Ala Ala Ser Pro Lys Asp Met Leu He Leu Val Asp Val Ser Gly 250 255 260 AGT GTT AGT GGA TTG ACA CTT AAA CTG ATC CGA ACA TCT GTC TCC GAA 868 Ser Val Ser Gly Leu Thr Leu Lys Leu He Arg Thr Ser Val Ser Glu 265 270 275 ATG TTA GAA ACC CTC TCA GAT GAT GAT TTC GTG AAT GTA GCT TCA TTT 916 Met Leu Glu Thr Leu Ser Asp Asp Asp Phe Val Asn Val Ala Ser Phe 280 285 290 AAC AGC AAT GCT CAG GAT GTA AGC TGT TTT CAG CAC CTT GTC CAA GCA 964 Asn Ser Asn Ala Gin Asp Val Ser Cys Phe Gin His Leu Val Gin Ala 295 300 305 310 AAT GTA AGA AAT AAA AAA GTG TTG AAA GAC GCG GTG AAT AAT ATC ACA 1012 Asn Val Arg Asn Lys Lys Val Leu Lys Asp Ala Val Asn Asn He Thr 315 320 325 GCC AAA GGA ATT ACA GAT TAT AAG AAG GGC TTT AGT TTT GCT TTT GAA 1060 Ala Lys Gly He Thr Asp Tyr Lys Lys Gly Phe Ser Phe Ala Phe Glu 330 335 340 CAG CTG CTT AAT TAT AAT GTT TCC AGA GCA AAC TGC AAT AAG ATT ATT 1108 Gin Leu Leu Asn Tyr Asn Val Ser Arg Ala Asn Cys Asn Lys He He 345 350 355 ATG CTA TTC ACG GAT GGA GGA GAA GAG AGA GCC CAG GAG ATA TTT AAC 1156 Met Leu Phe Thr Asp Gly Gly Glu Glu Arg Ala Gin Glu He Phe Asn 360 365 370 AAA TAC AAT AAA GAT AAA AAA GTA CGT GTA TTC AGG TTT TCA GTT GGT 1204 Lys Tyr Asn Lys Asp Lys Lys Val Arg Val Phe Arg Phe Ser Val Gly 375 380 385 390 CAA CAC AAT TAT GAG AGA GGA CCT ATT CAG TGG ATG GCC TGT GAA AAC 1252 Gin His Asn Tyr Glu Arg Gly Pro He Gin Trp Met Ala Cys Glu Asn 395 400 405 AAA GGT TAT TAT TAT GAA ATT CCT TCC ATT GGT GCA ATA AGA ATC AAT 1300 Lys Gly Tyr Tyr Tyr Glu He Pro Ser He Gly Ala He Arg He Asn 410 415 420 ACT CAG GAA TAT TTG GAT GTT TTG GGA AGA CCA ATG GTT TTA GCA GGA 1348 Thr Gin Glu Tyr Leu Asp Val Leu Gly Arg Pro Met Val Leu Ala Gly 425 430 435 GAC AAA GCT AAG CAA GTC CAA TGG ACA AAT GTG TAC CTG GAT GCA TTG 1396 Asp Lys Ala Lys Gin Val Gin Trp Thr Asn Val Tyr Leu Asp Ala Leu 440 445 450 GAA CTG GGA CTT GTC ATT ACT GGA ACT CTT CCG GTC TTC AAC ATA ACC 1444 Glu Leu Gly Leu Val He Thr Gly Thr Leu Pro Val Phe Asn He Thr 455 460 465 470 GGC CAA TTT GAA AAT AAG ACA AAC TTA AAG AAC CAG CTG ATT CTT GGT 1492 Gly Gin Phe Glu Asn Lys Thr Asn Leu Lys Asn Gin Leu He Leu Gly 475 480 485 GTG ATG GGA GTA GAT GTG TCT TTG GAA GAT ATT AAA AGA CTG ACA CCA 1540 Val Met Gly Val Asp Val Ser Leu Glu Asp He Lys Arg Leu Thr Pro 490 495 500 CGT TTT ACA CTG TGC CCC AAT GGG TAT TAC TTT GCA ATC GAT CCT AAT 1588 Arg Phe Thr Leu Cys Pro Asn Gly Tyr Tyr Phe Ala He Asp Pro Asn 505 510 515 GGT TAT GTT TTA TTA CAT CCA AAT CTT CAG CCA AAG AAC CCC AAA TCT 1636 Gly Tyr Val Leu Leu His Pro Asn Leu Gin Pro Lys Asn Pro Lys Ser 520 525 530 CAG GAG CCA GTA ACA TTG GAT TTC CTT GAT GCA GAG TTA GAG AAT GAT 1684 Gin Glu Pro Val Thr Leu Asp Phe Leu Asp Ala Glu Leu Glu Asn Asp 535 540 545 550 ATT AAA GTG GAG ATT CGA AAT AAG ATG ATT GAT GGG GAA AGT GGA GAA 1732 He Lys Val Glu He Arg Asn Lys Met He Asp Gly Glu Ser Gly Glu 555 560 565 AAA ACA TTC AGA ACT CTG GTT AAA TCT CAA GAT GAG AGA TAT ATT GAC 1780 Lys Thr Phe Arg Thr Leu Val Lys Ser Gin Asp Glu Arg Tyr He Asp 570 575 580 AAA GGA AAC AGG ACA TAC ACA TGG ACA CCT GTC AAT GGC ACA GAT TAC 1828 Lys Gly Asn Arg Thr Tyr Thr Trp Thr Pro Val Asn Gly Thr Asp Tyr 585 590 595 AGT TTG GCC TTG GTA TTA CCA ACC TAC AGT TTT TAC TAT ATA AAA GCC 1876 Ser Leu Ala Leu Val Leu Pro Thr Tyr Ser Phe Tyr Tyr He Lys Ala 600 605 610 AAA CTA GAA GAG ACA ATA ACT CAG GCC AGA TCA AAA AAG GGC AAA ATG 1924 Lys Leu Glu Glu Thr He Thr Gin Ala Arg Ser Lys Lys Gly Lys Met 615 620 625 630 AAG GAT TCG GAA ACC CTG AAG CCA GAT AAT TTT GAA GAA TCT GGC TAT 1972 Lys Asp Ser Glu Thr Leu Lys Pro Asp Asn Phe Glu Glu Ser Gly Tyr 635 640 645 ACA TTC ATA GCA CCA AGA GAT TAC TGC AAT GAC CTG AAA ATA TCG GAT 2020 Thr Phe He Ala Pro Arg Asp Tyr Cys Asn Asp Leu Lys He Ser Asp 650 655 660 AAT AAC ACT GAA TTT CTT TTA AAT TTC AAC GAG TTT ATT GAT AGA AAA 2068 Asn Asn Thr Glu Phe Leu Leu Asn Phe Asn Glu Phe He Asp Arg Lys 665 670 675 ACT CCA AAC AAC CCA TCA TGT AAC GCG GAT TTG ATT AAT AGA GTC TTG 2116 Thr Pro Asn Asn Pro Ser Cys Asn Ala Asp Leu He Asn Arg Val Leu 680 685 690 CTT GAT GCA GGC TTT ACA AAT GAA CTT GTC CAA AAT TAC TGG AGT AAG 2164 Leu Asp Ala Gly Phe Thr Asn Glu Leu Val Gin Asn Tyr Trp Ser Lys 695 700. 705 710 CAG AAA AAT ATC AAG GGA GTG AAA GCA CGA TTT GTT GTG ACT GAT GGT 2212 Gin Lys Asn He Lys Gly Val Lys Ala Arg Phe Val Val Thr Asp Gly 715 720 725 GGG ATT ACC AGA GTT TAT CCC AAA GAG GCT GGA GAA AAT TGG CAA GAA 2260 Gly He Thr Arg Val Tyr Pro Lys Glu Ala Gly Glu Asn Trp Gin Glu 730 735 740 AAC CCA GAG ACA TAT GAG GAC AGC TTC TAT AAA AGG AGC CTA GAT AAT 2308 Asn Pro Glu Thr Tyr Glu Asp Ser Phe Tyr Lys Arg Ser Leu Asp Asn 745 750 755 GAT AAC TAT GTT TTC ACT GCT CCC TAC TTT AAC AAA AGT GGA CCT GGT 2356 Asp Asn Tyr Val Phe Thr Ala Pro Tyr Phe Asn Lys Ser Gly Pro Gly 760 765 770 GCC TAT GAA TCG GGC ATT ATG GTA AGC AAA GCT GTA GAA ATA TAT ATT 2404 Ala Tyr Glu Ser Gly He Met Val Ser Lys Ala Val Glu He Tyr He 775 780 785 790 CAA GGG AAA CTT CTT AAA CCT GCA GTT GTT GGA ATT AAA ATT GAT GTA 2452 Gin Gly Lys Leu Leu Lys Pro Ala Val Val Gly He Lys He Asp Val 795 800 805 AAT TCC TGG ATA GAG AAT TTC ACC AAA ACC TCA ATC AGA GAT CCG TGT 2500 Asn Ser Trp He Glu Asn Phe Thr Lys Thr Ser He Arg Asp Pro Cys 810 815 820 GCT GGT CCA GTT TGT GAC TGC AAA AGA AAC AGT GAC GTA ATG GAT TGT 2548 Ala Gly Pro Val Cys Asp Cys Lys Arg Asn Ser Asp Val Met Asp Cys 825 830 835 GTG ATT CTG GAT GAT GGT GGG TTT CTT CTG ATG GCA AAT CAT GAT GAT 2596 Val He Leu Asp Asp Gly Gly Phe Leu Leu Met Ala Asn His Asp Asp 840 845 850 TAT ACT AAT CAG ATT GGA AGA TTT TTT GGA GAG ATT GAT CCC AGC TTG 2644 Tyr Thr Asn Gin He Gly Arg Phe Phe Gly Glu He Asp Pro Ser Leu 855 860 865 870 ATG AGA CAC CTG GTT AAT ATA TCA GTT TAT GCT TTT AAC AAA TCT TAT 2692 Met Arg His Leu Val Asn He Ser Val Tyr Ala Phe Asn Lys Ser Tyr 875 880 885 GAT TAT CAG TCA GTA TGT GAG CCC GGT GCT GCA CCA AAA CAA GGA GCA 2740 Asp Tyr Gin Ser Val Cys Glu Pro Gly Ala Ala Pro Lys Gin Gly Ala 890 895 900 GGA CAT CGC TCA GCA TAT GTG CCA TCA GTA GCA GAC ATA TTA CAA ATT 2788 Gly His Arg Ser Ala Tyr Val Pro Ser Val Ala Asp He Leu Gin He 905 910 915 GGC TGG TGG GCC ACT GCT GCT GCC TGG TCT ATT CTA CAG CAG TTT CTC 2836 Gly Trp Trp Ala Thr Ala Ala Ala Trp Ser He Leu Gin Gin Phe Leu 920 925 930 TTG AGT TTG ACC TTT CCA CGA CTC CTT GAG GCA GTT GAG ATG GAG GAT 2884 Leu Ser Leu Thr Phe Pro Arg Leu Leu Glu Ala Val Glu Met Glu Asp 935 940 945 950 GAT GAC TTC ACG GCC TCC CTG TCC AAG CAG AGC TGC ATT ACT GAA CAA 2932 Asp Asp Phe Thr Ala Ser Leu Ser Lys Gin Ser Cys He Thr Glu Gin 955 960 965 ACC CAG TAT TTC TTC GAT AAC GAC AGT AAA TCA TTC AGT GGT GTA TTA 2980 Thr Gin Tyr Phe Phe Asp Asn Asp Ser Lys Ser Phe Ser Gly Val Leu 970 975 980 GAC TGT GGA AAC TGT TCC AGA ATC TTT CAT GGA GAA AAG CTT ATG AAC 3028 Asp Cys Gly Asn Cys Ser Arg He Phe His Gly Glu Lys Leu Met Asn 985 990 995 ACC AAC TTA ATA TTC ATA ATG GTT GAG AGC AAA GGG ACA TGT CCA TGT 3076 Thr Asn Leu He Phe He Met Val Glu Ser Lys Gly Thr Cys Pro Cys 1000 1005 1010 GAC ACA CGA CTG CTC ATA CAA GCG GAG CAG ACT TCT GAC GGT CCA AAT 3124 Asp Thr Arg Leu Leu He Gin Ala Glu Gin Thr Ser Asp Gly Pro Asn 1015 1020 1025 1030 CCT TGT GAC ATG GTT AAG CAA CCT AGA TAC CGA AAA GGG CCT GAT GTC 3172 Pro Cys Asp Met Val Lys Gin Pro Arg Tyr Arg Lys Gly Pro Asp Val 1035 1040 1045 TGC TTT GAT AAC AAT GTC TTG GAG GAT TAT ACT GAC TGT GGT GGT GTT 3220 Cys Phe Asp Asn Asn Val Leu Glu Asp Tyr Thr Asp Cys Gly Gly Val 1050 1055 1060 TCT GGA TTA AAT CCC TCC CTG TGG TAT ATC ATT GGA ATC CAG TTT CTA 3268 Ser Gly Leu Asn Pro Ser Leu Trp Tyr He He Gly He Gin Phe Leu 1065 1070 1075 CTA CTT TGG CTG GTA TCT GGC AGC ACA CAC CGG CTG TTA TGACCTTCTA 3317 Leu Leu Trp Leu Val Ser Gly Ser Thr His Arg Leu Leu 1080 1085 1090 AAAACCAAAT CTGCATAGTT AAACTCCAGA CCCTGCCAAA ACATGAGCCC TGCCCTCAAT 3377 TACAGTAACG TAGGGTCAGC TATAAAATCA GACAAACATT AGCTGGGCCT GTTCCATGGC 3437 ATAACACTAA GGCGCAGACT CCTAAGGCAC CCACTGGCTG CATGTCAGGG TGTCAGATCC 3497 TTAAACGTGT GTGAATGCTG CATCATCTAT GTGTAACATC AAAGCAAAAT CCTATACGTG 3557 TCCTCTATTG GAAAATTTGG GCGTTTGTTG TTGCATTGTT GGT 3600 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 323 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: CCCCCTGCCA GTGGCCAAAC AGAAGCAGAA GTCGGGTAAT GAAATGACTA ACTTAGCCTT 60 TGAACTAGAC CCCCTAGAGT TAGAGGAGGA AGAGGCTGAG CTTGGTGAGC AGAGTGGCTC 120 TGCCAAGACT AGTGTTAGCA GTGTCACCAC CCCGCCACCC CATGGCAAAC GCATCCCCTT 180 CTTTAAGAAG ACAGAGCATG TGCCCCCCTA TGACGTGGTG CCTTCCATGA GGCCCATCAT 240 CCTGGTGGGA CCGTCGCTCA AGGGCTACGA GGTTACAGAC ATGATGCAGA AAGCTTTATT 300 TGACTTCTTG AAGCATCGGT TTG 323 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO-.13: CCTATTGGTG TAGGTATACC AACAATTAAT TTAAGAAAAA GGAGACCCAA TATCCAG 57 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 180 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..132 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: TGG TCC TTT GCC TGC GCC TGT GCC GCC TTC ATC CTC CTC TTT CTC GGC 48 Trp Ser Phe Ala Cys Ala Cys Ala Ala Phe He Leu Leu Phe Leu Gly 1 5 10 15 GGT CTC GCC CTC CTG CTG TTC TCC CTG CCT CGA ATG CCC CGG AAC CCA 96 Gly Leu Ala Leu Leu Leu Phe Ser Leu Pro Arg Met Pro Arg Asn Pro 20 25 30 TGG GAG TCC TGC ATG GAT GCT GAG CCC GAG CAC TAACCCTCCT GCGGCCCTAG 149 Trp Glu Ser Cys Met Asp Ala Glu Pro Glu His 35 40 CGACCCTCAG GCTTCTTCCC AGGAAGCGGG G 180 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Other nucleic acid; (A) DESCRIPTION: Oligonucleotide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:15: AATTCGGTAC GTACACTCGA GC 22 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Other nucleic acid; (A) DESCRIPTION: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: GCTCGAGTGT ACGTACCG 18 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Other nucleic acid; (A) DESCRIPTION: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: CCATGGTACC TTCGTTGACG 20 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Other nucleic acid; (A) DESCRIPTION: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: AATTCGTCAA CGAAGGTACC ATGG 24 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2153 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 53..1504 (D) OTHER INFORMATION: /standard_name= "Beta-3-1" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: CCGCCTCGGA CCCCCTGTCC CGGGGGAGGG GGAGAGCCCG CTACCCTGGT CT ATG 55 Met 1 TCT TTT TCT GAC TCC AGT GCA ACC TTC CTG CTG AAC GAG GGT TCA GCC 103 Ser Phe Ser Asp Ser Ser Ala Thr Phe Leu Leu Asn Glu Gly Ser Ala 5 10 15 GAC TCC TAC ACC AGC CGC CCA TCT CTG GAC TCA GAC GTC TCC CTG GAG 151 Asp Ser Tyr Thr Ser Arg Pro Ser Leu Asp Ser Asp Val Ser Leu Glu 20 25 30 GAG GAC CGG GAG AGT GCC CGG CGT GAA GTA GAG AGC CAG GCT CAG CAG 199 Glu Asp Arg Glu Ser Ala Arg Arg Glu Val Glu Ser Gin Ala Gin Gin 35 40 45 CAG CTC GAA AGG GCC AAG CAC AAA CCT GTG GCA TTT GCG GTG AGG ACC 247 Gin Leu Glu Arg Ala Lys His Lys Pro Val Ala Phe Ala Val Arg Thr 50 55 60 65 AAT GTC AGC TAC TGT GGC GTA CTG GAT GAG GAG TGC CCA GTC CAG GGC 295 Asn Val Ser Tyr Cys Gly Val Leu Asp Glu Glu Cys Pro Val Gin Gly 70 75 80 TCT GGA GTC AAC TTT GAG GCC AAA GAT TTT CTG CAC ATT AAA GAG AAG 343 Ser Gly Val Asn Phe Glu Ala Lys Asp Phe Leu His He Lys Glu Lys 85 90 95 TAC AGC AAT GAC TGG TGG ATC GGG CGG CTA GTG AAA GAG GGC GGG GAC 391 Tyr Ser Asn Asp Trp Trp He Gly Arg Leu Val Lys Glu Gly Gly Asp 100 105 110 ATC GCC TTC ATC CCC AGC CCC CAG CGC CTG GAG AGC ATC CGG CTC AAA 439 He Ala Phe He Pro Ser Pro Gin Arg Leu Glu Ser He Arg Leu Lys 115 120 125 CAG GAG CAG AAG GCC AGG AGA TCT GGG AAC CCT TCC AGC CTG AGT GAC 487 Gin Glu Gin Lys Ala Arg Arg Ser Gly Asn Pro Ser Ser Leu Ser Asp 130 135 140 145 ATT GGC AAC CGA CGC TCC CCT CCG CCA TCT CTA GCC AAG CAG AAG CAA 535 He Gly Asn Arg Arg Ser Pro Pro Pro Ser Leu Ala Lys Gin Lys Gin 150 155 160 AAG CAG GCG GAA CAT GTT CCC CCG TAT GAC GTG GTG CCC TCC ATG CGG 583 Lys Gin Ala Glu His Val Pro Pro Tyr Asp Val Val Pro Ser Met Arg 165 170 175 CCT GTG GTG CTG GTG GGA CCC TCT CTG AAA GGT TAT GAG GTC ACA GAC 631 Pro Val Val Leu Val Gly Pro Ser Leu Lys Gly Tyr Glu Val Thr Asp 180 185 190 ATG ATG CAG AAG GCT CTC TTC GAC TTC CTC AAA CAC AGA TTT GAT GGC 679 Met Met Gin Lys Ala Leu Phe Asp Phe Leu Lys His Arg Phe Asp Gly 195 200 205 AGG ATC TCC ATC ACC CGA GTC ACA GCC GAC CTC TCC CTG GCA AAG CGA 727 Arg He Ser He Thr Arg Val Thr Ala Asp Leu Ser Leu Ala Lys Arg 210 215 220 225 TCT GTG CTC AAC AAT CCG GGC AAG AGG ACC ATC ATT GAG CGC TCC TCT 775 Ser Val Leu Asn Asn Pro Gly Lys Arg Thr He He Glu Arg Ser Ser 230 235 240 GCC CGC TCC AGC ATT GCG GAA GTG CAG AGT GAG ATC GAG CGC ATA TTT 823 Ala Arg Ser Ser He Ala Glu Val Gin Ser Glu He Glu Arg He Phe 245 250 255 GAG CTG GCC AAA TCC CTG CAG CTA GTA GTG TTG GAC GCT GAC ACC ATC 871 Glu Leu Ala Lys Ser Leu Gin Leu Val Val Leu Asp Ala Asp Thr He 260 265 270 AAC CAC CCA GCA CAG CTG GCC AAG ACC TCG CTG GCC CCC ATC ATC GTC 919 Asn His Pro Ala Gin Leu Ala Lys Thr Ser Leu Ala Pro He He Val 275 280 285 TTT GTC AAA GTG TCC TCA CCA AAG GTA CTC CAG CGT CTC ATT CGC TCC 967 Phe Val Lys Val Ser Ser Pro Lys Val Leu Gin Arg Leu He Arg Ser 290 295 300 305 CGG GGG AAG TCA CAG ATG AAG CAC CTG ACC GTA CAG ATG ATG GCA TAT 1015 Arg Gly Lys Ser Gin Met Lys His Leu Thr Val Gin Met Met Ala Tyr 310 315 320 GAT AAG CTG GTT CAG TGC CCA CCG GAG TCA TTT GAT GTG ATT CTG GAT 1063 Asp Lys Leu Val Gin Cys Pro Pro Glu Ser Phe Asp Val He Leu Asp 325 330 335 GAG AAC CAG CTG GAG GAT GCC TGT GAG CAC CTG GCT GAG TAC CTG GAG 1111 Glu Asn Gin Leu Glu Asp Ala Cys Glu His Leu Ala Glu Tyr Leu Glu 340 345 350 GTT TAC TGG CGG GCC ACG CAC CAC CCA GCC CCT GGC CCC GGA CTT CTG 1159 Val Tyr Trp Arg Ala Thr His His Pro Ala Pro Gly Pro Gly Leu Leu 355 360 365 GGT CCT CCC AGT GCC ATC CCC GGA CTT CAG AAC CAG CAG CTG CTG GGG 1207 Gly Pro Pro Ser Ala He Pro Gly Leu Gin Asn Gin Gin Leu Leu Gly 370 375 380 385 GAG CGT GGC GAG GAG CAC TCC CCC CTT GAG CGG GAC AGC TTG ATG CCC 1255 Glu Arg Gly Glu Glu His Ser Pro Leu Glu Arg Asp Ser Leu Met Pro 390 395 400 TCT GAT GAG GCC AGC GAG AGC TCC CGC CAA GCC TGG ACA GGA TCT TCA 1303 Ser Asp Glu Ala Ser Glu Ser Ser Arg Gin Ala Trp Thr Gly Ser Ser 405 410 415 CAG CGT AGC TCC CGC CAC CTG GAG GAG GAC TAT GCA GAT GCC TAC CAG 1351 Gin Arg Ser Ser Arg His Leu Glu Glu Asp Tyr Ala Asp Ala Tyr Gin 420 425 430 GAC CTG TAC CAG CCT CAC CGC CAA CAC ACC TCG GGG CTG CCT AGT GCT 1399 Asp Leu Tyr Gin Pro His Arg Gin His Thr Ser Gly Leu Pro Ser Ala 435 440 445 AAC GGG CAT GAC CCC CAA GAC CGG CTT CTA GCC CAG GAC TCA GAA CAC 1447 Asn Gly His Asp Pro Gin Asp Arg Leu Leu Ala Gin Asp Ser Glu His 450 455 460 465 AAC CAC AGT GAC CGG AAC TGG CAG CGC AAC CGG CCT TGG CCC AAG GAT 1495 Asn His Ser Asp Arg Asn Trp Gin Arg Asn Arg Pro Trp Pro Lys Asp 470 475 480 AGC TAC TGA CAG C CTCCTGCTGC CCTACCCTGG CAGGCACAGG 1543 Ser Tyr * CGCAGCTGGC TGGGGGGCCC ACTCCAGGCA GGGTGGCGTT AGACTGGCAT 1593 CAGGCTGGCA CTAGGCTCAG CCCCCAAAAC CCCCTGCCCA GCCCCAGCTT CAGGGCTGCC 1648 TGTGGTCCCA AGGTTCTGGG AGAAACAGGG GACCCCCTCA CCTCCTGGGC AGTGACCCCT 1708 ACTAGGCTCC CATTCCAGGT ACTAGCTGTG TGTTCTGCAC CCCTGGCACC TTCCTCTCCT 1768 CCCACACAGG AAGCTGCCCC ACTGGGCAGT GCCCTCAGGC CAGGATCCCC TTAGCAGGGT 1828 CCTTCCCACC AGACTCAGGG AAGGGATGCC CCATTAAAGT GACAAAAGGG TGGGTGTGGG 1888 CACCATGGCA TGAGGAAGAA ACAAGGTCCC TGAGCAGGCA CAAGTCCTGA CAGTCAAGGG 1948 ACTGCTTTGG CATCCAGGGC CTCCAGTCAC CTCACTGCCA TACATTAGAA ATGAGACAAT 2008 TCAAAGCCCC CCCAGGGTGG CACACCCATC TGTTGCTGGG GTGTGGCAGC CACATCCAAG 2068 ACTGGAGCAG CAGGCTGGCC ACGCTTGGGC CAGAGAGAGC TCACAGCTGA AGCTCTTGGA 2128 GGGAAGGGCT CTCCTCACCC AATCG 2153 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2144 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 51..1492 (D) OTHER INFORMATION: /product= "A Beta3 subunit of human calcium channel" (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: CGCCCCCGGC GCCGCTCGTT CCCCCGACCC GGACTCCCCC ATGTATGACG ACTCCTACGT 60 GCCCGGGTTT GAGGACTCGG AGGCGGTTTC AGCCGACTCC TACACCAGCC GCCCATCTCT 120 GGACTCAGAC GTCTCCCTGG AGGAGGACCG GGAGAGTGCC CGGCGTGAAG TAGAGAGCCA 180 GGCTCAGCAG CAGCTCGAAA GGGCCAAGCA CAAACCTGTG GCATTTGCGG TGAGGACCAA 240 TGTCAGCTAC TGTGGCGTAC TGGATGAGGA GTGCCCAGTC CAGGGCTCTG GAGTCAACTT 300 TGAGGCCAAA GATTTTCTGC ACATTAAAGA GAAGTACAGC AATGACTGGT GGATCGGGCG 360 GCTAGTGAAA GAGGGCGGGG ACATCGCCTT CATCCCCAGC CCCCAGCGCC TGGAGAGCAT 420 CCGGCTCAAA CAGGAGCAGA AGGCCAGGAG ATCTGGGAAC CCTTCCAGCC TGAGTGACAT 480 TGGCAACCGA CGCTCCCCTC CGCCATCTCT AGCCAAGCAG AAGCAAAAGC AGGCGGAACA 540 TGTTCCCCCG TATGACGTGG TGCCCTCCAT GCGGCCTGTG GTGCTGGTGG GACCCTCTCT 600 GAAAGGTTAT GAGGTCACAG ACATGATGCA GAAGGCTCTC TTCGACTTCC TCAAACACAG 660 ATTTGATGGC AGGATCTCCA TCACCCGAGT CACAGCCGAC CTCTCCCTGG CAAAGCGATC 720 TGTGCTCAAC AATCCGGGCA AGAGGACCAT CATTGAGCGC TCCTCTGCCC GCTCCAGCAT 780 TGCGGAAGTG CAGAGTGAGA TCGAGCGCAT ATTTGAGCTG GCCAAATCCC TGCAGCTAGT 840 AGTGTTGGAC GCTGACACCA TCAACCACCC AGCACAGCTG GCCAAGACCT CGCTGGCCCC 900 CATCATCGTC TTTGTCAAAG TGTCCTCACC AAAGGTACTC CAGCGTCTCA TTCGCTCCCG 960 GGGGAAGTCA CAGATGAAGC ACCTGACCGT ACAGATGATG GCATATGATA AGCTGGTTCA 1020 GTGCCCACCG GAGTCATTTG ATGTGATTCT GGATGAGAAC CAGCTGGAGG ATGCCTGTGA 1080 GCACCTGGCT GAGTACCTGG AGGTTTACTG GCGGGCCACG CACCACCCAG CCCCTGGCCC 1140 CGGACTTCTG GGTCCTCCCA GTGCCATCCC CGGACTTCAG AACCAGCAGC TGCTGGGGGA 1200 GCGTGGCGAG GAGCACTCCC CCCTTGAGCG GGACAGCTTG ATGCCCTCTG ATGAGGCCAG 1260 CGAGAGCTCC CGCCAAGCCT GGACAGGATC TTCACAGCGT AGCTCCCGCC ACCTGGAGGA 1320 GGACTATGCA GATGCCTACC AGGACCTGTA CCAGCCTCAC CGCCAACACA CCTCGGGGCT 1380 GCCTAGTGCT AACGGGCATG ACCCCCAAGA CCGGCTTCTA GCCCAGGACT CAGAACACAA 1440 CCACAGTGAC CGGAACTGGC AGCGCAACCG GCCTTGGCCC AAGGATAGCT ACTGACAGCC 1500 TCCTGCTGCC CTACCCTGGC AGGCACAGGC GCAGCTGGCT GGGGGGCCCA CTCCAGGCAG 1560 GGTGGCGTTA GACTGGCATC AGGCTGGCAC TAGGCTCAGC CCCCAAAACC CCCTGCCCAG 1620 CCCCAGCTTC AGGGCTGCCT GTGGTCCCAA GGTTCTGGGA GAAACAGGGG ACCCCCTCAC 1680 CTCCTGGGCA GTGACCCCTA CTAGGCTCCC ATTCCAGGTA CTAGCTGTGT GTTCTGCACC 1740 CCTGGCACCT TCCTCTCCTC CCACACAGGA AGCTGCCCCA CTGGGCAGTG CCCTCAGGCC 1800 AGGATCCCCT TAGCAGGGTC CTTCCCACCA GACTCAGGGA AGGGATGCCC CATTAAAGTG 1860 ACAAAAGGGT GGGTGTGGGC ACCATGGCAT GAGGAAGAAA CAAGGTCCCT GAGCAGGCAC 1920 AAGTCCTGAC AGTCAAGGGA CTGCTTTGGC ATCCAGGGCC TCCAGTCACC TCACTGCCAT 1980 ACATTAGAAA TGAGACAATT CAAAGCCCCC CCAGGGTGGC ACACCCATCT GTTGCTGGGG 2040 TGTGGCAGCC ACATCCAAGA CTGGAGCAGC AGGCTGGCCA CGCTTGGGCC AGAGAGAGCT 2100 CACAGCTGAA GCTCTTGGAG GGAAGGGCTC TCCTCACCCA ATCG 2144 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Other nucleic acid; (A) DESCRIPTION: Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: CTCAGTACCA TCTCTGATAC CAGCCCCA 28 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7808 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 237..7769 (D) OTHER INFORMATION: /standard_name= "Alpha-lA-1" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: GATGTCCCGA GCTGCTATCC CCGGCTCGGC CCGGGCAGCC GCCTTCTGAG CCCCCGACCC 60 GAGGCGCCGA GCCGCCGCCG CCCGATGGGC TGGGCCGTGG AGCGTCTCCG CAGTCGTAGC 120 TCCAGCCGCC GCGCTCCCAG CCCCGGCAGC CTCAGCATCA GCGGCGGCGG CGGCGGCGGC 180 GGCGTCTTCC GCATCGTTCG CCGCAGCGTA ACCCGGAGCC CTTTGCTCTT TGCAGA 236 ATG GCC CGC TTC GGA GAC GAG ATG CCG GCC CGC TAC GGG GGA GGA GGC 284 Met Ala Arg Phe Gly Asp Glu Met Pro Ala Arg Tyr Gly Gly Gly Gly 1 5 10 15 TCC GGG GCA GCC GCC GGG GTG GTC GTG GGC AGC GGA GGC GGG CGA GGA 332 Ser Gly Ala Ala Ala Gly Val Val Val Gly Ser Gly Gly Gly Arg Gly 20 25 30 GCC GGG GGC AGC CGG CAG GGC GGG CAG CCC GGG GCG CAA AGG ATG TAC 380 Ala Gly Gly Ser Arg Gin Gly Gly Gin Pro Gly Ala Gin Arg Met Tyr 35 40 45 AAG CAG TCA ATG GCG CAG AGA GCG CGG ACC ATG GCA CTC TAC AAC CCC 428 Lys Gin Ser Met Ala Gin Arg Ala Arg Thr Met Ala Leu Tyr Asn Pro 50 55 60 ATC CCC GTC CGA CAG AAC TGC CTC ACG GTT AAC CGG TCT CTC TTC CTC 476 He Pro Val Arg Gin Asn Cys Leu Thr Val Asn Arg Ser Leu Phe Leu 65 70 75 80 TTC AGC GAA GAC AAC GTG GTG AGA AAA TAC GCC AAA AAG ATC ACC GAA 524 Phe Ser Glu Asp Asn Val Val Arg Lys Tyr Ala Lys Lys He Thr Glu 85 90 95 TGG CCT CCC TTT GAA TAT ATG ATT TTA GCC ACC ATC ATA GCG AAT TGC 572 Trp Pro Pro Phe Glu Tyr Met He Leu Ala Thr He He Ala Asn Cys 100 105 110 ATC GTC CTC GCA CTG GAG CAG CAT CTG CCT GAT GAT GAC AAG ACC CCG 620 He Val Leu Ala Leu Glu Gin His Leu Pro Asp Asp Asp Lys Thr Pro 115 120 125 ATG TCT GAA CGG CTG GAT GAC ACA GAA CCA TAC TTC ATT GGA ATT TTT 668 Met Ser Glu Arg Leu Asp Asp Thr Glu Pro Tyr Phe He Gly He Phe 130 135 140 TGT TTC GAG GCT GGA ATT AAA ATC ATT GCC CTT GGG TTT GCC TTC CAC 716 Cys Phe Glu Ala Gly He Lys He He Ala Leu Gly Phe Ala Phe His 145 150 155 160 AAA GGC TCC TAC TTG AGG AAT GGC TGG AAT GTC ATG GAC TTT GTG GTG 764 Lys Gly Ser Tyr Leu Arg Asn Gly Trp Asn Val Met Asp Phe Val Val 165 170 175 GTG CTA ACG GGC ATC TTG GCG ACA GTT GGG ACG GAG TTT GAC CTA CGG 812 Val Leu Thr Gly He Leu Ala Thr Val Gly Thr Glu Phe Asp Leu Arg 180 185 190 ACG CTG AGG GCA GTT CGA GTG CTG CGG CCG CTC AAG CTG GTG TCT GGA 860 Thr Leu Arg Ala Val Arg Val Leu Arg Pro Leu Lys Leu Val Ser Gly 195 200 205 ATC CCA AGT TTA CAA GTC GTC CTG AAG TCG ATC ATG AAG GCG ATG ATC 908 He Pro Ser Leu Gin Val Val Leu Lys Ser He Met Lys Ala Met He 210 215 220 CCT TTG CTG CAG ATC GGC CTC CTC CTA TTT TTT GCA ATC CTT ATT TTT 956 Pro Leu Leu Gin He Gly Leu Leu Leu Phe Phe Ala He Leu He Phe 225 230 235 240 GCA ATC ATA GGG TTA GAA TTT TAT ATG GGA AAA TTT CAT ACC ACC TGC 1004 Ala He He Gly Leu Glu Phe Tyr Met Gly Lys Phe His Thr Thr Cys 245 250 255 TTT GAA GAG GGG ACA GAT GAC ATT CAG GGT GAG TCT CCG GCT CCA TGT 1052 Phe Glu Glu Gly Thr Asp Asp He Gin Gly Glu Ser Pro Ala Pro Cys 260 265 270 GGG ACA GAA GAG CCC GCC CGC ACC TGC CCC AAT GGG ACC AAA TGT CAG 1100 Gly Thr Glu Glu Pro Ala Arg Thr Cys Pro Asn Gly Thr Lys Cys Gin 275 280 285 CCC TAC TGG GAA GGG CCC AAC AAC GGG ATC ACT CAG TTC GAC AAC ATC 1148 Pro Tyr Trp Glu Gly Pro Asn Asn Gly He Thr Gin Phe Asp Asn He 290 295 300 CTG TTT GCA GTG CTG ACT GTT TTC CAG TGC ATA ACC ATG GAA GGG TGG 1196 Leu Phe Ala Val Leu Thr Val Phe Gin Cys He Thr Met Glu Gly Trp 305 310 315 320 ACT GAT CTC CTC TAC AAT AGC AAC GAT GCC TCA GGG AAC ACT TGG AAC 1244 Thr Asp Leu Leu Tyr Asn Ser Asn Asp Ala Ser Gly Asn Thr Trp Asn 325 330 335 TGG TTG TAC TTC ATC CCC CTC ATC ATC ATC GGC TCC TTT TTT ATG CTG 1292 Trp Leu Tyr Phe He Pro Leu He He He Gly Ser Phe Phe Met Leu 340 345 350 AAC CTT GTG CTG GGT GTG CTG TCA GGG GAG TTT GCC AAA GAA AGG GAA 1340 Asn Leu Val Leu Gly Val Leu Ser Gly Glu Phe Ala Lys Glu Arg Glu 355 360 365 CGG GTG GAG AAC CGG CGG GCT TTT CTG AAG CTG AGG CGG CAA CAA CAG 1388 Arg Val Glu Asn Arg Arg Ala Phe Leu Lys Leu Arg Arg Gin Gin Gin 370 375 380 ATT GAA CGT GAG CTC AAT GGG TAC ATG GAA TGG ATC TCA AAA GCA GAA 1436 He Glu Arg Glu Leu Asn Gly Tyr Met Glu Trp He Ser Lys Ala Glu 385 390 395 400 GAG GTG ATC CTC GCC GAG GAT GAA ACT GAC GGG GAG CAG AGG CAT CCC 1484 Glu Val He Leu Ala Glu Asp Glu Thr Asp Gly Glu Gin Arg His Pro 405 410 415 TTT GAT GGA GCT CTG CGG AGA ACC ACC ATA AAG AAA AGC AAG ACA GAT 1532 Phe Asp Gly Ala Leu Arg Arg Thr Thr He Lys Lys Ser Lys Thr Asp 420 425 430 TTG CTC AAC CCC GAA GAG GCT GAG GAT CAG CTG GCT GAT ATA GCC TCT 1580 Leu Leu Asn Pro Glu Glu Ala Glu Asp Gin Leu Ala Asp He Ala Ser 435 440 445 GTG GGT TCT CCC TTC GCC CGA GCC AGC ATT AAA AGT GCC AAG CTG GAG 1628 Val Gly Ser Pro Phe Ala Arg Ala Ser He Lys Ser Ala Lys Leu Glu 450 455 460 AAC TCG ACC TTT TTT CAC AAA AAG GAG AGG AGG ATG CGT TTC TAC ATC 1676 Asn Ser Thr Phe Phe His Lys Lys Glu Arg Arg Met Arg Phe Tyr He 465 470 475 480 CGC CGC ATG GTC AAA ACT CAG GCC TTC TAC TGG ACT GTA CTC AGT TTG 1724 Arg Arg Met Val Lys Thr Gin Ala Phe Tyr Trp Thr Val Leu Ser Leu 485 490 495 GTA GCT CTC AAC ACG CTG TGT GTT GCT ATT GTT CAC TAC AAC CAG CCC 1772 Val Ala Leu Asn Thr Leu Cys Val Ala He Val His Tyr Asn Gin Pro 500 505 510 GAG TGG CTC TCC GAC TTC CTT TAC TAT GCA GAA TTC ATT TTC TTA GGA 1820 Glu Trp Leu Ser Asp Phe Leu Tyr Tyr Ala Glu Phe He Phe Leu Gly 515 520 525 CTC TTT ATG TCC GAA ATG TTT ATA AAA ATG TAC GGG CTT GGG ACG CGG 1868 Leu Phe Met Ser Glu Met Phe He Lys Met Tyr Gly Leu Gly Thr Arg 530 535 540 CCT TAC TTC CAC TCT TCC TTC AAC TGC TTT GAC TGT GGG GTT ATC ATT 1916 Pro Tyr Phe His Ser Ser Phe Asn Cys Phe Asp Cys Gly Val He He 545 550 555 560 GGG AGC ATC TTC GAG GTC ATC TGG GCT GTC ATA AAA CCT GGC ACA TCC 1964 Gly Ser He Phe Glu Val He Trp Ala Val He Lys Pro Gly Thr Ser 565 570 575 TTT GGA ATC AGC GTG TTA CGA GCC CTC AGG TTA TTG CGT ATT TTC AAA 2012 Phe Gly He Ser Val Leu Arg Ala Leu Arg Leu Leu Arg He Phe Lys 580 585 590 GTC ACA AAG TAC TGG GCA TCT CTC AGA AAC CTG GTC GTC TCT CTC CTC 2060 Val Thr Lys Tyr Trp Ala Ser Leu Arg Asn Leu Val Val Ser Leu Leu 595 600 605 AAC TCC ATG AAG TCC ATC ATC AGC CTG TTG TTT CTC CTT TTC CTG TTC 2108 Asn Ser Met Lys Ser He He Ser Leu Leu Phe Leu Leu Phe Leu Phe 610 615 620 ATT GTC GTC TTC GCC CTT TTG GGA ATG CAA CTC TTC GGC GGC CAG TTT 2156 He Val Val Phe Ala Leu Leu Gly Met Gin Leu Phe Gly Gly Gin Phe 625 630 635 640 AAT TTC GAT GAA GGG ACT CCT CCC ACC AAC TTC GAT ACT TTT CCA GCA 2204 Asn Phe Asp Glu Gly Thr Pro Pro Thr Asn Phe Asp Thr Phe Pro Ala 645 650 655 GCA ATA ATG ACG GTG TTT CAG ATC CTG ACG GGC GAA GAC TGG AAC GAG 2252 Ala He Met Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp Asn Glu 660 665 670 GTC ATG TAC GAC GGG ATC AAG TCT CAG GGG GGC GTG CAG GGC GGC ATG 2300 Val Met Tyr Asp Gly He Lys Ser Gin Gly Gly Val Gin Gly Gly Met 675 680 685 GTG TTC TCC ATC TAT TTC ATT GTA CTG ACG CTC TTT GGG AAC TAC ACC 2348 Val Phe Ser He Tyr Phe He Val Leu Thr Leu Phe Gly Asn Tyr Thr 690 695 700 CTC CTG AAT GTG TTC TTG GCC ATC GCT GTG GAC AAT CTG GCC AAC GCC 2396 Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala Asn Ala 705 710 715 720 CAG GAG CTC ACC AAG GTG GAG GCG GAC GAG CAA GAG GAA GAA GAA GCA 2444 Gin Glu Leu Thr Lys Val Glu Ala Asp Glu Gin Glu Glu Glu Glu Ala 725 730 735 GCG AAC CAG AAA CTT GCC CTA CAG AAA GCC AAG GAG GTG GCA GAA GTG 2492 Ala Asn Gin Lys Leu Ala Leu Gin Lys Ala Lys Glu Val Ala Glu Val 740 745 750 AGT CCT CTG TCC GCG GCC AAC ATG TCT ATA GCT GTG AAA GAG CAA CAG 2540 Ser Pro Leu Ser Ala Ala Asn Met Ser He Ala Val Lys Glu Gin Gin 755 760 765 AAG AAT CAA AAG CCA GCC AAG TCC GTG TGG GAG CAG CGG ACC AGT GAG 2588 Lys Asn Gin Lys Pro Ala Lys Ser Val Trp Glu Gin Arg Thr Ser Glu 770 775 780 ATG CGA AAG CAG AAC TTG CTG GCC AGC CGG GAG GCC CTG TAT AAC GAA 2636 Met Arg Lys Gin Asn Leu Leu Ala Ser Arg Glu Ala Leu Tyr Asn Glu 785 790 795 800 ATG GAC CCG GAC GAG CGC TGG AAG GCT GCC TAC ACG CGG CAC CTG CGG 2684 Met Asp Pro Asp Glu Arg Trp Lys Ala Ala Tyr Thr Arg His Leu Arg 805 810 815 CCA GAC ATG AAG ACG CAC TTG GAC CGG CCG CTG GTG GTG GAC CCG CAG 2732 Pro Asp Met Lys Thr His Leu Asp Arg Pro Leu Val Val Asp Pro Gin 820 825 830 GAG AAC CGC AAC AAC AAC ACC AAC AAG AGC CGG GCG GCC GAG CCC ACC 2780 Glu Asn Arg Asn Asn Asn Thr Asn Lys Ser Arg Ala Ala Glu Pro Thr 835 840 845 GTG GAC CAG CGC CTC GGC CAG CAG CGC GCC GAG GAC TTC CTC AGG AAA 2828 Val Asp Gin Arg Leu Gly Gin Gin Arg Ala Glu Asp Phe Leu Arg Lys 850 855 860 CAG GCC CGC TAC CAC GAT CGG GCC CGG GAC CCC AGC GGC TCG GCG GGC 2876 Gin Ala Arg Tyr His Asp Arg Ala Arg Asp Pro Ser Gly Ser Ala Gly 865 870 875 880 CTG GAC GCA CGG AGG CCC TGG GCG GGA AGC CAG GAG GCC GAG CTG AGC 2924 Leu Asp Ala Arg Arg Pro Trp Ala Gly Ser Gin Glu Ala Glu Leu Ser 885 890 895 CGG GAG GGA CCC TAC GGC CGC GAG TCG GAC CAC CAC GCC CGG GAG GGC 2972 Arg Glu Gly Pro Tyr Gly Arg Glu Ser Asp His His Ala Arg Glu Gly 900 905 910 AGC CTG GAG CAA CCC GGG TTC TGG GAG GGC GAG GCC GAG CGA GGC AAG 3020 Ser Leu Glu Gin Pro Gly Phe Trp Glu Gly Glu Ala Glu Arg Gly Lys 915 920 925 GCC GGG GAC CCC CAC CGG AGG CAC GTG CAC CGG CAG GGG GGC AGC AGG 3068 Ala Gly Asp Pro His Arg Arg His Val His Arg Gin Gly Gly Ser Arg 930 935 940 GAG AGC CGC AGC GGG TCC CCG CGC ACG GGC GCG GAC GGG GAG CAT CGA 3116 Glu Ser Arg Ser Gly Ser Pro Arg Thr Gly Ala Asp Gly Glu His Arg 945 950 955 960 CGT CAT CGC GCG CAC CGC AGG CCC GGG GAG GAG GGT CCG GAG GAC AAG 3164 Arg His Arg Ala His Arg Arg Pro Gly Glu Glu Gly Pro Glu Asp Lys 965 970 975 GCG GAG CGG AGG GCG CGG CAC CGC GAG GGC AGC CGG CCG GCC CGG GGC 3212 Ala Glu Arg Arg Ala Arg His Arg Glu Gly Ser Arg Pro Ala Arg Gly 980 985 990 GGC GAG GGC GAG GGC GAG GGC CCC GAC GGG GGC GAG CGC AGG AGA AGG 3260 Gly Glu Gly Glu Gly Glu Gly Pro Asp Gly Gly Glu Arg Arg Arg Arg 995 1000 1005 CAC CGG CAT GGC GCT CCA GCC ACG TAC GAG GGG GAC GCG CGG AGG GAG 3308 His Arg His Gly Ala Pro Ala Thr Tyr Glu Gly Asp Ala Arg Arg Glu 1010 1015 1020 GAC AAG GAG CGG AGG CAT CGG AGG AGG AAA GAG AAC CAG GGC TCC GGG 3356 Asp Lys Glu Arg Arg His Arg Arg Arg Lys Glu Asn Gin Gly Ser Gly 1025 1030 1035 1040 GTC CCT GTG TCG GGC CCC AAC CTG TCA ACC ACC CGG CCA ATC CAG CAG 3404 Val Pro Val Ser Gly Pro Asn Leu Ser Thr Thr Arg Pro He Gin Gin 1045 1050 1055 GAC CTG GGC CGC CAA GAC CCA CCC CTG GCA GAG GAT ATT GAC AAC ATG 3452 Asp Leu Gly Arg Gin Asp Pro Pro Leu Ala Glu Asp He Asp Asn Met 1060 1065 1070 AAG AAC AAC AAG CTG GCC ACC GCG GAG TCG GCC GCT CCC CAC GGC AGC 3500 Lys Asn Asn Lys Leu Ala Thr Ala Glu Ser Ala Ala Pro His Gly Ser 1075 1080 1085 CTT GGC CAC GCC GGC CTG CCC CAG AGC CCA GCC AAG ATG GGA AAC AGC 3548 Leu Gly His Ala Gly Leu Pro Gin Ser Pro Ala Lys Met Gly Asn Ser 1090 1095 1100 ACC GAC CCC GGC CCC ATG CTG GCC ATC CCT GCC ATG GCC ACC AAC CCC 3596 Thr Asp Pro Gly Pro Met Leu Ala He Pro Ala Met Ala Thr Asn Pro 1105 1110 1115 1120 CAG AAC GCC GCC AGC CGC CGG ACG CCC AAC AAC CCG GGG AAC CCA TCC 3644 Gin Asn Ala Ala Ser Arg Arg Thr Pro Asn Asn Pro Gly Asn Pro Ser 1125 1130 1135 AAT CCC GGC CCC CCC AAG ACC CCC GAG AAT AGC CTT ATC GTC ACC AAC 3692 Asn Pro Gly Pro Pro Lys Thr Pro Glu Asn Ser Leu He Val Thr Asn 1140 1145 1150 CCC AGC GGC ACC CAG ACC AAT TCA GCT AAG ACT GCC AGG AAA CCC GAC 3740 Pro Ser Gly Thr Gin Thr Asn Ser Ala Lys Thr Ala Arg Lys Pro Asp 1155 1160 1165 CAC ACC ACA GTG GAC ATC CCC CCA GCC TGC CCA CCC CCC CTC AAC CAC 3788 His Thr Thr Val Asp He Pro Pro Ala Cys Pro Pro Pro Leu Asn His 1170 1175 1180 ACC GTC GTA CAA GTG AAC AAA AAC GCC AAC CCA GAC CCA CTG CCA AAA 3836 Thr Val Val Gin Val Asn Lys Asn Ala Asn Pro Asp Pro Leu Pro Lys 1185 1190 1195 1200 AAA GAG GAA GAG AAG AAG GAG GAG GAG GAA GAC GAC CGT GGG GAA GAC 3884 Lys Glu Glu Glu Lys Lys Glu Glu Glu Glu Asp Asp Arg Gly Glu Asp 1205 1210 1215 GGC CCT AAG CCA ATG CCT CCC TAT AGC TCC ATG TTC ATC CTG TCC ACG 3932 Gly Pro Lys Pro Met Pro Pro Tyr Ser Ser Met Phe He Leu Ser Thr 1220 1225 1230 ACC AAC CCC CTT CGC CGC CTG TGC CAT TAC ATC CTG AAC CTG CGC TAC 3980 Thr Asn Pro Leu Arg Arg Leu Cys His Tyr He Leu Asn Leu Arg Tyr 1235 1240 1245 TTT GAG ATG TGC ATC CTC ATG GTC ATT GCC ATG AGC AGC ATC GCC CTG 4028 Phe Glu Met Cys He Leu Met Val He Ala Met Ser Ser He Ala Leu 1250 1255 1260 GCC GCC GAG GAC CCT GTG CAG CCC AAC GCA CCT CGG AAC AAC GTG CTG 4076 Ala Ala Glu Asp Pro Val Gin Pro Asn Ala Pro Arg Asn Asn Val Leu 1265 1270 1275 1280 CGA TAC TTT GAC TAC GTT TTT ACA GGC GTC TTC ACC TTT GAG ATG GTG 4124 Arg Tyr Phe Asp Tyr Val Phe Thr Gly Val Phe Thr Phe Glu Met Val 1285 1290 1295 ATC AAG ATG ATT GAC CTG GGG CTC GTC CTG CAT CAG GGT GCC TAC TTC 4172 He Lys Met He Asp Leu Gly Leu Val Leu His Gin Gly Ala Tyr Phe 1300 1305 1310 CGT GAC CTC TGG AAT ATT CTC GAC TTC ATA GTG GTC AGT GGG GCC CTG 4220 Arg Asp Leu Trp Asn He Leu Asp Phe He Val Val Ser Gly Ala Leu 1315 1320 1325 GTA GCC TTT GCC TTC ACT GGC AAT AGC AAA GGA AAA GAC ATC AAC ACG 4268 Val Ala Phe Ala Phe Thr Gly Asn Ser Lys Gly Lys Asp He Asn Thr 1330 1335 1340 ATT AAA TCC CTC CGA GTC CTC CGG GTG CTA CGA CCT CTT AAA ACC ATC 4316 He Lys Ser Leu Arg Val Leu Arg Val Leu Arg Pro Leu Lys Thr He 1345 1350 1355 1360 AAG CGG CTG CCA AAG CTC AAG GCT GTG TTT GAC TGT GTG GTG AAC TCA 4364 Lys Arg Leu Pro Lys Leu Lys Ala Val Phe Asp Cys Val Val Asn Ser 1365 1370 1375 CTT AAA AAC GTC TTC AAC ATC CTC ATC GTC TAC ATG CTA TTC ATG TTC 4412 Leu Lys Asn Val Phe Asn He Leu He Val Tyr Met Leu Phe Met Phe 1380 1385 1390 ATC TTC GCC GTG GTG GCT GTG CAG CTC TTC AAG GGG AAA TTC TTC CAC 4460 He Phe Ala Val Val Ala Val Gin Leu Phe Lys Gly Lys Phe Phe His 1395 1400 1405 TGC ACT GAC GAG TCC AAA GAG TTT GAG AAA GAT TGT CGA GGC AAA TAC 4508 Cys Thr Asp Glu Ser Lys Glu Phe Glu Lys Asp Cys Arg Gly Lys Tyr 1410 1415 1420 CTC CTC TAC GAG AAG AAT GAG GTG AAG GCG CGA GAC CGG GAG TGG AAG 4556 Leu Leu Tyr Glu Lys Asn Glu Val Lys Ala Arg Asp Arg Glu Trp Lys 1425 1430 1435 1440 AAG TAT GAA TTC CAT TAC GAC AAT GTG CTG TGG GCT CTG CTG ACC CTC 4604 Lys Tyr Glu Phe His Tyr Asp Asn Val Leu Trp Ala Leu Leu Thr Leu 1445 1450 1455 TTC ACC GTG TCC ACG GGA GAA GGC TGG CCA CAG GTC CTC AAG CAT TCG 4652 Phe Thr Val Ser Thr Gly Glu Gly Trp Pro Gin Val Leu Lys His Ser 1460 1465 1470 GTG GAC GCC ACC TTT GAG AAC CAG GGC CCC AGC CCC GGG TAC CGC ATG 4700 Val Asp Ala Thr Phe Glu Asn Gin Gly Pro Ser Pro Gly Tyr Arg Met 1475 1480 1485 GAG ATG TCC ATT TTC TAC GTC GTC TAC TTT GTG GTG TTC CCC TTC TTC 4748 Glu Met Ser He Phe Tyr Val Val Tyr Phe Val Val Phe Pro Phe Phe 1490 1495 1500 TTT GTC AAT ATC TTT GTG GCC TTG ATC ATC ATC ACC TTC CAG GAG CAA 4796 Phe Val Asn He Phe Val Ala Leu He He He Thr Phe Gin Glu Gin 1505 1510 1515 1520 GGG GAC AAG ATG ATG GAG GAA TAC AGC CTG GAG AAA AAT GAG AGG GCC 4844 Gly Asp Lys Met Met Glu Glu Tyr Ser Leu Glu Lys Asn Glu Arg Ala 1525 1530 1535 TGC ATT GAT TTC GCC ATC AGC GCC AAG CCG CTG ACC CGA CAC ATG CCG 892 Cys He Asp Phe Ala He Ser Ala Lys Pro Leu Thr Arg His Met Pro 1540 1545 1550 CAG AAC AAG CAG AGC TTC CAG TAC CGC ATG TGG CAG TTC GTG GTG TCT 4940 Gin Asn Lys Gin Ser Phe Gin Tyr Arg Met Trp Gin Phe Val Val Ser 1555 1560 1565 CCG CCT TTC GAG TAC ACG ATC ATG GCC ATG ATC GCC CTC AAC ACC ATC 4988 Pro Pro Phe Glu Tyr Thr He Met Ala Met He Ala Leu Asn Thr He 1570 1575 1580 GTG CTT ATG ATG AAG TTC TAT GGG GCT TCT GTT GCT TAT GAA AAT GCC 5036 Val Leu Met Met Lys Phe Tyr Gly Ala Ser Val Ala Tyr Glu Asn Ala 1585 1590 1595 1600 CTG CGG GTG TTC AAC ATC GTC TTC ACC TCC CTC TTC TCT CTG GAA TGT 5084 Leu Arg Val Phe Asn He Val Phe Thr Ser Leu Phe Ser Leu Glu Cys 1605 1610 1615 GTG CTG AAA GTC ATG GCT TTT GGG ATT CTG AAT TAT TTC CGC GAT GCC 5132 Val Leu Lys Val Met Ala Phe Gly He Leu Asn Tyr Phe Arg Asp Ala 1620 1625 1630 TGG AAC ATC TTC GAC TTT GTG ACT GTT CTG GGC AGC ATC ACC GAT ATC 5180 Trp Asn He Phe Asp Phe Val Thr Val Leu Gly Ser He Thr Asp He 1635 1640 1645 CTC GTG ACT GAG TTT GGG AAT CCG AAT AAC TTC ATC AAC CTG AGC TTT 5228 Leu Val Thr Glu Phe Gly Asn Pro Asn Asn Phe He Asn Leu Ser Phe 1650 1655 1660 CTC CGC CTC TTC CGA GCT GCC CGG CTC ATC AAA CTT CTC CGT CAG GGT 5276 Leu Arg Leu Phe Arg Ala Ala Arg Leu He Lys Leu Leu Arg Gin Gly 1665 1670 1675 1680 TAC ACC ATC CGC ATT CTT CTC TGG ACC TTT GTG CAG TCC TTC AAG GCC 5324 Tyr Thr He Arg He Leu Leu Trp Thr Phe Val Gin Ser Phe Lys Ala 1685 1690 1695 CTG CCT TAT GTC TGT CTG CTG ATC GCC ATG CTC TTC TTC ATC TAT GCC 5372 Leu Pro Tyr Val Cys Leu Leu He Ala Met Leu Phe Phe He Tyr Ala 1700 1705 1710 ATC ATT GGG ATG CAG GTG TTT GGT AAC ATT GGC ATC GAC GTG GAG GAC 5420 He He Gly Met Gin Val Phe Gly Asn He Gly He Asp Val Glu Asp 1715 1720 1725 GAG GAC AGT GAT GAA GAT GAG TTC CAA ATC ACT GAG CAC AAT AAC TTC 5468 Glu Asp Ser Asp Glu Asp Glu Phe Gin He Thr Glu His Asn Asn Phe 1730 1735 1740 CGG ACC TTC TTC CAG GCC CTC ATG CTT CTC TTC CGG AGT GCC ACC GGG 5516 Arg Thr Phe Phe Gin Ala Leu Met Leu Leu Phe Arg Ser Ala Thr Gly 1745 1750 1755 1760 GAA GCT TGG CAC AAC ATC ATG CTT TCC TGC CTC AGC GGG AAA CCG TGT 5564 Glu Ala Trp His Asn He Met Leu Ser Cys Leu Ser Gly Lys Pro Cys 1765 1770 1775 GAT AAG AAC TCT GGC ATC CTG ACT CGA GAG TGT GGC AAT GAA TTT GCT 5612 Asp Lys Asn Ser Gly He Leu Thr Arg Glu Cys Gly Asn Glu Phe Ala 1780 1785 1790 TAT TTT TAC TTT GTT TCC TTC ATC TTC CTC TGC TCG TTT CTG ATG CTG 5660 Tyr Phe Tyr Phe Val Ser Phe He Phe Leu Cys Ser Phe Leu Met Leu 1795 1800 1805 AAT CTC TTT GTC GCC GTC ATC ATG GAC AAC TTT GAG TAC CTC ACC CGA 5708 Asn Leu Phe Val Ala Val He Met Asp Asn Phe Glu Tyr Leu Thr Arg 1810 1815 1820 GAC TCC TCC ATC CTG GGC CCC CAC CAC CTG GAT GAG TAC GTG CGT GTC 5756 Asp Ser Ser He Leu Gly Pro His His Leu Asp Glu Tyr Val Arg Val 1825 1830 1835 1840 TGG GCC GAG TAT GAC CCC GCA GCT TGG GGC CGC ATG CCT TAC CTG GAC 5804 Trp Ala Glu Tyr Asp Pro Ala Ala Trp Gly Arg Met Pro Tyr Leu Asp 1845 1850 1855 ATG TAT CAG ATG CTG AGA CAC ATG TCT CCG CCC CTG GGT CTG GGG AAG 5852 Met Tyr Gin Met Leu Arg His Met Ser Pro Pro Leu Gly Leu Gly Lys 1860 1865 1870 AAG TGT CCG GCC AGA GTG GCT TAC AAG CGG CTT CTG CGG ATG GAC CTG 5900 Lys Cys Pro Ala Arg Val Ala Tyr Lys Arg Leu Leu Arg Met Asp Leu 1875 1880 1885 CCC GTC GCA GAT GAC AAC ACC GTC CAC TTC AAT TCC ACC CTC ATG GCT 5948 Pro Val Ala Asp Asp Asn Thr Val His Phe Asn Ser Thr Leu Met Ala 1890 1895 1900 CTG ATC CGC ACA GCC CTG GAC ATC AAG ATT GCC AAG GGA GGA GCC GAC 5996 Leu He Arg Thr Ala Leu Asp He Lys He Ala Lys Gly Gly Ala Asp 1905 1910 1915 1920 AAA CAG CAG ATG GAC GCT GAG CTG CGG AAG GAG ATG ATG GCG ATT TGG 6044 Lys Gin Gin Met Asp Ala Glu Leu Arg Lys Glu Met Met Ala He Trp 1925 1930 1935 CCC AAT CTG TCC CAG AAG ACG CTA GAC CTG CTG GTC ACA CCT CAC AAG 6092 Pro Asn Leu Ser Gin Lys Thr Leu Asp Leu Leu Val Thr Pro His Lys 1940 1945 1950 TCC ACG GAC CTC ACC GTG GGG AAG ATC TAC GCA GCC ATG ATG ATC ATG 6140 Ser Thr Asp Leu Thr Val Gly Lys He Tyr Ala Ala Met Met He Met 1955 1960 1965 GAG TAC TAC CGG CAG AGC AAG GCC AAG AAG CTG CAG GCC ATG CGC GAG 6188 Glu Tyr Tyr Arg Gin Ser Lys Ala Lys Lys Leu Gin Ala Met Arg Glu 1970 1975 1980 GAG CAG GAC CGG ACA CCC CTC ATG TTC CAG CGC ATG GAG CCC CCG TCC 6236 Glu Gin Asp Arg Thr Pro Leu Met Phe Gin Arg Met Glu Pro Pro Ser 1985 1990 1995 2000 CCA ACG CAG GAA GGG GGA CCT GGC CAG AAC GCC CTC CCC TCC ACC CAG 6284 Pro Thr Gin Glu Gly Gly Pro Gly Gin Asn Ala Leu Pro Ser Thr Gin 2005 2010 2015 CTG GAC CCA GGA GGA GCC CTG ATG GCT CAC GAA AGC GGC CTC AAG GAG 6332 Leu Asp Pro Gly Gly Ala Leu Met Ala His Glu Ser Gly Leu Lys Glu 2020 2025 2030 AGC CCG TCC TGG GTG ACC CAG CGT GCC CAG GAG ATG TTC CAG AAG ACG 6380 Ser Pro Ser Trp Val Thr Gin Arg Ala Gin Glu Met Phe Gin Lys Thr 2035 2040 2045 GGC ACA TGG AGT CCG GAA CAA GGC CCC CCT ACC GAC ATG CCC AAC AGC 6428 Gly Thr Trp Ser Pro Glu Gin Gly Pro Pro Thr Asp Met Pro Asn Ser 2050 2055 2060 CAG CCT AAC TCT CAG TCC GTG GAG ATG CGA GAG ATG GGC AGA GAT GGC 6476 Gin Pro Asn Ser Gin Ser Val Glu Met Arg Glu Met Gly Arg Asp Gly 2065 2070 2075 2080 TAC TCC GAC AGC GAG CAC TAC CTC CCC ATG GAA GGC CAG GGC CGG GCT 6524 Tyr Ser Asp Ser Glu His Tyr Leu Pro Met Glu Gly Gin Gly Arg Ala 2085 2090 2095 GCC TCC ATG CCC CGC CTC CCT GCA GAG AAC CAG AGG AGA AGG GGC CGG 6572 Ala Ser Met Pro Arg Leu Pro Ala Glu Asn Gin Arg Arg Arg Gly Arg 2100 2105 2110 CCA CGT GGG AAT AAC CTC AGT ACC ATC TCA GAC ACC AGC CCC ATG AAG 6620 Pro Arg Gly Asn Asn Leu Ser Thr He Ser Asp Thr Ser Pro Met Lys 2115 2120 2125 CGT TCA GCC TCC GTG CTG GGC CCC AAG GCC CGA CGC CTG GAC GAT TAC 6668 Arg Ser Ala Ser Val Leu Gly Pro Lys Ala Arg Arg Leu Asp Asp Tyr 2130 2135 2140 TCG CTG GAG CGG GTC CCG CCC GAG GAG AAC CAG CGG CAC CAC CAG CGG 6716 Ser Leu Glu Arg Val Pro Pro Glu Glu Asn Gin Arg His His Gin Arg 2145 2150 2155 2160 CGC CGC GAC CGC AGC CAC CGC GCC TCT GAG CGC TCC CTG GGC CGC TAC 6764 Arg Arg Asp Arg Ser His Arg Ala Ser Glu Arg Ser Leu Gly Arg Tyr 2165 2170 2175 ACC GAT GTG GAC ACA GGC TTG GGG ACA GAC CTG AGC ATG ACC ACC CAA 6812 Thr Asp Val Asp Thr Gly Leu Gly Thr Asp Leu Ser Met Thr Thr Gin 2180 2185 2190 TCC GGG GAC CTG CCG TCG AAG GAG CGG GAC CAG GAG CGG GGC CGG CCC 6860 Ser Gly Asp Leu Pro Ser Lys Glu Arg Asp Gin Glu Arg Gly Arg Pro 2195 2200 2205 AAG GAT CGG AAG CAT CGA CAG CAC CAC CAC CAC CAC CAC CAC CAC CAC 6908 Lys Asp Arg Lys His Arg Gin His His His His His His His His His 2210 2215 2220 CAT CCC CCG CCC CCC GAC AAG GAC CGC TAT GCC CAG GAA CGG CCG GAC 6956 His Pro Pro Pro Pro Asp Lys Asp Arg Tyr Ala Gin Glu Arg Pro Asp 2225 2230 2235 2240 CAC GGC CGG GCA CGG GCT CGG GAC CAG CGC TGG TCC CGC TCG CCC AGC 7004 His Gly Arg Ala Arg Ala Arg Asp Gin Arg Trp Ser Arg Ser Pro Ser 2245 2250 2255 GAG GGC CGA GAG CAC ATG GCG CAC CGG CAG GGC AGT AGT TCC GTA AGT 7052 Glu Gly Arg Glu His Met Ala His Arg Gin Gly Ser Ser Ser Val Ser 2260 2265 2270 GGA AGC CCA GCC CCC TCA ACA TCT GGT ACC AGC ACT CCG CGG CGG GGC 7100 Gly Ser Pro Ala Pro Ser Thr Ser Gly Thr Ser Thr Pro Arg Arg Gly 2275 2280 2285 CGC CGC CAG CTC CCC CAG ACC CCC TCC ACC CCC CGG CCA CAC GTG TCC 7148 Arg Arg Gin Leu Pro Gin Thr Pro Ser Thr Pro Arg Pro His Val Ser 2290 2295 2300 TAT TCC CCT GTG ATC CGT AAG GCC GGC GGC TCG GGG CCC CCG CAG CAG 7196 Tyr Ser Pro Val He Arg Lys Ala Gly Gly Ser Gly Pro Pro Gin Gin 2305 2310 2315 2320 CAG CAG CAG CAG CAG CAG CAG CAG CAG GCG GTG GCC AGG CCG GGC CGG 7244 Gin Gin Gin Gin Gin Gin Gin Gin Gin Ala Val Ala Arg Pro Gly Arg 2325 2330 2335 GCG GCC ACC AGC GGC CCT CGG AGG TAC CCA GGC CCC ACG GCC GAG CCT 7292 Ala Ala Thr Ser Gly Pro Arg Arg Tyr Pro Gly Pro Thr Ala Glu Pro 2340 2345 2350 CTG GCC GGA GAT CGG CCG CCC ACG GGG GGC CAC AGC AGC GGC CGC TCG 7340 Leu Ala Gly Asp Arg Pro Pro Thr Gly Gly His Ser Ser Gly Arg Ser 2355 2360 2365 CCC AGG ATG GAG AGG CGG GTC CCA GGC CCG GCC CGG AGC GAG TCC CCC 7388 Pro Arg Met Glu Arg Arg Val Pro Gly Pro Ala Arg Ser Glu Ser Pro 2370 2375 2380 AGG GCC TGT CGA CAC GGC GGG GCC CGG TGG CCG GCA TCT GGC CCG CAC 7436 Arg Ala Cys Arg His Gly Gly Ala Arg Trp Pro Ala Ser Gly Pro His 2385 2390 2395 2400 GTG TCC GAG GGG CCC CCG GGT CCC CGG CAC CAT GGC TAC TAC CGG GGC 7484 Val Ser Glu Gly Pro Pro Gly Pro Arg His His Gly Tyr Tyr Arg Gly 2405 2410 2415 TCC GAC TAC GAC GAG GCC GAT GGC CCG GGC AGC GGG GGC GGC GAG GAG 7532 Ser Asp Tyr Asp Glu Ala Asp Gly Pro Gly Ser Gly Gly Gly Glu Glu 2420 2425 2430 GCC ATG GCC GGG GCC TAC GAC GCG CCA CCC CCC GTA CGA CAC GCG TCC 7580 Ala Met Ala Gly Ala Tyr Asp Ala Pro Pro Pro Val Arg His Ala Ser 2435 2440 2445 TCG GGC GCC ACC GGG CGC TCG CCC AGG ACT CCC CGG GCC TCG GGC CCG 7628 Ser Gly Ala Thr Gly Arg Ser Pro Arg Thr Pro Arg Ala Ser Gly Pro 2450 2455 2460 GCC TGC GCC TCG CCT TCT CGG CAC GGC CGG CGA CTC CCC AAC GGC TAC 7676 Ala Cys Ala Ser Pro Ser Arg His Gly Arg Arg Leu Pro Asn Gly Tyr 2465 2470 2475 2480 TAC CCG GCG CAC GGA CTG GCC AGG CCC CGC GGG CCG GGC TCC AGG AAG 7724 Tyr Pro Ala His Gly Leu Ala Arg Pro Arg Gly Pro Gly Ser Arg Lys 2485 2490 2495 GGC CTG CAC GAA CCC TAC AGC GAG AGT GAC GAT GAT TGG TGC TAAGCCCGGG 7776 Gly Leu His Glu Pro Tyr Ser Glu Ser Asp Asp Asp Trp Cys 2500 2505 2510 CGAGGTGGCG CCCGCCCGGC CCCCCACGCA CC 7808 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7791 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 237..7037 (D) OTHER INFORMATION: /standard_name= "Alpha-lA-2" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: GATGTCCCGA GCTGCTATCC CCGGCTCGGC CCGGGCAGCC GCCTTCTGAG CCCCCGACCC 60 GAGGCGCCGA GCCGCCGCCG CCCGATGGGC TGGGCCGTGG AGCGTCTCCG CAGTCGTAGC 120 TCCAGCCGCC GCGCTCCCAG CCCCGGCAGC CTCAGCATCA GCGGCGGCGG CGGCGGCGGC 180 GGCGTCTTCC GCATCGTTCG CCGCAGCGTA ACCCGGAGCC CTTTGCTCTT TGCAGA 236 ATG GCC CGC TTC GGA GAC GAG ATG CCG GCC CGC TAC GGG GGA GGA GGC 284 Met Ala Arg Phe Gly Asp Glu Met Pro Ala Arg Tyr Gly Gly Gly Gly 1 5 10 15 TCC GGG GCA GCC GCC GGG GTG GTC GTG GGC AGC GGA GGC GGG CGA GGA 332 Ser Gly Ala Ala Ala Gly Val Val Val Gly Ser Gly Gly Gly Arg Gly 20 25 30 GCC GGG GGC AGC CGG CAG GGC GGG CAG CCC GGG GCG CAA AGG ATG TAC 380 Ala Gly Gly Ser Arg Gin Gly Gly Gin Pro Gly Ala Gin Arg Met Tyr 35 40 45 AAG CAG TCA ATG GCG CAG AGA GCG CGG ACC ATG GCA CTC TAC AAC CCC 428 Lys Gin Ser Met Ala Gin Arg Ala Arg Thr Met Ala Leu Tyr Asn Pro 50 55 60 ATC CCC GTC CGA CAG AAC TGC CTC ACG GTT AAC CGG TCT CTC TTC CTC 476 He Pro Val Arg Gin Asn Cys Leu Thr Val Asn Arg Ser Leu Phe Leu 65 70 75 80 TTC AGC GAA GAC AAC GTG GTG AGA AAA TAC GCC AAA AAG ATC ACC GAA 524 Phe Ser Glu Asp Asn Val Val Arg Lys Tyr Ala Lys Lys He Thr Glu 85 90 95 TGG CCT CCC TTT GAA TAT ATG ATT TTA GCC ACC ATC ATA GCG AAT TGC 572 Trp Pro Pro Phe Glu Tyr Met He Leu Ala Thr He He Ala Asn Cys 100 105 110 ATC GTC CTC GCA CTG GAG CAG CAT CTG CCT GAT GAT GAC AAG ACC CCG 620 He Val Leu Ala Leu Glu Gin His Leu Pro Asp Asp Asp Lys Thr Pro 115 120 125 ATG TCT GAA CGG CTG GAT GAC ACA GAA CCA TAC TTC ATT GGA ATT TTT 668 Met Ser Glu Arg Leu Asp Asp Thr Glu Pro Tyr Phe He Gly He Phe 130 135 140 TGT TTC GAG GCT GGA ATT AAA ATC ATT GCC CTT GGG TTT GCC TTC CAC 716 Cys Phe Glu Ala Gly He Lys He He Ala Leu Gly Phe Ala Phe His 145 150 155 160 AAA GGC TCC TAC TTG AGG AAT GGC TGG AAT GTC ATG GAC TTT GTG GTG 764 Lys Gly Ser Tyr Leu Arg Asn Gly Trp Asn Val Met Asp Phe Val Val 165 170 175 GTG CTA ACG GGC ATC TTG GCG ACA GTT GGG ACG GAG TTT GAC CTA CGG 812 Val Leu Thr Gly He Leu Ala Thr Val Gly Thr Glu Phe Asp Leu Arg 180 185 190 ACG CTG AGG GCA GTT CGA GTG CTG CGG CCG CTC AAG CTG GTG TCT GGA 860 Thr Leu Arg Ala Val Arg Val Leu Arg Pro Leu Lys Leu Val Ser Gly 195 200 205 ATC CCA AGT TTA CAA GTC GTC CTG AAG TCG ATC ATG AAG GCG ATG ATC 908 He Pro Ser Leu Gin Val Val Leu Lys Ser He Met Lys Ala Met He 210 215 220 CCT TTG CTG CAG ATC GGC CTC CTC CTA TTT TTT GCA ATC CTT ATT TTT 956 Pro Leu Leu Gin He Gly Leu Leu Leu Phe Phe Ala He Leu He Phe 225 230 235 240 GCA ATC ATA GGG TTA GAA TTT TAT ATG GGA AAA TTT CAT ACC ACC TGC 1004 Ala He He Gly Leu Glu Phe Tyr Met Gly Lys Phe His Thr Thr Cys 245 250 255 TTT GAA GAG GGG ACA GAT GAC ATT CAG GGT GAG TCT CCG GCT CCA TGT 1052 Phe Glu Glu Gly Thr Asp Asp He Gin Gly Glu Ser Pro Ala Pro Cys 260 265 270 GGG ACA GAA GAG CCC GCC CGC ACC TGC CCC AAT GGG ACC AAA TGT CAG 1100 Gly Thr Glu Glu Pro Ala Arg Thr Cys Pro Asn Gly Thr Lys Cys Gin 275 280 285 CCC TAC TGG GAA GGG CCC AAC AAC GGG ATC ACT CAG TTC GAC AAC ATC 1148 Pro Tyr Trp Glu Gly Pro Asn Asn Gly He Thr Gin Phe Asp Asn He 290 295 300 CTG TTT GCA GTG CTG ACT GTT TTC CAG TGC ATA ACC ATG GAA GGG TGG 1196 Leu Phe Ala Val Leu Thr Val Phe Gin Cys He Thr Met Glu Gly Trp 305 310 315 320 ACT GAT CTC CTC TAC AAT AGC AAC GAT GCC TCA GGG AAC ACT TGG AAC 1244 Thr Asp Leu Leu Tyr Asn Ser Asn Asp Ala Ser Gly Asn Thr Trp Asn 325 330 335 TGG TTG TAC TTC ATC CCC CTC ATC ATC ATC GGC TCC TTT TTT ATG CTG 1292 Trp Leu Tyr Phe He Pro Leu He He He Gly Ser Phe Phe Met Leu 340 345 350 AAC CTT GTG CTG GGT GTG CTG TCA GGG GAG TTT GCC AAA GAA AGG GAA 1340 Asn Leu Val Leu Gly Val Leu Ser Gly Glu Phe Ala Lys Glu Arg Glu 355 360 365 CGG GTG GAG AAC CGG CGG GCT TTT CTG AAG CTG AGG CGG CAA CAA CAG 1388 Arg Val Glu Asn Arg Arg Ala Phe Leu Lys Leu Arg Arg Gin Gin Gin 370 375 380 ATT GAA CGT GAG CTC AAT GGG TAC ATG GAA TGG ATC TCA AAA GCA GAA 1436 He Glu Arg Glu Leu Asn Gly Tyr Met Glu Trp He Ser Lys Ala Glu 385 390 395 400 GAG GTG ATC CTC GCC GAG GAT GAA ACT GAC GGG GAG CAG AGG CAT CCC 1484 Glu Val He Leu Ala Glu Asp Glu Thr Asp Gly Glu Gin Arg His Pro 405 410 415 TTT GAT GGA GCT CTG CGG AGA ACC ACC ATA AAG AAA AGC AAG ACA GAT 1532 Phe Asp Gly Ala Leu Arg Arg Thr Thr He Lys Lys Ser Lys Thr Asp 420 425 430 TTG CTC AAC CCC GAA GAG GCT GAG GAT CAG CTG GCT GAT ATA GCC TCT 1580 Leu Leu Asn Pro Glu Glu Ala Glu Asp Gin Leu Ala Asp He Ala Ser 435 440 445 GTG GGT TCT CCC TTC GCC CGA GCC AGC ATT AAA AGT GCC AAG CTG GAG 1628 Val Gly Ser Pro Phe Ala Arg Ala Ser He Lys Ser Ala Lys Leu Glu 450 455 460 AAC TCG ACC TTT TTT CAC AAA AAG GAG AGG AGG ATG CGT TTC TAC ATC 1676 Asn Ser Thr Phe Phe His Lys Lys Glu Arg Arg Met Arg Phe Tyr He 465 470 475 480 CGC CGC ATG GTC AAA ACT CAG GCC TTC TAC TGG ACT GTA CTC AGT TTG 1724 Arg Arg Met Val Lys Thr Gin Ala Phe Tyr Trp Thr Val Leu Ser Leu 485 490 495 GTA GCT CTC AAC ACG CTG TGT GTT GCT ATT GTT CAC TAC AAC CAG CCC 1772 Val Ala Leu Asn Thr Leu Cys Val Ala He Val His Tyr Asn Gin Pro 500 505 510 GAG TGG CTC TCC GAC TTC CTT TAC TAT GCA GAA TTC ATT TTC TTA GGA 1820 Glu Trp Leu Ser Asp Phe Leu Tyr Tyr Ala Glu Phe He Phe Leu Gly 515 520 525 CTC TTT ATG TCC GAA ATG TTT ATA AAA ATG TAC GGG CTT GGG ACG CGG 1868 Leu Phe Met Ser Glu Met Phe He Lys Met Tyr Gly Leu Gly Thr Arg 530 535 540 CCT TAC TTC CAC TCT TCC TTC AAC TGC TTT GAC TGT GGG GTT ATC ATT 1916 Pro Tyr Phe His Ser Ser Phe Asn Cys Phe Asp Cys Gly Val He He 545 550 555 560 GGG AGC ATC TTC GAG GTC ATC TGG GCT GTC ATA AAA CCT GGC ACA TCC 1964 Gly Ser He Phe Glu Val He Trp Ala Val He Lys Pro Gly Thr Ser 565 570 575 TTT GGA ATC AGC GTG TTA CGA GCC CTC AGG TTA TTG CGT ATT TTC AAA 2012 Phe Gly He Ser Val Leu Arg Ala Leu Arg Leu Leu Arg He Phe Lys 580 585 590 GTC ACA AAG TAC TGG GCA TCT CTC AGA AAC CTG GTC GTC TCT CTC CTC 2060 Val Thr Lys Tyr Trp Ala Ser Leu Arg Asn Leu Val Val Ser Leu Leu 595 600 605 AAC TCC ATG AAG TCC ATC ATC AGC CTG TTG TTT CTC CTT TTC CTG TTC 2108 Asn Ser Met Lys Ser He He Ser Leu Leu Phe Leu Leu Phe Leu Phe 610 615 620 ATT GTC GTC TTC GCC CTT TTG GGA ATG CAA CTC TTC GGC GGC CAG TTT 2156 He Val Val Phe Ala Leu Leu Gly Met Gin Leu Phe Gly Gly Gin Phe 625 630 635 640 AAT TTC GAT GAA GGG ACT CCT CCC ACC AAC TTC GAT ACT TTT CCA GCA 2204 Asn Phe Asp Glu Gly Thr Pro Pro Thr Asn Phe Asp Thr Phe Pro Ala 645 650 655 GCA ATA ATG ACG GTG TTT CAG ATC CTG ACG GGC GAA GAC TGG AAC GAG 2252 Ala He Met Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp Asn Glu 660 665 670 GTC ATG TAC GAC GGG ATC AAG TCT CAG GGG GGC GTG CAG GGC GGC ATG 2300 Val Met Tyr Asp Gly He Lys Ser Gin Gly Gly Val Gin Gly Gly Met 675 680 685 GTG TTC TCC ATC TAT TTC ATT GTA CTG ACG CTC TTT GGG AAC TAC ACC 2348 Val Phe Ser He Tyr Phe He Val Leu Thr Leu Phe Gly Asn Tyr Thr 690 695 700 CTC CTG AAT GTG TTC TTG GCC ATC GCT GTG GAC AAT CTG GCC AAC GCC 2396 Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala Asn Ala 705 710 715 720 CAG GAG CTC ACC AAG GTG GAG GCG GAC GAG CAA GAG GAA GAA GAA GCA 2444 Gin Glu Leu Thr Lys Val Glu Ala Asp Glu Gin Glu Glu Glu Glu Ala 725 730 735 GCG AAC CAG AAA CTT GCC CTA CAG AAA GCC AAG GAG GTG GCA GAA GTG 2492 Ala Asn Gin Lys Leu Ala Leu Gin Lys Ala Lys Glu Val Ala Glu Val 740 745 750 AGT CCT CTG TCC GCG GCC AAC ATG TCT ATA GCT GTG AAA GAG CAA CAG 2540 Ser Pro Leu Ser Ala Ala Asn Met Ser He Ala Val Lys Glu Gin Gin 755 760 765 AAG AAT CAA AAG CCA GCC AAG TCC GTG TGG GAG CAG CGG ACC AGT GAG 2588 Lys Asn Gin Lys Pro Ala Lys Ser Val Trp Glu Gin Arg Thr Ser Glu 770 775 780 ATG CGA AAG CAG AAC TTG CTG GCC AGC CGG GAG GCC CTG TAT AAC GAA 2636 Met Arg Lys Gin Asn Leu Leu Ala Ser Arg Glu Ala Leu Tyr Asn Glu 785 790 795 800 ATG GAC CCG GAC GAG CGC TGG AAG GCT GCC TAC ACG CGG CAC CTG CGG 2684 Met Asp Pro Asp Glu Arg Trp Lys Ala Ala Tyr Thr Arg His Leu Arg 805 810 815 CCA GAC ATG AAG ACG CAC TTG GAC CGG CCG CTG GTG GTG GAC CCG CAG 2732 Pro Asp Met Lys Thr His Leu Asp Arg Pro Leu Val Val Asp Pro Gin 820 825 830 GAG AAC CGC AAC AAC AAC ACC AAC AAG AGC CGG GCG GCC GAG CCC ACC 2780 Glu Asn Arg Asn Asn Asn Thr Asn Lys Ser Arg Ala Ala Glu Pro Thr 835 840 845 GTG GAC CAG CGC CTC GGC CAG CAG CGC GCC GAG GAC TTC CTC AGG AAA 2828 Val Asp Gin Arg Leu Gly Gin Gin Arg Ala Glu Asp Phe Leu Arg Lys 850 855 860 CAG GCC CGC TAC CAC GAT CGG GCC CGG GAC CCC AGC GGC TCG GCG GGC 2876 Gin Ala Arg Tyr His Asp Arg Ala Arg Asp Pro Ser Gly Ser Ala Gly 865 870 875 880 CTG GAC GCA CGG AGG CCC TGG GCG GGA AGC CAG GAG GCC GAG CTG AGC 2924 Leu Asp Ala Arg Arg Pro Trp Ala Gly Ser Gin Glu Ala Glu Leu Ser 885 890 895 CGG GAG GGA CCC TAC GGC CGC GAG TCG GAC CAC CAC GCC CGG GAG GGC 2972 Arg Glu Gly Pro Tyr Gly Arg Glu Ser Asp His His Ala Arg Glu Gly 900 905 910 AGC CTG GAG CAA CCC GGG TTC TGG GAG GGC GAG GCC GAG CGA GGC AAG 3020 Ser Leu Glu Gin Pro Gly Phe Trp Glu Gly Glu Ala Glu Arg Gly Lys 915 920 925 GCC GGG GAC CCC CAC CGG AGG CAC GTG CAC CGG CAG GGG GGC AGC AGG 3068 Ala Gly Asp Pro His Arg Arg His Val His Arg Gin Gly Gly Ser Arg 930 935 940 GAG AGC CGC AGC GGG TCC CCG CGC ACG GGC GCG GAC GGG GAG CAT CGA 3116 Glu Ser Arg Ser Gly Ser Pro Arg Thr Gly Ala Asp Gly Glu His Arg 945 950 955 960 CGT CAT CGC GCG CAC CGC AGG CCC GGG GAG GAG GGT CCG GAG GAC AAG 3164 Arg His Arg Ala His Arg Arg Pro Gly Glu Glu Gly Pro Glu Asp Lys 965 970 975 GCG GAG CGG AGG GCG CGG CAC CGC GAG GGC AGC CGG CCG GCC CGG GGC 3212 Ala Glu Arg Arg Ala Arg His Arg Glu Gly Ser Arg Pro Ala Arg Gly 980 985 990 GGC GAG GGC GAG GGC GAG GGC CCC GAC GGG GGC GAG CGC AGG AGA AGG 3260 Gly Glu Gly Glu Gly Glu Gly Pro Asp Gly Gly Glu Arg Arg Arg Arg 995 1000 1005 CAC CGG CAT GGC GCT CCA GCC ACG TAC GAG GGG GAC GCG CGG AGG GAG 3308 His Arg His Gly Ala Pro Ala Thr Tyr Glu Gly Asp Ala Arg Arg Glu 1010 1015 1020 GAC AAG GAG CGG AGG CAT CGG AGG AGG AAA GAG AAC CAG GGC TCC GGG 3356 Asp Lys Glu Arg Arg His Arg Arg Arg Lys Glu Asn Gin Gly Ser Gly 1025 1030 1035 1040 GTC CCT GTG TCG GGC CCC AAC CTG TCA ACC ACC CGG CCA ATC CAG CAG 3404 Val Pro Val Ser Gly Pro Asn Leu Ser Thr Thr Arg Pro He Gin Gin 1045 1050 1055 GAC CTG GGC CGC CAA GAC CCA CCC CTG GCA GAG GAT ATT GAC AAC ATG 3452 Asp Leu Gly Arg Gin Asp Pro Pro Leu Ala Glu Asp He Asp Asn Met 1060 1065 1070 AAG AAC AAC AAG CTG GCC ACC GCG GAG TCG GCC GCT CCC CAC GGC AGC 3500 Lys Asn Asn Lys Leu Ala Thr Ala Glu Ser Ala Ala Pro His Gly Ser 1075 1080 1085 CTT GGC CAC GCC GGC CTG CCC CAG AGC CCA GCC AAG ATG GGA AAC AGC 3548 Leu Gly His Ala Gly Leu Pro Gin Ser Pro Ala Lys Met Gly Asn Ser 1090 1095 1100 ACC GAC CCC GGC CCC ATG CTG GCC ATC CCT GCC ATG GCC ACC AAC CCC 3596 Thr Asp Pro Gly Pro Met Leu Ala He Pro Ala Met Ala Thr Asn Pro 1105 1110 1115 1120 CAG AAC GCC GCC AGC CGC CGG ACG CCC AAC AAC CCG GGG AAC CCA TCC 3644 Gin Asn Ala Ala Ser Arg Arg Thr Pro Asn Asn Pro Gly Asn Pro Ser 1125 1130 1135 AAT CCC GGC CCC CCC AAG ACC CCC GAG AAT AGC CTT ATC GTC ACC AAC 3692 Asn Pro Gly Pro Pro Lys Thr Pro Glu Asn Ser Leu He Val Thr Asn 1140 1145 1150 CCC AGC GGC ACC CAG ACC AAT TCA GCT AAG ACT GCC AGG AAA CCC GAC 3740 Pro Ser Gly Thr Gin Thr Asn Ser Ala Lys Thr Ala Arg Lys Pro Asp 1155 1160 1165 CAC ACC ACA GTG GAC ATC CCC CCA GCC TGC CCA CCC CCC CTC AAC CAC 3788 His Thr Thr Val Asp He Pro Pro Ala Cys Pro Pro Pro Leu Asn His 1170 1175 1180 ACC GTC GTA CAA GTG AAC AAA AAC GCC AAC CCA GAC CCA CTG CCA AAA 3836 Thr Val Val Gin Val Asn Lys Asn Ala Asn Pro Asp Pro Leu Pro Lys 1185 1190 1195 1200 AAA GAG GAA GAG AAG AAG GAG GAG GAG GAA GAC GAC CGT GGG GAA GAC 3884 Lys Glu Glu Glu Lys Lys Glu Glu Glu Glu Asp Asp Arg Gly Glu Asp 1205 1210 1215 GGC CCT AAG CCA ATG CCT CCC TAT AGC TCC ATG TTC ATC CTG TCC ACG 3932 Gly Pro Lys Pro Met Pro Pro Tyr Ser Ser Met Phe He Leu Ser Thr 1220 1225 1230 ACC AAC CCC CTT CGC CGC CTG TGC CAT TAC ATC CTG AAC CTG CGC TAC 3980 Thr Asn Pro Leu Arg Arg Leu Cys His Tyr He Leu Asn Leu Arg Tyr 1235 1240 1245 TTT GAG ATG TGC ATC CTC ATG GTC ATT GCC ATG AGC AGC ATC GCC CTG 4028 Phe Glu Met Cys He Leu Met Val He Ala Met Ser Ser He Ala Leu 1250 1255 1260 GCC GCC GAG GAC CCT GTG CAG CCC AAC GCA CCT CGG AAC AAC GTG CTG 4076 Ala Ala Glu Asp Pro Val Gin Pro Asn Ala Pro Arg Asn Asn Val Leu 1265 1270 1275 1280 CGA TAC TTT GAC TAC GTT TTT ACA GGC GTC TTC ACC TTT GAG ATG GTG 4124 Arg Tyr Phe Asp Tyr Val Phe Thr Gly Val Phe Thr Phe Glu Met Val 1285 1290 1295 ATC AAG ATG ATT GAC CTG GGG CTC GTC CTG CAT CAG GGT GCC TAC TTC 4172 He Lys Met He Asp Leu Gly Leu Val Leu His Gin Gly Ala Tyr Phe 1300 1305 1310 CGT GAC CTC TGG AAT ATT CTC GAC TTC ATA GTG GTC AGT GGG GCC CTG 4220 Arg Asp Leu Trp Asn He Leu Asp Phe He Val Val Ser Gly Ala Leu 1315 1320 1325 GTA GCC TTT GCC TTC ACT GGC AAT AGC AAA GGA AAA GAC ATC AAC ACG 4268 Val Ala Phe Ala Phe Thr Gly Asn Ser Lys Gly Lys Asp He Asn Thr 1330 1335 1340 ATT AAA TCC CTC CGA GTC CTC CGG GTG CTA CGA CCT CTT AAA ACC ATC 4316 He Lys Ser Leu Arg Val Leu Arg Val Leu Arg Pro Leu Lys Thr He 1345 1350 1355 1360 AAG CGG CTG CCA AAG CTC AAG GCT GTG TTT GAC TGT GTG GTG AAC TCA 4364 Lys Arg Leu Pro Lys Leu Lys Ala Val Phe Asp Cys Val Val Asn Ser 1365 1370 1375 CTT AAA AAC GTC TTC AAC ATC CTC ATC GTC TAC ATG CTA TTC ATG TTC 4412 Leu Lys Asn Val Phe Asn He Leu He Val Tyr Met Leu Phe Met Phe 1380 1385 1390 ATC TTC GCC GTG GTG GCT GTG CAG CTC TTC AAG GGG AAA TTC TTC CAC 4460 He Phe Ala Val Val Ala Val Gin Leu Phe Lys Gly Lys Phe Phe His 1395 1400 1405 TGC ACT GAC GAG TCC AAA GAG TTT GAG AAA GAT TGT CGA GGC AAA TAC 4508 Cys Thr Asp Glu Ser Lys Glu Phe Glu Lys Asp Cys Arg Gly Lys Tyr 1410 1415 1420 CTC CTC TAC GAG AAG AAT GAG GTG AAG GCG CGA GAC CGG GAG TGG AAG 4556 Leu Leu Tyr Glu Lys Asn Glu Val Lys Ala Arg Asp Arg Glu Trp Lys 1425 1430 1435 1440 AAG TAT GAA TTC CAT TAC GAC AAT GTG CTG TGG GCT CTG CTG ACC CTC 4604 Lys Tyr Glu Phe His Tyr Asp Asn Val Leu Trp Ala Leu Leu Thr Leu 1445 1450 1455 TTC ACC GTG TCC ACG GGA GAA GGC TGG CCA CAG GTC CTC AAG CAT TCG 4652 Phe Thr Val Ser Thr Gly Glu Gly Trp Pro Gin Val Leu Lys His Ser 1460 1465 1470 GTG GAC GCC ACC TTT GAG AAC CAG GGC CCC AGC CCC GGG TAC CGC ATG 4700 Val Asp Ala Thr Phe Glu Asn Gin Gly Pro Ser Pro Gly Tyr Arg Met 1475 1480 1485 GAG ATG TCC ATT TTC TAC GTC GTC TAC TTT GTG GTG TTC CCC TTC TTC 4748 Glu Met Ser He Phe Tyr Val Val Tyr Phe Val Val Phe Pro Phe Phe 1490 1495 1500 TTT GTC AAT ATC TTT GTG GCC TTG ATC ATC ATC ACC TTC CAG GAG CAA 4796 Phe Val Asn He Phe Val Ala Leu He He He Thr Phe Gin Glu Gin 1505 1510 1515 1520 GGG GAC AAG ATG ATG GAG GAA TAC AGC CTG GAG AAA AAT GAG AGG GCC 4844 Gly Asp Lys Met Met Glu Glu Tyr Ser Leu Glu Lys Asn Glu Arg Ala 1525 1530 1535 TGC ATT GAT TTC GCC ATC AGC GCC AAG CCG CTG ACC CGA CAC ATG CCG 4892 Cys He Asp Phe Ala He Ser Ala Lys Pro Leu Thr Arg His Met Pro 1540 1545 1550 CAG AAC AAG CAG AGC TTC CAG TAC CGC ATG TGG CAG TTC GTG GTG TCT 4940 Gin Asn Lys Gin Ser Phe Gin Tyr Arg Met Trp Gin Phe Val Val Ser 1555 1560 1565 CCG CCT TTC GAG TAC ACG ATC ATG GCC ATG ATC GCC CTC AAC ACC ATC 4988 Pro Pro Phe Glu Tyr Thr He Met Ala Met He Ala Leu Asn Thr He 1570 1575 1580 GTG CTT ATG ATG AAG TTC TAT GGG GCT TCT GTT GCT TAT GAA AAT GCC 5036 Val Leu Met Met Lys Phe Tyr Gly Ala Ser Val Ala Tyr Glu Asn Ala 1585 1590 1595 1600 CTG CGG GTG TTC AAC ATC GTC TTC ACC TCC CTC TTC TCT CTG GAA TGT 5084 Leu Arg Val Phe Asn He Val Phe Thr Ser Leu Phe Ser Leu Glu Cys 1605 1610 1615 GTG CTG AAA GTC ATG GCT TTT GGG ATT CTG AAT TAT TTC CGC GAT GCC 5132 Val Leu Lys Val Met Ala Phe Gly He Leu Asn Tyr Phe Arg Asp Ala 1620 1625 1630 TGG AAC ATC TTC GAC TTT GTG ACT GTT CTG GGC AGC ATC ACC GAT ATC 5180 Trp Asn He Phe Asp Phe Val Thr Val Leu Gly Ser He Thr Asp He 1635 1640 1645 CTC GTG ACT GAG TTT GGG AAT CCG AAT AAC TTC ATC AAC CTG AGC TTT 5228 Leu Val Thr Glu Phe Gly Asn Pro Asn Asn Phe He Asn Leu Ser Phe 1650 1655 1660 CTC CGC CTC TTC CGA GCT GCC CGG CTC ATC AAA CTT CTC CGT CAG GGT 5276 Leu Arg Leu Phe Arg Ala Ala Arg Leu He Lys Leu Leu Arg Gin Gly 1665 1670 1675 1680 TAC ACC ATC CGC ATT CTT CTC TGG ACC TTT GTG CAG TCC TTC AAG GCC 5324 Tyr Thr He Arg He Leu Leu Trp Thr Phe Val Gin Ser Phe Lys Ala 1685 1690 1695 CTG CCT TAT GTC TGT CTG CTG ATC GCC ATG CTC TTC TTC ATC TAT GCC 5372 Leu Pro Tyr Val Cys Leu Leu He Ala Met Leu Phe Phe He Tyr Ala 1700 1705 1710 ATC ATT GGG ATG CAG GTG TTT GGT AAC ATT GGC ATC GAC GTG GAG GAC 5420 He He Gly Met Gin Val Phe Gly Asn He Gly He Asp Val Glu Asp 1715 1720 1725 GAG GAC AGT GAT GAA GAT GAG TTC CAA ATC ACT GAG CAC AAT AAC TTC 5468 Glu Asp Ser Asp Glu Asp Glu Phe Gin He Thr Glu His Asn Asn Phe 1730 1735 1740 CGG ACC TTC TTC CAG GCC CTC ATG CTT CTC TTC CGG AGT GCC ACC GGG 5516 Arg Thr Phe Phe Gin Ala Leu Met Leu Leu Phe Arg Ser Ala Thr Gly 1745 1750 1755 1760 GAA GCT TGG CAC AAC ATC ATG CTT TCC TGC CTC AGC GGG AAA CCG TGT 5564 Glu Ala Trp His Asn He Met Leu Ser Cys Leu Ser Gly Lys Pro Cys 1765 1770 1775 GAT AAG AAC TCT GGC ATC CTG ACT CGA GAG TGT GGC AAT GAA TTT GCT 5612 Asp Lys Asn Ser Gly He Leu Thr Arg Glu Cys Gly Asn Glu Phe Ala 1780 1785 1790 TAT TTT TAC TTT GTT TCC TTC ATC TTC CTC TGC TCG TTT CTG ATG CTG 5660 Tyr Phe Tyr Phe Val Ser Phe He Phe Leu Cys Ser Phe Leu Met Leu 1795 1800 1805 AAT CTC TTT GTC GCC GTC ATC ATG GAC AAC TTT GAG TAC CTC ACC CGA 5708 Asn Leu Phe Val Ala Val He Met Asp Asn Phe Glu Tyr Leu Thr Arg 1810 1815 1820 GAC TCC TCC ATC CTG GGC CCC CAC CAC CTG GAT GAG TAC GTG CGT GTC 5756 Asp Ser Ser He Leu Gly Pro His His Leu Asp Glu Tyr Val Arg Val 1825 1830 1835 1840 TGG GCC GAG TAT GAC CCC GCA GCT TGG GGC CGC ATG CCT TAC CTG GAC 5804 Trp Ala Glu Tyr Asp Pro Ala Ala Trp Gly Arg Met Pro Tyr Leu Asp 1845 1850 1855 ATG TAT CAG ATG CTG AGA CAC ATG TCT CCG CCC CTG GGT CTG GGG AAG 5852 Met Tyr Gin Met Leu Arg His Met Ser Pro Pro Leu Gly Leu Gly Lys 1860 1865 1870 AAG TGT CCG GCC AGA GTG GCT TAC AAG CGG CTT CTG CGG ATG GAC CTG 5900 Lys Cys Pro Ala Arg Val Ala Tyr Lys Arg Leu Leu Arg Met Asp Leu 1875 1880 1885 CCC GTC GCA GAT GAC AAC ACC GTC CAC TTC AAT TCC ACC CTC ATG GCT 5948 Pro Val Ala Asp Asp Asn Thr Val His Phe Asn Ser Thr Leu Met Ala 1890 1895 1900 CTG ATC CGC ACA GCC CTG GAC ATC AAG ATT GCC AAG GGA GGA GCC GAC 5996 Leu He Arg Thr Ala Leu Asp He Lys He Ala Lys Gly Gly Ala Asp 1905 1910 1915 1920 AAA CAG CAG ATG GAC GCT GAG CTG CGG AAG GAG ATG ATG GCG ATT TGG 6044 Lys Gin Gin Met Asp Ala Glu Leu Arg Lys Glu Met Met Ala He Trp 1925 1930 1935 CCC AAT CTG TCC CAG AAG ACG CTA GAC CTG CTG GTC ACA CCT CAC AAG 6092 Pro Asn Leu Ser Gin Lys Thr Leu Asp Leu Leu Val Thr Pro His Lys 1940 1945 1950 TCC ACG GAC CTC ACC GTG GGG AAG ATC TAC GCA GCC ATG ATG ATC ATG 6140 Ser Thr Asp Leu Thr Val Gly Lys He Tyr Ala Ala Met Met He Met 1955 1960 1965 GAG TAC TAC CGG CAG AGC AAG GCC AAG AAG CTG CAG GCC ATG CGC GAG 6188 Glu Tyr Tyr Arg Gin Ser Lys Ala Lys Lys Leu Gin Ala Met Arg Glu 1970 1975 1980 GAG CAG GAC CGG ACA CCC CTC ATG TTC CAG CGC ATG GAG CCC CCG TCC 6236 Glu Gin Asp Arg Thr Pro Leu Met Phe Gin Arg Met Glu Pro Pro Ser 1985 1990 1995 2000 CCA ACG CAG GAA GGG GGA CCT GGC CAG AAC GCC CTC CCC TCC ACC CAG 6284 Pro Thr Gin Glu Gly Gly Pro Gly Gin Asn Ala Leu Pro Ser Thr Gin 2005 2010 2015 CTG GAC CCA GGA GGA GCC CTG ATG GCT CAC GAA AGC GGC CTC AAG GAG 6332 Leu Asp Pro Gly Gly Ala Leu Met Ala His Glu Ser Gly Leu Lys Glu 2020 2025 2030 AGC CCG TCC TGG GTG ACC CAG CGT GCC CAG GAG ATG TTC CAG AAG ACG 6380 Ser Pro Ser Trp Val Thr Gin Arg Ala Gin Glu Met Phe Gin Lys Thr 2035 2040 2045 GGC ACA TGG AGT CCG GAA CAA GGC CCC CCT ACC GAC ATG CCC AAC AGC 6428 Gly Thr Trp Ser Pro Glu Gin Gly Pro Pro Thr Asp Met Pro Asn Ser 2050 2055 2060 CAG CCT AAC TCT CAG TCC GTG GAG ATG CGA GAG ATG GGC AGA GAT GGC 6476 Gin Pro Asn Ser Gin Ser Val Glu Met Arg Glu Met Gly Arg Asp Gly 2065 2070 2075 2080 TAC TCC GAC AGC GAG CAC TAC CTC CCC ATG GAA GGC CAG GGC CGG GCT 6524 Tyr Ser Asp Ser Glu His Tyr Leu Pro Met Glu Gly Gin Gly Arg Ala 2085 2090 2095 GCC TCC ATG CCC CGC CTC CCT GCA GAG AAC CAG AGG AGA AGG GGC CGG 6572 Ala Ser Met Pro Arg Leu Pro Ala Glu Asn Gin Arg Arg Arg Gly Arg 2100 2105 2110 CCA CGT GGG AAT AAC CTC AGT ACC ATC TCA GAC ACC AGC CCC ATG AAG 6620 Pro Arg Gly Asn Asn Leu Ser Thr He Ser Asp Thr Ser Pro Met Lys 2115 2120 2125 CGT TCA GCC TCC GTG CTG GGC CCC AAG GCC CGA CGC CTG GAC GAT TAC 6668 Arg Ser Ala Ser Val Leu Gly Pro Lys Ala Arg Arg Leu Asp Asp Tyr 2130 2135 2140 TCG CTG GAG CGG GTC CCG CCC GAG GAG AAC CAG CGG CAC CAC CAG CGG 6716 Ser Leu Glu Arg Val Pro Pro Glu Glu Asn Gin Arg His His Gin Arg 2145 2150 2155 2160 CGC CGC GAC CGC AGC CAC CGC GCC TCT GAG CGC TCC CTG GGC CGC TAC 6764 Arg Arg Asp Arg Ser His Arg Ala Ser Glu Arg Ser Leu Gly Arg Tyr 2165 2170 2175 ACC GAT GTG GAC ACA GGC TTG GGG ACA GAC CTG AGC ATG ACC ACC CAA 6812 Thr Asp Val Asp Thr Gly Leu Gly Thr Asp Leu Ser Met Thr Thr Gin 2180 2185 2190 TCC GGG GAC CTG CCG TCG AAG GAG CGG GAC CAG GAG CGG GGC CGG CCC 6860 Ser Gly Asp Leu Pro Ser Lys Glu Arg Asp Gin Glu Arg Gly Arg Pro 2195 2200 2205 AAG GAT CGG AAG CAT CGA CAG CAC CAC CAC CAC CAC CAC CAC CAC CAC 6908 Lys Asp Arg Lys His Arg Gin His His His His His His His His His 2210 2215 2220 CAT CCC CCG CCC CCC GAC AAG GAC CGC TAT GCC CAG GAA CGG CCG GAC 6956 His Pro Pro Pro Pro Asp Lys Asp Arg Tyr Ala Gin Glu Arg Pro Asp 2225 2230 2235 2240 CAC GGC CGG GCA CGG GCT CGG GAC CAG CGC TGG TCC CGC TCG CCC AGC 7004 His Gly Arg Ala Arg Ala Arg Asp Gin Arg Trp Ser Arg Ser Pro Ser 2245 2250 2255 GAG GGC CGA GAG CAC ATG GCG CAC CGG CAG TAGTTCCGTA AGTGGAAGCC 7054 Glu Gly Arg Glu His Met Ala His Arg Gin 2260 2265 CAGCCCCCTC AACATCTGGT ACCAGCACTC CGCGGCGGGG CCGCCGCCAG CTCCCCCAGA 7114 CCCCCTCCAC CCCCCGGCCA CACGTGTCCT ATTCCCCTGT GATCCGTAAG GCCGGCGGCT 7174 CGGGGCCCCC GCAGCAGCAG CAGCAGCAGC AGGCGGTGGC CAGGCCGGGC CGGGCGGCCA 7234 CCAGCGGCCC TCGGAGGTAC CCAGGCCCCA CGGCCGAGCC TCTGGCCGGA GATCGGCCGC 7294 CCACGGGGGG CCACAGCAGC GGCCGCTCGC CCAGGATGGA GAGGCGGGTC CCAGGCCCGG 7354 CCCGGAGCGA GTCCCCCAGG GCCTGTCGAC ACGGCGGGGC CCGGTGGCCG GCATCTGGCC 7414 CGCACGTGTC CGAGGGGCCC CCGGGTCCCC GGCACCATGG CTACTACCGG GGCTCCGACT 7474 ACGACGAGGC CGATGGCCCG GGCAGCGGGG GCGGCGAGGA GGCCATGGCC GGGGCCTACG 7534 ACGCGCCACC CCCCGTACGA CACGCGTCCT CGGGCGCCAC CGGGCGCTCG CCCAGGACTC 7594 CCCGGGCCTC GGGCCCGGCC TGCGCCTCGC CTTCTCGGCA CGGCCGGCGA CTCCCCAACG 7654 GCTACTACCC GGCGCACGGA CTGGCCAGGC CCCGCGGGCC GGGCTCCAGG AAGGGCCTGC 7714 ACGAACCCTA CAGCGAGAGT GACGATGATT GGTGCTAAGC CCGGGCGAGG TGGCGCCCGC 7774 CCGGCCCCCC ACGCACC 7791 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7032 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 166..6921 (D) OTHER INFORMATION: /standard_name= "Alpha-IE-1" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: GCTGCTGCTG CCTCTCCGAA GAGCTCGCGG AGCTCCCCAG AGGCGGTGGT CCCCGTGCTT 60 GTCTGGATGC GGCTCTGAGT CTCCGTGTGT CTTTCTGCTT GTTGCTGTGT GCGGGTGTTC 120 GGCCGCGATC ACCTTTGTGT GTCTTCTGTC TGTTTAAACC TCAGG ATG GCT CGC 174 Met Ala Arg 1 TTC GGG GAG GCG GTG GTC GCC AGG CCA GGG TCC GGC GAT GGA GAC TCG 222 Phe Gly Glu Ala Val Val Ala Arg Pro Gly Ser Gly Asp Gly Asp Ser 5 10 15 GAC CAG AGC AGG AAC CGG CAA GGA ACC CCC GTG CCG GCC TCG GGG CAG 270 Asp Gin Ser Arg Asn Arg Gin Gly Thr Pro Val Pro Ala Ser Gly Gin 20 25 30 35 GCG GCC GCC TAC AAG CAG ACG AAA GCA CAG AGG GCG CGG ACT ATG GCT 318 Ala Ala Ala Tyr Lys Gin Thr Lys Ala Gin Arg Ala Arg Thr Met Ala 40 45 50 TTG TAC AAC CCC ATT CCC GTC CGG CAG AAC TGT TTC ACC GTC AAC AGA 366 Leu Tyr Asn Pro He Pro Val Arg Gin Asn Cys Phe Thr Val Asn Arg 55 60 65 TCC CTG TTC ATC TTC GGA GAA GAT AAC ATT GTC AGG AAA TAT GCC AAG 414 Ser Leu Phe He Phe Gly Glu Asp Asn He Val Arg Lys Tyr Ala Lys 70 75 80 AAG CTC ATC GAT TGG CCG CCA TTT GAG TAC ATG ATC CTG GCC ACC ATC 462 Lys Leu He Asp Trp Pro Pro Phe Glu Tyr Met He Leu Ala Thr He 85 90 95 ATT GCC AAC TGC ATC GTC CTG GCC CTG GAG CAG CAT CTT CCT GAG GAT 510 He Ala Asn Cys He Val Leu Ala Leu Glu Gin His Leu Pro Glu Asp 100 105 110 115 GAC AAG ACC CCC ATG TCC CGA AGA CTG GAG AAG ACA GAA CCT TAT TTC 558 Asp Lys Thr Pro Met Ser Arg Arg Leu Glu Lys Thr Glu Pro Tyr Phe 120 125 130 ATT GGG ATC TTT TGC TTT GAA GCT GGG ATC AAA ATT GTG GCC CTG GGG 606 He Gly He Phe Cys Phe Glu Ala Gly He Lys He Val Ala Leu Gly 135 140 145 TTC ATC TTC CAT AAG GGC TCT TAC CTC CGC AAT GGC TGG AAT GTC ATG 654 Phe He Phe His Lys Gly Ser Tyr Leu Arg Asn Gly Trp Asn Val Met 150 155 160 GAC TTC ATC GTG GTC CTC AGT GGC ATC CTG GCC ACT GCA GGA ACC CAC 702 Asp Phe He Val Val Leu Ser Gly He Leu Ala Thr Ala Gly Thr His 165 170 175 TTC AAT ACT CAC GTG GAC CTG AGG ACC CTC CGG GCT GTG CGT GTC CTG 750 Phe Asn Thr His Val Asp Leu Arg Thr Leu Arg Ala Val Arg Val Leu 180 185 190 195 CGG CCT TTG AAG CTC GTG TCA GGG ATA CCT AGC CTG CAG ATT GTG TTG 798 Arg Pro Leu Lys Leu Val Ser Gly He Pro Ser Leu Gin He Val Leu 200 205 210 AAG TCC ATC ATG AAG GCC ATG GTA CCT CTT CTG CAG ATT GGC CTT CTG 846 Lys Ser He Met Lys Ala Met Val Pro Leu Leu Gin He Gly Leu Leu 215 220 225 CTC TTC TTT GCC ATC CTG ATG TTT GCT ATC ATT GGT TTG GAG TTC TAC 894 Leu Phe Phe Ala He Leu Met Phe Ala He He Gly Leu Glu Phe Tyr 230 235 240 AGT GGC AAG TTA CAT CGA GCG TGC TTC ATG AAC AAT TCA GGT ATT CTA 942 Ser Gly Lys Leu His Arg Ala Cys Phe Met Asn Asn Ser Gly He Leu 245 250 255 GAA GGA TTT GAC CCC CCT CAC CCA TGT GGT GTG CAG GGC TGC CCA GCT 990 Glu Gly Phe Asp Pro Pro His Pro Cys Gly Val Gin Gly Cys Pro Ala 260 265 270 275 GGT TAT GAA TGC AAG GAC TGG ATC GGC CCC AAT GAT GGG ATC ACC CAG 1038 Gly Tyr Glu Cys Lys Asp Trp He Gly Pro Asn Asp Gly He Thr Gin 280 285 290 TTT GAT AAC ATC CTT TTT GCT GTG CTG ACT GTC TTC CAG TGC ATC ACC 1086 Phe Asp Asn He Leu Phe Ala Val Leu Thr Val Phe Gin Cys He Thr 295 300 305 ATG GAA GGG TGG ACC ACT GTG CTG TAC AAT ACC AAT GAT GCC TTA GGA 1134 Met Glu Gly Trp Thr Thr Val Leu Tyr Asn Thr Asn Asp Ala Leu Gly 310 315 320 GCC ACC TGG AAT TGG CTG TAC TTC ATC CCC CTC ATC ATC ATT GGA TCC 1182 Ala Thr Trp Asn Trp Leu Tyr Phe He Pro Leu He He He Gly Ser 325 330 335 TTC TTT GTT CTC AAC CTA GTC CTG GGA GTG CTT TCC GGG GAA TTT GCC 1230 Phe Phe Val Leu Asn Leu Val Leu Gly Val Leu Ser Gly Glu Phe Ala 340 345 350 355 AAA GAG AGA GAG AGA GTG GAG AAC CGA AGG GCT TTC ATG AAG CTG CGG 1278 Lys Glu Arg Glu Arg Val Glu Asn Arg Arg Ala Phe Met Lys Leu Arg 360 365 370 CGC CAG CAG CAG ATT GAG CGT GAG CTG AAT GGC TAC CGT GCC TGG ATA 1326 Arg Gin Gin Gin He Glu Arg Glu Leu Asn Gly Tyr Arg Ala Trp He 375 380 385 GAC AAA GCA GAG GAA GTC ATG CTC GCT GAA GAA AAT AAA AAT GCT GGA 1374 Asp Lys Ala Glu Glu Val Met Leu Ala Glu Glu Asn Lys Asn Ala Gly 390 395 400 ACA TCC GCC TTA GAA GTG CTT CGA AGG GCA ACC ATC AAG AGG AGC CGG 1422 Thr Ser Ala Leu Glu Val Leu Arg Arg Ala Thr He Lys Arg Ser Arg 405 410 415 ACA GAG GCC ATG ACT CGA GAC TCC AGT GAT GAG CAC TGT GTT GAT ATC 1470 Thr Glu Ala Met Thr Arg Asp Ser Ser Asp Glu His Cys Val Asp He 420 425 430 435 TCC TCT GTG GGC ACA CCT CTG GCC CGA GCC AGT ATC AAA AGT GCA AAG 1518 Ser Ser Val Gly Thr Pro Leu Ala Arg Ala Ser He Lys Ser Ala Lys 440 445 450 GTA GAC GGG GTC TCT TAT TTC CGG CAC AAG GAA AGG CTT CTG CGC ATC 1566 Val Asp Gly Val Ser Tyr Phe Arg His Lys Glu Arg Leu Leu Arg He 455 460 465 TCC ATT CGC CAC ATG GTT AAA TCC CAG GTG TTT TAC TGG ATT GTG CTG 1614 Ser He Arg His Met Val Lys Ser Gin Val Phe Tyr Trp He Val Leu 470 475 480 AGC CTT GTG GCA CTC AAC ACT GCC TGT GTG GCC ATT GTC CAT CAC AAC 1662 Ser Leu Val Ala Leu Asn Thr Ala Cys Val Ala He Val His His Asn 485 490 495 CAG CCC CAG TGG CTC ACC CAC CTC CTC TAC TAT GCA GAA TTT CTG TTT 1710 Gin Pro Gin Trp Leu Thr His Leu Leu Tyr Tyr Ala Glu Phe Leu Phe 500 505 510 515 CTG GGA CTC TTC CTC TTG GAG ATG TCC CTG AAG ATG TAT GGC ATG GGG 1758 Leu Gly Leu Phe Leu Leu Glu Met Ser Leu Lys Met Tyr Gly Met Gly 520 525 530 CCT CGC CTT TAT TTT CAC TCT TCA TTC AAC TGC TTT GAT TTT GGG GTC 1806 Pro Arg Leu Tyr Phe His Ser Ser Phe Asn Cys Phe Asp Phe Gly Val 535 540 545 ACA GTG GGC AGT ATC TTT GAA GTG GTC TGG GCA ATC TTC AGA CCT GGT 1854 Thr Val Gly Ser He Phe Glu Val Val Trp Ala He Phe Arg Pro Gly 550 555 560 ACG TCT TTT GGA ATC AGT GTC TTG CGA GCC CTC CGG CTT CTA AGA ATA 1902 Thr Ser Phe Gly He Ser Val Leu Arg Ala Leu Arg Leu Leu Arg He 565 570 575 TTT AAA ATA ACC AAG TAT TGG GCT TCC CTA CGG AAT TTG GTG GTC TCC 1950 Phe Lys He Thr Lys Tyr Trp Ala Ser Leu Arg Asn Leu Val Val Ser 580 585 590 595 TTG ATG AGC TCA ATG AAG TCT ATC ATC AGT TTG CTT TTC CTC CTC TTC 1998 Leu Met Ser Ser Met Lys Ser He He Ser Leu Leu Phe Leu Leu Phe 600 605 610 CTC TTC ATC GTT GTC TTT GCT CTC CTA GGA ATG CAG TTA TTT GGA GGC 2046 Leu Phe He Val Val Phe Ala Leu Leu Gly Met Gin Leu Phe Gly Gly 615 620 625 AGG TTT AAC TTT AAT GAT GGG ACT CCT TCG GCA AAT TTT GAT ACC TTC 2094 Arg Phe Asn Phe Asn Asp Gly Thr Pro Ser Ala Asn Phe Asp Thr Phe 630 635 640 CCT GCA GCC ATC ATG ACT GTG TTC CAG ATC CTG ACG GGT GAG GAC TGG 2142 Pro Ala Ala He Met Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp 645 650 655 AAT GAG GTG ATG TAC AAT GGG ATC CGC TCC CAG GGT GGG GTC AGC TCA 2190 Asn Glu Val Met Tyr Asn Gly He Arg Ser Gin Gly Gly Val Ser Ser 660 665 670 675 GGC ATG TGG TCT GCC ATC TAC TTC ATT GTG CTC ACC TTG TTT GGC AAC 2238 Gly Met Trp Ser Ala He Tyr Phe He Val Leu Thr Leu Phe Gly Asn 680 685 690 TAC ACG CTA CTG AAT GTG TTC TTG GCT ATC GCT GTG GAT AAT CTC GCC 2286 Tyr Thr Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala 695 700 705 AAC GCC CAG GAA CTG ACC AAG GAT GAA CAG GAG GAA GAA GAG GCC TTC 2334 Asn Ala Gin Glu Leu Thr Lys Asp Glu Gin Glu Glu Glu Glu Ala Phe 710 715 720 AAC CAG AAA CAT GCA CTG CAG AAG GCC AAG GAG GTC AGC CCG ATG TCT 2382 Asn Gin Lys His Ala Leu Gin Lys Ala Lys Glu Val Ser Pro Met Ser 725 730 735 GCA CCC AAC ATG CCT TCG ATC GAG AGG GAG CGG AGG CGC CGG CAC CAC 2430 Ala Pro Asn Met Pro Ser He Glu Arg Glu Arg Arg Arg Arg His His 740 745 750 755 ATG TCC GTG TGG GAG CAG CGT ACC AGC CAG CTG AGG AAG CAC ATG CAG 2478 Met Ser Val Trp Glu Gin Arg Thr Ser Gin Leu Arg Lys His Met Gin 760 765 770 ATG TCC AGC CAG GAG GCC CTC AAC AGA GAG GAG GCG CCG ACC ATG AAC 2526 Met Ser Ser Gin Glu Ala Leu Asn Arg Glu Glu Ala Pro Thr Met Asn 775 780 785 CCG CTC AAC CCC CTC AAC CCG CTC AGC TCC CTC AAC CCG CTC AAT GCC 2574 Pro Leu Asn Pro Leu Asn Pro Leu Ser Ser Leu Asn Pro Leu Asn Ala 790 795 800 CAC CCC AGC CTT TAT CGG CGA CCC AGG GCC ATT GAG GGC CTG GCC CTG 2622 His Pro Ser Leu Tyr Arg Arg Pro Arg Ala He Glu Gly Leu Ala Leu 805 810 815 GGC CTG GCC CTG GAG AAG TTC GAG GAG GAG CGC ATC AGC CGT GGG GGG 2670 Gly Leu Ala Leu Glu Lys Phe Glu Glu Glu Arg He Ser Arg Gly Gly 820 825 830 835 TCC CTC AAG GGG GAT GGA GGG GAC CGA TCC AGT GCC CTG GAC AAC CAG 2718 Ser Leu Lys Gly Asp Gly Gly Asp Arg Ser Ser Ala Leu Asp Asn Gin 840 845 850 AGG ACC CCT TTG TCC CTG GGC CAG CGG GAG CCA CCA TGG CTG GCC AGG 2766 Arg Thr Pro Leu Ser Leu Gly Gin Arg Glu Pro Pro Trp Leu Ala Arg 855 860 865 CCC TGT CAT GGA AAC TGT GAC CCG ACT CAG CAG GAG GCA GGG GGA GGA 2814 Pro Cys His Gly Asn Cys Asp Pro Thr Gin Gin Glu Ala Gly Gly Gly 870 875 880 GAG GCT GTG GTG ACC TTT GAG GAC CGG GCC AGG CAC AGG CAG AGC CAA 2862 Glu Ala Val Val Thr Phe Glu Asp Arg Ala Arg His Arg Gin Ser Gin 885 890 895 CGG CGC AGC CGG CAT CGC CGC GTC AGG ACA GAA GGC AAG GAG TCC TCT 2910 Arg Arg Ser Arg His Arg Arg Val Arg Thr Glu Gly Lys Glu Ser Ser 900 905 910 915 TCA GCC TCC CGG AGC AGG TCT GCC AGC CAG GAA CGC AGT CTG GAT GAA 2958 Ser Ala Ser Arg Ser Arg Ser Ala Ser Gin Glu Arg Ser Leu Asp Glu 920 925 930 GCC ATG CCC ACT GAA GGG GAG AAG GAC CAT GAG CTC AGG GGC AAC CAT 3006 Ala Met Pro Thr Glu Gly Glu Lys Asp His Glu Leu Arg Gly Asn His 935 940 945 GGT GCC AAG GAG CCA ACG ATC CAA GAA GAG AGA GCC CAG GAT TTA AGG 3054 Gly Ala Lys Glu Pro Thr He Gin Glu Glu Arg Ala Gin Asp Leu Arg 950 955 960 AGG ACC AAC AGT CTG ATG GTG TCC AGA GGC TCC GGG CTG GCA GGA GGC 3102 Arg Thr Asn Ser Leu Met Val Ser Arg Gly Ser Gly Leu Ala Gly Gly 965 970 975 CTT GAT GAG GCT GAC ACC CCC CTA GTC CTG CCC CAT CCT GAG CTG GAA 3150 Leu Asp Glu Ala Asp Thr Pro Leu Val Leu Pro His Pro Glu Leu Glu 980 985 990 995 GTG GGG AAG CAC GTG GTG CTG ACG GAG CAG GAG CCA GAA GGC AGC AGT 3198 Val Gly Lys His Val Val Leu Thr Glu Gin Glu Pro Glu Gly Ser Ser 1000 1005 1010 GAG CAG GCC CTG CTG GGG AAT GTG CAG CTA GAC ATG GGC CGG GTC ATC 3246 Glu Gin Ala Leu Leu Gly Asn Val Gin Leu Asp Met Gly Arg Val He 1015 1020 1025 AGC CAG AGC GAG CCT GAC CTC TCC TGC ATC ACG GCC AAC ACG GAC AAG 3294 Ser Gin Ser Glu Pro Asp Leu Ser Cys He Thr Ala Asn Thr Asp Lys 1030 1035 1040 GCC ACC ACC GAG AGC ACC AGC GTC ACC GTC GCC ATC CCC GAC GTG GAC 3342 Ala Thr Thr Glu Ser Thr Ser Val Thr Val Ala He Pro Asp Val Asp 1045 1050 1055 CCC TTG GTG GAC TCA ACC GTG GTG CAC ATT AGC AAC AAG ACG GAT GGG 3390 Pro Leu Val Asp Ser Thr Val Val His He Ser Asn Lys Thr Asp Gly 1060 1065 1070 1075 GAA GCC AGT CCC TTG AAG GAG GCA GAG ATC AGA GAG GAT GAG GAG GAG 3438 Glu Ala Ser Pro Leu Lys Glu Ala Glu He Arg Glu Asp Glu Glu Glu 1080 1085 1090 GTG GAG AAG AAG AAG CAG AAG AAG GAG AAG CGT GAG ACA GGC AAA GCC 3486 Val Glu Lys Lys Lys Gin Lys Lys Glu Lys Arg Glu Thr Gly Lys Ala 1095 1100 1105 ATG GTG CCC CAC AGC TCA ATG TTC ATC TTC AGC ACC ACC AAC CCG ATC 3534 Met Val Pro His Ser Ser Met Phe He Phe Ser Thr Thr Asn Pro He 1110 1115 1120 CGG AGG GCC TGC CAC TAC ATC GTG AAC CTG CGC TAC TTT GAG ATG TGC 3582 Arg Arg Ala Cys His Tyr He Val Asn Leu Arg Tyr Phe Glu Met Cys 1125 1130 1135 ATC CTC CTG GTG ATT GCA GCC AGC AGC ATC GCC CTG GCG GCA GAG GAC 3630 He Leu Leu Val He Ala Ala Ser Ser He Ala Leu Ala Ala Glu Asp 1140 1145 1150 1155 CCC GTC CTG ACC AAC TCG GAG CGC AAC AAA GTC CTG AGG TAT TTT GAC 3678 Pro Val Leu Thr Asn Ser Glu Arg Asn Lys Val Leu Arg Tyr Phe Asp 1160 1165 1170 TAT GTG TTC ACG GGC GTG TTC ACC TTT GAG ATG GTT ATA AAG ATG ATA 3726 Tyr Val Phe Thr Gly Val Phe Thr Phe Glu Met Val He Lys Met He 1175 1180 1185 GAC CAA GGC TTG ATC CTG CAG GAT GGG TCC TAC TTC CGA GAC TTG TGG 3774 Asp Gin Gly Leu He Leu Gin Asp Gly Ser Tyr Phe Arg Asp Leu Trp 1190 1195 1200 AAC ATC CTG GAC TTT GTG GTG GTC GTT GGC GCA TTG GTG GCC TTT GCT 3822 Asn He Leu Asp Phe Val Val Val Val Gly Ala Leu Val Ala Phe Ala 1205 ..1210 1215 CTG GCG AAC GCT TTG GGA ACC AAC AAA GGA CGG GAC ATC AAG ACC ATC 3870 Leu Ala Asn Ala Leu Gly Thr Asn Lys Gly Arg Asp He Lys Thr He 1220 1225 1230 1235 AAG TCT CTG CGG GTG CTC CGA GTT CTA AGG CCA CTG AAA ACC ATC AAG 3918 Lys Ser Leu Arg Val Leu Arg Val Leu Arg Pro Leu Lys Thr He Lys 1240 1245 1250 CGC TTG CCC AAG CTC AAG GCC GTC TTC GAC TGC GTA GTG ACC TCC TTG 3966 Arg Leu Pro Lys Leu Lys Ala Val Phe Asp Cys Val Val Thr Ser Leu 1255 1260 1265 AAG AAT GTC TTC AAC ATA CTC ATT GTG TAC AAG CTC TTC ATG TTC ATC 4014 Lys Asn Val Phe Asn He Leu He Val Tyr Lys Leu Phe Met Phe He 1270 1275 1280 TTT GCT GTC ATC GCA GTT CAG CTC TTC AAG GGA AAG TTC TTT TAT TGC 4062 Phe Ala Val He Ala Val Gin Leu Phe Lys Gly Lys Phe Phe Tyr Cys 1285 1290 1295 ACG GAC AGT TCC AAG GAC ACA GAG AAG GAG TGC ATA GGC AAC TAT GTA 4110 Thr Asp Ser Ser Lys Asp Thr Glu Lys Glu Cys He Gly Asn Tyr Val 1300 1305 1310 1315 GAT CAC GAG AAA AAC AAG ATG GAG GTG AAG GGC CGG GAA TGG AAG CGC 4158 Asp His Glu Lys Asn Lys Met Glu Val Lys Gly Arg Glu Trp Lys Arg 1320 1325 1330 CAT GAA TTC CAC TAC GAC AAC ATT ATC TGG GCC CTG CTG ACC CTC TTC 4206 His Glu Phe His Tyr Asp Asn He He Trp Ala Leu Leu Thr Leu Phe 1335 1340 1345 ACC GTC TCC ACA GGG GAA GGA TGG CCT CAA GTT CTG CAG CAC TCT GTA 4254 Thr Val Ser Thr Gly Glu Gly Trp Pro Gin Val Leu Gin His Ser Val 1350 1355 1360 GAT GTG ACA GAG GAA GAC CGA GGC CCA AGC CGC AGC AAC CGC ATG GAG 4302 Asp Val Thr Glu Glu Asp Arg Gly Pro Ser Arg Ser Asn Arg Met Glu 1365 1370 1375 ATG TCT ATC TTT TAT GTA GTC TAC TTT GTG GTC TTC CCC TTC TTC TTT 4350 Met Ser He Phe Tyr Val Val Tyr Phe Val Val Phe Pro Phe Phe Phe 1380 1385 1390 1395 GTC AAT ATC TTT GTG GCT CTC ATC ATC ATC ACC TTC CAG GAG CAA GGG 4398 Val Asn He Phe Val Ala Leu He He He Thr Phe Gin Glu Gin Gly 1400 1405 1410 GAT AAG ATG ATG GAG GAG TGC AGC CTG GAG AAG AAT GAG AGG GCG TGC 4446 Asp Lys Met Met Glu Glu Cys Ser Leu Glu Lys Asn Glu Arg Ala Cys 1415 1420 1425 ATC GAC TTC GCC ATC AGC GCC AAA CCT CTC ACC CGC TAC ATG CCG CAG 4494 He Asp Phe Ala He Ser Ala Lys Pro Leu Thr Arg Tyr Met Pro Gin 1430 1435 1440 AAC AGA CAC ACC TTC CAG TAC CGC GTG TGG CAC TTT GTG GTG TCT CCG 4542 Asn Arg His Thr Phe Gin Tyr Arg Val Trp His Phe Val Val Ser Pro 1445 1450 1455 TCC TTT GAG TAC ACC ATT ATG GCC ATG ATC GCC TTG AAT ACT GTT GTG 4590 Ser Phe Glu Tyr Thr He Met Ala Met He Ala Leu Asn Thr Val Val 1460 1465 1470 1475 CTG ATG ATG AAG TAT TAT TCT GCT CCC TGT ACC TAT GAG CTG GCC CTG 4638 Leu Met Met Lys Tyr Tyr Ser Ala Pro Cys Thr Tyr Glu Leu Ala Leu 1480 1485 1490 AAG TAC CTG AAT ATC GCC TTC ACC ATG GTG TTT TCC CTG GAA TGT GTC 4686 Lys Tyr Leu Asn He Ala Phe Thr Met Val Phe Ser Leu Glu Cys Val 1495 1500 1505 CTG AAG GTC ATC GCT TTT GGC TTT TTG AAC TAT TTC CGA GAC ACC TGG 4734 Leu Lys Val He Ala Phe Gly Phe Leu Asn Tyr Phe Arg Asp Thr Trp 1510 1515 1520 AAT ATC TTT GAC TTC ATC ACC GTG ATT GGC AGT ATC ACA GAA ATT ATC 4782 Asn He Phe Asp Phe He Thr Val He Gly Ser He Thr Glu He He 1525 1530 1535 CTG ACA GAC AGC AAG CTG GTG AAC ACC AGT GGC TTC AAT ATG AGC TTT 4830 Leu Thr Asp Ser Lys Leu Val Asn Thr Ser Gly Phe Asn Met Ser Phe 1540 1545 1550 1555 CTG AAG CTC TTC CGA GCT GCC CGC CTC ATA AAG CTC CTG CGT CAG GGC 4878 Leu Lys Leu Phe Arg Ala Ala Arg Leu He Lys Leu Leu Arg Gin Gly 1560 1565 1570 TAT ACC ATA CGC ATT TTG CTG TGG ACC TTT GTG CAG TCC TTT AAG GCC 4926 Tyr Thr He Arg He Leu Leu Trp Thr Phe Val Gin Ser Phe Lys Ala 1575 1580 1585 CTC CCT TAT GTC TGC CTT TTA ATT GCC ATG CTT TTC TTC ATT TAT GCC 4974 Leu Pro Tyr Val Cys Leu Leu He Ala Met Leu Phe Phe He Tyr Ala 1590 1595 1600 ATC ATT GGG ATG CAG GTA TTT GGA AAC ATA AAA TTA GAC GAG GAG AGT 5022 He He Gly Met Gin Val Phe Gly Asn He Lys Leu Asp Glu Glu Ser 1605 1610 1615 CAC ATC AAC CGG CAC AAC AAC TTC CGG AGT TTC TTT GGG TCC CTA ATG 5070 His He Asn Arg His Asn Asn Phe Arg Ser Phe Phe Gly Ser Leu Met 1620 1625 1630 1635 CTA CTC TTC AGG AGT GCC ACA GGT GAG GCC TGG CAG GAG ATT ATG CTG 5118 Leu Leu Phe Arg Ser Ala Thr Gly Glu Ala Trp Gin Glu He Met Leu 1640 1645 1650 TCA TGC CTT GGG GAG AAG GGC TGT GAG CCT GAC ACC ACC GCA CCA TCA 5166 Ser Cys Leu Gly Glu Lys Gly Cys Glu Pro Asp Thr Thr Ala Pro Ser 1655 1660 1665 GGG CAG AAC GAG AAT GAA CGC TGC 'GGC ACC GAT CTG GCC TAC GTG TAC 5214 Gly Gin Asn Glu Asn Glu Arg Cys Gly Thr Asp Leu Ala Tyr Val Tyr 1670 1675 1680 TTT GTC TCC TTC ATC TTC TTC TGC TCC TTC TTG ATG CTC AAC CTG TTT 5262 Phe Val Ser Phe He Phe Phe Cys Ser Phe Leu Met Leu Asn Leu Phe 1685 1690 1695 GTG GCC GTC ATC ATG GAC AAC TTT GAG TAC CTG ACT CGG GAC TCC TCC 5310 Val Ala Val He Met Asp Asn Phe Glu Tyr Leu Thr Arg Asp Ser Ser 1700 1705 1710 1715 ATC CTG GGG CCT CAC CAC TTG GAC GAG TTT GTC CGC GTC TGG GCA GAA 5358 He Leu Gly Pro His His Leu Asp Glu Phe Val Arg Val Trp Ala Glu 1720 1725 1730 TAT GAC CGA GCA GCA TGT GGC CGC ATC CAT TAC ACT GAG ATG TAT GAA 5406 Tyr Asp Arg Ala Ala Cys Gly Arg He His Tyr Thr Glu Met Tyr Glu 1735 1740 1745 ATG CTG ACT CTC ATG TCA CCT CCG CTA GGC CTC GGC AAG AGA TGT CCC 5454 Met Leu Thr Leu Met Ser Pro Pro Leu Gly Leu Gly Lys Arg Cys Pro 1750 1755 1760 TCC AAA GTG GCA TAT AAG AGG TTG GTC CTG ATG AAC ATG CCA GTA GCT 5502 Ser Lys Val Ala Tyr Lys Arg Leu Val Leu Met Asn Met Pro Val Ala 1765 1770 1775 GAG GAC ATG ACG GTC CAC TTC ACC TCC ACA CTT ATG GCT CTG ATC CGG 5550 Glu Asp Met Thr Val His Phe Thr Ser Thr Leu Met Ala Leu He Arg 1780 1785 1790 1795 ACA GCT CTG GAC ATT AAA ATT GCC AAA GGT GGT GCA GAC AGG CAG CAG 5598 Thr Ala Leu Asp He Lys He Ala Lys Gly Gly Ala Asp Arg Gin Gin 1800 1805 1810 CTA GAC TCA GAG CTA CAA AAG GAG ACC CTA GCC ATC TGG CCT CAC CTA 5646 Leu Asp Ser Glu Leu Gin Lys Glu Thr Leu Ala He Trp Pro His Leu 1815 1820 1825 TCC CAG AAG ATG CTG GAT CTG CTT GTG CCC ATG CCC AAA GCC TCT GAC 5694 Ser Gin Lys Met Leu Asp Leu Leu Val Pro Met Pro Lys Ala Ser Asp 1830 1835 1840 CTG ACT GTG GGC AAA ATC TAT GCA GCA ATG ATG ATC ATG GAC TAC TAT 5742 Leu Thr Val Gly Lys He Tyr Ala Ala Met Met He Met Asp Tyr Tyr 1845 1850 1855 AAG CAG AGT AAG GTG AAG AAG CAG AGG CAG CAG CTG GAG GAA CAG AAA 5790 Lys Gin Ser Lys Val Lys Lys Gin Arg Gin Gin Leu Glu Glu Gin Lys 1860 1865 1870 1875 AAT GCC CCC ATG TTC CAG CGC ATG GAG CCT TCA TCT CTG CCT CAG GAG 5838 Asn Ala Pro Met Phe Gin Arg Met Glu Pro Ser Ser Leu Pro Gin Glu 1880 1885 1890 ATC ATT GCT AAT GCC AAA GCC CTG CCT TAC CTC CAG CAG GAC CCC GTT 5886 He He Ala Asn Ala Lys Ala Leu Pro Tyr Leu Gin Gin Asp Pro Val 1895 1900 1905 TCA GGC CTG AGT GGC CGG AGT GGA TAC CCT TCG ATG AGT CCA CTC TCT 5934 Ser Gly Leu Ser Gly Arg Ser Gly Tyr Pro Ser Met Ser Pro Leu Ser 1910 1915 1920 CCC CAG GAT ATA TTC CAG TTG GCT TGT ATG GAC CCC GCC GAT GAC GGA 5982 Pro Gin Asp He Phe Gin Leu Ala Cys Met Asp Pro Ala Asp Asp Gly 1925 1930 1935 CAG TTC CAA GAA CGG CAG TCT CTG GTG GTG ACA GAC CCT AGC TCC ATG 6030 Gin Phe Gin Glu Arg Gin Ser Leu Val Val Thr Asp Pro Ser Ser Met 1940 1945 1950 1955 AGA CGT TCA TTT TCC ACT ATT CGG GAT AAG CGT TCA AAT TCC TCG TGG 6078 Arg Arg Ser Phe Ser Thr He Arg Asp Lys Arg Ser Asn Ser Ser Trp 1960 1965 1970 TTG GAG GAA TTC TCC ATG GAG CGA AGC AGT GAA AAT ACC TAC AAG TCC 6126 Leu Glu Glu Phe Ser Met Glu Arg Ser Ser Glu Asn Thr Tyr Lys Ser 1975 1980 1985 CGT CGC CGG AGT TAC CAC TCC TCC TTG CGG CTG TCA GCC CAC CGC CTG 6174 Arg Arg Arg Ser Tyr His Ser Ser Leu Arg Leu Ser Ala His Arg Leu 1990 1995 2000 AAC TCT GAT TCA GGC CAC AAG TCT GAC ACT CAC CCC TCA GGG GGC AGG 6222 Asn Ser Asp Ser Gly His Lys Ser Asp Thr His Pro Ser Gly Gly Arg 2005 2010 2015 GAG CGG CGA CGA TCA AAA GAG CGA AAG CAT CTT CTC TCT CCT GAT GTC 6270 Glu Arg Arg Arg Ser Lys Glu Arg Lys His Leu Leu Ser Pro Asp Val 2020 2025 2030 2035 TCC CGC TGC AAT TCA GAA GAG CGA GGG ACC CAG GCT GAC TGG GAG TCC 6318 Ser Arg Cys Asn Ser Glu Glu Arg Gly Thr Gin Ala Asp Trp Glu Ser 2040 2045 2050 CCA GAG CGC CGT CAA TCC AGG TCA CCC AGT GAG GGC AGG TCA CAG ACG 6366 Pro Glu Arg Arg Gin Ser Arg Ser Pro Ser Glu Gly Arg Ser Gin Thr 2055 2060 2065 CCC AAC AGA CAG GGC ACA GGT TCC CTA AGT GAG AGC TCC ATC CCC TCT 6414 Pro Asn Arg Gin Gly Thr Gly Ser Leu Ser Glu Ser Ser He Pro Ser 2070 2075 2080 GTC TCT GAC ACC AGC ACC CCA AGA AGA AGT CGT CGG CAG CTC CCA CCC 6462 Val Ser Asp Thr Ser Thr Pro Arg Arg Ser Arg Arg Gin Leu Pro Pro 2085 2090 2095 GTC CCG CCA AAG CCC CGG CCC CTC CTT TCC TAC AGC TCC CTG ATT CGA 6510 Val Pro Pro Lys Pro Arg Pro Leu Leu Ser Tyr Ser Ser Leu He Arg 2100 2105 2110 2115 CAC GCG GGC AGC ATC TCT CCA CCT GCT GAT GGA AGC GAG GAG GGC TCC 6558 His Ala Gly Ser He Ser Pro Pro Ala Asp Gly Ser Glu Glu Gly Ser 2120 2125 2130 CCG CTG ACC TCC CAA GCT CTG GAG AGC AAC AAT GCT TGG CTG ACC GAG 6606 Pro Leu Thr Ser Gin Ala Leu Glu Ser Asn Asn Ala Trp Leu Thr Glu 2135 2140 2145 TCT TCC AAC TCT CCG CAC CCC CAG CAG AGG CAA CAT GCC TCC CCA CAG 6654 Ser Ser Asn Ser Pro His Pro Gin Gin Arg Gin His Ala Ser Pro Gin 2150 2155 2160 CGC TAC ATC TCC GAG CCC TAC TTG GCC CTG CAC GAA GAC TCC CAC GCC 6702 Arg Tyr He Ser Glu Pro Tyr Leu Ala Leu His Glu Asp Ser His Ala 2165 2170 2175 TCA GAC TGT GTT GAG GAG GAG ACG CTC ACT TTC GAA GCA GCC GTG GCT 6750 Ser Asp Cys Val Glu Glu Glu Thr Leu Thr Phe Glu Ala Ala Val Ala 2180 2185 2190 2195 ACT AGC CTG GGC CGT TCC AAC ACC ATC GGC TCA GCC CCA CCC CTG CGG 6798 Thr Ser Leu Gly Arg Ser Asn Thr He Gly Ser Ala Pro Pro Leu Arg 2200 2205 2210 CAT AGC TGG CAG ATG CCC AAC GGG CAC TAT CGG CGG CGG AGG CGC GGG 6846 His Ser Trp Gin Met Pro Asn Gly His Tyr Arg Arg Arg Arg Arg Gly 2215 2220 2225 GGG CCT GGG CCA GGC ATG ATG TGT GGG GCT GTC AAC AAC CTG CTA AGT 6894 Gly Pro Gly Pro Gly Met Met Cys Gly Ala Val Asn Asn Leu Leu Ser 2230 2235 2240 GAC ACG GAA GAA GAT GAC AAA TGC TAGAGGCTGC TCCCCCCTCC GATGCATGCT 6948 Asp Thr Glu Glu Asp Asp Lys Cys 2245 2250 CTTCTCTCAC ATGGAGAAAA CCAAGACAGA ATTGGGAAGC CAGTGCGGCC CCGCGGGGAG 7008 GAAGAGGGAA AAGGAAGATG GAAG 7032 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7089 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 166..6978 (D) OTHER INFORMATION: /standard_name= "Alpha-lE-3" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GCTGCTGCTG CCTCTCCGAA GAGCTCGCGG AGCTCCCCAG AGGCGGTGGT CCCCGTGCTT 60 GTCTGGATGC GGCTCTGAGT CTCCGTGTGT CTTTCTGCTT GTTGCTGTGT GCGGGTGTTC 120 GGCCGCGATC ACCTTTGTGT GTCTTCTGTC TGTTTAAACC TCAGG ATG GCT CGC 174 Met Ala Arg 1 TTC GGG GAG GCG GTG GTC GCC AGG CCA GGG TCC GGC GAT GGA GAC TCG 222 Phe Gly Glu Ala Val Val Ala Arg Pro Gly Ser Gly Asp Gly Asp Ser 5 10 15 GAC CAG AGC AGG AAC CGG CAA GGA ACC CCC GTG CCG GCC TCG GGG CAG 270 Asp Gin Ser Arg Asn Arg Gin Gly Thr Pro Val Pro Ala Ser Gly Gin 20 25 30 35 GCG GCC GCC TAC AAG CAG ACG AAA GCA CAG AGG GCG CGG ACT ATG GCT 318 Ala Ala Ala Tyr Lys Gin Thr Lys Ala Gin Arg Ala Arg Thr Met Ala 40 45 50 TTG TAC AAC CCC ATT CCC GTC CGG CAG AAC TGT TTC ACC GTC AAC AGA 366 Leu Tyr Asn Pro He Pro Val Arg Gin Asn Cys Phe Thr Val Asn Arg 55 60 65 TCC CTG TTC ATC TTC GGA GAA GAT AAC ATT GTC AGG AAA TAT GCC AAG 414 Ser Leu Phe He Phe Gly Glu Asp Asn He Val Arg Lys Tyr Ala Lys 70 75 80 AAG CTC ATC GAT TGG CCG CCA TTT GAG TAC ATG ATC CTG GCC ACC ATC 462 Lys Leu He Asp Trp Pro Pro Phe Glu Tyr Met He Leu Ala Thr He 85 90 95 ATT GCC AAC TGC ATC GTC CTG GCC CTG GAG CAG CAT CTT CCT GAG GAT 510 He Ala Asn Cys He Val Leu Ala Leu Glu Gin His Leu Pro Glu Asp 100 105 110 115 GAC AAG ACC CCC ATG TCC CGA AGA CTG GAG AAG ACA GAA CCT TAT TTC 558 Asp Lys Thr Pro Met Ser Arg Arg Leu Glu Lys Thr Glu Pro Tyr Phe 120 125 130 ATT GGG ATC TTT TGC TTT GAA GCT GGG ATC AAA ATT GTG GCC CTG GGG 606 He Gly He Phe Cys Phe Glu Ala Gly He Lys He Val Ala Leu Gly 135 140 145 TTC ATC TTC CAT AAG GGC TCT TAC CTC CGC AAT GGC TGG AAT GTC ATG 654 Phe He Phe His Lys Gly Ser Tyr Leu Arg Asn Gly Trp Asn Val Met 150 155 160 GAC TTC ATC GTG GTC CTC AGT GGC ATC CTG GCC ACT GCA GGA ACC CAC 702 Asp Phe He Val Val Leu Ser Gly He Leu Ala Thr Ala Gly Thr His 165 170 175 TTC AAT ACT CAC GTG GAC CTG AGG ACC CTC CGG GCT GTG CGT GTC CTG 750 Phe Asn Thr His Val Asp Leu Arg Thr Leu Arg Ala Val Arg Val Leu 180 185 190 195 CGG CCT TTG AAG CTC GTG TCA GGG ATA CCT AGC CTG CAG ATT GTG TTG 798 Arg Pro Leu Lys Leu Val Ser Gly He Pro Ser Leu Gin He Val Leu 200 205 210 AAG TCC ATC ATG AAG GCC ATG GTA CCT CTT CTG CAG ATT GGC CTT CTG 846 Lys Ser He Met Lys Ala Met Val Pro Leu Leu Gin He Gly Leu Leu 215 220 225 CTC TTC TTT GCC ATC CTG ATG TTT GCT ATC ATT GGT TTG GAG TTC TAC 894 Leu Phe Phe Ala He Leu Met Phe Ala He He Gly Leu Glu Phe Tyr 230 235 240 AGT GGC AAG TTA CAT CGA GCG TGC TTC ATG AAC AAT TCA GGT ATT CTA 942 Ser Gly Lys Leu His Arg Ala Cys Phe Met Asn Asn Ser Gly He Leu 245 250 255 GAA GGA TTT GAC CCC CCT CAC CCA TGT GGT GTG CAG GGC TGC CCA GCT 990 Glu Gly Phe Asp Pro Pro His Pro Cys Gly Val Gin Gly Cys Pro Ala 260 265 270 275 GGT TAT GAA TGC AAG GAC TGG ATC GGC CCC AAT GAT GGG ATC ACC CAG 1038 Gly Tyr Glu Cys Lys Asp Trp He Gly Pro Asn Asp Gly He Thr Gin 280 285 290 TTT GAT AAC ATC CTT TTT GCT GTG CTG ACT GTC TTC CAG TGC ATC ACC 1086 Phe Asp Asn He Leu Phe Ala Val Leu Thr Val Phe Gin Cys He Thr 295 300 305 ATG GAA GGG TGG ACC ACT GTG CTG TAC AAT ACC AAT GAT GCC TTA GGA 1134 Met Glu Gly Trp Thr Thr Val Leu Tyr Asn Thr Asn Asp Ala Leu Gly 310 315 320 GCC ACC TGG AAT TGG CTG TAC TTC ATC CCC CTC ATC ATC ATT GGA TCC 1182 Ala Thr Trp Asn Trp Leu Tyr Phe He Pro Leu He He He Gly Ser 325 330 335 TTC TTT GTT CTC AAC CTA GTC CTG GGA GTG CTT TCC GGG GAA TTT GCC 1230 Phe Phe Val Leu Asn Leu Val Leu Gly Val Leu Ser Gly Glu Phe Ala 340 345 350 355 AAA GAG AGA GAG AGA GTG GAG AAC CGA AGG GCT TTC ATG AAG CTG CGG 1278 Lys Glu Arg Glu Arg Val Glu Asn Arg Arg Ala Phe Met Lys Leu Arg 360 365 370 CGC CAG CAG CAG ATT GAG CGT GAG CTG AAT GGC TAC CGT GCC TGG ATA 1326 Arg Gin Gin Gin He Glu Arg Glu Leu Asn Gly Tyr Arg Ala Trp He 375 380 385 GAC AAA GCA GAG GAA GTC ATG CTC GCT GAA GAA AAT AAA AAT GCT GGA 1374 Asp Lys Ala Glu Glu Val Met Leu Ala Glu Glu Asn Lys Asn Ala Gly 390 395 400 ACA TCC GCC TTA GAA GTG CTT CGA AGG GCA ACC ATC AAG AGG AGC CGG 1422 Thr Ser Ala Leu Glu Val Leu Arg Arg Ala Thr He Lys Arg Ser Arg 405 410 415 ACA GAG GCC ATG ACT CGA GAC TCC AGT GAT GAG CAC TGT GTT GAT ATC 1470 Thr Glu Ala Met Thr Arg Asp Ser Ser Asp Glu His Cys Val Asp He 420 425 430 435 TCC TCT GTG GGC ACA CCT CTG GCC CGA GCC AGT ATC AAA AGT GCA AAG 1518 Ser Ser Val Gly Thr Pro Leu Ala Arg Ala Ser He Lys Ser Ala Lys 440 445 450 GTA GAC GGG GTC TCT TAT TTC CGG CAC AAG GAA AGG CTT CTG CGC ATC 1566 Val Asp Gly Val Ser Tyr Phe Arg His Lys Glu Arg Leu Leu Arg He 455 460 465 TCC ATT CGC CAC ATG GTT AAA TCC CAG GTG TTT TAC TGG ATT GTG CTG 1614 Ser He Arg His Met Val Lys Ser Gin Val Phe Tyr Trp He Val Leu 470 475 480 AGC CTT GTG GCA CTC AAC ACT GCC TGT GTG GCC ATT GTC CAT CAC AAC 1662 Ser Leu Val Ala Leu Asn Thr Ala Cys Val Ala He Val His His Asn 485 490 495 CAG CCC CAG TGG CTC ACC CAC CTC CTC TAC TAT GCA GAA TTT CTG TTT 1710 Gin Pro Gin Trp Leu Thr His Leu Leu Tyr Tyr Ala Glu Phe Leu Phe 500 505 510 515 CTG GGA CTC TTC CTC TTG GAG ATG TCC CTG AAG ATG TAT GGC ATG GGG 1758 Leu Gly Leu Phe Leu Leu Glu Met Ser Leu Lys Met Tyr Gly Met Gly 520 525 530 CCT CGC CTT TAT TTT CAC TCT TCA TTC AAC TGC TTT GAT TTT GGG GTC 1806 Pro Arg Leu Tyr Phe His Ser Ser Phe Asn Cys Phe Asp Phe Gly Val 535 540 545 ACA GTG GGC AGT ATC TTT GAA GTG GTC TGG GCA ATC TTC AGA CCT GGT 1854 Thr Val Gly Ser He Phe Glu Val Val Trp Ala He Phe Arg Pro Gly 550 555 560 ACG TCT TTT GGA ATC AGT GTC TTG CGA GCC CTC CGG CTT CTA AGA ATA 1902 Thr Ser Phe Gly He Ser Val Leu Arg Ala Leu Arg Leu Leu Arg He 565 570 575 TTT AAA ATA ACC AAG TAT TGG GCT TCC CTA CGG AAT TTG GTG GTC TCC 1950 Phe Lys He Thr Lys Tyr Trp Ala Ser Leu Arg Asn Leu Val Val Ser 580 585 590 595 TTG ATG AGC TCA ATG AAG TCT ATC ATC AGT TTG CTT TTC CTC CTC TTC 1998 Leu Met Ser Ser Met Lys Ser He He Ser Leu Leu Phe Leu Leu Phe 600 605 610 CTC TTC ATC GTT GTC TTT GCT CTC CTA GGA ATG CAG TTA TTT GGA GGC 2046 Leu Phe He Val Val Phe Ala Leu Leu Gly Met Gin Leu Phe Gly Gly 615 620 625 AGG TTT AAC TTT AAT GAT GGG ACT CCT TCG GCA AAT TTT GAT ACC TTC 2094 Arg Phe Asn Phe Asn Asp Gly Thr Pro Ser Ala Asn Phe Asp Thr Phe 630 635 640 CCT GCA GCC ATC ATG ACT GTG TTC CAG ATC CTG ACG GGT GAG GAC TGG 2142 Pro Ala Ala He Met Thr Val Phe Gin He Leu Thr Gly Glu Asp Trp 645 650 655 AAT GAG GTG ATG TAC AAT GGG ATC CGC TCC CAG GGT GGG GTC AGC TCA 2190 Asn Glu Val Met Tyr Asn Gly He Arg Ser Gin Gly Gly Val Ser Ser 660 665 670 675 GGC ATG TGG TCT GCC ATC TAC TTC ATT GTG CTC ACC TTG TTT GGC AAC 2238 Gly Met Trp Ser Ala He Tyr Phe He Val Leu Thr Leu Phe Gly Asn 680 685 690 TAC ACG CTA CTG AAT GTG TTC TTG GCT ATC GCT GTG GAT AAT CTC GCC 2286 Tyr Thr Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn Leu Ala 695 700 705 AAC GCC CAG GAA CTG ACC AAG GAT GAA CAG GAG GAA GAA GAG GCC TTC 2334 Asn Ala Gin Glu Leu Thr Lys Asp Glu Gin Glu Glu Glu Glu Ala Phe 710 715 720 AAC CAG AAA CAT GCA CTG CAG AAG GCC AAG GAG GTC AGC CCG ATG TCT 2382 Asn Gin Lys His Ala Leu Gin Lys Ala Lys Glu Val Ser Pro Met Ser 725 730 735 GCA CCC AAC ATG CCT TCG ATC GAA AGA GAC AGA AGG AGA AGA CAC CAC 2430 Ala Pro Asn Met Pro Ser He Glu Arg Asp Arg Arg Arg Arg His His 740 745 750 755 ATG TCG ATG TGG GAG CCA CGC AGC AGC CAC CTG AGG GAG CGG AGG CGC 2478 Met Ser Met Trp Glu Pro Arg Ser Ser His Leu Arg Glu Arg Arg Arg 760 765 770 CGG CAC CAC ATG TCC GTG TGG GAG CAG CGT ACC AGC CAG CTG AGG AAG 2526 Arg His His Met Ser Val Trp Glu Gin Arg Thr Ser Gin Leu Arg Lys 775 780 785 CAC ATG CAG ATG TCC AGC CAG GAG GCC CTC AAC AGA GAG GAG GCG CCG 2574 His Met Gin Met Ser Ser Gin Glu Ala Leu Asn Arg Glu Glu Ala Pro 790 795 800 ACC ATG AAC CCG CTC AAC CCC CTC AAC CCG CTC AGC TCC CTC AAC CCG 2622 Thr Met Asn Pro Leu Asn Pro Leu Asn Pro Leu Ser Ser Leu Asn Pro 805 810 815 CTC AAT GCC CAC CCC AGC CTT TAT CGG CGA CCC AGG GCC ATT GAG GGC 2670 Leu Asn Ala His Pro Ser Leu Tyr Arg Arg Pro Arg Ala He Glu Gly 820 825 830 835 CTG GCC CTG GGC CTG GCC CTG GAG AAG TTC GAG GAG GAG CGC ATC AGC 2718 Leu Ala Leu Gly Leu Ala Leu Glu Lys Phe Glu Glu Glu Arg He Ser 840 845 850 CGT GGG GGG TCC CTC AAG GGG GAT GGA GGG GAC CGA TCC AGT GCC CTG 2766 Arg Gly Gly Ser Leu Lys Gly Asp Gly Gly Asp Arg Ser Ser Ala Leu 855 860 865 GAC AAC CAG AGG ACC CCT TTG TCC CTG GGC CAG CGG GAG CCA CCA TGG 2814 Asp Asn Gin Arg Thr Pro Leu Ser Leu Gly Gin Arg Glu Pro Pro Trp 870 875 880 CTG GCC AGG CCC TGT CAT GGA AAC TGT GAC CCG ACT CAG CAG GAG GCA 2862 Leu Ala Arg Pro Cys His Gly Asn Cys Asp Pro Thr Gin Gin Glu Ala 885 890 895 GGG GGA GGA GAG GCT GTG GTG ACC TTT GAG GAC CGG GCC AGG CAC AGG 2910 Gly Gly Gly Glu Ala Val Val Thr Phe Glu Asp Arg Ala Arg His Arg 900 905 910 915 CAG AGC CAA CGG CGC AGC CGG CAT CGC CGC GTC AGG ACA GAA GGC AAG 2958 Gin Ser Gin Arg Arg Ser Arg His Arg Arg Val Arg Thr Glu Gly Lys 920 925 930 GAG TCC TCT TCA GCC TCC CGG AGC AGG TCT GCC AGC CAG GAA CGC AGT 3006 Glu Ser Ser Ser Ala Ser Arg Ser Arg Ser Ala Ser Gin Glu Arg Ser 935 940 945 CTG GAT GAA GCC ATG CCC ACT GAA GGG GAG AAG GAC CAT GAG CTC AGG 3054 Leu Asp Glu Ala Met Pro Thr Glu Gly Glu Lys Asp His Glu Leu Arg 950 955 960 GGC AAC CAT GGT GCC AAG GAG CCA ACG ATC CAA GAA GAG AGA GCC CAG 3102 Gly Asn His Gly Ala Lys Glu Pro Thr He Gin Glu Glu Arg Ala Gin 965 970 975 GAT TTA AGG AGG ACC AAC AGT CTG ATG GTG TCC AGA GGC TCC GGG CTG 3150 Asp Leu Arg Arg Thr Asn Ser Leu Met Val Ser Arg Gly Ser Gly Leu 980 985 990 995 GCA GGA GGC CTT GAT GAG GCT GAC ACC CCC CTA GTC CTG CCC CAT CCT 3198 Ala Gly Gly Leu Asp Glu Ala Asp Thr Pro Leu Val Leu Pro His Pro 1000 1005 1010 GAG CTG GAA GTG GGG AAG CAC GTG GTG CTG ACG GAG CAG GAG CCA GAA 3246 Glu Leu Glu Val Gly Lys His Val Val Leu Thr Glu Gin Glu Pro Glu 1015 1020 1025 GGC AGC AGT GAG CAG GCC CTG CTG GGG AAT GTG CAG CTA GAC ATG GGC 3294 Gly Ser Ser Glu Gin Ala Leu Leu Gly Asn Val Gin Leu Asp Met Gly 1030 1035 1040 CGG GTC ATC AGC CAG AGC GAG CCT GAC CTC TCC TGC ATC ACG GCC AAC 3342 Arg Val He Ser Gin Ser Glu Pro Asp Leu Ser Cys He Thr Ala Asn 1045 1050 1055 ACG GAC AAG GCC ACC ACC GAG AGC ACC AGC GTC ACC GTC GCC ATC CCC 3390 Thr Asp Lys Ala Thr Thr Glu Ser Thr Ser Val Thr Val Ala He Pro 1060 1065 1070 1075 GAC GTG GAC CCC TTG GTG GAC TCA ACC GTG GTG CAC ATT AGC AAC AAG 3438 Asp Val Asp Pro Leu Val Asp Ser Thr Val Val His He Ser Asn Lys 1080 1085 1090 ACG GAT GGG GAA GCC AGT CCC TTG AAG GAG GCA GAG ATC AGA GAG GAT 3486 Thr Asp Gly Glu Ala Ser Pro Leu Lys Glu Ala Glu He Arg Glu Asp 1095 1100 1105 GAG GAG GAG GTG GAG AAG AAG AAG CAG AAG AAG GAG AAG CGT GAG ACA 3534 Glu Glu Glu Val Glu Lys Lys Lys Gin Lys Lys Glu Lys Arg Glu Thr 1110 1115 1120 GGC AAA GCC ATG GTG CCC CAC AGC TCA ATG TTC ATC TTC AGC ACC ACC 3582 Gly Lys Ala Met Val Pro His Ser Ser Met Phe He Phe Ser Thr Thr 1125 1130 1135 AAC CCG ATC CGG AGG GCC TGC CAC TAC ATC GTG AAC CTG CGC TAC TTT 3630 Asn Pro He Arg Arg Ala Cys His Tyr He Val Asn Leu Arg Tyr Phe 1140 1145 1150 1155 GAG ATG TGC ATC CTC CTG GTG ATT GCA GCC AGC AGC ATC GCC CTG GCG 3678 Glu Met Cys He Leu Leu Val He Ala Ala Ser Ser He Ala Leu Ala 1160 1165 1170 GCA GAG GAC CCC GTC CTG ACC AAC TCG GAG CGC AAC AAA GTC CTG AGG 3726 Ala Glu Asp Pro Val Leu Thr Asn Ser Glu Arg Asn Lys Val Leu Arg 1175 1180 1185 TAT TTT GAC TAT GTG TTC ACG GGC GTG TTC ACC TTT GAG ATG GTT ATA 3774 Tyr Phe Asp Tyr Val Phe Thr Gly Val Phe Thr Phe Glu Met Val He 1190 1195 1200 AAG ATG ATA GAC CAA GGC TTG ATC CTG CAG GAT GGG TCC TAC TTC CGA 3822 Lys Met He Asp Gin Gly Leu He Leu Gin Asp Gly Ser Tyr Phe Arg 1205 1210 1215 GAC TTG TGG AAC ATC CTG GAC TTT GTG GTG GTC GTT GGC GCA TTG GTG 3870 Asp Leu Trp Asn He Leu Asp Phe Val Val Val Val Gly Ala Leu Val 1220 1225 1230 1235 GCC TTT GCT CTG GCG AAC GCT TTG GGA ACC AAC AAA GGA CGG GAC ATC 3918 Ala Phe Ala Leu Ala Asn Ala Leu Gly Thr Asn Lys Gly Arg Asp He 1240 1245 1250 AAG ACC ATC AAG TCT CTG CGG GTG CTC CGA GTT CTA AGG CCA CTG AAA 3966 Lys Thr He Lys Ser Leu Arg Val Leu Arg Val Leu Arg Pro Leu Lys 1255 1260 1265 ACC ATC AAG CGC TTG CCC AAG CTC AAG GCC GTC TTC GAC TGC GTA GTG 4014 Thr He Lys Arg Leu Pro Lys Leu Lys Ala Val Phe Asp Cys Val Val 1270 1275 1280 ACC TCC TTG AAG AAT GTC TTC AAC ATA CTC ATT GTG TAC AAG CTC TTC 4062 Thr Ser Leu Lys Asn Val Phe Asn He Leu He Val Tyr Lys Leu Phe 1285 1290 1295 ATG TTC ATC TTT GCT GTC ATC GCA GTT CAG CTC TTC AAG GGA AAG TTC 4110 Met Phe He Phe Ala Val He Ala Val Gin Leu Phe Lys Gly Lys Phe 1300 1305 1310 1315 TTT TAT TGC ACG GAC AGT TCC AAG GAC ACA GAG AAG GAG TGC ATA GGC 4158 Phe Tyr Cys Thr Asp Ser Ser Lys Asp Thr Glu Lys Glu Cys He Gly 1320 1325 1330 AAC TAT GTA GAT CAC GAG AAA AAC AAG ATG GAG GTG AAG GGC CGG GAA 4206 Asn Tyr Val Asp His Glu Lys Asn Lys Met Glu Val Lys Gly Arg Glu 1335 1340 1345 TGG AAG CGC CAT GAA TTC CAC TAC GAC AAC ATT ATC TGG GCC CTG CTG 4254 Trp Lys Arg His Glu Phe His Tyr Asp Asn He He Trp Ala Leu Leu 1350 1355 1360 ACC CTC TTC ACC GTC TCC ACA GGG GAA GGA TGG CCT CAA GTT CTG CAG 4302 Thr Leu Phe Thr Val Ser Thr Gly Glu Gly Trp Pro Gin Val Leu Gin 1365 1370 1375 CAC TCT GTA GAT GTG ACA GAG GAA GAC CGA GGC CCA AGC CGC AGC AAC 4350 His Ser Val Asp Val Thr Glu Glu Asp Arg Gly Pro Ser Arg Ser Asn 1380 1385 1390 1395 CGC ATG GAG ATG TCT ATC TTT TAT GTA GTC TAC TTT GTG GTC TTC CCC 4398 Arg Met Glu Met Ser He Phe Tyr Val Val Tyr Phe Val Val Phe Pro 1400 1405 1410 TTC TTC TTT GTC AAT ATC TTT GTG GCT CTC ATC ATC ATC ACC TTC CAG 4446 Phe Phe Phe Val Asn He Phe Val Ala Leu He He He Thr Phe Gin 1415 1420 1425 GAG CAA GGG GAT AAG ATG ATG GAG GAG TGC AGC CTG GAG AAG AAT GAG 4494 Glu Gin Gly Asp Lys Met Met Glu Glu Cys Ser Leu Glu Lys Asn Glu 1430 1435 1440 AGG GCG TGC ATC GAC TTC GCC ATC AGC GCC AAA CCT CTC ACC CGC TAC 4542 Arg Ala Cys He Asp Phe Ala He Ser Ala Lys Pro Leu Thr Arg Tyr 1445 1450 1455 ATG CCG CAG AAC AGA CAC ACC TTC CAG TAC CGC GTG TGG CAC TTT GTG 4590 Met Pro Gin Asn Arg His Thr Phe Gin Tyr Arg Val Trp His Phe Val 1460 1465 1470 1475 GTG TCT CCG TCC TTT GAG TAC ACC ATT ATG GCC ATG ATC GCC TTG AAT 4638 Val Ser Pro Ser Phe Glu Tyr Thr He Met Ala Met He Ala Leu Asn 1480 1485 1490 ACT GTT GTG CTG ATG ATG AAG TAT TAT TCT GCT CCC TGT ACC TAT GAG 4686 Thr Val Val Leu Met Met Lys Tyr Tyr Ser Ala Pro Cys Thr Tyr Glu 1495 1500 1505 CTG GCC CTG AAG TAC CTG AAT ATC GCC TTC ACC ATG GTG TTT TCC CTG 4734 Leu Ala Leu Lys Tyr Leu Asn He Ala Phe Thr Met Val Phe Ser Leu 1510 1515 1520 GAA TGT GTC CTG AAG GTC ATC GCT TTT GGC TTT TTG AAC TAT TTC CGA 4782 Glu Cys Val Leu Lys Val He Ala Phe Gly Phe Leu Asn Tyr Phe Arg 1525 1530 1535 GAC ACC TGG AAT ATC TTT GAC TTC ATC ACC GTG ATT GGC AGT ATC ACA 4830 Asp Thr Trp Asn He Phe Asp Phe He Thr Val He Gly Ser He Thr 1540 1545 1550 1555 GAA ATT ATC CTG ACA GAC AGC AAG CTG GTG AAC ACC AGT GGC TTC AAT 4878 Glu He He Leu Thr Asp Ser Lys Leu Val Asn Thr Ser Gly Phe Asn 1560 1565 1570 ATG AGC TTT CTG AAG CTC TTC CGA GCT GCC CGC CTC ATA AAG CTC CTG 4926 Met Ser Phe Leu Lys Leu Phe Arg Ala Ala Arg Leu He Lys Leu Leu 1575 1580 1585 CGT CAG GGC TAT ACC ATA CGC ATT TTG CTG TGG ACC TTT GTG CAG TCC 4974 Arg Gin Gly Tyr Thr He Arg He Leu Leu Trp Thr Phe Val Gin Ser 1590 1595 1600 TTT AAG GCC CTC CCT TAT GTC TGC CTT TTA ATT GCC ATG CTT TTC TTC 5022 Phe Lys Ala Leu Pro Tyr Val Cys Leu Leu He Ala Met Leu Phe Phe 1605 1610 1615 ATT TAT GCC ATC ATT GGG ATG CAG GTA TTT GGA AAC ATA AAA TTA GAC 5070 He Tyr Ala He He Gly Met Gin Val Phe Gly Asn He Lys Leu Asp 1620 1625 1630 1635 GAG GAG AGT CAC ATC AAC CGG CAC AAC AAC TTC CGG AGT TTC TTT GGG 5118 Glu Glu Ser His He Asn Arg His Asn Asn Phe Arg Ser Phe Phe Gly 1640 1645 1650 TCC CTA ATG CTA CTC TTC AGG AGT GCC ACA GGT GAG GCC TGG CAG GAG 5166 Ser Leu Met Leu Leu Phe Arg Ser Ala Thr Gly Glu Ala Trp Gin Glu 1655 1660 1665 ATT ATG CTG TCA TGC CTT GGG GAG AAG GGC TGT GAG CCT GAC ACC ACC 5214 He Met Leu Ser Cys Leu Gly Glu Lys Gly Cys Glu Pro Asp Thr Thr 1670 1675 1680 GCA CCA TCA GGG CAG AAC GAG AAT GAA CGC TGC GGC ACC GAT CTG GCC 5262 Ala Pro Ser Gly Gin Asn Glu Asn Glu Arg Cys Gly Thr Asp Leu Ala 1685 1690 1695 TAC GTG TAC TTT GTC TCC TTC ATC TTC TTC TGC TCC TTC TTG ATG CTC 5310 Tyr Val Tyr Phe Val Ser Phe He Phe Phe Cys Ser Phe Leu Met Leu 1700 1705 1710 1715 AAC CTG TTT GTG GCC GTC ATC ATG GAC AAC TTT GAG TAC CTG ACT CGG 5358 Asn Leu Phe Val Ala Val He Met Asp Asn Phe Glu Tyr Leu Thr Arg 1720 1725 1730 GAC TCC TCC ATC CTG GGG CCT CAC CAC TTG GAC GAG TTT GTC CGC GTC 5406 Asp Ser Ser He Leu Gly Pro His His Leu Asp Glu Phe Val Arg Val 1735 1740 1745 TGG GCA GAA TAT GAC CGA GCA GCA TGT GGC CGC ATC CAT TAC ACT GAG 5454 Trp Ala Glu Tyr Asp Arg Ala Ala Cys Gly Arg He His Tyr Thr Glu 1750 1755 1760 ATG TAT GAA ATG CTG ACT CTC ATG TCA CCT CCG CTA GGC CTC GGC AAG 5502 Met Tyr Glu Met Leu Thr Leu Met Ser Pro Pro Leu Gly Leu Gly Lys 1765 1770 1775 AGA TGT CCC TCC AAA GTG GCA TAT AAG AGG TTG GTC CTG ATG AAC ATG 5550 Arg Cys Pro Ser Lys Val Ala Tyr Lys Arg Leu Val Leu Met Asn Met 1780 1785 1790 1795 CCA GTA GCT GAG GAC ATG ACG GTC CAC TTC ACC TCC ACA CTT ATG GCT 5598 Pro Val Ala Glu Asp Met Thr Val His Phe Thr Ser Thr Leu Met Ala 1800 1805 1810 CTG ATC CGG ACA GCT CTG GAC ATT AAA ATT GCC AAA GGT GGT GCA GAC 5646 Leu He Arg Thr Ala Leu Asp He Lys He Ala Lys Gly Gly Ala Asp 1815 1820 1825 AGG CAG CAG CTA GAC TCA GAG CTA CAA AAG GAG ACC CTA GCC ATC TGG 5694 Arg Gin Gin Leu Asp Ser Glu Leu Gin Lys Glu Thr Leu Ala He Trp 1830 1835 1840 CCT CAC CTA TCC CAG AAG ATG CTG GAT CTG CTT GTG CCC ATG CCC AAA 5742 Pro His Leu Ser Gin Lys Met Leu Asp Leu Leu Val Pro Met Pro Lys 1845 1850 1855 GCC TCT GAC CTG ACT GTG GGC AAA ATC TAT GCA GCA ATG ATG ATC ATG 5790 Ala Ser Asp Leu Thr Val Gly Lys He Tyr Ala Ala Met Met He Met 1860 1865 1870 1875 GAC TAC TAT AAG CAG AGT AAG GTG AAG AAG CAG AGG CAG CAG CTG GAG 5838 Asp Tyr Tyr Lys Gin Ser Lys Val Lys Lys Gin Arg Gin Gin Leu Glu 1880 1885 1890 GAA CAG AAA AAT GCC CCC ATG TTC CAG CGC ATG GAG CCT TCA TCT CTG 5886 Glu Gin Lys Asn Ala Pro Met Phe Gin Arg Met Glu Pro Ser Ser Leu 1895 1900 1905 CCT CAG GAG ATC ATT GCT AAT GCC AAA GCC CTG CCT TAC CTC CAG CAG 5934 Pro Gin Glu He He Ala Asn Ala Lys Ala Leu Pro Tyr Leu Gin Gin 1910 1915 1920 GAC CCC GTT TCA GGC CTG AGT GGC CGG AGT GGA TAC CCT TCG ATG AGT 5982 Asp Pro Val Ser Gly Leu Ser Gly Arg Ser Gly Tyr Pro Ser Met Ser 1925 1930 1935 CCA CTC TCT CCC CAG GAT ATA TTC CAG TTG GCT TGT ATG GAC CCC GCC 6030 Pro Leu Ser Pro Gin Asp He Phe Gin Leu Ala Cys Met Asp Pro Ala 1940 1945 1950 1955 GAT GAC GGA CAG TTC CAA GAA CGG CAG TCT CTG GTG GTG ACA GAC CCT 6078 Asp Asp Gly Gin Phe Gin Glu Arg Gin Ser Leu Val Val Thr Asp Pro 1960 1965 1970 AGC TCC ATG AGA CGT TCA TTT TCC ACT ATT CGG GAT AAG CGT TCA AAT 6126 Ser Ser Met Arg Arg Ser Phe Ser Thr He Arg Asp Lys Arg Ser Asn 1975 1980 1985 TCC TCG TGG TTG GAG GAA TTC TCC ATG GAG CGA AGC AGT GAA AAT ACC 6174 Ser Ser Trp Leu Glu Glu Phe Ser Met Glu Arg Ser Ser Glu Asn Thr 1990 1995 2000 TAC AAG TCC CGT CGC CGG AGT TAC CAC TCC TCC TTG CGG CTG TCA GCC 6222 Tyr Lys Ser Arg Arg Arg Ser Tyr His Ser Ser Leu Arg Leu Ser Ala 2005 2010 2015 CAC CGC CTG AAC TCT GAT TCA GGC CAC AAG TCT GAC ACT CAC CCC TCA 6270 His Arg Leu Asn Ser Asp Ser Gly His Lys Ser Asp Thr His Pro Ser 2020 2025 2030 2035 GGG GGC AGG GAG CGG CGA CGA TCA AAA GAG CGA AAG CAT CTT CTC TCT 6318 Gly Gly Arg Glu Arg Arg Arg Ser Lys Glu Arg Lys His Leu Leu Ser 2040 2045 2050 CCT GAT GTC TCC CGC TGC AAT TCA GAA GAG CGA GGG ACC CAG GCT GAC 6366 Pro Asp Val Ser Arg Cys Asn Ser Glu Glu Arg Gly Thr Gin Ala Asp 2055 2060 2065 TGG GAG TCC CCA GAG CGC CGT CAA TCC AGG TCA CCC AGT GAG GGC AGG 6414 Trp Glu Ser Pro Glu Arg Arg Gin Ser Arg Ser Pro Ser Glu Gly Arg 2070 2075 2080 TCA CAG ACG CCC AAC AGA CAG GGC ACA GGT TCC CTA AGT GAG AGC TCC 6462 Ser Gin Thr Pro Asn Arg Gin Gly Thr Gly Ser Leu Ser Glu Ser Ser 2085 2090 2095 ATC CCC TCT GTC TCT GAC ACC AGC ACC CCA AGA AGA AGT CGT CGG CAG 6510 He Pro Ser Val Ser Asp Thr Ser Thr Pro Arg Arg Ser Arg Arg Gin 2100 2105 2110 2115 CTC CCA CCC GTC CCG CCA AAG CCC CGG CCC CTC CTT TCC TAC AGC TCC 6558 Leu Pro Pro Val Pro Pro Lys Pro Arg Pro Leu Leu Ser Tyr Ser Ser 2120 2125 2130 CTG ATT CGA CAC GCG GGC AGC ATC TCT CCA CCT GCT GAT GGA AGC GAG 6606 Leu He Arg His Ala Gly Ser He Ser Pro Pro Ala Asp Gly Ser Glu 2135 2140 2145 GAG GGC TCC CCG CTG ACC TCC CAA GCT CTG GAG AGC AAC AAT GCT TGG 6654 Glu Gly Ser Pro Leu Thr Ser Gin Ala Leu Glu Ser Asn Asn Ala Trp 2150 2155 2160 CTG ACC GAG TCT TCC AAC TCT CCG CAC CCC CAG CAG AGG CAA CAT GCC 6702 Leu Thr Glu Ser Ser Asn Ser Pro His Pro Gin Gin Arg Gin His Ala 2165 2170 2175 TCC CCA CAG CGC TAC ATC TCC GAG CCC TAC TTG GCC CTG CAC GAA GAC 6750 Ser Pro Gin Arg Tyr He Ser Glu Pro Tyr Leu Ala Leu His Glu Asp 2180 2185 2190 2195 TCC CAC GCC TCA GAC TGT GTT GAG GAG GAG ACG CTC ACT TTC GAA GCA 6798 Ser His Ala Ser Asp Cys Val Glu Glu Glu Thr Leu Thr Phe Glu Ala 2200 2205 2210 GCC GTG GCT ACT AGC CTG GGC CGT TCC AAC ACC ATC GGC TCA GCC CCA 6846 Ala Val Ala Thr Ser Leu Gly Arg Ser Asn Thr He Gly Ser Ala Pro 2215 2220 2225 CCC CTG CGG CAT AGC TGG CAG ATG CCC AAC GGG CAC TAT CGG CGG CGG 6894 Pro Leu Arg His Ser Trp Gin Met Pro Asn Gly His Tyr Arg Arg Arg ' 2230 2235 2240 AGG CGC GGG GGG CCT GGG CCA GGC ATG ATG TGT GGG GCT GTC AAC AAC 6942 Arg Arg Gly Gly Pro Gly Pro Gly Met Met Cys Gly Ala Val Asn Asn 2245 2250 2255 CTG CTA AGT GAC ACG GAA GAA GAT GAC AAA TGC TAGAGGCTGC TCCCCCCTCC 6995 Leu Leu Ser Asp Thr Glu Glu Asp Asp Lys Cys 2260 2265 2270 GATGCATGCT CTTCTCTCAC ATGGAGAAAA CCAAGACAGA ATTGGGAAGC CAGTGCGGCC 7055 CCGCGGGGAG GAAGAGGGAA AAGGAAGATG GAAG 7089 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2634 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1983 (D) OTHER INFORMATION: /standard_name= "Beta-2d" ( i) SEQUENCE DESCRIPTION: SEQ ID NO:26: ATG GTC CAA AGG GAC ATG TCC AAG TCT CCT CCC ACA CCG GCG GCG GCG 48 Met Val Gin Arg Asp Met Ser Lys Ser Pro Pro Thr Pro Ala Ala Ala 1 5 10 15 GTG GCG CAG GAG ATC CAG ATG GAA CTG CTA GAG AAC GTG GCT CCC GCG 96 Val Ala Gin Glu He Gin Met Glu Leu Leu Glu Asn Val Ala Pro Ala 20 25 30 GGG GCG CTC GGA GCC GCC GCA CAG TCA TAT GGA AAA GGA GCC AGA AGG 144 Gly Ala Leu Gly Ala Ala Ala Gin Ser Tyr Gly Lys Gly Ala Arg Arg 35 40 45 AAA AAC AGA TTT AAA GGA TCT GAT GGA AGC ACG TCA TCT GAT ACT ACC 192 Lys Asn Arg Phe Lys Gly Ser Asp Gly Ser Thr Ser Ser Asp Thr Thr 50 55 60 TCA AAT AGT TTT GTT CGC CAG GGT TCG GCA GAC TCC TAC ACT AGC CGT 240 Ser Asn Ser Phe Val Arg Gin Gly Ser Ala Asp Ser Tyr Thr Ser Arg 65 70 75 80 CCA TCC GAT TCC GAT GTA TCT CTG GAG GAG GAC CGG GAG GCA GTG CGC 288 Pro Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala Val Arg 85 90 95 AGA GAA GCG GAG CGG CAG GCC CAG GCA CAG TTG GAA AAA GCA AAG ACA 336 Arg Glu Ala Glu Arg Gin Ala Gin Ala Gin Leu Glu Lys Ala Lys Thr 100 105 110 AAG CCC GTT GCA TTT GCG GTT CGG ACA AAT GTC AGC TAC AGT GCG GCC 384 Lys Pro Val Ala Phe Ala Val Arg Thr Asn Val Ser Tyr Ser Ala Ala 115 120 125 CAT GAA GAT GAT GTT CCA GTG CCT GGC ATG GCC ATC TCA TTC GAA GCA 432 His Glu Asp Asp Val Pro Val Pro Gly Met Ala He Ser Phe Glu Ala 130 135 140 AAA GAT TTT CTG CAT GTT AAG GAA AAA TTT AAC AAT GAC TGG TGG ATA 480 Lys Asp Phe Leu His Val Lys Glu Lys Phe Asn Asn Asp Trp Trp He 145 150 155 160 GGG CGA TTG GTA AAA GAA GGC TGT GAA ATC GGA TTC ATT CCA AGC CCA 528 Gly Arg Leu Val Lys Glu Gly Cys Glu He Gly Phe He Pro Ser Pro 165 170 175 GTC AAA CTA GAA AAC ATG AGG CTG CAG CAT GAA CAG AGA GCC AAG CAA 576 Val Lys Leu Glu Asn Met Arg Leu Gin His Glu Gin Arg Ala Lys Gin 180 185 190 GGG AAA TTC TAC TCC AGT AAA TCA GGA GGA AAT TCA TCA TCC AGT TTG 624 Gly Lys Phe Tyr Ser Ser Lys Ser Gly Gly Asn Ser Ser Ser Ser Leu 195 200 205 GGT GAC ATA GTA CCT AGT TCC AGA AAA TCA ACA CCT CCA TCA TCT GCT 672 Gly Asp He Val Pro Ser Ser Arg Lys Ser Thr Pro Pro Ser Ser Ala 210 215 220 ATA GAC ATA GAT GCT ACT GGC TTA GAT GCA GAA GAA AAT GAT ATT CCA 720 He Asp He Asp Ala Thr Gly Leu Asp Ala Glu Glu Asn Asp He Pro 225 230 235 240 GCA AAC CAC CGC TCC CCT AAA CCC AGT GCA AAC AGT GTA ACG TCA CCC 768 Ala Asn His Arg Ser Pro Lys Pro Ser Ala Asn Ser Val Thr Ser Pro 245 250 255 CAC TCC AAA GAG AAA AGA ATG CCC TTC TTT AAG AAG ACA GAG CAC ACT 816 His Ser Lys Glu Lys Arg Met Pro Phe Phe Lys Lys Thr Glu His Thr 260 265 270 CCT CCG TAT GAT GTG GTA CCT TCC ATG CGA CCA GTG GTC CTA GTG GGC 864 Pro Pro Tyr Asp Val Val Pro Ser Met Arg Pro Val Val Leu Val Gly 275 280 285 CCT TCT CTG AAG GGC TAC GAG GTC ACA GAT ATG ATG CAA AAA GCG CTG 912 Pro Ser Leu Lys Gly Tyr Glu Val Thr Asp Met Met Gin Lys Ala Leu 290 295 300 TTT GAT TTT TTA AAA CAC AGA TTT GAA GGG CGG ATA TCC ATC ACA AGG 960 Phe Asp Phe Leu Lys His Arg Phe Glu Gly Arg He Ser He Thr Arg 305 310 315 320 GTC ACC GCT GAC ATC TCG CTT GCC AAA CGC TCG GTA TTA AAC AAT CCC 1008 Val Thr Ala Asp He Ser Leu Ala Lys Arg Ser Val Leu Asn Asn Pro 325 330 335 AGT AAG CAC GCA ATA ATA GAA AGA TCC AAC ACA AGG TCA AGC TTA GCG 1056 Ser Lys His Ala He He Glu Arg Ser Asn Thr Arg Ser Ser Leu Ala 340 345 350 GAA GTT CAG AGT GAA ATC GAA AGG ATT TTT GAA CTT GCA AGA ACA TTG 1104 Glu Val Gin Ser Glu He Glu Arg He Phe Glu Leu Ala Arg Thr Leu 355 360 365 CAG TTG GTG GTC CTT GAC GCG GAT ACA ATT AAT CAT CCA GCT CAA CTC 1152 Gin Leu Val Val Leu Asp Ala Asp Thr He Asn His Pro Ala Gin Leu 370 375 380 AGT AAA ACC TCC TTG GCC CCT ATT ATA GTA TAT GTA AAG ATT TCT TCT 1200 Ser Lys Thr Ser Leu Ala Pro He He Val Tyr Val Lys He Ser Ser 385 390 395 400 CCT AAG GTT TTA CAA AGG TTA ATA AAA TCT CGA GGG AAA TCT CAA GCT 1248 Pro Lys Val Leu Gin Arg Leu He Lys Ser Arg Gly Lys Ser Gin Ala 405 410 415 AAA CAC CTC AAC GTC CAG ATG GTA GCA GCT GAT AAA CTG GCT CAG TGT 1296 Lys His Leu Asn Val Gin Met Val Ala Ala Asp Lys Leu Ala Gin Cys 420 425 430 CCT CCA GAG CTG TTC GAT GTG ATC TTG GAT GAG AAC CAG CTT GAG GAT 1344 Pro Pro Glu Leu Phe Asp Val He Leu Asp Glu Asn Gin Leu Glu Asp 435 440 445 GCC TGT GAG CAC CTT GCC GAC TAT CTG GAG GCC TAC TGG AAG GCC ACC 1392 Ala Cys Glu His Leu Ala Asp Tyr Leu Glu Ala Tyr Trp Lys Ala Thr 450 455 460 CAT CCT CCC AGC AGT AGC CTC CCC AAC CCT CTC CTT AGC CGT ACA TTA 1440 His Pro Pro Ser Ser Ser Leu Pro Asn Pro Leu Leu Ser Arg Thr Leu 465 470 475 480 GCC ACT TCA AGT CTG CCT CTT AGC CCC ACC CTA GCC TCT AAT TCA CAG 1488 Ala Thr Ser Ser Leu Pro Leu Ser Pro Thr Leu Ala Ser Asn Ser Gin 485 490 495 GGT TCT CAA GGT GAT CAG AGG ACT GAT CGC TCC GCT CCT ATC CGT TCT 1536 Gly Ser Gin Gly Asp Gin Arg Thr Asp Arg Ser Ala Pro He Arg Ser 500 505 510 GCT TCC CAA GCT GAA GAA GAA CCT AGT GTG GAA CCA GTC AAG AAA TCC 1584 Ala Ser Gin Ala Glu Glu Glu Pro Ser Val Glu Pro Val Lys Lys Ser 515 520 525 CAG CAC CGC TCT TCC TCC TCA GCC CCA CAC CAC AAC CAT CGC AGT GGG 1632 Gin His Arg Ser Ser Ser Ser Ala Pro His His Asn His Arg Ser Gly 530 535 540 ACA AGT CGC GGC CTC TCC AGG CAA GAG ACA TTT GAC TCG GAA ACC CAG 1680 Thr Ser Arg Gly Leu Ser Arg Gin Glu Thr Phe Asp Ser Glu Thr Gin 545 550 555 560 GAG AGT CGA GAC TCT GCC TAC GTA GAG CCA AAG GAA GAT TAT TCC CAT 1728 Glu Ser Arg Asp Ser Ala Tyr Val Glu Pro Lys Glu Asp Tyr Ser His 565 570 575 GAC CAC GTG GAC CAC TAT GCC TCA CAC CGT GAC CAC AAC CAC AGA GAC 1776 Asp His Val Asp His Tyr Ala Ser His Arg Asp His Asn His Arg Asp 580 585 590 GAG ACC CAC GGG AGC AGT GAC CAC AGA CAC AGG GAG TCC CGG CAC CGT 1824 Glu Thr His Gly Ser Ser Asp His Arg His Arg Glu Ser Arg His Arg 595 600 605 TCC CGG GAC GTG GAT CGA GAG CAG GAC CAC AAC GAG TGC AAC AAG CAG 1872 Ser Arg Asp Val Asp Arg Glu Gin Asp His Asn Glu Cys Asn Lys Gin 610 615 620 CGC AGC CGT CAT AAA TCC AAG GAT CGC TAC TGT GAA AAG GAT GGA GAA 1920 Arg Ser Arg His Lys Ser Lys Asp Arg Tyr Cys Glu Lys Asp Gly Glu 625 630 635 640 GTG ATA TCA AAA AAA CGG AAT GAG GCT GGG GAG TGG AAC AGG GAT GTT 1968 Val He Ser Lys Lys Arg Asn Glu Ala Gly Glu Trp Asn Arg Asp Val 645 650 655 TAC ATC CCC CAA TGAGTTTTGC CCTTTTGTGT TTTTTTTTTT TTTTTTTTGA 2020 Tyr He Pro Gin 660 AGTCTTGTAT AACTAACAGC ATCCCCAAAA CAAAAAGTCT TTGGGGTCTA CACTGCAATC 2080 ATATGTGATC TGTCTTGTAA TATTTTGTAT TATTGCTGTT GCTTGAATAG CAATAGCATG 2140 GATAGAGTAT TGAGATACTT TTTCTTTTGT AAGTGCTACA TAAATTGGCC TGGTATGGCT 2200 GCAGTCCTCC GGTTGCATAC TGGACTCTTC AAAAACTGTT TTGGGTAGCT GCCACTTGAA 2260 CAAAATCTGT TGCCACCCAG GTGATGTTAG TGTTTTAAGA AATGTAGTTG ATGTATCCAA 2320 CAAGCCAGAA TCAGCACAGA TAAAAAGTGG AATTTCTTGT TTCTCCAGAT TTTTAATACG 2380 TTAATACGCA GGCATCTGAT TTGCATATTC ATTCATGGAC CACTGTTTCT TGCTTGTACC 2440 TCTGGCTGAC TAAATTTGGG GACAGATTCA GTCTTGCCTT ACACAAAGGG GATCATAAAG 2500 TTAGAATCTA TTTTCTATGT ACTAGTACTG TGTACTGTAT AGACAGTTTG TAAATGTTAT 2560 TTCTGCAAAC AAACACCTCC TTATTATATA TAATATATAT ATATATATCA GTTTGATCAC 2620 ACTATTTTAG AGTC 2634 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1823 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 69..1631 (D) OTHER INFORMATION: /standard_name= "Beta-4" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: AGCCCAGCCT CGGGGGCCAG CCCCCTCCGC CCACCGCACA CGGGCTGGCC ATGCGGCGGC 60 TCTGAACG ATG TCC TCC TCC TCC TAC GCC AAG AAC GGG ACC GCG GAC GGG 110 Met Ser Ser Ser Ser Tyr Ala Lys Asn Gly Thr Ala Asp Gly 1 5 10 CCG CAC TCC CCC ACC TCG CAG GTG GCC CGA GGC ACC ACA ACC CGG AGG 158 Pro His Ser Pro Thr Ser Gin Val Ala Arg Gly Thr Thr Thr Arg Arg 15 20 25 30 AGC AGG TTG AAA AGA TCC GAT GGC AGC ACC ACT TCG ACC AGC TTC ATC 206 Ser Arg Leu Lys Arg Ser Asp Gly Ser Thr Thr Ser Thr Ser Phe He 35 40 45 CTC AGA CAG GGT TCA GCG GAT TCC TAC ACA AGC AGG CCG TCT GAC TCC 254 Leu Arg Gin Gly Ser Ala Asp Ser Tyr Thr Ser Arg Pro Ser Asp Ser 50 55 60 GAT GTC TCT TTG GAA GAG GAC CGG GAA GCA ATT CGA CAG GAG AGA GAA 302 Asp Val Ser Leu Glu Glu Asp Arg Glu Ala He Arg Gin Glu Arg Glu 65 70 75 CAG CAA GCA GCT ATC CAG CTT GAG AGA GCA AAG TCC AAA CCT GTA GCA 350 Gin Gin Ala Ala He Gin Leu Glu Arg Ala Lys Ser Lys Pro Val Ala 80 85 90 TTT GCC GTG AAG ACA AAT GTG AGC TAC TGC GGC GCC CTG GAC GAG GAT 398 Phe Ala Val Lys Thr Asn Val Ser Tyr Cys Gly Ala Leu Asp Glu Asp 95 100 105 110 GTG CCT GTT CCA AGC ACA GCT ATC TCC TTT GAT GCT AAA GAC TTT CTA 446 Val Pro Val Pro Ser Thr Ala He Ser Phe Asp Ala Lys Asp Phe Leu 115 120 125 CAT ATT AAA GAG AAA TAT AAC AAT GAT TGG TGG ATA GGA AGG CTG GTG 494 His He Lys Glu Lys Tyr Asn Asn Asp Trp Trp He Gly Arg Leu Val 130 135 140 AAA GAG GGC TGT GAA ATT GGC TTC ATT CCA AGT CCA CTC AGA TTG GAG 542 Lys Glu Gly Cys Glu He Gly Phe He Pro Ser Pro Leu Arg Leu Glu 145 150 155 AAC ATA CGG ATC CAG CAA GAA CAA AAA AGA GGA CGT TTT CAC GGA GGG 590 Asn He Arg He Gin Gin Glu Gin Lys Arg Gly Arg Phe His Gly Gly 160 165 170 AAA TCA AGT GGA AAT TCT TCT TCA AGT CTT GGA GAA ATG GTA TCT GGG 638 Lys Ser Ser Gly Asn Ser Ser Ser Ser Leu Gly Glu Met Val Ser Gly 175 180 185 190 ACA TTC CGA GCA ACT CCC ACA TCA ACA GCA AAA CAG AAG CAA AAA GTG 686 Thr Phe Arg Ala Thr Pro Thr Ser Thr Ala Lys Gin Lys Gin Lys Val 195 200 205 ACG GAG CAC ATT CCT CCT TAC GAT GTT GTA CCG TCA ATG CGT CCG GTG 734 Thr Glu His He Pro Pro Tyr Asp Val Val Pro Ser Met Arg Pro Val 210 215 220 GTG TTA GTG GGG CCG TCA CTG AAA GGT TAC GAG GTA ACA GAC ATG ATG 782 Val Leu Val Gly Pro Ser Leu Lys Gly Tyr Glu Val Thr Asp Met Met 225 230 235 CAG AAA GCC CTC TTT GAT TCC CTG AAG CAC AGG TTT GAT GGG AGG ATT 830 Gin Lys Ala Leu Phe Asp Ser Leu Lys His Arg Phe Asp Gly Arg He 240 245 250 TCA ATA ACG AGA GTG ACA GCT GAC ATT TCT CTT GCT AAG AGG TCT GTC 878 Ser He Thr Arg Val Thr Ala Asp He Ser Leu Ala Lys Arg Ser Val 255 260 265 270 CTA AAT AAT CCC AGC AAG AGA GCA ATA ATT GAA CGT TCG AAC ACC CGG ' 926 Leu Asn Asn Pro Ser Lys Arg Ala He He Glu Arg Ser Asn Thr Arg 275 280 285 TCC AGC TTA GCG GAA GTA CAA AGT GAA ATT GAA AGA ATC TTT GAG TTG 974 Ser Ser Leu Ala Glu Val Gin Ser Glu He Glu Arg He Phe Glu Leu 290 295 300 GCA AGA TCT TTG CAA CTG GTT GTT CTT GAT GCA GAC ACC ATC AAT CAC 1022 Ala Arg Ser Leu Gin Leu Val Val Leu Asp Ala Asp Thr He Asn His 305 310 315 CCA GCA CAA CTT ATA AAG ACT TCC TTA GCA CCA ATT ATT GTT CAT GTA 1070 Pro Ala Gin Leu He Lys Thr Ser Leu Ala Pro He He Val His Val 320 325 330 AAA GTC TCA TCT CCA AAG GTT TTA CAG CGG TTG ATT AAA TCT AGA GGA 1118 Lys Val Ser Ser Pro Lys Val Leu Gin Arg Leu He Lys Ser Arg Gly 335 340 345 350 AAG TCA CAA AGT AAA CAC TTG AAT GTT CAA CTG GTG GCA GCT GAT AAA 1166 Lys Ser Gin Ser Lys His Leu Asn Val Gin Leu Val Ala Ala Asp Lys 355 360 365 CTT GCA CAA TGC CCC CCA GAA ATG TTT GAT GTT ATA TTG GAT GAA AAT 1214 Leu Ala Gin Cys Pro Pro Glu Met Phe Asp Val He Leu Asp Glu Asn 370 375 380 CAG CTT GAG GAT GCA TGT GAA CAT CTA GGG GAG TAC CTG GAG GCG TAC 1262 Gin Leu Glu Asp Ala Cys Glu His Leu Gly Glu Tyr Leu Glu Ala Tyr 385 390 395 TGG CGT GCC ACC CAC ACA ACC AGT AGC ACA CCC ATG ACC CCG CTG CTG 1310 Trp Arg Ala Thr His Thr Thr Ser Ser Thr Pro Met Thr Pro Leu Leu 400 405 410 GGA AGG AAT TTG GGC TCC ACG GCA CTC TCA CCA TAT CCC ACA GCA ATT 1358 Gly Arg Asn Leu Gly Ser Thr Ala Leu Ser Pro Tyr Pro Thr Ala He 415 420 425 430 TCT GGG TTA CAG AGT CAG CGA ATG AGG CAC AGC AAC CAC TCC ACA GAG 1406 Ser Gly Leu Gin Ser Gin Arg Met Arg His Ser Asn His Ser Thr Glu 435 440 445 AAC TCT CCA ATT GAA AGA CGA AGT CTA ATG ACC TCT GAT GAA AAT TAT 1454 Asn Ser Pro He Glu Arg Arg Ser Leu Met Thr Ser Asp Glu Asn Tyr 450 455 460 CAC AAT GAA AGG GCT CGG AAG AGT AGG AAC CGC TTG TCT TCC AGT TCT 1502 His Asn Glu Arg Ala Arg Lys Ser Arg Asn Arg Leu Ser Ser Ser Ser 465 470 475 CAG CAT AGC CGA GAT CAT TAC CCT CTT GTG GAA GAA GAT TAC CCT GAC 1550 Gin His Ser Arg Asp His Tyr Pro Leu Val Glu Glu Asp Tyr Pro Asp 480 485 490 TCA TAC CAG GAC ACT TAC AAA CCC CAT AGG AAC CGA GGA TCA CCT GGG 1598 Ser Tyr Gin Asp Thr Tyr Lys Pro His Arg Asn Arg Gly Ser Pro Gly 495 500 505 510 GGA TAT AGC CAT GAC TCC CGA CAT AGG CTT TGAGTCTAAT GAAACAAAAA 1648 Gly Tyr Ser His Asp Ser Arg His Arg Leu 515 520 ATATTCATCT GTTGACAATT TGCCATAGCA GTGCTAGGAT AAACCAATCA TCTTAACTTG 1708 GCTAACATAG CACAGTATTT ACTGTGCTAA TGGGCTGCTG TCATTTTATG CTAAGTAAGG 1768 GGCAAAAAAA AAAATTACAT TATGCCCTTG AGTCTAGATG GATATTAGAT GCCCG 1823 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 520 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Met Ser Ser Ser Ser Tyr Ala Lys Asn Gly Thr Ala Asp Gly Pro His 1 5 10 15 Ser Pro Thr Ser Gin Val Ala Arg Gly Thr Thr Thr Arg Arg Ser Arg 20 25 30 Leu Lys Arg Ser Asp Gly Ser Thr Thr Ser Thr Ser Phe He Leu Arg 35 40 45 Gin Gly Ser Ala Asp Ser Tyr Thr Ser Arg Pro Ser Asp Ser Asp Val 50 55 60 Ser Leu Glu Glu Asp Arg Glu Ala He Arg Gin Glu Arg Glu Gin Gin 65 70 75 80 Ala Ala He Gin Leu Glu Arg Ala Lys Ser Lys Pro Val Ala Phe Ala 85 90 95 Val Lys Thr Asn Val Ser Tyr Cys Gly Ala Leu Asp Glu Asp Val Pro 100 105 110 Val Pro Ser Thr Ala He Ser Phe Asp Ala Lys Asp Phe Leu His He 115 120 125 Lys Glu Lys Tyr Asn Asn Asp Trp Trp He Gly Arg Leu Val Lys Glu 130 135 140 Gly Cys Glu He Gly Phe He Pro Ser Pro Leu Arg Leu Glu Asn He 145 150 155 160 Arg He Gin Gin Glu Gin Lys Arg Gly Arg Phe His Gly Gly Lys Ser 165 170 175 Ser Gly Asn Ser Ser Ser Ser Leu Gly Glu Met Val Ser Gly Thr Phe 180 185 190 Arg Ala Thr Pro Thr Ser Thr Ala Lys Gin Lys Gin Lys Val Thr Glu 195 200 205 His He Pro Pro Tyr Asp Val Val Pro Ser Met Arg Pro Val Val Leu 210 215 220 Val Gly Pro Ser Leu Lys Gly Tyr Glu Val Thr Asp Met Met Gin Lys 225 230 235 240 Ala Leu Phe Asp Ser Leu Lys His Arg Phe Asp Gly Arg He Ser He 245 250 255 Thr Arg Val Thr Ala Asp He Ser Leu Ala Lys Arg Ser Val Leu Asn 260 265 270 Asn Pro Ser Lys Arg Ala He He Glu Arg Ser Asn Thr Arg Ser Ser 275 280 285 Leu Ala Glu Val Gin Ser Glu He Glu Arg He Phe Glu Leu Ala Arg 290 295 300 Ser Leu Gin Leu Val Val Leu Asp Ala Asp Thr He Asn His Pro Ala 305 310 315 320 Gin Leu He Lys Thr Ser Leu Ala Pro He He Val His Val Lys Val 325 330 335 Ser Ser Pro Lys Val Leu Gin Arg Leu He Lys Ser Arg Gly Lys Ser 340 345 350 Gin Ser Lys His Leu Asn Val Gin Leu Val Ala Ala Asp Lys Leu Ala 355 360 365 Gin Cys Pro Pro Glu Met Phe Asp Val He Leu Asp Glu Asn Gin Leu 370 375 380 Glu Asp Ala Cys Glu His Leu Gly Glu Tyr Leu Glu Ala Tyr Trp Arg 385 390 395 400 Ala Thr His Thr Thr Ser Ser Thr Pro Met Thr Pro Leu Leu Gly Arg 405 410 415 Asn Leu Gly Ser Thr Ala Leu Ser Pro Tyr Pro Thr Ala He Ser Gly 420 425 430 Leu Gin Ser Gin Arg Met Arg His Ser Asn His Ser Thr Glu Asn Ser 435 440 445 Pro He Glu Arg Arg Ser Leu Met Thr Ser Asp Glu Asn Tyr His Asn 450 455 460 Glu Arg Ala Arg Lys Ser Arg Asn Arg Leu Ser Ser Ser Ser Gin His 465 470 475 480 Ser Arg Asp His Tyr Pro Leu Val Glu Glu Asp Tyr Pro Asp Ser Tyr 485 490 495 Gln Asp Thr Tyr Lys Pro His Arg Asn Arg Gly Ser Pro Gly Gly Tyr 500 505 510 Ser His Asp Ser Arg His Arg Leu 515 520 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3636 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 35..3346 (D) OTHER INFORMATION: /standard_name= "Alpha-2a" (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..34 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 3347. -3636 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GCGGGGGAGG GGGCATTGAT CTTCGATCGC GAAG ATG GCT GCT GGC TGC CTG 52 Met Ala Ala Gly Cys Leu 1 5 CTG GCC TTG ACT CTG ACA CTT TTC CAA TCT TTG CTC ATC GGC CCC TCG 100 Leu Ala Leu Thr Leu Thr Leu Phe Gin Ser Leu Leu He Gly Pro Ser 10 15 20 TCG GAG GAG CCG TTC CCT TCG GCC GTC ACT ATC AAA TCA TGG GTG GAT 148 Ser Glu Glu Pro Phe Pro Ser Ala Val Thr He Lys Ser Trp Val Asp 25 30 35 AAG ATG CAA GAA GAC CTT GTC ACA CTG GCA AAA ACA GCA AGT GGA GTC 196 Lys Met Gin Glu Asp Leu Val Thr Leu Ala Lys Thr Ala Ser Gly Val 40 45 50 AAT CAG CTT GTT GAT ATT TAT GAG AAA TAT CAA GAT TTG TAT ACT GTG 244 Asn Gin Leu Val Asp He Tyr Glu Lys Tyr Gin Asp Leu Tyr Thr Val 55 60 65 70 GAA CCA AAT AAT GCA CGC CAG CTG GTA GAA ATT GCA GCC AGG GAT ATT 292 Glu Pro Asn Asn Ala Arg Gin Leu Val Glu He Ala Ala Arg Asp He 75 80 85 GAG AAA CTT CTG AGC AAC AGA TCT AAA GCC CTG GTG AGC CTG GCA TTG 340 Glu Lys Leu Leu Ser Asn Arg Ser Lys Ala Leu Val Ser Leu Ala Leu 90 95 100 GAA GCG GAG AAA GTT CAA GCA GCT CAC CAG TGG AGA GAA GAT TTT GCA 388 Glu Ala Glu Lys Val Gin Ala Ala His Gin Trp Arg Glu Asp Phe Ala 105 110 115 AGC AAT GAA GTT GTC TAC TAC AAT GCA AAG GAT GAT CTC GAT CCT GAG 436 Ser Asn Glu Val Val Tyr Tyr Asn Ala Lys Asp Asp Leu Asp Pro Glu 120 125 130 AAA AAT GAC AGT GAG CCA GGC AGC CAG AGG ATA AAA CCT GTT TTC ATT 484 Lys Asn Asp Ser Glu Pro Gly Ser Gin Arg He Lys Pro Val Phe He 135 140 145 150 GAA GAT GCT AAT TTT GGA CGA CAA ATA TCT TAT CAG CAC GCA GCA GTC 532 Glu Asp Ala Asn Phe Gly Arg Gin He Ser Tyr Gin His Ala Ala Val 155 160 165 CAT ATT CCT ACT GAC ATC TAT GAG GGC TCA ACA ATT GTG TTA AAT GAA 580 His He Pro Thr Asp He Tyr Glu Gly Ser Thr He Val Leu Asn Glu 170 175 180 CTC AAC TGG ACA AGT GCC TTA GAT GAA GTT TTC AAA AAG AAT CGC GAG 628 Leu Asn Trp Thr Ser Ala Leu Asp Glu Val Phe Lys Lys Asn Arg Glu 185 190 195 GAA GAC CCT TCA TTA TTG TGG CAG GTT TTT GGC AGT GCC ACT GGC CTA 676 Glu Asp Pro Ser Leu Leu Trp Gin Val Phe Gly Ser Ala Thr Gly Leu 200 205 210 GCT CGA TAT TAT CCA GCT TCA CCA TGG GTT GAT AAT AGT AGA ACT CCA 724 Ala Arg Tyr Tyr Pro Ala Ser Pro Trp Val Asp Asn Ser Arg Thr Pro 215 220 225 230 AAT AAG ATT GAC CTT TAT GAT GTA CGC AGA AGA CCA TGG TAC ATC CAA 772 Asn Lys He Asp Leu Tyr Asp Val Arg Arg Arg Pro Trp Tyr He Gin 235 240 245 GGA GCT GCA TCT CCT AAA GAC ATG CTT ATT CTG GTG GAT GTG AGT GGA 820 Gly Ala Ala Ser Pro Lys Asp Met Leu He Leu Val Asp Val Ser Gly 250 255 260 AGT GTT AGT GGA TTG ACA CTT AAA CTG ATC CGA ACA TCT GTC TCC GAA 868 Ser Val Ser Gly Leu Thr Leu Lys Leu He Arg Thr Ser Val Ser Glu 265 270 275 ATG TTA GAA ACC CTC TCA GAT GAT GAT TTC GTG AAT GTA GCT TCA TTT 916 Met Leu Glu Thr Leu Ser Asp Asp Asp Phe Val Asn Val Ala Ser Phe 280 285 290 AAC AGC AAT GCT CAG GAT GTA AGC TGT TTT CAG CAC CTT GTC CAA GCA 964 Asn Ser Asn Ala Gin Asp Val Ser Cys Phe Gin His Leu Val Gin Ala 295 300 305 310 AAT GTA AGA AAT AAA AAA GTG TTG AAA GAC GCG GTG AAT AAT ATC ACA 1012 Asn Val Arg Asn Lys Lys Val Leu Lys Asp Ala Val Asn Asn He Thr 315 320 325 GCC AAA GGA ATT ACA GAT TAT AAG AAG GGC TTT AGT TTT GCT TTT GAA 1060 Ala Lys Gly He Thr Asp Tyr Lys Lys Gly Phe Ser Phe Ala Phe Glu 330 335 340 CAG CTG CTT AAT TAT AAT GTT TCC AGA GCA AAC TGC AAT AAG ATT ATT 1108 Gin Leu Leu Asn Tyr Asn Val Ser Arg Ala Asn Cys Asn Lys He He 345 350 355 ATG CTA TTC ACG GAT GGA GGA GAA GAG AGA GCC CAG GAG ATA TTT AAC 1156 Met Leu Phe Thr Asp Gly Gly Glu Glu Arg Ala Gin Glu He Phe Asn 360 365 370 AAA TAC AAT AAA GAT AAA AAA GTA CGT GTA TTC AGG TTT TCA GTT GGT 1204 Lys Tyr Asn Lys Asp Lys Lys Val Arg Val Phe Arg Phe Ser Val Gly 375 380 385 390 CAA CAC AAT TAT GAG AGA GGA CCT ATT CAG TGG ATG GCC TGT GAA AAC 1252 Gin His Asn Tyr Glu Arg Gly Pro He Gin Trp Met Ala Cys Glu Asn 395 400 405 AAA GGT TAT TAT TAT GAA ATT CCT TCC ATT GGT GCA ATA AGA ATC AAT 1300 Lys Gly Tyr Tyr Tyr Glu He Pro Ser He Gly Ala He Arg He Asn 410 415 420 ACT CAG GAA TAT TTG GAT GTT TTG GGA AGA CCA ATG GTT TTA GCA GGA 1348 Thr Gin Glu Tyr Leu Asp Val Leu Gly Arg Pro Met Val Leu Ala Gly 425 430 435 GAC AAA GCT AAG CAA GTC CAA TGG ACA AAT GTG TAC CTG GAT GCA TTG 1396 Asp Lys Ala Lys Gin Val Gin Trp Thr Asn Val Tyr Leu Asp Ala Leu 440 445 450 GAA CTG GGA CTT GTC ATT ACT GGA ACT CTT CCG GTC TTC AAC ATA ACC 1444 Glu Leu Gly Leu Val He Thr Gly Thr Leu Pro Val Phe Asn He Thr 455 460 465 470 GGC CAA TTT GAA AAT AAG ACA AAC TTA AAG AAC CAG CTG ATT CTT GGT 1492 Gly Gin Phe Glu Asn Lys Thr Asn Leu Lys Asn Gin Leu He Leu Gly 475 480 485 GTG ATG GGA GTA GAT GTG TCT TTG GAA GAT ATT AAA AGA CTG ACA CCA 1540 Val Met Gly Val Asp Val Ser Leu Glu Asp He Lys Arg Leu Thr Pro 490 495 500 CGT TTT ACA CTG TGC CCC AAT GGG TAT TAC TTT GCA ATC GAT CCT AAT 1588 Arg Phe Thr Leu Cys Pro Asn Gly Tyr Tyr Phe Ala He Asp Pro Asn 505 510 515 GGT TAT GTT TTA TTA CAT CCA AAT CTT CAG CCA AAG CCT ATT GGT GTA 1636 Gly Tyr Val Leu Leu His Pro Asn Leu Gin Pro Lys Pro He Gly Val 520 525 530 GGT ATA CCA ACA ATT AAT TTA AGA AAA AGG AGA CCC AAT ATC CAG AAC 1684 Gly He Pro Thr He Asn Leu Arg Lys Arg Arg Pro Asn He Gin Asn 535 540 545 550 CCC AAA TCT CAG GAG CCA GTA ACA TTG GAT TTC CTT GAT GCA GAG TTA 1732 Pro Lys Ser Gin Glu Pro Val Thr Leu Asp Phe Leu Asp Ala Glu Leu 555 560 565 GAG AAT GAT ATT AAA GTG GAG ATT CGA AAT AAG ATG ATT GAT GGG GAA 1780 Glu Asn Asp He Lys Val Glu He Arg Asn Lys Met He Asp Gly Glu 570 575 580 AGT GGA GAA AAA ACA TTC AGA ACT CTG GTT AAA TCT CAA GAT GAG AGA 1828 Ser Gly Glu Lys Thr Phe Arg Thr Leu Val Lys Ser Gin Asp Glu Arg 585 590 595 TAT ATT GAC AAA GGA AAC AGG ACA TAC ACA TGG ACA CCT GTC AAT GGC 1876 Tyr He Asp Lys Gly Asn Arg Thr Tyr Thr Trp Thr Pro Val Asn Gly 600 605 610 ACA GAT TAC AGT TTG GCC TTG GTA TTA CCA ACC TAC AGT TTT TAC TAT 1924 Thr Asp Tyr Ser Leu Ala Leu Val Leu Pro Thr Tyr Ser Phe Tyr Tyr 615 620 625 630 ATA AAA GCC AAA CTA GAA GAG ACA ATA ACT CAG GCC AGA TAT TCG GAA 1972 He Lys Ala Lys Leu Glu Glu Thr He Thr Gin Ala Arg Tyr Ser Glu 635 640 645 ACC CTG AAG CCA GAT AAT TTT GAA GAA TCT GGC TAT ACA TTC ATA GCA 2020 Thr Leu Lys Pro Asp Asn Phe Glu Glu Ser Gly Tyr Thr Phe He Ala 650 655 660 CCA AGA GAT TAC TGC AAT GAC CTG AAA ATA TCG GAT AAT AAC ACT GAA 2068 Pro Arg Asp Tyr Cys Asn Asp Leu Lys He Ser Asp Asn Asn Thr Glu 665 670 675 TTT CTT TTA AAT TTC AAC GAG TTT ATT GAT AGA AAA ACT CCA AAC AAC 2116 Phe Leu Leu Asn Phe Asn Glu Phe He Asp Arg Lys Thr Pro Asn Asn 680 685 690 CCA TCA TGT AAC GCG GAT TTG ATT AAT AGA GTC TTG CTT GAT GCA GGC 2164 Pro Ser Cys Asn Ala Asp Leu He Asn Arg Val Leu Leu Asp Ala Gly 695 700 705 710 TTT ACA AAT GAA CTT GTC CAA AAT TAC TGG AGT AAG CAG AAA AAT ATC 2212 Phe Thr Asn Glu Leu Val Gin Asn Tyr Trp Ser Lys Gin Lys Asn He 715 720 725 AAG GGA GTG AAA GCA CGA TTT GTT GTG ACT GAT GGT GGG ATT ACC AGA 2260 Lys Gly Val Lys Ala Arg Phe Val Val Thr Asp Gly Gly He Thr Arg 730 735 740 GTT TAT CCC AAA GAG GCT GGA GAA AAT TGG CAA GAA AAC CCA GAG ACA 2308 Val Tyr Pro Lys Glu Ala Gly Glu Asn Trp Gin Glu Asn Pro Glu Thr 745 750 755 TAT GAG GAC AGC TTC TAT AAA AGG AGC CTA GAT AAT GAT AAC TAT GTT 2356 Tyr Glu Asp Ser Phe Tyr Lys Arg Ser Leu Asp Asn Asp Asn Tyr Val 760 765 770 TTC ACT GCT CCC TAC TTT AAC AAA AGT GGA CCT GGT GCC TAT GAA TCG 2404 Phe Thr Ala Pro Tyr Phe Asn Lys Ser Gly Pro Gly Ala Tyr Glu Ser 775 780 785 790 GGC ATT ATG GTA AGC AAA GCT GTA GAA ATA TAT ATT CAA GGG AAA CTT 2452 Gly He Met Val Ser Lys Ala Val Glu He Tyr He Gin Gly Lys Leu 795 800 805 CTT AAA CCT GCA GTT GTT GGA ATT AAA ATT GAT GTA AAT TCC TGG ATA 2500 Leu Lys Pro Ala Val Val Gly He Lys He Asp Val Asn Ser Trp He 810 815 820 GAG AAT TTC ACC AAA ACC TCA ATC AGA GAT CCG TGT GCT GGT CCA GTT 2548 Glu Asn Phe Thr Lys Thr Ser He Arg Asp Pro Cys Ala Gly Pro Val 825 830 835 TGT GAC TGC AAA AGA AAC AGT GAC GTA ATG GAT TGT GTG ATT CTG GAT 2596 Cys Asp Cys Lys Arg Asn Ser Asp Val Met Asp Cys Val He Leu Asp 840 845 850 GAT GGT GGG TTT CTT CTG ATG GCA AAT CAT GAT GAT TAT ACT AAT CAG 2644 Asp Gly Gly Phe Leu Leu Met Ala Asn His Asp Asp Tyr Thr Asn Gin 855 860 865 870 ATT GGA AGA TTT TTT GGA GAG ATT GAT CCC AGC TTG ATG AGA CAC CTG 2692 He Gly Arg Phe Phe Gly Glu He Asp Pro Ser Leu Met Arg His Leu 875 880 885 GTT AAT ATA TCA GTT TAT GCT TTT AAC AAA TCT TAT GAT TAT CAG TCA 2740 Val Asn He Ser Val Tyr Ala Phe Asn Lys Ser Tyr Asp Tyr Gin Ser 890 895 900 GTA TGT GAG CCC GGT GCT GCA CCA AAA CAA GGA GCA GGA CAT CGC TCA 2788 Val Cys Glu Pro Gly Ala Ala Pro Lys Gin Gly Ala Gly His Arg Ser 905 910 915 GCA TAT GTG CCA TCA GTA GCA GAC ATA TTA CAA ATT GGC TGG TGG GCC 2836 Ala Tyr Val Pro Ser Val Ala Asp He Leu Gin He Gly Trp Trp Ala 920 925 930 ACT GCT GCT GCC TGG TCT ATT CTA CAG CAG TTT CTC TTG AGT TTG ACC 2884 Thr Ala Ala Ala Trp Ser He Leu Gin Gin Phe Leu Leu Ser Leu Thr 935 940 945 950 TTT CCA CGA CTC CTT GAG GCA GTT GAG ATG GAG GAT GAT GAC TTC ACG 2932 Phe Pro Arg Leu Leu Glu Ala Val Glu Met Glu Asp Asp Asp Phe Thr 955 960 965 GCC TCC CTG TCC AAG CAG AGC TGC ATT ACT GAA CAA ACC CAG TAT TTC 2980 Ala Ser Leu Ser Lys Gin Ser Cys He Thr Glu Gin Thr Gin Tyr Phe 970 975 980 TTC GAT AAC GAC AGT AAA TCA TTC AGT GGT GTA TTA GAC TGT GGA AAC 3028 Phe Asp Asn Asp Ser Lys Ser Phe Ser Gly Val Leu Asp Cys Gly Asn 985 990 995 TGT TCC AGA ATC TTT CAT GGA GAA AAG CTT ATG AAC ACC AAC TTA ATA 3076 Cys Ser Arg He Phe His Gly Glu Lys Leu Met Asn Thr Asn Leu He 1000 1005 1010 TTC ATA ATG GTT GAG AGC AAA GGG ACA TGT CCA TGT GAC ACA CGA CTG 3124 Phe He Met Val Glu Ser Lys Gly Thr Cys Pro Cys Asp Thr Arg Leu 1015 1020 1025 1030 CTC ATA CAA GCG GAG CAG ACT TCT GAC GGT CCA AAT CCT TGT GAC ATG 3172 Leu He Gin Ala Glu Gin Thr Ser Asp Gly Pro Asn Pro Cys Asp Met 1035 1040 1045 GTT AAG CAA CCT AGA TAC CGA AAA GGG CCT GAT GTC TGC TTT GAT AAC 3220 Val Lys Gin Pro Arg Tyr Arg Lys Gly Pro Asp Val Cys Phe Asp Asn 1050 1055 1060 AAT GTC TTG GAG GAT TAT ACT GAC TGT GGT GGT GTT TCT GGA TTA AAT 3268 Asn Val Leu Glu Asp Tyr Thr Asp Cys Gly Gly Val Ser Gly Leu Asn 1065 1070 1075 CCC TCC CTG TGG TAT ATC ATT GGA ATC CAG TTT CTA CTA CTT TGG CTG 3316 Pro Ser Leu Trp Tyr He He Gly He Gin Phe Leu Leu Leu Trp Leu 1080 1085 1090 GTA TCT GGC AGC ACA CAC CGG CTG TTA TGACCTTCTA AAAACCAAAT 3363 Val Ser Gly Ser Thr His Arg Leu Leu 1095 1100 CTGCATAGTT AAACTCCAGA CCCTGCCAAA ACATGAGCCC TGCCCTCAAT TACAGTAACG 3423 TAGGGTCAGC TATAAAATCA GACAAACATT AGCTGGGCCT GTTCCATGGC ATAACACTAA 3483 GGCGCAGACT CCTAAGGCAC CCACTGGCTG CATGTCAGGG TGTCAGATCC TTAAACGTGT 3543 GTGAATGCTG CATCATCTAT GTGTAACATC AAAGCAAAAT CCTATACGTG TCCTCTATTG 3603 GAAAATTTGG GCGTTTGTTG TTGCATTGTT GGT 3636 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3585 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 35..3295 (D) OTHER INFORMATION: /standard_name= "Alpha-2c" (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..34 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 3296..3585 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: GCGGGGGAGG GGGCATTGAT CTTCGATCGC GAAG ATG GCT GCT GGC TGC CTG 52 Met Ala Ala Gly Cys Leu 1 5 CTG GCC TTG ACT CTG ACA CTT TTC CAA TCT TTG CTC ATC GGC CCC TCG 100 Leu Ala Leu Thr Leu Thr Leu Phe Gin Ser Leu Leu He Gly Pro Ser 10 15 20 TCG GAG GAG CCG TTC CCT TCG GCC GTC ACT ATC AAA TCA TGG GTG GAT 148 Ser Glu Glu Pro Phe Pro Ser Ala Val Thr He Lys Ser Trp Val Asp 25 30 35 AAG ATG CAA GAA GAC CTT GTC ACA CTG GCA AAA ACA GCA AGT GGA GTC 196 Lys Met Gin Glu Asp Leu Val Thr Leu Ala Lys Thr Ala Ser Gly Val 40 45 50 AAT CAG CTT GTT GAT ATT TAT GAG AAA TAT CAA GAT TTG TAT ACT GTG 244 Asn Gin Leu Val Asp He Tyr Glu Lys Tyr Gin Asp Leu Tyr Thr Val 55 60 65 70 GAA CCA AAT AAT GCA CGC CAG CTG GTA GAA ATT GCA GCC AGG GAT ATT 292 Glu Pro Asn Asn Ala Arg Gin Leu Val Glu He Ala Ala Arg Asp He 75 80 85 GAG AAA CTT CTG AGC AAC AGA TCT AAA GCC CTG GTG AGC CTG GCA TTG 340 Glu Lys Leu Leu Ser Asn Arg Ser Lys Ala Leu Val Ser Leu Ala Leu 90 95 100 GAA GCG GAG AAA GTT CAA GCA GCT CAC CAG TGG AGA GAA GAT TTT GCA 388 Glu Ala Glu Lys Val Gin Ala Ala His Gin Trp Arg Glu Asp Phe Ala 105 110 115 AGC AAT GAA GTT GTC TAC TAC AAT GCA AAG GAT GAT CTC GAT CCT GAG 436 Ser Asn Glu Val Val Tyr Tyr Asn Ala Lys Asp Asp Leu Asp Pro Glu 120 125 130 AAA AAT GAC AGT GAG CCA GGC AGC CAG AGG ATA AAA CCT GTT TTC ATT 484 Lys Asn Asp Ser Glu Pro Gly Ser Gin Arg He Lys Pro Val Phe He 135 140 145 150 GAA GAT GCT AAT TTT GGA CGA CAA ATA TCT TAT CAG CAC GCA GCA GTC 532 Glu Asp Ala Asn Phe Gly Arg Gin He Ser Tyr Gin His Ala Ala Val 155 160 165 CAT ATT CCT ACT GAC ATC TAT GAG GGC TCA ACA ATT GTG TTA AAT GAA 580 His He Pro Thr Asp He Tyr Glu Gly Ser Thr He Val Leu Asn Glu 170 175 180 CTC AAC TGG ACA AGT GCC TTA GAT GAA GTT TTC AAA AAG AAT CGC GAG 628 Leu Asn Trp Thr Ser Ala Leu Asp Glu Val Phe Lys Lys Asn Arg Glu 185 190 195 GAA GAC CCT TCA TTA TTG TGG CAG GTT TTT GGC AGT GCC ACT GGC CTA 676 Glu Asp Pro Ser Leu Leu Trp Gin Val Phe Gly Ser Ala Thr Gly Leu 200 205 210 GCT CGA TAT TAT CCA GCT TCA CCA TGG GTT GAT AAT AGT AGA ACT CCA 724 Ala Arg Tyr Tyr Pro Ala Ser Pro Trp Val Asp Asn Ser Arg Thr Pro 215 220 225 230 AAT AAG ATT GAC CTT TAT GAT GTA CGC AGA AGA CCA TGG TAC ATC CAA 772 Asn Lys He Asp Leu Tyr Asp Val Arg Arg Arg Pro Trp Tyr He Gin 235 240 245 GGA GCT GCA TCT CCT AAA GAC ATG CTT ATT CTG GTG GAT GTG AGT GGA 820 Gly Ala Ala Ser Pro Lys Asp Met Leu He Leu Val Asp Val Ser Gly 250 255 260 AGT GTT AGT GGA TTG ACA CTT AAA CTG ATC CGA ACA TCT GTC TCC GAA 868 Ser Val Ser Gly Leu Thr Leu Lys Leu He Arg Thr Ser Val Ser Glu 265 270 275 ATG TTA GAA ACC CTC TCA GAT GAT GAT TTC GTG AAT GTA GCT TCA TTT 916 Met Leu Glu Thr Leu Ser Asp Asp Asp Phe Val Asn Val Ala Ser Phe 280 285 290 AAC AGC AAT GCT CAG GAT GTA AGC TGT TTT CAG CAC CTT GTC CAA GCA 964 Asn Ser Asn Ala Gin Asp Val Ser Cys Phe Gin His Leu Val Gin Ala 295 300 305 310 AAT GTA AGA AAT AAA AAA GTG TTG AAA GAC GCG GTG AAT AAT ATC ACA 1012 Asn Val Arg Asn Lys Lys Val Leu Lys Asp Ala Val Asn Asn He Thr 315 320 325 GCC AAA GGA ATT ACA GAT TAT AAG AAG GGC TTT AGT TTT GCT TTT GAA 1060 Ala Lys Gly He Thr Asp Tyr Lys Lys Gly Phe Ser Phe Ala Phe Glu 330 335 340 CAG CTG CTT AAT TAT AAT GTT TCC AGA GCA AAC TGC AAT AAG ATT ATT 1108 Gin Leu Leu Asn Tyr Asn Val Ser Arg Ala Asn Cys Asn Lys He He 345 350 355 ATG CTA TTC ACG GAT GGA GGA GAA GAG AGA GCC CAG GAG ATA TTT AAC 1156 Met Leu Phe Thr Asp Gly Gly Glu Glu Arg Ala Gin Glu He Phe Asn 360 365 370 AAA TAC AAT AAA GAT AAA AAA GTA CGT GTA TTC AGG TTT TCA GTT GGT 1204 Lys Tyr Asn Lys Asp Lys Lys Val Arg Val Phe Arg Phe Ser Val Gly 375 380 385 390 CAA CAC AAT TAT GAG AGA GGA CCT ATT CAG TGG ATG GCC TGT GAA AAC 1252 Gin His Asn Tyr Glu Arg Gly Pro He Gin Trp Met Ala Cys Glu Asn 395 400 405 AAA GGT TAT TAT TAT GAA ATT CCT TCC ATT GGT GCA ATA AGA ATC AAT 1300 Lys Gly Tyr Tyr Tyr Glu He Pro Ser He Gly Ala He Arg He Asn 410 415 420 ACT CAG GAA TAT TTG GAT GTT TTG GGA AGA CCA ATG GTT TTA GCA GGA 1348 Thr Gin Glu Tyr Leu Asp Val Leu Gly Arg Pro Met Val Leu Ala Gly 425 430 435 GAC AAA GCT AAG CAA GTC CAA TGG ACA AAT GTG TAC CTG GAT GCA TTG 1396 Asp Lys Ala Lys Gin Val Gin Trp Thr Asn Val Tyr Leu Asp Ala Leu 440 445 450 GAA CTG GGA CTT GTC ATT ACT GGA ACT CTT CCG GTC TTC AAC ATA ACC 1444 Glu Leu Gly Leu Val He Thr Gly Thr Leu Pro Val Phe Asn He Thr 455 460 465 470 GGC CAA TTT GAA AAT AAG ACA AAC TTA AAG AAC CAG CTG ATT CTT GGT 1492 Gly Gin Phe Glu Asn Lys Thr Asn Leu Lys Asn Gin Leu He Leu Gly 475 480 485 GTG ATG GGA GTA GAT GTG TCT TTG GAA GAT ATT AAA AGA CTG ACA CCA 1540 Val Met Gly Val Asp Val Ser Leu Glu Asp He Lys Arg Leu Thr Pro 490 495 500 CGT TTT ACA CTG TGC CCC AAT GGG TAT TAC TTT GCA ATC GAT CCT AAT 1588 Arg Phe Thr Leu Cys Pro Asn Gly Tyr Tyr Phe Ala He Asp Pro Asn 505 510 515 GGT TAT GTT TTA TTA CAT CCA AAT CTT CAG CCA AAG GAG CCA GTA ACA 1636 Gly Tyr Val Leu Leu His Pro Asn Leu Gin Pro Lys Glu Pro Val Thr 520 525 530 TTG GAT TTC CTT GAT GCA GAG TTA GAG AAT GAT ATT AAA GTG GAG ATT 1684 Leu Asp Phe Leu Asp Ala Glu Leu Glu Asn Asp He Lys Val Glu He 535 540 545 550 CGA AAT AAG ATG ATT GAT GGG GAA AGT GGA GAA AAA ACA TTC AGA ACT 1732 Arg Asn Lys Met He Asp Gly Glu Ser Gly Glu Lys Thr Phe Arg Thr 555 560 565 CTG GTT AAA TCT CAA GAT GAG AGA TAT ATT GAC AAA GGA AAC AGG ACA 1780 Leu Val Lys Ser Gin Asp Glu Arg Tyr He Asp Lys Gly Asn Arg Thr 570 575 580 TAC ACA TGG ACA CCT GTC AAT GGC ACA GAT TAC AGT TTG GCC TTG GTA 1828 Tyr Thr Trp Thr Pro Val Asn Gly Thr Asp Tyr Ser Leu Ala Leu Val 585 590 595 TTA CCA ACC TAC AGT TTT TAC TAT ATA AAA GCC AAA CTA GAA GAG ACA 1876 Leu Pro Thr Tyr Ser Phe Tyr Tyr He Lys Ala Lys Leu Glu Glu Thr 600 605 610 ATA ACT CAG GCC AGA TCA AAA AAG GGC AAA ATG AAG GAT TCG GAA ACC 1924 He Thr Gin Ala Arg Ser Lys Lys Gly Lys Met Lys Asp Ser Glu Thr 615 620 625 630 CTG AAG CCA GAT AAT TTT GAA GAA TCT GGC TAT ACA TTC ATA GCA CCA 1972 Leu Lys Pro Asp Asn Phe Glu Glu Ser Gly Tyr Thr Phe He Ala Pro 635 640 645 AGA GAT TAC TGC AAT GAC CTG AAA ATA TCG GAT AAT AAC ACT GAA TTT 2020 Arg Asp Tyr Cys Asn Asp Leu Lys He Ser Asp Asn Asn Thr Glu Phe 650 655 660 CTT TTA AAT TTC AAC GAG TTT ATT GAT AGA AAA ACT CCA AAC AAC CCA 2068 Leu Leu Asn Phe Asn Glu Phe He Asp Arg Lys Thr Pro Asn Asn Pro 665 670 675 TCA TGT AAC GCG GAT TTG ATT AAT AGA GTC TTG CTT GAT GCA GGC TTT 2116 Ser Cys Asn Ala Asp Leu He Asn Arg Val Leu Leu Asp Ala Gly Phe 680 685 690 ACA AAT GAA CTT GTC CAA AAT TAC TGG AGT AAG CAG AAA AAT ATC AAG 2164 Thr Asn Glu Leu Val Gin Asn Tyr Trp Ser Lys Gin Lys Asn He Lys 695 700 705 710 GGA GTG AAA GCA CGA TTT GTT GTG ACT GAT GGT GGG ATT ACC AGA GTT 2212 Gly Val Lys Ala Arg Phe Val Val Thr Asp Gly Gly He Thr Arg Val 715 720 725 TAT CCC AAA GAG GCT GGA GAA AAT TGG CAA GAA AAC CCA GAG ACA TAT 2260 Tyr Pro Lys Glu Ala Gly Glu Asn Trp Gin Glu Asn Pro Glu Thr Tyr 730 735 740 GAG GAC AGC TTC TAT AAA AGG AGC CTA GAT AAT GAT AAC TAT GTT TTC 2308 Glu Asp Ser Phe Tyr Lys Arg Ser Leu Asp Asn Asp Asn Tyr Val Phe 745 750 755 ACT GCT CCC TAC TTT AAC AAA AGT GGA CCT GGT GCC TAT GAA TCG GGC 2356 Thr Ala Pro Tyr Phe Asn Lys Ser Gly Pro Gly Ala Tyr Glu Ser Gly 760 765 770 ATT ATG GTA AGC AAA GCT GTA GAA ATA TAT ATT CAA GGG AAA CTT CTT 2404 He Met Val Ser Lys Ala Val Glu He Tyr He Gin Gly Lys Leu Leu 775 780 785 790 AAA CCT GCA GTT GTT GGA ATT AAA ATT GAT GTA AAT TCC TGG ATA GAG 2452 Lys Pro Ala Val Val Gly He Lys He Asp Val Asn Ser Trp He Glu 795 800 805 AAT TTC ACC AAA ACC TCA ATC AGA GAT CCG TGT GCT GGT CCA GTT TGT 2500 Asn Phe Thr Lys Thr Ser He Arg Asp Pro Cys Ala Gly Pro Val Cys 810 815 820 GAC TGC AAA AGA AAC AGT GAC GTA ATG GAT TGT GTG ATT CTG GAT GAT 2548 Asp Cys Lys Arg Asn Ser Asp Val Met Asp Cys Val He Leu Asp Asp 825 830 835 GGT GGG TTT CTT CTG ATG GCA AAT CAT GAT GAT TAT ACT AAT CAG ATT 2596 Gly Gly Phe Leu Leu Met Ala Asn His Asp Asp Tyr Thr Asn Gin He 840 845 850 GGA AGA TTT TTT GGA GAG ATT GAT CCC AGC TTG ATG AGA CAC CTG GTT 2644 Gly Arg Phe Phe Gly Glu He Asp Pro Ser Leu Met Arg His Leu Val 855 860 865 870 AAT ATA TCA GTT TAT GCT TTT AAC AAA TCT TAT GAT TAT CAG TCA GTA 2692 Asn He Ser Val Tyr Ala Phe Asn Lys Ser Tyr Asp Tyr Gin Ser Val 875 880 885 TGT GAG CCC GGT GCT GCA CCA AAA CAA GGA GCA GGA CAT CGC TCA GCA 2740 Cys Glu Pro Gly Ala Ala Pro Lys Gin Gly Ala Gly His Arg Ser Ala 890 895 900 TAT GTG CCA TCA GTA GCA GAC ATA TTA CAA ATT GGC TGG TGG GCC ACT 2788 Tyr Val Pro Ser Val Ala Asp He Leu Gin He Gly Trp Trp Ala Thr 905 910 915 GCT GCT GCC TGG TCT ATT CTA CAG CAG TTT CTC TTG AGT TTG ACC TTT 2836 Ala Ala Ala Trp Ser He Leu Gin Gin Phe Leu Leu Ser Leu Thr Phe 920 925 930 CCA CGA CTC CTT GAG GCA GTT GAG ATG GAG GAT GAT GAC TTC ACG GCC 2884 Pro Arg Leu Leu Glu Ala Val Glu Met Glu Asp Asp Asp Phe Thr Ala 935 940 945 950 TCC CTG TCC AAG CAG AGC TGC ATT ACT GAA CAA ACC CAG TAT TTC TTC 2932 Ser Leu Ser Lys Gin Ser Cys He Thr Glu Gin Thr Gin Tyr Phe Phe 955 960 965 GAT AAC GAC AGT AAA TCA TTC AGT GGT GTA TTA GAC TGT GGA AAC TGT 2980 Asp Asn Asp Ser Lys Ser Phe Ser Gly Val Leu Asp Cys Gly Asn Cys 970 975 980 TCC AGA ATC TTT CAT GGA GAA AAG CTT ATG AAC ACC AAC TTA ATA TTC 3028 Ser Arg He Phe His Gly Glu Lys Leu Met Asn Thr Asn Leu He Phe 985 990 995 ATA ATG GTT GAG AGC AAA GGG ACA TGT CCA TGT GAC ACA CGA CTG CTC 3076 He Met Val Glu Ser Lys Gly Thr Cys Pro Cys Asp Thr Arg Leu Leu 1000 1005 1010 ATA CAA GCG GAG CAG ACT TCT GAC GGT CCA AAT CCT TGT GAC ATG GTT 3124 He Gin Ala Glu Gin Thr Ser Asp Gly Pro Asn Pro Cys Asp Met Val 1015 1020 1025 1030 AAG CAA CCT AGA TAC CGA AAA GGG CCT GAT GTC TGC TTT GAT AAC AAT 3172 Lys Gin Pro Arg Tyr Arg Lys Gly Pro Asp Val Cys Phe Asp Asn Asn 1035 1040 1045 GTC TTG GAG GAT TAT ACT GAC TGT GGT GGT GTT TCT GGA TTA AAT CCC 3220 Val Leu Glu Asp Tyr Thr Asp Cys Gly Gly Val Ser Gly Leu Asn Pro 1050 1055 1060 TCC CTG TGG TAT ATC ATT GGA ATC CAG TTT CTA CTA CTT TGG CTG GTA 3268 Ser Leu Trp Tyr He He Gly He Gin Phe Leu Leu Leu Trp Leu Val 1065 1070 1075 TCT GGC AGC ACA CAC CGG CTG TTA TGACCTTCTA AAAACCAAAT CTGCATAGTT 3322 Ser Gly Ser Thr His Arg Leu Leu 1080 1085 AAACTCCAGA CCCTGCCAAA ACATGAGCCC TGCCCTCAAT TACAGTAACG TAGGGTCAGC 3382 TATAAAATCA GACAAACATT AGCTGGGCCT GTTCCATGGC ATAACACTAA GGCGCAGACT 3442 CCTAAGGCAC CCACTGGCTG CATGTCAGGG TGTCAGATCC TTAAACGTGT GTGAATGCTG 3505 CATCATCTAT GTGTAACATC AAAGCAAAAT CCTATACGTG TCCTCTATTG GAAAATTTGG 3562 GCGTTTGTTG TTGCATTGTT GGT 3585 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3564 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 35..3374 (01625 to 1639 & 01908 to 1928) (D) OTHER INFORMATION: /standard_name= "Alpha-2d" (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..34 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 3375..3565 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: GCGGGGGAGG GGGCATTGAT CTTCGATCGC GAAG ATG GCT GCT GGC TGC CTG 52 Met Ala Ala Gly Cys Leu 1 5 CTG GCC TTG ACT CTG ACA CTT TTC CAA TCT TTG CTC ATC GGC CCC TCG 100 Leu Ala Leu Thr Leu Thr Leu Phe Gin Ser Leu Leu He Gly Pro Ser 10 15 20 TCG GAG GAG CCG TTC CCT TCG GCC GTC ACT ATC AAA TCA TGG GTG GAT 148 Ser Glu Glu Pro Phe Pro Ser Ala Val Thr He Lys Ser Trp Val Asp 25 30 35 AAG ATG CAA GAA GAC CTT GTC ACA CTG GCA AAA ACA GCA AGT GGA GTC 196 Lys Met Gin Glu Asp Leu Val Thr Leu Ala Lys Thr Ala Ser Gly Val 40 45 50 AAT CAG CTT GTT GAT ATT TAT GAG AAA TAT CAA GAT TTG TAT ACT GTG 244 Asn Gin Leu Val Asp He Tyr Glu Lys Tyr Gin Asp Leu Tyr Thr Val 55 60 65 70 GAA CCA AAT AAT GCA CGC CAG CTG GTA GAA ATT GCA GCC AGG GAT ATT 292 Glu Pro Asn Asn Ala Arg Gin Leu Val Glu He Ala Ala Arg Asp He 75 80 85 GAG AAA CTT CTG AGC AAC AGA TCT AAA GCC CTG GTG AGC CTG GCA TTG 340 Glu Lys Leu Leu Ser Asn Arg Ser Lys Ala Leu Val Ser Leu Ala Leu 90 95 100 GAA GCG GAG AAA GTT CAA GCA GCT CAC CAG TGG AGA GAA GAT TTT GCA 388 Glu Ala Glu Lys Val Gin Ala Ala His Gin Trp Arg Glu Asp Phe Ala 105 110 115 AGC AAT GAA GTT GTC TAC TAC AAT GCA AAG GAT GAT CTC GAT CCT GAG 436 Ser Asn Glu Val Val Tyr Tyr Asn Ala Lys Asp Asp Leu Asp Pro Glu 120 125 130 AAA AAT GAC AGT GAG CCA GGC AGC CAG AGG ATA AAA CCT GTT TTC ATT 484 Lys Asn Asp Ser Glu Pro Gly Ser Gin Arg He Lys Pro Val Phe He 135 140 145 150 GAA GAT GCT AAT TTT GGA CGA CAA ATA TCT TAT CAG CAC GCA GCA GTC 532 Glu Asp Ala Asn Phe Gly Arg Gin He Ser Tyr Gin His Ala Ala Val 155 160 165 CAT ATT CCT ACT GAC ATC TAT GAG GGC TCA ACA ATT GTG TTA AAT GAA 580 His He Pro Thr Asp He Tyr Glu Gly Ser Thr He Val Leu Asn Glu 170 175 180 CTC AAC TGG ACA AGT GCC TTA GAT GAA GTT TTC AAA AAG AAT CGC GAG 628 Leu Asn Trp Thr Ser Ala Leu Asp Glu Val Phe Lys Lys Asn Arg Glu 185 190 195 GAA GAC CCT TCA TTA TTG TGG CAG GTT TTT GGC AGT GCC ACT GGC CTA 676 Glu Asp Pro Ser Leu Leu Trp Gin Val Phe Gly Ser Ala Thr Gly Leu 200 205 210 GCT CGA TAT TAT CCA GCT TCA CCA TGG GTT GAT AAT AGT AGA ACT CCA 724 Ala Arg Tyr Tyr Pro Ala Ser Pro Trp Val Asp Asn Ser Arg Thr Pro 215 220 225 230 AAT AAG ATT GAC CTT TAT GAT GTA CGC AGA AGA CCA TGG TAC ATC CAA 772 Asn Lys He Asp Leu Tyr Asp Val Arg Arg Arg Pro Trp Tyr He Gin 235 240 245 GGA GCT GCA TCT CCT AAA GAC ATG CTT ATT CTG GTG GAT GTG AGT GGA 820 Gly Ala Ala Ser Pro Lys Asp Met Leu He Leu Val Asp Val Ser Gly 250 255 260 AGT GTT AGT GGA TTG ACA CTT AAA CTG ATC CGA ACA TCT GTC TCC GAA 868 Ser Val Ser Gly Leu Thr Leu Lys Leu He Arg Thr Ser Val Ser Glu 265 270 275 ATG TTA GAA ACC CTC TCA GAT GAT GAT TTC GTG AAT GTA GCT TCA TTT 916 Met Leu Glu Thr Leu Ser Asp Asp Asp Phe Val Asn Val Ala Ser Phe 280 285 290 AAC AGC AAT GCT CAG GAT GTA AGC TGT TTT CAG CAC CTT GTC CAA GCA 964 Asn Ser Asn Ala Gin Asp Val Ser Cys Phe Gin His Leu Val Gin Ala 295 300 305 310 AAT GTA AGA AAT AAA AAA GTG TTG AAA GAC GCG GTG AAT AAT ATC ACA 1012 Asn Val Arg Asn Lys Lys Val Leu Lys Asp Ala Val Asn Asn He Thr 315 320 325 GCC AAA GGA ATT ACA GAT TAT AAG AAG GGC TTT AGT TTT GCT TTT GAA 1060 Ala Lys Gly He Thr Asp Tyr Lys Lys Gly Phe Ser Phe Ala Phe Glu 330 335 340 CAG CTG CTT AAT TAT AAT GTT TCC AGA GCA AAC TGC AAT AAG ATT ATT 1108 Gin Leu Leu Asn Tyr Asn Val Ser Arg Ala Asn Cys Asn Lys He He 345 350 355 ATG CTA TTC ACG GAT GGA GGA GAA GAG AGA GCC CAG GAG ATA TTT AAC 1156 Met Leu Phe Thr Asp Gly Gly Glu Glu Arg Ala Gin Glu He Phe Asn 360 365 370 AAA TAC AAT AAA GAT AAA AAA GTA CGT GTA TTC AGG TTT TCA GTT GGT 1204 Lys Tyr Asn Lys Asp Lys Lys Val Arg Val Phe Arg Phe Ser Val Gly 375 380 385 390 CAA CAC AAT TAT GAG AGA GGA CCT ATT CAG TGG ATG GCC TGT GAA AAC 1252 Gin His Asn Tyr Glu Arg Gly Pro He Gin Trp Met Ala Cys Glu Asn 395 400 405 AAA GGT TAT TAT TAT GAA ATT CCT TCC ATT GGT GCA ATA AGA ATC AAT 1300 Lys Gly Tyr Tyr Tyr Glu He Pro Ser He Gly Ala He Arg He Asn 410 415 420 ACT CAG GAA TAT TTG GAT GTT TTG GGA AGA CCA ATG GTT TTA GCA GGA 1348 Thr Gin Glu Tyr Leu Asp Val Leu Gly Arg Pro Met Val Leu Ala Gly 425 430 435 GAC AAA GCT AAG CAA GTC CAA TGG ACA AAT GTG TAC CTG GAT GCA TTG 1396 Asp Lys Ala Lys Gin Val Gin Trp Thr Asn Val Tyr Leu Asp Ala Leu 440 445 450 GAA CTG GGA CTT GTC ATT ACT GGA ACT CTT CCG GTC TTC AAC ATA ACC 1444 Glu Leu Gly Leu Val He Thr Gly Thr Leu Pro Val Phe Asn He Thr 455 460 465 470 GGC CAA TTT GAA AAT AAG ACA AAC TTA AAG AAC CAG CTG ATT CTT GGT 1492 Gly Gin Phe Glu Asn Lys Thr Asn Leu Lys Asn Gin Leu He Leu Gly 475 480 485 GTG ATG GGA GTA GAT GTG TCT TTG GAA GAT ATT AAA AGA CTG ACA CCA 1540 Val Met Gly Val Asp Val Ser Leu Glu Asp He Lys Arg Leu Thr Pro 490 495 500 CGT TTT ACA CTG TGC CCC AAT GGG TAT TAC TTT GCA ATC GAT CCT AAT 1588 Arg Phe Thr Leu Cys Pro Asn Gly Tyr Tyr Phe Ala He Asp Pro Asn 505 510 515 GGT TAT GTT TTA TTA CAT CCA AAT CTT CAG CCA AAG GAG CCA GTA ACA 1636 Gly Tyr Val Leu Leu His Pro Asn Leu Gin Pro Lys Glu Pro Val Thr 520 525 530 TTG GAT TTC CTT GAT GCA GAG TTA GAG AAT GAT ATT AAA GTG GAG ATT 1684 Leu Asp Phe Leu Asp Ala Glu Leu Glu Asn Asp He Lys Val Glu He 535 540 545 550 CGA AAT AAG ATG ATT GAT GGG GAA AGT GGA GAA AAA ACA TTC AGA ACT 1732 Arg Asn Lys Met He Asp Gly Glu Ser Gly Glu Lys Thr Phe Arg Thr 555 560 565 CTG GTT AAA TCT CAA GAT GAG AGA TAT ATT GAC AAA GGA AAC AGG ACA 1780 Leu Val Lys Ser Gin Asp Glu Arg Tyr He Asp Lys Gly Asn Arg Thr 570 575 580 TAC ACA TGG ACA CCT GTC AAT GGC ACA GAT TAC AGT TTG GCC TTG GTA 1828 Tyr Thr Trp Thr Pro Val Asn Gly Thr Asp Tyr Ser Leu Ala Leu Val 585 590 595 TTA CCA ACC TAC AGT TTT TAC TAT ATA AAA GCC AAA CTA GAA GAG ACA 1876 Leu Pro Thr Tyr Ser Phe Tyr Tyr He Lys Ala Lys Leu Glu Glu Thr 600 605 610 ATA ACT CAG GCC AGA TAT TCG GAA ACC CTG AAG CCA GAT AAT TTT GAA 1924 He Thr Gin Ala Arg Tyr Ser Glu Thr Leu Lys Pro Asp Asn Phe Glu 615 620 625 630 GAA TCT GGC TAT ACA TTC ATA GCA CCA AGA GAT TAC TGC AAT GAC CTG 1972 Glu Ser Gly Tyr Thr Phe He Ala Pro Arg Asp Tyr Cys Asn Asp Leu 635 640 645 AAA ATA TCG GAT AAT AAC ACT GAA TTT CTT TTA AAT TTC AAC GAG TTT 2020 Lys He Ser Asp Asn Asn Thr Glu Phe Leu Leu Asn Phe Asn Glu Phe 650 655 660 ATT GAT AGA AAA ACT CCA AAC AAC CCA TCA TGT AAC GCG GAT TTG ATT 2068 He Asp Arg Lys Thr Pro Asn Asn Pro Ser Cys Asn Ala Asp Leu He 665 670 675 AAT AGA GTC TTG CTT GAT GCA GGC TTT ACA AAT GAA CTT GTC CAA AAT 2116 Asn Arg Val Leu Leu Asp Ala Gly Phe Thr Asn Glu Leu Val Gin Asn 680 685 690 TAC TGG AGT AAG CAG AAA AAT ATC AAG GGA GTG AAA GCA CGA TTT GTT 2164 Tyr Trp Ser Lys Gin Lys Asn He Lys Gly Val Lys Ala Arg Phe Val 695 700 705 710 GTG ACT GAT GGT GGG ATT ACC AGA GTT TAT CCC AAA GAG GCT GGA GAA 2212 Val Thr Asp Gly Gly He Thr Arg Val Tyr Pro Lys Glu Ala Gly Glu 715 720 725 AAT TGG CAA GAA AAC CCA GAG ACA TAT GAG GAC AGC TTC TAT AAA AGG 2260 Asn Trp Gin Glu Asn Pro Glu Thr Tyr Glu Asp Ser Phe Tyr Lys Arg 730 735 740 AGC CTA GAT AAT GAT AAC TAT GTT TTC ACT GCT CCC TAC TTT AAC AAA 2308 Ser Leu Asp Asn Asp Asn Tyr Val Phe Thr Ala Pro Tyr Phe Asn Lys 745 750 755 AGT GGA CCT GGT GCC TAT GAA TCG GGC ATT ATG GTA AGC AAA GCT GTA 2356 Ser Gly Pro Gly Ala Tyr Glu Ser Gly He Met Val Ser Lys Ala Val 760 765 770 GAA ATA TAT ATT CAA GGG AAA CTT CTT AAA CCT GCA GTT GTT GGA ATT 2404 Glu He Tyr He Gin Gly Lys Leu Leu Lys Pro Ala Val Val Gly He 775 780 785 790 AAA ATT GAT GTA AAT TCC TGG ATA GAG AAT TTC ACC AAA ACC TCA ATC 2452 Lys He Asp Val Asn Ser Trp He Glu Asn Phe Thr Lys Thr Ser He 795 800 805 AGA GAT CCG TGT GCT GGT CCA GTT TGT GAC TGC AAA AGA AAC AGT GAC 2500 Arg Asp Pro Cys Ala Gly Pro Val Cys Asp Cys Lys Arg Asn Ser Asp 810 815 820 GTA ATG GAT TGT GTG ATT CTG GAT GAT GGT GGG TTT CTT CTG ATG GCA 2548 Val Met Asp Cys Val He Leu Asp Asp Gly Gly Phe Leu Leu Met Ala 825 830 835 AAT CAT GAT GAT TAT ACT AAT CAG ATT GGA AGA TTT TTT GGA GAG ATT 2596 Asn His Asp Asp Tyr Thr Asn Gin He Gly Arg Phe Phe Gly Glu He 840 845 850 GAT CCC AGC TTG ATG AGA CAC CTG GTT AAT ATA TCA GTT TAT GCT TTT 2644 Asp Pro Ser Leu Met Arg His Leu Val Asn He Ser Val Tyr Ala Phe 855 860 865 870 AAC AAA TCT TAT GAT TAT CAG TCA GTA TGT GAG CCC GGT GCT GCA CCA 2692 Asn Lys Ser Tyr Asp Tyr Gin Ser Val Cys Glu Pro Gly Ala Ala Pro 875 880 885 AAA CAA GGA GCA GGA CAT CGC TCA GCA TAT GTG CCA TCA GTA GCA GAC 2740 Lys Gin Gly Ala Gly His Arg Ser Ala Tyr Val Pro Ser Val Ala Asp 890 895 900 ATA TTA CAA ATT GGC TGG TGG GCC ACT GCT GCT GCC TGG TCT ATT CTA 2788 He Leu Gin He Gly Trp Trp Ala Thr Ala Ala Ala Trp Ser He Leu 905 910 915 CAG CAG TTT CTC TTG AGT TTG ACC TTT CCA CGA CTC CTT GAG GCA GTT 2836 Gin Gin Phe Leu Leu Ser Leu Thr Phe Pro Arg Leu Leu Glu Ala Val 920 925 930 GAG ATG GAG GAT GAT GAC TTC ACG GCC TCC CTG TCC AAG CAG AGC TGC 2884 Glu Met Glu Asp Asp Asp Phe Thr Ala Ser Leu Ser Lys Gin Ser Cys 935 940 945 950 ATT ACT GAA CAA ACC CAG TAT TTC TTC GAT AAC GAC AGT AAA TCA TTC 2932 He Thr Glu Gin Thr Gin Tyr Phe Phe Asp Asn Asp Ser Lys Ser Phe 955 960 965 AGT GGT GTA TTA GAC TGT GGA AAC TGT TCC AGA ATC TTT CAT GGA GAA 2980 Ser Gly Val Leu Asp Cys Gly Asn Cys Ser Arg He Phe His Gly Glu 970 975 980 AAG CTT ATG AAC ACC AAC TTA ATA TTC ATA ATG GTT GAG AGC AAA GGG 3028 Lys Leu Met Asn Thr Asn Leu He Phe He Met Val Glu Ser Lys Gly 985 990 995 ACA TGT CCA TGT GAC ACA CGA CTG CTC ATA CAA GCG GAG CAG ACT TCT 3076 Thr Cys Pro Cys Asp Thr Arg Leu Leu He Gin Ala Glu Gin Thr Ser 1000 1005 1010 GAC GGT CCA AAT CCT TGT GAC ATG GTT AAG CAA CCT AGA TAC CGA AAA 3124 Asp Gly Pro Asn Pro Cys Asp Met Val Lys Gin Pro Arg Tyr Arg Lys 1015 1020 1025 1030 GGG CCT GAT GTC TGC TTT GAT AAC AAT GTC TTG GAG GAT TAT ACT GAC " 3172 Gly Pro Asp Val Cys Phe Asp Asn Asn Val Leu Glu Asp Tyr Thr Asp 1035 1040 1045 TGT GGT GGT GTT TCT GGA TTA AAT CCC TCC CTG TGG TAT ATC ATT GGA 3220 Cys Gly Gly Val Ser Gly Leu Asn Pro Ser Leu Trp Tyr He He Gly 1050 1055 1060 ATC CAG TTT CTA CTA CTT TGG CTG GTA TCT GGC AGC ACA CAC CGG CTG 3268 He Gin Phe Leu Leu Leu Trp Leu Val Ser Gly Ser Thr His Arg Leu 1065 1070 1075 TTA TGACCTTCTA AAAACCAAAT CTGCATAGTT AAACTCCAGA CCCTGCCAAA 3321 Leu ACATGAGCCC TGCCCTCAAT TACAGTAACG TAGGGTCAGC TATAAAATCA GACAAACATT 3381 AGCTGGGCCT GTTCCATGGC ATAACACTAA GGCGCAGACT CCTAAGGCAC CCACTGGCTG 3441 CATGTCAGGG TGTCAGATCC TTAAACGTGT GTGAATGCTG CATCATCTAT GTGTAACATC 3501 AAAGCAAAAT CCTATACGTG TCCTCTATTG GAAAATTTGG GCGTTTGTTG TTGCATTGTT 3561 GGT 3564 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3579 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 35..3289 (D) OTHER INFORMATION: /standard_name= "Alpha-2e" (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..34 (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 3289..3579 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: GCGGGGGAGG GGGCATTGAT CTTCGATCGC GAAG ATG GCT GCT GGC TGC CTG 52 Met Ala Ala Gly Cys Leu 1 5 CTG GCC TTG ACT CTG ACA CTT TTC CAA TCT TTG CTC ATC GGC CCC TCG 100 Leu Ala Leu Thr Leu Thr Leu Phe Gin Ser Leu Leu He Gly Pro Ser 10 15 20 TCG GAG GAG CCG TTC CCT TCG GCC GTC ACT ATC AAA TCA TGG GTG GAT 148 Ser Glu Glu Pro Phe Pro Ser Ala Val Thr He Lys Ser Trp Val Asp 25 30 35 AAG ATG CAA GAA GAC CTT GTC ACA CTG GCA AAA ACA GCA AGT GGA GTC 196 Lys Met Gin Glu Asp Leu Val Thr Leu Ala Lys Thr Ala Ser Gly Val 40 45 50 AAT CAG CTT GTT GAT ATT TAT GAG AAA TAT CAA GAT TTG TAT ACT GTG 244 Asn Gin Leu Val Asp He Tyr Glu Lys Tyr Gin Asp Leu Tyr Thr Val 55 60 65 70 GAA CCA AAT AAT GCA CGC CAG CTG GTA GAA ATT GCA GCC AGG GAT ATT .292 Glu Pro Asn Asn Ala Arg Gin Leu Val Glu He Ala Ala Arg Asp He 75 80 85 GAG AAA CTT CTG AGC AAC AGA TCT AAA GCC CTG GTG AGC CTG GCA TTG 340 Glu Lys Leu Leu Ser Asn Arg Ser Lys Ala Leu Val Ser Leu Ala Leu 90 95 100 GAA GCG GAG AAA GTT CAA GCA GCT CAC CAG TGG AGA GAA GAT TTT GCA 388 Glu Ala Glu Lys Val Gin Ala Ala His Gin Trp Arg Glu Asp Phe Ala 105 110 115 AGC AAT GAA GTT GTC TAC TAC AAT GCA AAG GAT GAT CTC GAT CCT GAG 436 Ser Asn Glu Val Val Tyr Tyr Asn Ala Lys Asp Asp Leu Asp Pro Glu 120 125 130 AAA AAT GAC AGT GAG CCA GGC AGC CAG AGG ATA AAA CCT GTT TTC ATT 484 Lys Asn Asp Ser Glu Pro Gly Ser Gin Arg He Lys Pro Val Phe He 135 140 145 150 GAA GAT GCT AAT TTT GGA CGA CAA ATA TCT TAT CAG CAC GCA GCA GTC 532 Glu Asp Ala Asn Phe Gly Arg Gin He Ser Tyr Gin His Ala Ala Val 155 160 165 CAT ATT CCT ACT GAC ATC TAT GAG GGC TCA ACA ATT GTG TTA AAT GAA 580 His He Pro Thr Asp He Tyr Glu Gly Ser Thr He Val Leu Asn Glu 170 175 180 CTC AAC TGG ACA AGT GCC TTA GAT GAA GTT TTC AAA AAG AAT CGC GAG 628 Leu Asn Trp Thr Ser Ala Leu Asp Glu Val Phe Lys Lys Asn Arg Glu 185 190 195 GAA GAC CCT TCA TTA TTG TGG CAG GTT TTT GGC AGT GCC ACT GGC CTA 676 Glu Asp Pro Ser Leu Leu Trp Gin Val Phe Gly Ser Ala Thr Gly Leu 200 205 210 GCT CGA TAT TAT CCA GCT TCA CCA TGG GTT GAT AAT AGT AGA ACT CCA 724 Ala Arg Tyr Tyr Pro Ala Ser Pro Trp Val Asp Asn Ser Arg Thr Pro 215 220 225 230 AAT AAG ATT GAC CTT TAT GAT GTA CGC AGA AGA CCA TGG TAC ATC CAA 772 Asn Lys He Asp Leu Tyr Asp Val Arg Arg Arg Pro Trp Tyr He Gin 235 240 245 GGA GCT GCA TCT CCT AAA GAC ATG CTT ATT CTG GTG GAT GTG AGT GGA 820 Gly Ala Ala Ser Pro Lys Asp Met Leu He Leu Val Asp Val Ser Gly 250 255 260 AGT GTT AGT GGA TTG ACA CTT AAA CTG ATC CGA ACA TCT GTC TCC GAA 868 Ser Val Ser Gly Leu Thr Leu Lys Leu He Arg Thr Ser Val Ser Glu 265 270 275 ATG TTA GAA ACC CTC TCA GAT GAT GAT TTC GTG AAT GTA GCT TCA TTT 916 Met Leu Glu Thr Leu Ser Asp Asp Asp Phe Val Asn Val Ala Ser Phe 280 285 290 AAC AGC AAT GCT CAG GAT GTA AGC TGT TTT CAG CAC CTT GTC CAA GCA 964 Asn Ser Asn Ala Gin Asp Val Ser Cys Phe Gin His Leu Val Gin Ala 295 300 305 310 AAT GTA AGA AAT AAA AAA GTG TTG AAA GAC GCG GTG AAT AAT ATC ACA 1012 Asn Val Arg Asn Lys Lys Val Leu Lys Asp Ala Val Asn Asn He Thr 315 320 325 GCC AAA GGA ATT ACA GAT TAT AAG AAG GGC TTT AGT TTT GCT TTT GAA 1060 Ala Lys Gly He Thr Asp Tyr Lys Lys Gly Phe Ser Phe Ala Phe Glu 330 335 340 CAG CTG CTT AAT TAT AAT GTT TCC AGA GCA AAC TGC AAT AAG ATT ATT 1108 Gin Leu Leu Asn Tyr Asn Val Ser Arg Ala Asn Cys Asn Lys He He 345 350 355 ATG CTA TTC ACG GAT GGA GGA GAA GAG AGA GCC CAG GAG ATA TTT AAC 1156 Met Leu Phe Thr Asp Gly Gly Glu Glu Arg Ala Gin Glu He Phe Asn 360 365 370 AAA TAC AAT AAA GAT AAA AAA GTA CGT GTA TTC AGG TTT TCA GTT GGT 1204 Lys Tyr Asn Lys Asp Lys Lys Val Arg Val Phe Arg Phe Ser Val Gly 375 380 385 390 CAA CAC AAT TAT GAG AGA GGA CCT ATT CAG TGG ATG GCC TGT GAA AAC 1252 Gin His Asn Tyr Glu Arg Gly Pro He Gin Trp Met Ala Cys Glu Asn 395 400 405 AAA GGT TAT TAT TAT GAA ATT CCT TCC ATT GGT GCA ATA AGA ATC AAT 1300 Lys Gly Tyr Tyr Tyr Glu He Pro Ser He Gly Ala He Arg He Asn 410 415 420 ACT CAG GAA TAT TTG GAT GTT TTG GGA AGA CCA ATG GTT TTA GCA GGA 1348 Thr Gin Glu Tyr Leu Asp Val Leu Gly Arg Pro Met Val Leu Ala Gly 425 430 435 GAC AAA GCT AAG CAA GTC CAA TGG ACA AAT GTG TAC CTG GAT GCA TTG 1396 Asp Lys Ala Lys Gin Val Gin Trp Thr Asn Val Tyr Leu Asp Ala Leu 440 445 450 GAA CTG GGA CTT GTC ATT ACT GGA ACT CTT CCG GTC TTC AAC ATA ACC 1444 Glu Leu Gly Leu Val He Thr Gly Thr Leu Pro Val Phe Asn He Thr 455 460 465 470 GGC CAA TTT GAA AAT AAG ACA AAC TTA AAG AAC CAG CTG ATT CTT GGT 1492 Gly Gin Phe Glu Asn Lys Thr Asn Leu Lys Asn Gin Leu He Leu Gly 475 480 485 GTG ATG GGA GTA GAT GTG TCT TTG GAA GAT ATT AAA AGA CTG ACA CCA 1540 Val Met Gly Val Asp Val Ser Leu Glu Asp He Lys Arg Leu Thr Pro 490 495 500 CGT TTT ACA CTG TGC CCC AAT GGG TAT TAC TTT GCA ATC GAT CCT AAT 1588 Arg Phe Thr Leu Cys Pro Asn Gly Tyr Tyr Phe Ala He Asp Pro Asn 505 510 515 GGT TAT GTT TTA TTA CAT CCA AAT CTT CAG CCA AAG AAC CCC AAA TCT 1636 Gly Tyr Val Leu Leu His Pro Asn Leu Gin Pro Lys Asn Pro Lys Ser 520 525 530 CAG GAG CCA GTA ACA TTG GAT TTC CTT GAT GCA GAG TTA GAG AAT GAT 1684 Gin Glu Pro Val Thr Leu Asp Phe Leu Asp Ala Glu Leu Glu Asn Asp 535 540 545 550 ATT AAA GTG GAG ATT CGA AAT AAG ATG ATT GAT GGG GAA AGT GGA GAA 1732 He Lys Val Glu He Arg Asn Lys Met He Asp Gly Glu Ser Gly Glu 555 560 565 AAA ACA TTC AGA ACT CTG GTT AAA TCT CAA GAT GAG AGA TAT ATT GAC 1780 Lys Thr Phe Arg Thr Leu Val Lys Ser Gin Asp Glu Arg Tyr He Asp 570 575 580 AAA GGA AAC AGG ACA TAC ACA TGG ACA CCT GTC AAT GGC ACA GAT TAC 1828 Lys Gly Asn Arg Thr Tyr Thr Trp Thr Pro Val Asn Gly Thr Asp Tyr 585 590 595 AGT TTG GCC TTG GTA TTA CCA ACC TAC AGT TTT TAC TAT ATA AAA GCC 1876 Ser Leu Ala Leu Val Leu Pro Thr Tyr Ser Phe Tyr Tyr He Lys Ala 600 605 610 AAA CTA GAA GAG ACA ATA ACT CAG GCC AGA TAT TCG GAA ACC CTG AAG 1924 Lys Leu Glu Glu Thr He Thr Gin Ala Arg Tyr Ser Glu Thr Leu Lys 615 620 625 630 CCA GAT AAT TTT GAA GAA TCT GGC TAT ACA TTC ATA GCA CCA AGA GAT 1972 Pro Asp Asn Phe Glu Glu Ser Gly Tyr Thr Phe He Ala Pro Arg Asp 635 640 645 TAC TGC AAT GAC CTG AAA ATA TCG GAT AAT AAC ACT GAA TTT CTT TTA 2020 Tyr Cys Asn Asp Leu Lys He Ser Asp Asn Asn Thr Glu Phe Leu Leu 650 655 660 AAT TTC AAC GAG TTT ATT GAT AGA AAA ACT CCA AAC AAC CCA TCA TGT 2068 Asn Phe Asn Glu Phe He Asp Arg Lys Thr Pro Asn Asn Pro Ser Cys 665 670 675 AAC GCG GAT TTG ATT AAT AGA GTC TTG CTT GAT GCA GGC TTT ACA AAT 2116 Asn Ala Asp Leu He Asn Arg Val Leu Leu Asp Ala Gly Phe Thr Asn 680 685 690 GAA CTT GTC CAA AAT TAC TGG AGT AAG CAG AAA AAT ATC AAG GGA GTG 2164 Glu Leu Val Gin Asn Tyr Trp Ser Lys Gin Lys Asn He Lys Gly Val 695 700 705 710 AAA GCA CGA TTT GTT GTG ACT GAT GGT GGG ATT ACC AGA GTT TAT CCC 2212 Lys Ala Arg Phe Val Val Thr Asp Gly Gly He Thr Arg Val Tyr Pro 715 720 725 AAA GAG GCT GGA GAA AAT TGG CAA GAA AAC CCA GAG ACA TAT GAG GAC 2260 Lys Glu Ala Gly Glu Asn Trp Gin Glu Asn Pro Glu Thr Tyr Glu Asp 730 735 740 AGC TTC TAT AAA AGG AGC CTA GAT AAT GAT AAC TAT GTT TTC ACT GCT 2308 Ser Phe Tyr Lys Arg Ser Leu Asp Asn Asp Asn Tyr Val Phe Thr Ala 745 750 755 CCC TAC TTT AAC AAA AGT GGA CCT GGT GCC TAT GAA TCG GGC ATT ATG 2356 Pro Tyr Phe Asn Lys Ser Gly Pro Gly Ala Tyr Glu Ser Gly He Met 760 765 770 GTA AGC AAA GCT GTA GAA ATA TAT ATT CAA GGG AAA CTT CTT AAA CCT 2 04 Val Ser Lys Ala Val Glu He Tyr He Gin Gly Lys Leu Leu Lys Pro 775 780 785 790 GCA GTT GTT GGA ATT AAA ATT GAT GTA AAT TCC TGG ATA GAG AAT TTC 2452 Ala Val Val Gly He Lys He Asp Val Asn Ser Trp He Glu Asn Phe 795 800 805 ACC AAA ACC TCA ATC AGA GAT CCG TGT GCT GGT CCA GTT TGT GAC TGC 2500 Thr Lys Thr Ser He Arg Asp Pro Cys Ala Gly Pro Val Cys Asp Cys 810 815 820 AAA AGA AAC AGT GAC GTA ATG GAT TGT GTG ATT CTG GAT GAT GGT GGG 2548 Lys Arg Asn Ser Asp Val Met Asp Cys Val He Leu Asp Asp Gly Gly 825 830 835 TTT CTT CTG ATG GCA AAT CAT GAT GAT TAT ACT AAT CAG ATT GGA AGA 2596 Phe Leu Leu Met Ala Asn His Asp Asp Tyr Thr Asn Gin He Gly Arg 840 845 850 TTT TTT GGA GAG ATT GAT CCC AGC TTG ATG AGA CAC CTG GTT AAT ATA 2644 Phe Phe Gly Glu He Asp Pro Ser Leu Met Arg His Leu Val Asn He 855 860 865 870 TCA GTT TAT GCT TTT AAC AAA TCT TAT GAT TAT CAG TCA GTA TGT GAG 2692 Ser Val Tyr Ala Phe Asn Lys Ser Tyr Asp Tyr Gin Ser Val Cys Glu 875 880 885 CCC GGT GCT GCA CCA AAA CAA GGA GCA GGA CAT CGC TCA GCA TAT GTG 2740 Pro Gly Ala Ala Pro Lys Gin Gly Ala Gly His Arg Ser Ala Tyr Val 890 895 900 CCA TCA GTA GCA GAC ATA TTA CAA ATT GGC TGG TGG GCC ACT GCT GCT 2788 Pro Ser Val Ala Asp He Leu Gin He Gly Trp Trp Ala Thr Ala Ala 905 910 915 GCC TGG TCT ATT CTA CAG CAG TTT CTC TTG AGT TTG ACC TTT CCA CGA 2836 Ala Trp Ser He Leu Gin Gin Phe Leu Leu Ser Leu Thr Phe Pro Arg 920 925 930 CTC CTT GAG GCA GTT GAG ATG GAG GAT GAT GAC TTC ACG GCC TCC CTG 2884 Leu Leu Glu Ala Val Glu Met Glu Asp Asp Asp Phe Thr Ala Ser Leu 935 940 945 950 TCC AAG CAG AGC TGC ATT ACT GAA CAA ACC CAG TAT TTC TTC GAT AAC 2932 Ser Lys Gin Ser Cys He Thr Glu Gin Thr Gin Tyr Phe Phe Asp Asn 955 960 965 GAC AGT AAA TCA TTC AGT GGT GTA TTA GAC TGT GGA AAC TGT TCC AGA 2980 Asp Ser Lys Ser Phe Ser Gly Val Leu Asp Cys Gly Asn Cys Ser Arg 970 975 980 ATC TTT CAT GGA GAA AAG CTT ATG AAC ACC AAC TTA ATA TTC ATA ATG 3028 He Phe His Gly Glu Lys Leu Met Asn Thr Asn Leu He Phe He Met 985 990 995 GTT GAG AGC AAA GGG ACA TGT CCA TGT GAC ACA CGA CTG CTC ATA CAA 3076 Val Glu Ser Lys Gly Thr Cys Pro Cys Asp Thr Arg Leu Leu He Gin 1000 1005 1010 GCG GAG CAG ACT TCT GAC GGT CCA AAT CCT TGT GAC ATG GTT AAG CAA 3124 Ala Glu Gin Thr Ser Asp Gly Pro Asn Pro Cys Asp Met Val Lys Gin 1015 1020 1025 1030 CCT AGA TAC CGA AAA GGG CCT GAT GTC TGC TTT GAT AAC AAT GTC TTG 3172 Pro Arg Tyr Arg Lys Gly Pro Asp Val Cys Phe Asp Asn Asn Val Leu 1035 1040 1045 GAG GAT TAT ACT GAC TGT GGT GGT GTT TCT GGA TTA AAT CCC TCC CTG 3220 Glu Asp Tyr Thr Asp Cys Gly Gly Val Ser Gly Leu Asn Pro Ser Leu 1050 1055 1060 TGG TAT ATC ATT GGA ATC CAG TTT CTA CTA CTT TGG CTG GTA TCT GGC 3268 Trp Tyr He He Gly He Gin Phe Leu Leu Leu Trp Leu Val Ser Gly 1065 1070 1075 AGC ACA CAC CGG CTG TTA TGACCTTCTA AAAACCAAAT CTGCATAGTT 3316 Ser Thr His Arg Leu Leu 1080 108 AAACTCCAGA CCCTGCCAAA ACATGAGCCC TGCCCTCAAT TACAGTAACG TAGGGTCAGC 3376 TATAAAATCA GACAAACATT AGCTGGGCCT GTTCCATGGC ATAACACTAA GGCGCAGACT 3436 CCTAAGGCAC CCACTGGCTG CATGTCAGGG TGTCAGATCC TTAAACGTGT GTGAATGCTG 3496 CATCATCTAT GTGTAACATC AAAGCAAAAT CCTATACGTG TCCTCTATTG GAAAATTTGG 3556 GCGTTTGTTG TTGCATTGTT GGT 3579 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1681 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1437 (D) OTHER INFORMATION: /standard_name= "Beta-1-1" (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1435..1681 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: ATG GTC CAG AAG ACC AGC ATG TCC CGG GGC CCT TAC CCA CCC TCC CAG 48 Met Val Gin Lys Thr Ser Met Ser Arg Gly Pro Tyr Pro Pro Ser Gin 1 5 10 15 GAG ATC CCC ATG GAG GTC TTC GAC CCC AGC CCG CAG GGC AAA TAC AGC 96 Glu He Pro Met Glu Val Phe Asp Pro Ser Pro Gin Gly Lys Tyr Ser 20 25 30 AAG AGG AAA GGG CGA TTC AAA CGG TCA GAT GGG AGC ACG TCC TCG GAT 144 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gly Ser Thr Ser Ser Asp 35 40 45 ACC ACA TCC AAC AGC TTT GTC CGC CAG GGC TCA GCG GAG TCC TAC ACC 192 Thr Thr Ser Asn Ser Phe Val Arg Gin Gly Ser Ala Glu Ser Tyr Thr 50 55 60 AGC CGT CCA TCA GAC TCT GAT GTA TCT CTG GAG GAG GAC CGG GAA GCC 240 Ser Arg Pro Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala 65 70 75 80 TTA AGG AAG GAA GCA GAG CGC CAG GCA TTA GCG CAG CTC GAG AAG GCC 288 Leu Arg Lys Glu Ala Glu Arg Gin Ala Leu Ala Gin Leu Glu Lys Ala 85 90 95 AAG ACC AAG CCA GTG GCA TTT GCT GTG CGG ACA AAT GTT GGC TAC AAT 336 Lys Thr Lys Pro Val Ala Phe Ala Val Arg Thr Asn Val Gly Tyr Asn 100 105 110 CCG TCT CCA GGG GAT GAG GTG CCT GTG CAG GGA GTG GCC ATC ACC TTC 384 Pro Ser Pro Gly Asp Glu Val Pro Val Gin Gly Val Ala He Thr Phe 115 120 125 GAG CCC AAA GAC TTC CTG CAC ATC AAG GAG AAA TAC AAT AAT GAC TGG 432 Glu Pro Lys Asp Phe Leu His He Lys Glu Lys Tyr Asn Asn Asp Trp 130 135 140 TGG ATC GGG CGG CTG GTG AAG GAG GGC TGT GAG GTT GGC TTC ATT CCC 480 Trp He Gly Arg Leu Val Lys Glu Gly Cys Glu Val Gly Phe He Pro 145 150 155 160 AGC CCC GTC AAA CTG GAC AGC CTT CGC CTG CTG CAG GAA CAG AAG CTG 528 Ser Pro Val Lys Leu Asp Ser Leu Arg Leu Leu Gin Glu Gin Lys Leu 165 170 175 CGC CAG AAC CGC CTC GGC TCC AGC AAA TCA GGC GAT AAC TCC AGT TCC 576 Arg Gin Asn Arg Leu Gly Ser Ser Lys Ser Gly Asp Asn Ser Ser Ser 180 185 190 AGT CTG GGA GAT GTG GTG ACT GGC ACC CGC CGC CCC ACA CCC CCT GCC 624 Ser Leu Gly Asp Val Val Thr Gly Thr Arg Arg Pro Thr Pro Pro Ala 195 200 205 AGT GGT AAT GAA ATG ACT AAC TTA GCC TTT GAA CTA GAC CCC CTA GAG 672 Ser Gly Asn Glu Met Thr Asn Leu Ala Phe Glu Leu Asp Pro Leu Glu 210 215 220 TTA GAG GAG GAA GAG GCT GAG CTT GGT GAG CAG AGT GGC TCT GCC AAG 720 Leu Glu Glu Glu Glu Ala Glu Leu Gly Glu Gin Ser Gly Ser Ala Lys 225 230 235 240 ACT AGT GTT AGC AGT GTC ACC ACC CCG CCA CCC CAT GGC AAA CGC ATC 768 Thr Ser Val Ser Ser Val Thr Thr Pro Pro Pro His Gly Lys Arg He 245 250 255 CCC TTC TTT AAG AAG ACA GAG CAT GTG CCC CCC TAT GAC GTG GTG CCT 816 Pro Phe Phe Lys Lys Thr Glu His Val Pro Pro Tyr Asp Val Val Pro 260 265 270 TCC ATG AGG CCC ATC ATC CTG GTG GGA CCG TCG CTC AAG GGC TAC GAG 864 Ser Met Arg Pro He He Leu Val Gly Pro Ser Leu Lys Gly Tyr Glu 275 280 285 GTT ACA GAC ATG ATG CAG AAA GCT TTA TTT GAC TTC TTG AAG CAT CGG 912 Val Thr Asp Met Met Gin Lys Ala Leu Phe Asp Phe Leu Lys His Arg 290 295 300 TTT GAT GGC AGG ATC TCC ATC ACT CGT GTG ACG GCA GAT ATT TCC CTG 960 Phe Asp Gly Arg He Ser He Thr Arg Val Thr Ala Asp He Ser Leu 305 310 315 320 GCT AAG CGC TCA GTT CTC AAC AAC CCC AGC AAA CAC ATC ATC ATT GAG 1008 Ala Lys Arg Ser Val Leu Asn Asn Pro Ser Lys His He He He Glu 325 330 335 CGC TCC AAC ACA CGC TCC AGC CTG GCT GAG GTG CAG AGT GAA ATC GAG 1056 Arg Ser Asn Thr Arg Ser Ser Leu Ala Glu Val Gin Ser Glu He Glu 340 345 350 CGA ATC TTC GAG CTG GCC CGG ACC CTT CAG TTG GTC GCT CTG GAT GCT 1104 Arg He Phe Glu Leu Ala Arg Thr Leu Gin Leu Val Ala Leu Asp Ala 355 360 365 GAC ACC ATC AAT CAC CCA GCC CAG CTG TCC AAG ACC TCG CTG GCC CCC 1152 Asp Thr He Asn His Pro Ala Gin Leu Ser Lys Thr Ser Leu Ala Pro 370 375 380 ATC ATT GTT TAC ATC AAG ATC ACC TCT CCC AAG GTA CTT CAA AGG CTC 1200 He He Val Tyr He Lys He Thr Ser Pro Lys Val Leu Gin Arg Leu 385 390 395 400 ATC AAG TCC CGA GGA AAG TCT CAG TCC AAA CAC CTC AAT GTC CAA ATA 12 8 He Lys Ser Arg Gly Lys Ser Gin Ser Lys His Leu Asn Val Gin He 405 410 415 GCG GCC TCG GAA AAG CTG GCA CAG TGC CCC CCT GAA ATG TTT GAC ATC 1296 Ala Ala Ser Glu Lys Leu Ala Gin Cys Pro Pro Glu Met Phe Asp He 420 425 430 ATC CTG GAT GAG AAC CAA TTG GAG GAT GCC TGC GAG CAT CTG GCG GAG 1344 He Leu Asp Glu Asn Gin Leu Glu Asp Ala Cys Glu His Leu Ala Glu 435 440 445 TAC TTG GAA GCC TAT TGG AAG GCC ACA CAC CCG CCC AGC AGC ACG CCA 1392 Tyr Leu Glu Ala Tyr Trp Lys Ala Thr His Pro Pro Ser Ser Thr Pro 450 455 460 CCC AAT CCG CTG CTG AAC CGC ACC ATG GCT ACC GCA GCC CTG GCT 1437 Pro Asn Pro Leu Leu Asn Arg Thr Met Ala Thr Ala Ala Leu Ala 465 470 475 GCCAGCCCTG CCCCTGTCTC CAACCTCCAG GTACAGGTGC TCACCTCGCT CAGGAGAAAC 1497 CTCGGCTTCT GGGGCGGGCT GGAGTCCTCA CAGCGGGGCA GTGTGGTGCC CCAGGAGCAG 1557 GAACATGCCA TGTAGTGGGC GCCCTGCCCG TCTTCCCTCC TGCTCTGGGG TCGGAACTGG 1617 AGTGCAGGGA ACATGGAGGA GGAAGGGAAG AGCTTTATTT TGTAAAAAAA TAAGATGAGC 1677 GGCA 1681 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1526 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..651 (D) OTHER INFORMATION: /standard_name= "Beta-1-4" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: ATG GTC CAG AAG ACC AGC ATG TCC CGG GGC CCT TAC CCA CCC TCC CAG 48 Met Val Gin Lys Thr Ser Met Ser Arg Gly Pro Tyr Pro Pro Ser Gin 1 5 10 15 GAG ATC CCC ATG GAG GTC TTC GAC CCC AGC CCG CAG GGC AAA TAC AGC 96 Glu He Pro Met Glu Val Phe Asp Pro Ser Pro Gin Gly Lys Tyr Ser 20 25 30 AAG AGG AAA GGG CGA TTC AAA CGG TCA GAT GGG AGC ACG TCC TCG GAT 144 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gly Ser Thr Ser Ser Asp 35 40 45 ACC ACA TCC AAC AGC TTT GTC CGC CAG GGC TCA GCG GAG TCC TAC ACC 192 Thr Thr Ser Asn Ser Phe Val Arg Gin Gly Ser Ala Glu Ser Tyr Thr 50 55 60 AGC CGT CCA TCA GAC TCT GAT GTA TCT CTG GAG GAG GAC CGG GAA GCC 240 Ser Arg Pro Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala 65 70 75 80 TTA AGG AAG GAA GCA GAG CGC CAG GCA TTA GCG CAG CTC GAG AAG GCC 288 Leu Arg Lys Glu Ala Glu Arg Gin Ala Leu Ala Gin Leu Glu Lys Ala 85 90 95 AAG ACC AAG CCA GTG GCA TTT GCT GTG CGG ACA AAT GTT GGC TAC AAT 336 Lys Thr Lys Pro Val Ala Phe Ala Val Arg Thr Asn Val Gly Tyr Asn 100 105 110 CCG TCT CCA GGG GAT GAG GTG CCT GTG CAG GGA GTG GCC ATC ACC TTC 384 Pro Ser Pro Gly Asp Glu Val Pro Val Gin Gly Val Ala He Thr Phe 115 120 125 GAG CCC AAA GAC TTC CTG CAC ATC AAG GAG AAA TAC AAT AAT GAC TGG 432 Glu Pro Lys Asp Phe Leu His He Lys Glu Lys Tyr Asn Asn Asp Trp 130 135 140 TGG ATC GGG CGG CTG GTG AAG GAG GGC TGT GAG GTT GGC TTC ATT CCC 480 Trp He Gly Arg Leu Val Lys Glu Gly Cys Glu Val Gly Phe He Pro 145 150 155 160 AGC CCC GTC AAA CTG GAC AGC CTT CGC CTG CTG CAG GAA CAG AAG CTG 528 Ser Pro Val Lys Leu Asp Ser Leu Arg Leu Leu Gin Glu Gin Lys Leu 165 170 175 CGC CAG AAC CGC CTC GGC TCC AGC AAA TCA GGC GAT AAC TCC AGT TCC 576 Arg Gin Asn Arg Leu Gly Ser Ser Lys Ser Gly Asp Asn Ser Ser Ser 180 185 190 AGT CTG GGA GAT GTG GTG ACT GGC ACC CGC CGC CCC ACA CCC CCT GCC 624 Ser Leu Gly Asp Val Val Thr Gly Thr Arg Arg Pro Thr Pro Pro Ala 195 200 205 AGT GAC AGA GCA TGT GCC CCC CTA TGACGTGGTG CCTTCCATGA GGCCCATCAT 678 Ser Asp Arg Ala Cys Ala Pro Leu 210 215 CCTGGTGGGA CCGTCGCTCA AGGGCTACGA GGTTACAGAC ATGATGCAGA AAGCTTTATT 738 TGACTTCTTG AAGCATCGGT TTGATGGCAG GATCTCCATC ACTCGTGTGA CGGCAGATAT 798 TTCCCTGGCT AAGCGCTCAG TTCTCAACAA CCCCAGCAAA CACATCATCA TTGAGCGCTC 858 CAACACACGC TCCAGCCTGG CTGAGGTGCA GAGTGAAATC GAGCGAATCT TCGAGCTGGC 918 CCGGACCCTT CAGTTGGTCG CTCTGGATGC TGACACCATC AATCACCCAG CCCAGCTGTC 978 CAAGACCTCG CTGGCCCCCA TCATTGTTTA CATCAAGATC ACCTCTCCCA AGGTACTTCA 1038 AAGGCTCATC AAGTCCCGAG GAAAGTCTCA GTCCAAACAC CTCAATGTCC AAATAGCGGC 1098 CTCGGAAAAG CTGGCACAGT GCCCCCCTGA AATGTTTGAC ATCATCCTGG ATGAGAACCA 1158 ATTGGAGGAT GCCTGCGAGC ATCTGGCGGA GTACTTGGAA GCCTATTGGA AGGCCACACA 1218 CCCGCCCAGC AGCACGCCAC CCAATCCGCT GCTGAACCGC ACCATGGCTA CCGCAGCCCT 1278 GGCTGCCAGC CCTGCCCCTG TCTCCAACCT CCAGGTACAG GTGCTCACCT CGCTCAGGAG 1338 AAACCTCGGC TTCTGGGGCG GGCTGGAGTC CTCACAGCGG GGCAGTGTGG TGCCCCAGGA 1398 GCAGGAACAT GCCATGTAGT GGGCGCCCTG CCCGTCTTCC CTCCTGCTCT GGGGTCGGAA 1458 CTGGAGTGCA GGGAACATGG AGGAGGAAGG GAAGAGCTTT ATTTTGTAAA AAAATAAGAT 1518 GAGCGGCA 1526 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1393 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..660 (D) OTHER INFORMATION: /standard_name= "Beta-1-5" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: ATG GTC CAG AAG ACC AGC ATG TCC CGG GGC CCT TAC CCA CCC TCC CAG 48 Met Val Gin Lys Thr Ser Met Ser Arg Gly Pro Tyr Pro Pro Ser Gin 1 5 10 15 GAG ATC CCC ATG GAG GTC TTC GAC CCC AGC CCG CAG GGC AAA TAC AGC 96 Glu He Pro Met Glu Val Phe Asp Pro Ser Pro Gin Gly Lys Tyr Ser 20 25 30 AAG AGG AAA GGG CGA TTC AAA CGG TCA GAT GGG AGC ACG TCC TCG GAT 144 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gly Ser Thr Ser Ser Asp 35 40 45 ACC ACA TCC AAC AGC TTT GTC CGC CAG GGC TCA GCG GAG TCC TAC ACC 192 Thr Thr Ser Asn Ser Phe Val Arg Gin Gly Ser Ala Glu Ser Tyr Thr 50 55 60 AGC CGT CCA TCA GAC TCT GAT GTA TCT CTG GAG GAG GAC CGG GAA GCC 240 Ser Arg Pro Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala 65 70 75 80 TTA AGG AAG GAA GCA GAG CGC CAG GCA TTA GCG CAG CTC GAG AAG GCC 288 Leu Arg Lys Glu Ala Glu Arg Gin Ala Leu Ala Gin Leu Glu Lys Ala 85 90 95 AAG ACC AAG CCA GTG GCA TTT GCT GTG CGG ACA AAT GTT GGC TAC AAT 336 Lys Thr Lys Pro Val Ala Phe Ala Val Arg Thr Asn Val Gly Tyr Asn 100 105 110 CCG TCT CCA GGG GAT GAG GTG CCT GTG CAG GGA GTG GCC ATC ACC TTC 384 Pro Ser Pro Gly Asp Glu Val Pro Val Gin Gly Val Ala He Thr Phe 115 120 125 GAG CCC AAA GAC TTC CTG CAC ATC AAG GAG AAA TAC AAT AAT GAC TGG 432 Glu Pro Lys Asp Phe Leu His He Lys Glu Lys Tyr Asn Asn Asp Trp 130 135 140 TGG ATC GGG CGG CTG GTG AAG GAG GGC TGT GAG GTT GGC TTC ATT CCC 480 Trp He Gly Arg Leu Val Lys Glu Gly Cys Glu Val Gly Phe He Pro 145 150 155 160 AGC CCC GTC AAA CTG GAC AGC CTT CGC CTG CTG CAG GAA CAG AAG CTG 528 Ser Pro Val Lys Leu Asp Ser Leu Arg Leu Leu Gin Glu Gin Lys Leu 165 170 175 CGC CAG AAC CGC CTC GGC TCC AGC AAA TCA GGC GAT AAC TCC AGT TCC 576 Arg Gin Asn Arg Leu Gly Ser Ser Lys Ser Gly Asp Asn Ser Ser Ser 180 185 190 AGT CTG GGA GAT GTG GTG ACT GGC ACC CGC CGC CCC ACA CCC CCT GCC 624 Ser Leu Gly Asp Val Val Thr Gly Thr Arg Arg Pro Thr Pro Pro Ala 195 200 205 AGT GGT TAC AGA CAT GAT GCA GAA AGC TTT ATT TGACTTCTTG AAGCATCGGT 677 Ser Gly Tyr Arg His Asp Ala Glu Ser Phe He 210 215 220 TTGATGGCAG GATCTCCATC ACTCGTGTGA CGGCAGATAT TTCCCTGGCT AAGCGCTCAG 737 TTCTCAACAA CCCCAGCAAA CACATCATCA TTGAGCGCTC CAACACACGC TCCAGCCTGG 797 CTGAGGTGCA GAGTGAAATC GAGCGAATCT TCGAGCTGGC CCGGACCCTT CAGTTGGTCG 857 CTCTGGATGC TGACACCATC AATCACCCAG CCCAGCTGTC CAAGACCTCG CTGGCCCCCA 917 TCATTGTTTA CATCAAGATC ACCTCTCCCA AGGTACTTCA AAGGCTCATC AAGTCCCGAG 977 GAAAGTCTCA GTCCAAACAC CTCAATGTCC AAATAGCGGC CTCGGAAAAG CTGGCACAGT 1037 GCCCCCCTGA AATGTTTGAC ATCATCCTGG ATGAGAACCA ATTGGAGGAT GCCTGCGAGC 1097 ATCTGGCGGA GTACTTGGAA GCCTATTGGA AGGCCACACA CCCGCCCAGC AGCACGCCAC 1157 CCAATCCGCT GCTGAACCGC ACCATGGCTA CCGCAGCCCT GGCTGCCAGC CCTGCCCCTG 1217 TCTCCAACCT CCAGGTACAG GTGCTCACCT CGCTCAGGAG AAACCTCGGC TTCTGGGGCG 1277 GGCTGGAGTC CTCACAGCGG GGCAGTGTGG TGCCCCAGGA GCAGGAACAT GCCATGTAGT 1337 GGGCGCCCTG CCCGTCTTCC CTCCTGCTCT GGGGTCGGAA CTGGAGTGCA GGGAAC 1393 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6725 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 226..6642 (D) OTHER INFORMATION: /standard name- "Alpha-lC-2" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: CTCGAGGAGG CAGTAGTGGA AAGGAGCAGT TTTTGGGGTT TGATGCCATA ATGGGAATCA 60 GGTAATCGTC GGCGGGGAAG AAGAAACGCT GCAGACCACG GCTTCCTCGA ATCTTGCGCG 120 AAAGCCGCCG GCCTCGGAGG AGGGATTAAT CCAGACCCGC CGGGGGGTGT TTTCACATTT 180 CTTCCTCTTC GTGGCTGCTC CTCCTATTAA AACCATTTTT GGTCC ATG GTC AAT 234 Met Val Asn 1 GAG AAT ACG AGG ATG TAC ATT CCA GAG GAA AAC CAC CAA GGT TCC AAC 282 Glu Asn Thr Arg Met Tyr He Pro Glu Glu Asn His Gin Gly Ser Asn 5 10 15 TAT GGG AGC CCA CGC CCC GCC CAT GCC AAC ATG AAT GCC AAT GCG GCA 330 Tyr Gly Ser Pro Arg Pro Ala His Ala Asn Met Asn Ala Asn Ala Ala 20 25 30 35 GCG GGG CTG GCC CCT GAG CAC ATC CCC ACC CCG GGG GCT GCC CTG TCG 378 Ala Gly Leu Ala Pro Glu His He Pro Thr Pro Gly Ala Ala Leu Ser 40 45 50 TGG CAG GCG GCC ATC GAC GCA GCC CGG CAG GCT AAG CTG ATG GGC AGC 426 Trp Gin Ala Ala He Asp Ala Ala Arg Gin Ala Lys Leu Met Gly Ser 55 60 65 GCT GGC AAT GCG ACC ATC TCC ACA GTC AGC TCC ACG CAG CGG AAG CGG 474 Ala Gly Asn Ala Thr He Ser Thr Val Ser Ser Thr Gin Arg Lys Arg 70 75 80 CAG CAA TAT GGG AAA CCC AAG AAG CAG GGC AGC ACC ACG GCC ACA CGC 522 Gin Gin Tyr Gly Lys Pro Lys Lys Gin Gly Ser Thr Thr Ala Thr Arg 85 90 95 CCG CCC CGA GCC CTG CTC TGC CTG ACC CTG AAG AAC CCC ATC CGG AGG 570 Pro Pro Arg Ala Leu Leu Cys Leu Thr Leu Lys Asn Pro He Arg Arg 100 105 110 115 GCC TGC ATC AGC ATT GTC GAA TGG AAA CCA TTT GAA ATA ATT ATT TTA 618 Ala Cys He Ser He Val Glu Trp Lys Pro Phe Glu He He He Leu 120 125 130 CTG ACT ATT TTT GCC AAT TGT GTG GCC TTA GCG ATC TAT ATT CCC TTT 666 Leu Thr He Phe Ala Asn Cys Val Ala Leu Ala He Tyr He Pro Phe 135 140 145 CCA GAA GAT GAT TCC AAC GCC ACC AAT TCC AAC CTG GAA CGA GTG GAA 714 Pro Glu Asp Asp Ser Asn Ala Thr Asn Ser Asn Leu Glu Arg Val Glu 150 155 160 TAT CTC TTT CTC ATA ATT TTT ACG GTG GAA GCG TTT TTA AAA GTA ATC 762 Tyr Leu Phe Leu He He Phe Thr Val Glu Ala Phe Leu Lys Val He 165 170 175 GCC TAT GGA CTC CTC TTT CAC CCC AAT GCC TAC CTC CGC AAC GGC TGG 810 Ala Tyr Gly Leu Leu Phe His Pro Asn Ala Tyr Leu Arg Asn Gly Trp 180 185 190 195 AAC CTA CTA GAT TTT ATA ATT GTG GTT GTG GGG CTT TTT AGT GCA ATT 858 Asn Leu Leu Asp Phe He He Val Val Val Gly Leu Phe Ser Ala He 200 205 210 TTA GAA CAA GCA ACC AAA GCA GAT GGG GCA AAC GCT CTC GGA GGG AAA 906 Leu Glu Gin Ala Thr Lys Ala Asp Gly Ala Asn Ala Leu Gly Gly Lys 215 220 225 GGG GCC GGA TTT GAT GTG AAG GCG CTG AGG GCC TTC CGC GTG CTG CGC 954 Gly Ala Gly Phe Asp Val Lys Ala Leu Arg Ala Phe Arg Val Leu Arg 230 235 240 CCC CTG CGG CTG GTG TCC GGA GTC CCA AGT CTC CAG GTG GTC CTG AAT 1002 Pro Leu Arg Leu Val Ser Gly Val Pro Ser Leu Gin Val Val Leu Asn 245 250 255 TCC ATC ATC AAG GCC ATG GTC CCC CTG CTG CAC ATC GCC CTG CTT GTG 1050 Ser He He Lys Ala Met Val Pro Leu Leu His He Ala Leu Leu Val 260 265 270 275 CTG TTT GTC ATC ATC ATC TAC GCC ATC ATC GGC TTG GAG CTC TTC ATG 1098 Leu Phe Val He He He Tyr Ala He He Gly Leu Glu Leu Phe Met 280 285 290 GGG AAG ATG CAC AAG ACC TGC TAC AAC CAG GAG GGC ATA GCA GAT GTT 1146 Gly Lys Met His Lys Thr Cys Tyr Asn Gin Glu Gly He Ala Asp Val 295 300 305 CCA GCA GAA GAT GAC CCT TCC CCT TGT GCG CTG GAA ACG GGC CAC GGG 1194 Pro Ala Glu Asp Asp Pro Ser Pro Cys Ala Leu Glu Thr Gly His Gly 310 315 320 CGG CAG TGC CAG AAC GGC ACG GTG TGC AAG CCC GGC TGG GAT GGT CCC 1242 Arg Gin Cys Gin Asn Gly Thr Val Cys Lys Pro Gly Trp Asp Gly Pro 325 330 335 AAG CAC GGC ATC ACC AAC TTT GAC AAC TTT GCC TTC GCC ATG CTC ACG 1290 Lys His Gly He Thr Asn Phe Asp Asn Phe Ala Phe Ala Met Leu Thr 340 345 350 355 GTG TTC CAG TGC ATC ACC ATG GAG GGC TGG ACG GAC GTG CTG TAC TGG 1338 Val Phe Gin Cys He Thr Met Glu Gly Trp Thr Asp Val Leu Tyr Trp 360 365 370 GTC AAT GAT GCC GTA GGA AGG GAC TGG CCC TGG ATC TAT TTT GTT ACA 1386 Val Asn Asp Ala Val Gly Arg Asp Trp Pro Trp He Tyr Phe Val Thr 375 380 385 CTA ATC ATC ATA GGG TCA TTT TTT GTA CTT AAC TTG GTT CTC GGT GTG 1434 Leu He He He Gly Ser Phe Phe Val Leu Asn Leu Val Leu Gly Val 390 395 400 CTT AGC GGA GAG TTT TCC AAA GAG AGG GAG AAG GCC AAG GCC CGG GGA 1482 Leu Ser Gly Glu Phe Ser Lys Glu Arg Glu Lys Ala Lys Ala Arg Gly 405 410 415 GAT TTC CAG AAG CTG CGG GAG AAG CAG CAG CTA GAA GAG GAT CTC AAA 1530 Asp Phe Gin Lys Leu Arg Glu Lys Gin Gin Leu Glu Glu Asp Leu Lys 420 425 430 435 GGC TAC CTG GAT TGG ATC ACT CAG GCC GAA GAC ATC GAT CCT GAG AAT 1578 Gly Tyr Leu Asp Trp He Thr Gin Ala Glu Asp He Asp Pro Glu Asn 440 445 450 GAG GAC GAA GGC ATG GAT GAG GAG AAG CCC CGA AAC ATG AGC ATG CCC 1626 Glu Asp Glu Gly Met Asp Glu Glu Lys Pro Arg Asn Met Ser Met Pro . 455 460 465 ACC AGT GAG ACC GAG TCC GTC AAC ACC GAA AAC GTG GCT GGA GGT GAC 1674 Thr Ser Glu Thr Glu Ser Val Asn Thr Glu Asn Val Ala Gly Gly Asp 470 475 480 ATC GAG GGA GAA AAC TGC GGG GCC AGG CTG GCC CAC CGG ATC TCC AAG 1722 He Glu Gly Glu Asn Cys Gly Ala Arg Leu Ala His Arg He Ser Lys 485 490 495 TCA AAG TTC AGC CGC TAC TGG CGC CGG TGG AAT CGG TTC TGC AGA AGG 1770 Ser Lys Phe Ser Arg Tyr Trp Arg Arg Trp Asn Arg Phe Cys Arg Arg 500 505 510 515 AAG TGC CGC GCC GCA GTC AAG TCT AAT GTC TTC TAC TGG CTG GTG ATT 1818 Lys Cys Arg Ala Ala Val Lys Ser Asn Val Phe Tyr Trp Leu Val He 520 525 530 TTC CTG GTG TTC CTC AAC ACG CTC ACC ATT GCC TCT GAG CAC TAC AAC 1866 Phe Leu Val Phe Leu Asn Thr Leu Thr He Ala Ser Glu His Tyr Asn 535 540 545 CAG CCC AAC TGG CTC ACA GAA GTC CAA GAC ACG GCA AAC AAG GCC CTG 1914 Gin Pro Asn Trp Leu Thr Glu Val Gin Asp Thr Ala Asn Lys Ala Leu 550 555 560 CTG GCC CTG TTC ACG GCA GAG ATG CTC CTG AAG ATG TAC AGC CTG GGC 1962 Leu Ala Leu Phe Thr Ala Glu Met Leu Leu Lys Met Tyr Ser Leu Gly 565 570 575 CTG CAG GCC TAC TTC GTG TCC CTC TTC AAC CGC TTT GAC TGC TTC GTC 2010 Leu Gin Ala Tyr Phe Val Ser Leu Phe Asn Arg Phe Asp Cys Phe Val 580 585 590 595 GTG TGT GGC GGC ATC CTG GAG ACC ATC CTG GTG GAG ACC AAG ATC ATG 2058 Val Cys Gly Gly He Leu Glu Thr He Leu Val Glu Thr Lys He Met 600 605 610 TCC CCA CTG GGC ATC TCC GTG CTC AGA TGC GTC CGG CTG CTG AGG ATT 2106 Ser Pro Leu Gly He Ser Val Leu Arg Cys Val Arg Leu Leu Arg He 615 620 625 TTC AAG ATC ACG AGG TAC TGG AAC TCC TTG AGC AAC CTG GTG GCA TCC 2154 Phe Lys He Thr Arg Tyr Trp Asn Ser Leu Ser Asn Leu Val Ala Ser 630 635 640 TTG CTG AAC TCT GTG CGC TCC ATC GCC TCC CTG CTC CTT CTC CTC TTC 2202 Leu Leu Asn Ser Val Arg Ser He Ala Ser Leu Leu Leu Leu Leu Phe 645 650 655 CTC TTC ATC ATC ATC TTC TCC CTC CTG GGG ATG CAG CTC TTT GGA GGA 2250 Leu Phe He He He Phe Ser Leu Leu Gly Met Gin Leu Phe Gly Gly 660 665 670 675 AAG TTC AAC TTT GAT GAG ATG CAG ACC CGG AGG AGC ACA TTC GAT AAC 2298 Lys Phe Asn Phe Asp Glu Met Gin Thr Arg Arg Ser Thr Phe Asp Asn 680 685 690 TTC CCC CAG TCC CTC CTC ACT GTG TTT CAG ATC CTG ACC GGG GAG GAC 2346 Phe Pro Gin Ser Leu Leu Thr Val Phe Gin He Leu Thr Gly Glu Asp 695 700 705 TGG AAT TCG GTG ATG TAT GAT GGG ATC ATG GCT TAT GGC GGC CCC TCT 2394 Trp Asn Ser Val Met Tyr Asp Gly He Met Ala Tyr Gly Gly Pro Ser 710 715 720 TTT CCA GGG ATG TTA GTC TGT ATT TAC TTC ATC ATC CTC TTC ATC TGT 2442 Phe Pro Gly Met Leu Val Cys He Tyr Phe He He Leu Phe He Cys 725 730 735 GGA AAC TAT ATC CTA CTG AAT GTG TTC TTG GCC ATT GCT GTG GAC AAC 2490 Gly Asn Tyr He Leu Leu Asn Val Phe Leu Ala He Ala Val Asp Asn 740 745 750 755 CTG GCT GAT GCT GAG AGC CTC ACA TCT GCC CAA AAG GAG GAG GAA GAG 2538 Leu Ala Asp Ala Glu Ser Leu Thr Ser Ala Gin Lys Glu Glu Glu Glu 760 765 770 GAG AAG GAG AGA AAG AAG CTG GCC AGG ACT GCC AGC CCA GAG AAG AAA 2586 Glu Lys Glu Arg Lys Lys Leu Ala Arg Thr Ala Ser Pro Glu Lys Lys 775 780 785 CAA GAG TTG GTG GAG AAG CCG GCA GTG GGG GAA TCC AAG GAG GAG AAG 2634 Gin Glu Leu Val Glu Lys Pro Ala Val Gly Glu Ser Lys Glu Glu Lys 790 795 800 ATT GAG CTG AAA TCC ATC ACG GCT GAC GGA GAG TCT CCA CCC GCC ACC 2682 He Glu Leu Lys Ser He Thr Ala Asp Gly Glu Ser Pro Pro Ala Thr 805 810 815 AAG ATC AAC ATG GAT GAC CTC CAG CCC AAT GAA AAT GAG GAT AAG AGC 2730 Lys He Asn Met Asp Asp Leu Gin Pro Asn Glu Asn Glu Asp Lys Ser 820 825 830 835 CCC TAC CCC AAC CCA GAA ACT ACA GGA GAA GAG GAT GAG GAG GAG CCA 2778 Pro Tyr Pro Asn Pro Glu Thr Thr Gly Glu Glu Asp Glu Glu Glu Pro 840 845 850 GAG ATG CCT GTC GGC CCT CGC CCA CGA CCA CTC TCT GAG CTT CAC CTT 2826 Glu Met Pro Val Gly Pro Arg Pro Arg Pro Leu Ser Glu Leu His Leu 855 860 865 AAG GAA AAG GCA GTG CCC ATG CCA GAA GCC AGC GCG TTT TTC ATC TTC 2874 Lys Glu Lys Ala Val Pro Met Pro Glu Ala Ser Ala Phe Phe He Phe 870 875 880 AGC TCT AAC AAC AGG TTT CGC CTC CAG TGC CAC CGC ATT GTC AAT GAC 2922 Ser Ser Asn Asn Arg Phe Arg Leu Gin Cys His Arg He Val Asn Asp 885 890 895 ACG ATC TTC ACC AAC CTG ATC CTC TTC TTC ATT CTG CTC AGC AGC ATT 2970 Thr He Phe Thr Asn Leu He Leu Phe Phe He Leu Leu Ser Ser He 900 905 910 915 TCC CTG GCT GCT GAG GAC CCG GTC CAG CAC ACC TCC TTC AGG AAC CAT 3018 Ser Leu Ala Ala Glu Asp Pro Val Gin His Thr Ser Phe Arg Asn His 920 925 930 ATT CTG TTT TAT TTT GAT ATT GTT TTT ACC ACC ATT TTC ACC ATT GAA 3066 He Leu Phe Tyr Phe Asp He Val Phe Thr Thr He Phe Thr He Glu 935 940 945 ATT GCT CTG AAG ATG ACT GCT TAT GGG GCT TTC TTG CAC AAG GGT TCT 3114 He Ala Leu Lys Met Thr Ala Tyr Gly Ala Phe Leu His Lys Gly Ser 950 955 960 TTC TGC CGG AAC TAC TTC AAC ATC CTG GAC CTG CTG GTG GTC AGC GTG 3162 Phe Cys Arg Asn Tyr Phe Asn He Leu Asp Leu Leu Val Val Ser Val 965 970 975 TCC CTC ATC TCC TTT GGC ATC CAG TCC AGT GCA ATC AAT GTC GTG AAG 3210 Ser Leu He Ser Phe Gly He Gin Ser Ser Ala He Asn Val Val Lys 980 985 990 995 ATC TTG CGA GTC CTG CGA GTA CTC AGG CCC CTG AGG GCC ATC AAC AGG 3258 He Leu Arg Val Leu Arg Val Leu Arg Pro Leu Arg Ala He Asn Arg 1000 1005 1010 GCC AAG GGG CTA AAG CAT GTG GTT CAG TGT GTG TTT GTC GCC ATC CGG 3306 Ala Lys Gly Leu Lys His Val Val Gin Cys Val Phe Val Ala He Arg 1015 1020 1025 ACC ATC GGG AAC ATC GTG ATT GTC ACC ACC CTG CTG CAG TTC ATG TTT 3354 Thr He Gly Asn He Val He Val Thr Thr Leu Leu Gin Phe Met Phe 1030 1035 1040 GCC TGC ATC GGG GTC CAG CTC TTC AAG GGA AAG CTG TAC ACC TGT TCA 3402 Ala Cys He Gly Val Gin Leu Phe Lys Gly Lys Leu Tyr Thr Cys Ser 1045 1050 1055 GAC AGT TCC AAG CAG ACA GAG GCG GAA TGC AAG GGC AAC TAC ATC ACG 3450 Asp Ser Ser Lys Gin Thr Glu Ala Glu Cys Lys Gly Asn Tyr He Thr 1060 1065 1070 1075 TAC AAA GAC GGG GAG GTT GAC CAC CCC ATC ATC CAA CCC CGC AGC TGG 3498 Tyr Lys Asp Gly Glu Val Asp His Pro He He Gin Pro Arg Ser Trp 1080 1085 1090 GAG AAC AGC AAG TTT GAC TTT GAC AAT GTT CTG GCA GCC ATG ATG GCC 3546 Glu Asn Ser Lys Phe Asp Phe Asp Asn Val Leu Ala Ala Met Met Ala 1095 1100 1105 CTC TTC ACC GTC TCC ACC TTC GAA GGG TGG CCA GAG CTG CTG TAC CGC 3594 Leu Phe Thr Val Ser Thr Phe Glu Gly Trp Pro Glu Leu Leu Tyr Arg 1110 1115 1120 TCC ATC GAC TCC CAC ACG GAA GAC AAG GGC CCC ATC TAC AAC TAC CGT 3642 Ser He Asp Ser His Thr Glu Asp Lys Gly Pro He Tyr Asn Tyr Arg 1125 1130 1135 GTG GAG ATC TCC ATC TTC TTC ATC ATC TAC ATC ATC ATC ATC GCC TTC 3690 Val Glu He Ser He Phe Phe He He Tyr He He He He Ala Phe 1140 1145 1150 1155 TTC ATG ATG AAC ATC TTC GTG GGC TTC GTC ATC GTC ACC TTT CAG GAG 3738 Phe Met Met Asn He Phe Val Gly Phe Val He Val Thr Phe Gin Glu 1160 1165 1170 CAG GGG GAG CAG GAG TAC AAG AAC TGT GAG CTG GAC AAG AAC CAG CGA 3786 Gin Gly Glu Gin Glu Tyr Lys Asn Cys Glu Leu Asp Lys Asn Gin Arg 1175 1180 1185 CAG TGC GTG GAA TAC GCC CTC AAG GCC CGG CCC CTG CGG AGG TAC ATC 3834 Gin Cys Val Glu Tyr Ala Leu Lys Ala Arg Pro Leu Arg Arg Tyr He 1190 1195 1200 CCC AAG AAC CAG CAC CAG TAC AAA GTG TGG TAC GTG GTC AAC TCC ACC 3882 Pro Lys Asn Gin His Gin Tyr Lys Val Trp Tyr Val Val Asn Ser Thr 1205 1210 1215 TAC TTC GAG TAC CTG ATG TTC GTC CTC ATC CTG CTC AAC ACC ATC TGC 3930 Tyr Phe Glu Tyr Leu Met Phe Val Leu He Leu Leu Asn Thr He Cys 1220 1225 1230 1235 CTG GCC ATG CAG CAC TAC GGC CAG AGC TGC CTG TTC AAA ATC GCC ATG 3978 Leu Ala Met Gin His Tyr Gly Gin Ser Cys Leu Phe Lys He Ala Met 1240 1245 1250 AAC ATC CTC AAC ATG CTC TTC ACT GGC CTC TTT ACC GTG GAG ATG ATC 4026 Asn He Leu Asn Met Leu Phe Thr Gly Leu Phe Thr Val Glu Met He 1255 1260 1265 CTG AAG CTC ATT GCC TTC AAA CCC AAG CAC TAT TTC TGT GAT GCA TGG 4074 Leu Lys Leu He Ala Phe Lys Pro Lys His Tyr Phe Cys Asp Ala Trp 1270 1275 1280 AAT ACA TTT GAC GCC TTG ATT GTT GTG GGT AGC ATT GTT GAT ATA GCA 4122 Asn Thr Phe Asp Ala Leu He Val Val Gly Ser He Val Asp He Ala 1285 1290 1295 ATC ACC GAG GTA AAC CCA GCT GAA CAT ACC CAA TGC TCT CCC TCT ATG 4170 He Thr Glu Val Asn Pro Ala Glu His Thr Gin Cys Ser Pro Ser Met 1300 1305 1310 1315 AAC GCA GAG GAA AAC TCC CGC ATC TCC ATC ACC TTC TTC CGC CTG TTC 4218 Asn Ala Glu Glu Asn Ser Arg He Ser He Thr Phe Phe Arg Leu Phe 1320 1325 1330 CGG GTC ATG CGT CTG GTG AAG CTG CTG AGC CGT GGG GAG GGC ATC CGG 4266 Arg Val Met Arg Leu Val Lys Leu Leu Ser Arg Gly Glu Gly He Arg 1335 1340 1345 ACG CTG CTG TGG ACC TTC ATC AAG TCC TTC CAG GCC CTG CCC TAT GTG 4314 Thr Leu Leu Trp Thr Phe He Lys Ser Phe Gin Ala Leu Pro Tyr Val 1350 1355 1360 GCC CTC CTG ATC GTG ATG CTG TTC TTC ATC TAC GCG GTG ATC GGG ATG 4362 Ala Leu Leu He Val Met Leu Phe Phe He Tyr Ala Val He Gly Met 1365 1370 1375 CAG GTG TTT GGG AAA ATT GCC CTG AAT GAT ACC ACA GAG ATC AAC CGG 4410 Gin Val Phe Gly Lys He Ala Leu Asn Asp Thr Thr Glu He Asn Arg 1380 1385 1390 1395 AAC AAC AAC TTT CAG ACC TTC CCC CAG GCC GTG CTG CTC CTC TTC AGG 4458 Asn Asn Asn Phe Gin Thr Phe Pro Gin Ala Val Leu Leu Leu Phe Arg 1400 1405 1410 TGT GCC ACC GGG GAG GCC TGG CAG GAC ATC ATG CTG GCC TGC ATG CCA 4506 Cys Ala Thr Gly Glu Ala Trp Gin Asp He Met Leu Ala Cys Met Pro 1415 1420 1425 GGC AAG AAG TGT GCC CCA GAG TCC GAG CCC AGC AAC AGC ACG GAG GGT 4554 Gly Lys Lys Cys Ala Pro Glu Ser Glu Pro Ser Asn Ser Thr Glu Gly 1430 1435 1440 GAA ACA CCC TGT GGT AGC AGC TTT GCT GTC TTC TAC TTC ATC AGC TTC 4602 Glu Thr Pro Cys Gly Ser Ser Phe Ala Val Phe Tyr Phe He Ser Phe 1445 1450 1455 TAC ATG CTC TGT GCC TTC CTG ATC ATC AAC CTC TTT GTA GCT GTC ATC 4650 Tyr Met Leu Cys Ala Phe Leu He He Asn Leu Phe Val Ala Val He 1460 1465 1470 1475 ATG GAC AAC TTT GAC TAC CTG ACA AGG GAC TGG TCC ATC CTT GGT CCC 4698 Met Asp Asn Phe Asp Tyr Leu Thr Arg Asp Trp Ser He Leu Gly Pro 1480 1485 1490 CAC CAC CTG GAT GAG TTT AAA AGA ATC TGG GCA GAG TAT GAC CCT GAA 4746 His His Leu Asp Glu Phe Lys Arg He Trp Ala Glu Tyr Asp Pro Glu 1495 1500 1505 GCC AAG GGT CGT ATC AAA CAC CTG GAT GTG GTG ACC CTC CTC CGG CGG 4794 Ala Lys Gly Arg He Lys His Leu Asp Val Val Thr Leu Leu Arg Arg 1510 1515 1520 ATT CAG CCG CCA CTA GGT TTT GGG AAG CTG TGC CCT CAC CGC GTG GCT 4842 He Gin Pro Pro Leu Gly Phe Gly Lys Leu Cys Pro His Arg Val Ala 1525 1530 1535 TGC AAA CGC CTG GTC TCC ATG AAC ATG CCT CTG AAC AGC GAC GGG ACA 4890 Cys Lys Arg Leu Val Ser Met Asn Met Pro Leu Asn Ser Asp Gly Thr 1540 1545 1550 1555 GTC ATG TTC AAT GCC ACC CTG TTT GCC CTG GTC AGG ACG GCC CTG AGG 4938 Val Met Phe Asn Ala Thr Leu Phe Ala Leu Val Arg Thr Ala Leu Arg 1560 1565 1570 ATC AAA ACA GAA GGG AAC CTA GAA CAA GCC AAT GAG GAG CTG CGG GCG 4986 He Lys Thr Glu Gly Asn Leu Glu Gin Ala Asn Glu Glu Leu Arg Ala 1575 1580 1585 ATC ATC AAG AAG ATC TGG AAG CGG ACC AGC ATG AAG CTG CTG GAC CAG 5034 He He Lys Lys He Trp Lys Arg Thr Ser Met Lys Leu Leu Asp Gin 1590 1595 1600 GTG GTG CCC CCT GCA GGT GAT GAT GAG GTC ACC GTT GGC AAG TTC TAC 5082 Val Val Pro Pro Ala Gly Asp Asp Glu Val Thr Val Gly Lys Phe Tyr 1605 1610 1615 GCC ACG TTC CTG ATC CAG GAG TAC TTC CGG AAG TTC AAG AAG CGC AAA 5130 Ala Thr Phe Leu He Gin Glu Tyr Phe Arg Lys Phe Lys Lys Arg Lys 1620 1625 1630 1635 GAG CAG GGC CTT GTG GGC AAG CCC TCC CAG AGG AAC GCG CTG TCT CTG 5178 Glu Gin Gly Leu Val Gly Lys Pro Ser Gin Arg Asn Ala Leu Ser Leu 1640 1645 1650 CAG GCT GGC TTG CGC ACA CTG CAT GAC ATC GGG CCT GAG ATC CGA CGG 5226 Gin Ala Gly Leu Arg Thr Leu His Asp He Gly Pro Glu He Arg Arg 1655 1660 1665 GCC ATC TCT GGA GAT CTC ACC GCT GAG GAG GAG CTG GAC AAG GCC ATG 5274 Ala He Ser Gly Asp Leu Thr Ala Glu Glu Glu Leu Asp Lys Ala Met 1670 1675 1680 AAG GAG GCT GTG TCC GCT GCT TCT GAA GAT GAC ATC TTC AGG AGG GCC 5322 Lys Glu Ala Val Ser Ala Ala Ser Glu Asp Asp He Phe Arg Arg Ala 1685 1690 1695 GGT GGC CTG TTC GGC AAC CAC GTC AGC TAC TAC CAA AGC GAC GGC CGG 5370 Gly Gly Leu Phe Gly Asn His Val Ser Tyr Tyr Gin Ser Asp Gly Arg 1700 1705 1710 1715 AGC GCC TTC CCC CAG ACC TTC ACC ACT CAG CGC CCG CTG CAC ATC AAC 5418 Ser Ala Phe Pro Gin Thr Phe Thr Thr Gin Arg Pro Leu His He Asn 1720 1725 1730 AAG GCG GGC AGC AGC CAG GGC GAC ACT GAG TCG CCA TCC CAC GAG AAG 5466 Lys Ala Gly Ser Ser Gin Gly Asp Thr Glu Ser Pro Ser His Glu Lys 1735 1740 1745 CTG GTG GAC TCC ACC TTC ACC CCG AGC AGC TAC TCG TCC ACC GGC TCC 5514 Leu Val Asp Ser Thr Phe Thr Pro Ser Ser Tyr Ser Ser Thr Gly Ser 1750 1755 1760 AAC GCC AAC ATC AAC AAC GCC AAC AAC ACC GCC CTG GGT CGC CTC CCT 5562 Asn Ala Asn He Asn Asn Ala Asn Asn Thr Ala Leu Gly Arg Leu Pro 1765 1770 1775 CGC CCC GCC GGC TAC CCC AGC ACG GTC AGC ACT GTG GAG GGC CAC GGG 5610 Arg Pro Ala Gly Tyr Pro Ser Thr Val Ser Thr Val Glu Gly His Gly 1780 1785 1790 1795 CCC CCC TTG TCC CCT GCC ATC CGG GTG CAG GAG GTG GCG TGG AAG CTC 5658 Pro Pro Leu Ser Pro Ala He Arg Val Gin Glu Val Ala Trp Lys Leu 1800 1805 1810 AGC TCC AAC AGG TGC CAC TCC CGG GAG AGC CAG GCA GCC ATG GCG GGT 5706 Ser Ser Asn Arg Cys His Ser Arg Glu Ser Gin Ala Ala Met Ala Gly 1815 1820 1825 CAG GAG GAG ACG TCT CAG GAT GAG ACC TAT GAA GTG AAG ATG AAC CAT 5754 Gin Glu Glu Thr Ser Gin Asp Glu Thr Tyr Glu Val Lys Met Asn His 1830 1835 1840 GAC ACG GAG GCC TGC AGT GAG CCC AGC CTG CTC TCC ACA GAG ATG CTC 5802 Asp Thr Glu Ala Cys Ser Glu Pro Ser Leu Leu Ser Thr Glu Met Leu 1845 1850 1855 TCC TAC CAG GAT GAC GAA AAT CGG CAA CTG ACG CTC CCA GAG GAG GAC 5850 Ser Tyr Gin Asp Asp Glu Asn Arg Gin Leu Thr Leu Pro Glu Glu Asp 1860 1865 1870 1875 AAG AGG GAC ATC CGG CAA TCT CCG AAG AGG GGT TTC CTC CGC TCT GCC 5898 Lys Arg Asp He Arg Gin Ser Pro Lys Arg Gly Phe Leu Arg Ser Ala 1880 1885 1890 TCA CTA GGT CGA AGG GCC TCC TTC CAC CTG GAA TGT CTG AAG CGA CAG 5946 Ser Leu Gly Arg Arg Ala Ser Phe His Leu Glu Cys Leu Lys Arg Gin 1895 1900 1905 AAG GAC CGA GGG GGA GAC ATC TCT CAG AAG ACA GTC CTG CCC TTG CAT 5994 Lys Asp Arg Gly Gly Asp He Ser Gin Lys Thr Val Leu Pro Leu His 1910 1915 1920 CTG GTT CAT CAT CAG GCA TTG GCA GTG GCA GGC CTG AGC CCC CTC CTC 6042 Leu Val His His Gin Ala Leu Ala Val Ala Gly Leu Ser Pro Leu Leu 1925 1930 1935 CAG AGA AGC CAT TCC CCT GCC TCA TTC CCT AGG CCT TTT GCC ACC CCA 6090 Gin Arg Ser His Ser Pro Ala Ser Phe Pro Arg Pro Phe Ala Thr Pro 1940 1945 1950 1955 CCA GCC ACA CCT GGC AGC CGA GGC TGG CCC CCA CAG CCC GTC CCC ACC 6138 Pro Ala Thr Pro Gly Ser Arg Gly Trp Pro Pro Gin Pro Val Pro Thr 1960 1965 1970 CTG CGG CTT GAG GGG GTC GAG TCC AGT GAG AAA CTC AAC AGC AGC TTC 6186 Leu Arg Leu Glu Gly Val Glu Ser Ser Glu Lys Leu Asn Ser Ser Phe 1975 1980 1985 CCA TCC ATC CAC TGC GGC TCC TGG GCT GAG ACC ACC CCC GGT GGC GGG 6234 Pro Ser He His Cys Gly Ser Trp Ala Glu Thr Thr Pro Gly Gly Gly 1990 1995 2000 GGC AGC AGC GCC GCC CGG AGA GTC CGG CCC GTC TCC CTC ATG GTG CCC 6282 Gly Ser Ser Ala Ala Arg Arg Val Arg Pro Val Ser Leu Met Val Pro 2005 2010 2015 AGC CAG GCT GGG GCC CCA GGG AGG CAG TTC CAC GGC AGT GCC AGC AGC 6330 Ser Gin Ala Gly Ala Pro Gly Arg Gin Phe His Gly Ser Ala Ser Ser 2020 2025 2030 2035 CTG GTG GAA GCG GTC TTG ATT TCA GAA GGA CTG GGG CAG TTT GCT CAA 6378 Leu Val Glu Ala Val Leu He Ser Glu Gly Leu Gly Gin Phe Ala Gin 2040 2045 2050 GAT CCC AAG TTC ATC GAG GTC ACC ACC CAG GAG CTG GCC GAC GCC TGC 6426 Asp Pro Lys Phe He Glu Val Thr Thr Gin Glu Leu Ala Asp Ala Cys 2055 2060 2065 GAC ATG ACC ATA GAG GAG ATG GAG AGC GCG GCC GAC AAC ATC CTC AGC 6474 Asp Met Thr He Glu Glu Met Glu Ser Ala Ala Asp Asn He Leu Ser 2070 2075 2080 GGG GGC GCC CCA CAG AGC CCC AAT GGC GCC CTC TTA CCC TTT GTG AAC 6522 Gly Gly Ala Pro Gin Ser Pro Asn Gly Ala Leu Leu Pro Phe Val Asn 2085 2090 2095 TGC AGG GAC GCG GGG CAG GAC CGA GCC GGG GGC GAA GAG GAC GCG GGC 6570 Cys Arg Asp Ala Gly Gin Asp Arg Ala Gly Gly Glu Glu Asp Ala Gly 2100 2105 2110 2115 TGT GTG CGC GCG CGG GGT CGA CCG AGT GAG GAG GAG CTC CAG GAC AGC 6618 Cys Val Arg Ala Arg Gly Arg Pro Ser Glu Glu Glu Leu Gin Asp Ser 2120 2125 2130 AGG GTC TAC GTC AGC AGC CTG TAGTGGGCGC TGCCAGATGC GGGCTTTTTT 6669 Arg Val Tyr Val Ser Ser Leu 2135 TTATTTGTTT CAATGTTCCT AATGGGTTCG TTTCAGAAGT GCCTCACTGT TCTCGT 6725 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2970 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 502..2316 (D) OTHER INFORMATION: /standard_name= "Beta-2C" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: CAGCAGCGTG CTAAGAAGCA GTCACATAAA CAGCAGCAGG AGTAGGCCTC CTGCTTTTCA 60 AAAGCAGAGT ACTGCAGGGT CGCGAAATGC AAGACACTCA GATGTTTGAA AATCTCCCGA 120 GTTGAGAATG GCTACTGTAA AAGCGTCACC AAGAAACTCT GACGATCTGG ACAGTCCTAA 180 CTCTGTGTTA GCAATACTTA CTTCCGGAAA ATTAATGCTA CTTCTTGTAG ATTTTTGCAA 240 ATAGGAAACC CCCTTGAAGA AGATCTCAAA TTACGCCCCC CACCCCCAAA AAAAGACAAA 300 CAGGGGAGAA CAAAGTTTTG GCATGCCTGC AGGAACGGTG GCTTTTTTAG AAACTACCTA 360 GGAGGCAGAA GCTAAGTGAT TTGCTCATGC CTCTTACCTG GGAGTAGAAG GTGGGAAGAA 420 ATGGACCGAG GCTGTGACGA GAAGACAAGG CACAGTGCAG CTTGGTGAAG CCACACGCTG 480 ACTGCGTTCT GCCCCCTCTT C ATG CAG TGC TGC GGG CTG GTG CAT CGC CGG 531 Met Gin Cys Cys Gly Leu Val His Arg Arg 1 5 10 CGA GTA CGG GTG TCC TAT GGT TCG GCA GAC TCC TAC ACT AGC CGT CCA 579 Arg Val Arg Val Ser Tyr Gly Ser Ala Asp Ser Tyr Thr Ser Arg Pro 15 20 25 TCC GAT TCC GAT GTA TCT CTG GAG GAG GAC CGG GAG GCA GTG CGC AGA 627 Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala Val Arg Arg 30 35 40 GAA GCG GAG CGG CAG GCC CAG GCA CAG TTG GAA AAA GCA AAG ACA AAG 675 Glu Ala Glu Arg Gin Ala Gin Ala Gin Leu Glu Lys Ala Lys Thr Lys 45 50 55 CCC GTT GCA TTT GCG GTT CGG ACA AAT GTC AGC TAC AGT GCG GCC CAT 723 Pro Val Ala Phe Ala Val Arg Thr Asn Val Ser Tyr Ser Ala Ala His 60 65 70 GAA GAT GAT GTT CCA GTG CCT GGC ATG GCC ATC TCA TTC GAA GCA AAA 771 Glu Asp Asp Val Pro Val Pro Gly Met Ala He Ser Phe Glu Ala Lys 75 80 85 90 GAT TTT CTG CAT GTT AAG GAA AAA TTT AAC AAT GAC TGG TGG ATA GGG 819 Asp Phe Leu His Val Lys Glu Lys Phe Asn Asn Asp Trp Trp He Gly 95 100 105 CGA TTG GTA AAA GAA GGC TGT GAA ATC GGA TTC ATT CCA AGC CCA GTC 867 Arg Leu Val Lys Glu Gly Cys Glu He Gly Phe He Pro Ser Pro Val 110 115 120 AAA CTA GAA AAC ATG AGG CTG CAG CAT GAA CAG AGA GCC AAG CAA GGG 915 Lys Leu Glu Asn Met Arg Leu Gin His Glu Gin Arg Ala Lys Gin Gly 125 130 135 AAA TTC TAC TCC AGT AAA TCA GGA GGA AAT TCA TCA TCC AGT TTG GGT 963 Lys Phe Tyr Ser Ser Lys Ser Gly Gly Asn Ser Ser Ser Ser Leu Gly 140 145 150 GAC ATA GTA CCT AGT TCC AGA AAA TCA ACA CCT CCA TCA TCT GCT ATA 1011 Asp He Val Pro Ser Ser Arg Lys Ser Thr Pro Pro Ser Ser Ala He 155 160 165 170 GAC ATA GAT GCT ACT GGC TTA GAT GCA GAA GAA AAT GAT ATT CCA GCA 1059 Asp He Asp Ala Thr Gly Leu Asp Ala Glu Glu Asn Asp He Pro Ala 175 180 185 AAC CAC CGC TCC CCT AAA CCC AGT GCA AAC AGT GTA ACG TCA CCC CAC 1107 Asn His Arg Ser Pro Lys Pro Ser Ala Asn Ser Val Thr Ser Pro His 190 195 200 TCC AAA GAG AAA AGA ATG CCC TTC TTT AAG AAG ACA GAG CAC ACT CCT 1155 Ser Lys Glu Lys Arg Met Pro Phe Phe Lys Lys Thr Glu His Thr Pro 205 210 215 CCG TAT GAT GTG GTA CCT TCC ATG CGA CCA GTG GTC CTA GTG GGC CCT 1203 Pro Tyr Asp Val Val Pro Ser Met Arg Pro Val Val Leu Val Gly Pro 220 225 230 TCT CTG AAG GGC TAC GAG GTC ACA GAT ATG ATG CAA AAA GCG CTG TTT 1251 Ser Leu Lys Gly Tyr Glu Val Thr Asp Met Met Gin Lys Ala Leu Phe 235 240 245 250 GAT TTT TTA AAA CAC AGA TTT GAA GGG CGG ATA TCC ATC ACA AGG GTC 1299 Asp Phe Leu Lys His Arg Phe Glu Gly Arg He Ser He Thr Arg Val 255 260 265 ACC GCT GAC ATC TCG CTT GCC AAA CGC TCG GTA TTA AAC AAT CCC AGT 1347 Thr Ala Asp He Ser Leu Ala Lys Arg Ser Val Leu Asn Asn Pro Ser 270 275 280 AAG CAC GCA ATA ATA GAA AGA TCC AAC ACA AGG TCA AGC TTA GCG GAA 1395 Lys His Ala He He Glu Arg Ser Asn Thr Arg Ser Ser Leu Ala Glu 285 290 295 GTT CAG AGT GAA ATC GAA AGG ATT TTT GAA CTT GCA AGA ACA TTG CAG 1443 Val Gin Ser Glu He Glu Arg He Phe Glu Leu Ala Arg Thr Leu Gin 300 305 310 TTG GTG GTC CTT GAC GCG GAT ACA ATT AAT CAT CCA GCT CAA CTC AGT 1491 Leu Val Val Leu Asp Ala Asp Thr He Asn His Pro Ala Gin Leu Ser 315 320 325 330 AAA ACC TCC TTG GCC CCT ATT ATA GTA TAT GTA AAG ATT TCT TCT CCT 1539 Lys Thr Ser Leu Ala Pro He He Val Tyr Val Lys He Ser Ser Pro 335 340 345 AAG GTT TTA CAA AGG TTA ATA AAA TCT CGA GGG AAA TCT CAA GCT AAA 1587 Lys Val Leu Gin Arg Leu He Lys Ser Arg Gly Lys Ser Gin Ala Lys 350 355 360 CAC CTC AAC GTC CAG ATG GTA GCA GCT GAT AAA CTG GCT CAG TGT CCT 1635 His Leu Asn Val Gin Met Val Ala Ala Asp Lys Leu Ala Gin Cys Pro 365 370 375 CCA GAG CTG TTC GAT GTG ATC TTG GAT GAG AAC CAG CTT GAG GAT GCC 1683 Pro Glu Leu Phe Asp Val He Leu Asp Glu Asn Gin Leu Glu Asp Ala 380 385 390 TGT GAG CAC CTT GCC GAC TAT CTG GAG GCC TAC TGG AAG GCC ACC CAT 1731 Cys Glu His Leu Ala Asp Tyr Leu Glu Ala Tyr Trp Lys Ala Thr His 395 400 405 410 CCT CCC AGC AGT AGC CTC CCC AAC CCT CTC CTT AGC CGT ACA TTA GCC 1779 Pro Pro Ser Ser Ser Leu Pro Asn Pro Leu Leu Ser Arg Thr Leu Ala 415 420 425 ACT TCA AGT CTG CCT CTT AGC CCC ACC CTA GCC TCT AAT TCA CAG GGT 1827 Thr Ser Ser Leu Pro Leu Ser Pro Thr Leu Ala Ser Asn Ser Gin Gly 430 435 440 TCT CAA GGT GAT CAG AGG ACT GAT CGC TCC GCT CCT ATC CGT TCT GCT 1875 Ser Gin Gly Asp Gin Arg Thr Asp Arg Ser Ala Pro He Arg Ser Ala 445 450 455 TCC CAA GCT GAA GAA GAA CCT AGT GTG GAA CCA GTC AAG AAA TCC CAG 1923 Ser Gin Ala Glu Glu Glu Pro Ser Val Glu Pro Val Lys Lys Ser Gin 460 465 470 CAC CGC TCT TCC TCC TCA GCC CCA CAC CAC AAC CAT CGC AGT GGG ACA 1971 His Arg Ser Ser Ser Ser Ala Pro His His Asn His Arg Ser Gly Thr 475 480 485 490 AGT CGC GGC CTC TCC AGG CAA GAG ACA TTT GAC TCG GAA ACC CAG GAG 2019 Ser Arg Gly Leu Ser Arg Gin Glu Thr Phe Asp Ser Glu Thr Gin Glu 495 500 505 AGT CGA GAC TCT GCC TAC GTA GAG CCA AAG GAA GAT TAT TCC CAT GAC 2067 Ser Arg Asp Ser Ala Tyr Val Glu Pro Lys Glu Asp Tyr Ser His Asp 510 515 520 CAC GTG GAC CAC TAT GCC TCA CAC CGT GAC CAC AAC CAC AGA GAC GAG 2115 His Val Asp His Tyr Ala Ser His Arg Asp His Asn His Arg Asp Glu 525 530 535 ACC CAC GGG AGC AGT GAC CAC AGA CAC AGG GAG TCC CGG CAC CGT TCC 2163 Thr His Gly Ser Ser Asp His Arg His Arg Glu Ser Arg His Arg Ser 540 545 550 CGG GAC GTG GAT CGA GAG CAG GAC CAC AAC GAG TGC AAC AAG CAG CGC 2211 Arg Asp Val Asp Arg Glu Gin Asp His Asn Glu Cys Asn Lys Gin Arg 555 560 565 570 AGC CGT CAT AAA TCC AAG GAT CGC TAC TGT GAA AAG GAT GGA GAA GTG 2259 Ser Arg His Lys Ser Lys Asp Arg Tyr Cys Glu Lys Asp Gly Glu Val 575 580 585 ATA TCA AAA AAA CGG AAT GAG GCT GGG GAG TGG AAC AGG GAT GTT TAC 2307 He Ser Lys Lys Arg Asn Glu Ala Gly Glu Trp Asn Arg Asp Val Tyr 590 595 600 ATC CCC CAA TGAGTTTTGC CCTTTTGTGT TTTTTTTTTT TTTTTTTTGA 2356 He Pro Gin 605 AGTCTTGTAT AACTAACAGC ATCCCCAAAA CAAAAAGTCT TTGGGGTCTA CACTGCAATC 2416 ATATGTGATC TGTCTTGTAA TATTTTGTAT TATTGCTGTT GCTTGAATAG CAATAGCATG 2476 GATAGAGTAT TGAGATACTT TTTCTTTTGT AAGTGCTACA TAAATTGGCC TGGTATGGCT 2536 GCAGTCCTCC GGTTGCATAC TGGACTCTTC AAAAACTGTT TTGGGTAGCT GCCACTTGAA 2596 CAAAATCTGT TGCCACCCAG GTGATGTTAG TGTTTTAAGA AATGTAGTTG ATGTATCCAA 2656 CAAGCCAGAA TCAGCACAGA TAAAAAGTGG AATTTCTTGT TTCTCCAGAT TTTTAATACG 2716 TTAATACGCA GGCATCTGAT TTGCATATTC ATTCATGGAC CACTGTTTCT TGCTTGTACC 2776 TCTGGCTGAC TAAATTTGGG GACAGATTCA GTCTTGCCTT ACACAAAGGG GATCATAAAG 2836 TTAGAATCTA TTTTCTATGT ACTAGTACTG TGTACTGTAT AGACAGTTTG TAAATGTTAT 2896 TTCTGCAAAC AAACACCTCC TTATTATATA TAATATATAT ATATATATCA GTTTGATCAC 2956 ACTATTTTAG AGTC 2970 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2712 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 223..2061 (D) OTHER INFORMATION: /standard_name= "Beta-2E" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: AGTGTGTGTT TTCAGCCCCT CCTGGAATGG GAAAATAAGA ATCTCCCTGG ATGGGAGTCC 60 TCTGGGGCAG GGAGTGAAAG CCCCGGAGGC AGAAAGGGAC GGAGAACAGG GGCTTGCCCA 120 GAGCATGGAT AGGAAAGGAG CTGGGGTTCT CCGGGGCTCA GCGCGCACTG AGAACCTGTG 180 CCCGGGGCTG CAGCTGCGGA CGATAAAGGC GCTGTCTGGC TC ATG AAG GCC ACC 234 Met Lys Ala Thr 1 TGG ATC AGG CTT CTG AAA AGA GCC AAG GGA GGA AGG CTG AAG AAT TCT 282 Trp He Arg Leu Leu Lys Arg Ala Lys Gly Gly Arg Leu Lys Asn Ser 5 10 15 20 GAT ATC TGT GGT TCG GCA GAC TCC TAC ACT AGC CGT CCA TCC GAT TCC 330 Asp He Cys Gly Ser Ala Asp Ser Tyr Thr Ser Arg Pro Ser Asp Ser 25 30 35 GAT GTA TCT CTG GAG GAG GAC CGG GAG GCA GTG CGC AGA GAA GCG GAG 378 Asp Val Ser Leu Glu Glu Asp Arg Glu Ala Val Arg Arg Glu Ala Glu 40 45 50 CGG CAG GCC CAG GCA CAG TTG GAA AAA GCA AAG ACA AAG CCC GTT GCA 426 Arg Gin Ala Gin Ala Gin Leu Glu Lys Ala Lys Thr Lys Pro Val Ala 55 60 65 TTT GCG GTT CGG ACA AAT GTC AGC TAC AGT GCG GCC CAT GAA GAT GAT 474 Phe Ala Val Arg Thr Asn Val Ser Tyr Ser Ala Ala His Glu Asp Asp 70 75 80 GTT CCA GTG CCT GGC ATG GCC ATC TCA TTC GAA GCA AAA GAT TTT CTG 522 Val Pro Val Pro Gly Met Ala He Ser Phe Glu Ala Lys Asp Phe Leu 85 90 95 100 CAT GTT AAG GAA AAA TTT AAC AAT GAC TGG TGG ATA GGG CGA TTG GTA 570 His Val Lys Glu Lys Phe Asn Asn Asp Trp Trp He Gly Arg Leu Val 105 110 115 AAA GAA GGC TGT GAA ATC GGA TTC ATT CCA AGC CCA GTC AAA CTA GAA 618 Lys Glu Gly Cys Glu He Gly Phe He Pro Ser Pro Val Lys Leu Glu 120 125 130 AAC ATG AGG CTG CAG CAT GAA CAG AGA GCC AAG CAA GGG AAA TTC TAC 666 Asn Met Arg Leu Gin His Glu Gin Arg Ala Lys Gin Gly Lys Phe Tyr 135 140 145 TCC AGT AAA TCA GGA GGA AAT TCA TCA TCC AGT TTG GGT GAC ATA GTA 714 Ser Ser Lys Ser Gly Gly Asn Ser Ser Ser Ser Leu Gly Asp He Val 150 155 160 CCT AGT TCC AGA AAA TCA ACA CCT CCA TCA TCT GCT ATA GAC ATA GAT 762 Pro Ser Ser Arg Lys Ser Thr Pro Pro Ser Ser Ala He Asp He Asp 165 170 175 180 GCT ACT GGC TTA GAT GCA GAA GAA AAT GAT ATT CCA GCA AAC CAC CGC 810 Ala Thr Gly Leu Asp Ala Glu Glu Asn Asp He Pro Ala Asn His Arg 185 190 195 TCC CCT AAA CCC AGT GCA AAC AGT GTA ACG TCA CCC CAC TCC AAA GAG 858 Ser Pro Lys Pro Ser Ala Asn Ser Val Thr Ser Pro His Ser Lys Glu 200 205 210 AAA AGA ATG CCC TTC TTT AAG AAG ACA GAG CAC ACT CCT CCG TAT GAT 906 Lys Arg Met Pro Phe Phe Lys Lys Thr Glu His Thr Pro Pro Tyr Asp 215 220 225 GTG GTA CCT TCC ATG CGA CCA GTG GTC CTA GTG GGC CCT TCT CTG AAG 954 Val Val Pro Ser Met Arg Pro Val Val Leu Val Gly Pro Ser Leu Lys 230 235 240 GGC TAC GAG GTC ACA GAT ATG ATG CAA AAA GCG CTG TTT GAT TTT TTA 1002 Gly Tyr Glu Val Thr Asp Met Met Gin Lys Ala Leu Phe Asp Phe Leu 245 250 255 260 AAA CAC AGA TTT GAA GGG CGG ATA TCC ATC ACA AGG GTC ACC GCT GAC 1050 Lys His Arg Phe Glu Gly Arg He Ser He Thr Arg Val Thr Ala Asp 265 270 275 ATC TCG CTT GCC AAA CGC TCG GTA TTA AAC AAT CCC AGT AAG CAC GCA 1098 He Ser Leu Ala Lys Arg Ser Val Leu Asn Asn Pro Ser Lys His Ala 280 285 290 ATA ATA GAA AGA TCC AAC ACA AGG TCA AGC TTA GCG GAA GTT CAG AGT 11 6 He He Glu Arg Ser Asn Thr Arg Ser Ser Leu Ala Glu Val Gin Ser 295 300 305 GAA ATC GAA AGG ATT TTT GAA CTT GCA AGA ACA TTG CAG TTG GTG GTC 1194 Glu He Glu Arg He Phe Glu Leu Ala Arg Thr Leu Gin Leu Val Val 310 315 320 CTT GAC GCG GAT ACA ATT AAT CAT CCA GCT CAA CTC AGT AAA ACC TCC 1242 Leu Asp Ala Asp Thr He Asn His Pro Ala Gin Leu Ser Lys Thr Ser 325 330 335 340 TTG GCC CCT ATT ATA GTA TAT GTA AAG ATT TCT TCT CCT AAG GTT TTA 1290 Leu Ala Pro He He Val Tyr Val Lys He Ser Ser Pro Lys Val Leu 345 350 355 CAA AGG TTA ATA AAA TCT CGA GGG AAA TCT CAA GCT AAA CAC CTC AAC 1338 Gin Arg Leu He Lys Ser Arg Gly Lys Ser Gin Ala Lys His Leu Asn 360 365 370 GTC CAG ATG GTA GCA GCT GAT AAA CTG GCT CAG TGT CCT CCA GAG CTG 1386 Val Gin Met Val Ala Ala Asp Lys Leu Ala Gin Cys Pro Pro Glu Leu 375 380 385 TTC GAT GTG ATC TTG GAT GAG AAC CAG CTT GAG GAT GCC TGT GAG CAC 1434 Phe Asp Val He Leu Asp Glu Asn Gin Leu Glu Asp Ala Cys Glu His 390 395 400 CTT GCC GAC TAT CTG GAG GCC TAC TGG AAG GCC ACC CAT CCT CCC AGC 1482 Leu Ala Asp Tyr Leu Glu Ala Tyr Trp Lys Ala Thr His Pro Pro Ser 405 410 415 420 AGT AGC CTC CCC AAC CCT CTC CTT AGC CGT ACA TTA GCC ACT TCA AGT 1530 Ser Ser Leu Pro Asn Pro Leu Leu Ser Arg Thr Leu Ala Thr Ser Ser 425 430 435 CTG CCT CTT AGC CCC ACC CTA GCC TCT AAT TCA CAG GGT TCT CAA GGT 1578 Leu Pro Leu Ser Pro Thr Leu Ala Ser Asn Ser Gin Gly Ser Gin Gly 440 445 450 GAT CAG AGG ACT GAT CGC TCC GCT CCT ATC CGT TCT GCT TCC CAA GCT 1626 Asp Gin Arg Thr Asp Arg Ser Ala Pro He Arg Ser Ala Ser Gin Ala 455 460 465 GAA GAA GAA CCT AGT GTG GAA CCA GTC AAG AAA TCC CAG CAC CGC TCT 1674 Glu Glu Glu Pro Ser Val Glu Pro Val Lys Lys Ser Gin His Arg Ser 470 475 480 TCC TCC TCA GCC CCA CAC CAC AAC CAT CGC AGT GGG ACA AGT CGC GGC 1722 Ser Ser Ser Ala Pro His His Asn His Arg Ser Gly Thr Ser Arg Gly 485 490 495 500 CTC TCC AGG CAA GAG ACA TTT GAC TCG GAA ACC CAG GAG AGT CGA GAC 1770 Leu Ser Arg Gin Glu Thr Phe Asp Ser Glu Thr Gin Glu Ser Arg Asp 505 510 515 TCT GCC TAC GTA GAG CCA AAG GAA GAT TAT TCC CAT GAC CAC GTG GAC 1818 Ser Ala Tyr Val Glu Pro Lys Glu Asp Tyr Ser His Asp His Val Asp 520 525 530 CAC TAT GCC TCA CAC CGT GAC CAC AAC CAC AGA GAC GAG ACC CAC GGG 1866 His Tyr Ala Ser His Arg Asp His Asn His Arg Asp Glu Thr His Gly 535 540 545 AGC AGT GAC CAC AGA CAC AGG GAG TCC CGG CAC CGT TCC CGG GAC GTG 1914 Ser Ser Asp His Arg His Arg Glu Ser Arg His Arg Ser Arg Asp Val 550 555 560 GAT CGA GAG CAG GAC CAC AAC GAG TGC AAC AAG CAG CGC AGC CGT CAT 1962 Asp Arg Glu Gin Asp His Asn Glu Cys Asn Lys Gin Arg Ser Arg His 565 570 575 580 s> AAA TCC AAG GAT CGC TAC TGT GAA AAG GAT GGA GAA GTG ATA TCA AAA 2010 Lys Ser Lys Asp Arg Tyr Cys Glu Lys Asp Gly Glu Val He Ser Lys 585 590 595 AAA CGG AAT GAG GCT GGG GAG TGG AAC AGG GAT GTT TAC ATC CCC CAA 2058 Lys Arg Asn Glu Ala Gly Glu Trp Asn Arg Asp Val Tyr He Pro Gin 600 605 610 TGAGTTTTGC CCTTTTGTGT TTTTTTTTTT TTTTTTTTGA AGTCTTGTAT AACTAACAGC 2118 ATCCCCAAAA CAAAAAGTCT TTGGGGTCTA CACTGCAATC ATATGTGATC TGTCTTGTAA 2178 TATTTTGTAT TATTGCTGTT GCTTGAATAG CAATAGCATG GATAGAGTAT TGAGATACTT 2238 TTTCTTTTGT AAGTGCTACA TAAATTGGCC TGGTATGGCT GCAGTCCTCC GGTTGCATAC 2298 TGGACTCTTC AAAAACTGTT TTGGGTAGCT GCCACTTGAA CAAAATCTGT TGCCACCCAG 2358 GTGATGTTAG TGTTTTAAGA AATGTAGTTG ATGTATCCAA CAAGCCAGAA TCAGCACAGA 2418 TAAAAAGTGG AATTTCTTGT TTCTCCAGAT TTTTAATACG TTAATACGCA GGCATCTGAT 2478 TTGCATATTC ATTCATGGAC CACTGTTTCT TGCTTGTACC TCTGGCTGAC TAAATTTGGG 2538 GACAGATTCA GTCTTGCCTT ACACAAAGGG GATCATAAAG TTAGAATCTA TTTTCTATGT 2598 ACTAGTACTG TGTACTGTAT AGACAGTTTG TAAATGTTAT TTCTGCAAAC AAACACCTCC 2658 TTATTATATA TAATATATAT ATATATATCA GTTTGATCAC ACTATTTTAG AGTC 2712

Claims: HAT IS CLAIMED IS: I. An isolated DNA fragment, comprising a sequence of nucleotides that encodes an α x subunit selected from the group consisting of α 1A _., α 1A _ 2 , α 1E _., α ιc _ 2 and α 1E _ 3 . 2. The DNA fragment of claim 1, wherein the α. subunit is α 1A .. or α 1A _ 2. 3. The DNA fragment of claim 1, wherein the α. subunit is α 1E _. or α 1E _ 3 . 4. The DNA fragment of claim 1, wherein the α. subunit is α lc _ 2 . 5. An isolated DNA fragment, comprising a sequence of nucleotides that encodes a 0 subunit selected from the group consisting of 0 2 , 0 3 and 0 4 . 6. The DNA fragment of claim 5, wherein the subunit is a 0 2C , 0 2D or 0 2E subunit. 7. The DNA fragment of claim 5, wherein the subunit is a 0 3 subunit. 8. The DNA fragment of claim 7, wherein the subunit is a 0 3 _. subunit. 9. The DNA fragment of claim 5, wherein the subunit is a 0 4 subunit. 10. The DNA fragment of claim 9, wherein the subunit has an amino acid sequence set forth in SEQ ID No. 28. II. A eukaryotic cell, comprising heterologous DNA that encodes an α α subunit selected from the group of subunits consisting of α 1A _., α 1A _ 2 , α ιc _ 2 , a 1E _ l t and α 1E _ 3 . 12. A eukaryotic cell, comprising heterologous DNA that encodes an α. subunit and heterologous DNA that encodes a 0 subunit, wherein at least one subunit is selected from the group of subunits consisting of α^.., α 1A _ 2 , α lc _ 2 , α 1E _ 1# a 1E . 3 , 0 2C , β 2 -. β 2 E> β-- > .' a β* subunit. 13. The eukaryotic cell of claim 12, wherein the 0 subunit is a 0 2 subunit. 14. The eukaryotic cell of claim 12, wherein the 0 subunit is a 0 4 subunit. 15. The eukaryotic cell of claim 11, selected from the group consisting of HEK 293 cells, Chinese hamster ovary cells, African green monkey cells, and mouse L cells. 16. The eukaryotic cell of claim 12 selected from the group consisting of HEK 293 cells, Chinese hamster ovary cells, African green monkey cells, and mouse L cells. 17. A eukaryotic cell with a functional, heterologous calcium channel, produced by a process comprising: introducing into the cell heterologous nucleic acid that encodes an α.-subunit of a human calcium channel, wherein: the α. subunit is selected from the group consisting of a itκ-l ' 0i l.Α-2 l α iC-2 "^lE-l 3nd Q ?lE-3 /' the heterologous calcium channel contains at least one subunit encoded by the heterologous nucleic acid; and the only heterologous ion channels are calcium channels. 18. A eukaryotic cell with a functional, heterologous calcium channel, produced by a process comprising: introducing into the cell nucleic acid that encodes an α. subunit of a human calcium channel and introducing into the cell nucleic acid that encodes a 0 subunit of a human calcium channel, wherein: at least one of the subunits is s elected from the group consisting of α 1A _.., α 1A _ 2 , α 1E .., α 1E _ 3 , 0 2C , 0 2D , 0 2E , a 0 3 and a 0 4 subunit; the heterologous calcium channel contains at least one subunit encoded by the heterologous nucleic acid; and the only heterologous ion channels are calcium channels. 19. The eukaryotic cell of claim 17 selected from the group consisting of HEK 293 cells, Chinese hamster ovary cells, African green monkey cells, mouse L cells and amphibian oocytes. 20. The eukaryotic cell of claim 18 selected from the group consisting of HEK 293 cells, Chinese hamster ovary cells, African green monkey cells, mouse L cells and amphibian oocytes. 21. The eukaryotic cell of claim 18, wherein the 0 subunit is a 0 2 , 0 3 or 0 4 subunit of a human calcium channel. 22. The eukaryotic cell of claim 18, wherein the calcium channel includes an α 2b subunit of a human calcium channel, an α 1B .. subunit of a human calcium channel and a 0 3 subunit of a human calcium channel. 23. The eukaryotic cell of claim 18, wherein the calcium channel includes an or 1B _ x , α 2b , and a 0._ 2 subunit, or an α 1B _ α , α 2b , and a 0,_ 3 subunit, or an α 1B _ 2 , α 2b , and a 0._ 3 subunit, or an α 1A _ 2 , α 2b , and a 0 3 _. subunit, or a α 1B _., α 2b , and an 0 3 .. subunit. 24. The eukaryotic cell of claim 18, wherein the calcium channel contains an α 2b subunit of a human calcium channel, an α 1B or an α 1D subunit of a human calcium channel and a 0 ! .., 0-_ 2 or 0._ 3 subunit of a human calcium channel. 25. A method for identifying a compound that modulates the activity of a calcium channel, comprising; suspending a eukaryotic cell that has a functional, heterologous calcium channel, in a solution containing the compound and a calcium channel-selective ion: depolarizing the cell membrane of the cell; and detecting the current flowing into the cell, wherein: the heterologous calcium channel includes at least one human calcium channel subunit encoded by DNA or RNA that is heterologous to the cell; at least one subunit is selected from the group consisting of α 1A _!, α..A-2» ~ > 1E -ι> α iE-3» α _c-2/ β o β 2o> ^2E» a 03 subunit and a 0 4 subunit; the current that is detected is different from that produced by depolarizing the same or a substantially identical cell in the presence of the same calcium channel selective ion but in the absence of the compound. 26. The method of claim 25, wherein the heterologous DNA or RNA encodes a 0 3 subunit. 27. The method of claim 26, wherein the heterologous DNA or RNA encodes a 0 4 subunit. 28. A subunit-specific antibody selected from the group consisting of antibodies that bind to an α subunit type or α subunit subtype of a human calcium channels, wherein the subunit is an α. subunit. 29. The antibody of claim 28, wherein antibody is subtype specific and the x subunit is α 1A , α 1E and α 1B . 30. An RNA or single-stranded DNA probe of at least 16 bases in length comprising at least 16 substantially contiguous bases from nucleic acids that encode a subunit of a human calcium channel selected from the group of subunits consisting of ^.., α^, α 1E .., α ιc _ 2 , α 1E _ 3 , 0 3 _., 0 2C , 0 2D , 0 2E and 31. The probe of claim 30 that contains at least 30 bases that are from nucleic acids that encode a subunit of a human calcium channel selected from the group of subunits consisting of α 1A _ lf α-^, α 1E _., α ιc _ 2 , α 1E _ 3 , β 3 . x , 0 2C , 0 2D , 0 2E and 0 4 subunits. 32. A method for identifying nucleic acids that encode a human calcium channel subunit, comprising hybridizing under conditions of at least low stringency a probe of claim 30 to a library of nucleic acid fragments, and selecting hybridizing fragments. . 33. A method for identifying cells or tissues that express a calcium channel subunit-encoding nucleic acid, comprising hybridizing under conditions of at least low stringency a probe of claim 30 with mRNA expressed in the cells or tissues or cDNA produced from the mRNA, and thereby identifying cells or tissue that express mRNA that encodes the subunit. 34. A substantially pure human calcium channel subunit selected from the group consisting of α 1A .., α 1A _ 2 , α 1E .., α lc . 2 , α 1E _ 3 , 03-1 β 2 C 02D 02E aIld β* •

Inventors: ELLIS STEVEN B, GILLESPIE ALISON, HARPOLD MICHAEL M, MCCUE ANN F, WILLIAMS MARK E, ELLIS, STEVEN, B., GILLESPIE, ALISON, HARPOLD, MICHAEL, M., MCCUE, ANN, F., WILLIAMS, MARK, E.
Applicants: SALK INST BIOTECH IND, THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCI
Application year: 1994
Main classification: C12N15
IPC codes: C07K14, C07K16, C12N1, C12N5, C12N15, C12P21, C12Q1, C12R1, G01N33